


10/785,120



G1 C,N

G2 O,N

G3 X,Cy,C,O,S,N

Structure attributes must be viewed using STN Express query preparation.  
L4 QUE ABB=ON PLU=ON L3

(FILE 'HOME' ENTERED AT 15:02:16 ON 01 MAR 2006)

FILE 'REGISTRY' ENTERED AT 15:02:41 ON 01 MAR 2006  
ACT A10785120/A

L1 STR  
L2 3101 SEA FILE=REGISTRY SSS FUL L1

FILE 'STNGUIDE' ENTERED AT 15:03:13 ON 01 MAR 2006

L3 FILE 'REGISTRY' ENTERED AT 15:05:08 ON 01 MAR 2006  
L4 STRUCTURE UPLOADED  
L5 QUE L3  
L6 46 S L4 SAM SUB=L2  
1087 S L4 FUL SUB=L2

L7 FILE 'CAPLUS' ENTERED AT 15:06:47 ON 01 MAR 2006  
128 S L6

L8 FILE 'REGISTRY' ENTERED AT 15:06:58 ON 01 MAR 2006  
L9 45 S L6  
1151 S L6 FUL

L10 FILE 'CAPLUS' ENTERED AT 15:08:55 ON 01 MAR 2006  
129 S L9

COST IN U.S. DOLLARS

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

SINCE FILE  
ENTRY  
661.95


SINCE FILE  
ENTRY  
-96.75

TOTAL  
SESSION  
871.78

TOTAL  
SESSION  
-96.75

10/785,120


L10 ANSWER 1 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2005:1117988 CAPLUS  
 DN 144:22900  
 TI Synthetic Utilization of Polynitroaromatic Compounds. 3. Preparation of Substituted Dibenz[b,f][1,4]oxazepine-11(10H)-ones from 2,4,6-Trinitrobenzoic Acid via Nucleophilic Displacement of Nitro Groups  
 AU Samet, Alexander V.; Marshalkin, Victor N.; Kislyi, Konstantine A.; Chernysheva, Natalya B.; Strelenko, Yuri A.; Semenov, Victor V.  
 CS N. D. Zelinsky Institute of Organic Chemistry, RAS, Moscow, 119991, Russia  
 SO Journal of Organic Chemistry (2005), 70(23), 9371-9376  
 CODEN: JOCEAH; ISSN: 0022-3263  
 PB American Chemical Society  
 DT Journal  
 LA English  
 GI



AB 1,3-Dinitrodibenz[b,f][1,4]oxazepin-11(10H)-one, prepared by intramol. displacement of nitro group in N-(2-hydroxyphenyl)-2,4,6-trinitrobenzamide, reacts with O- and S-nucleophiles to yield the products of mono- or bis-substitution of the nitro groups. The nitro group in position 3 is displaced first. This observation is in contrast with earlier results for the nitro-substituted benzoannulated five-membered heterocycles. This difference in reactivity is likely due to the increased steric hindrance for peri-nitro group displacement in the case of the benzoannulated seven-membered heterocycle. N-Alkylation of the nitro-substituted dibenz[b,f][1,4]oxazepin-11(10H)-ones yields analogs of a known antidepressant drug Sintamil, e. g. I. The structure of the products is confirmed by NOE expts. and alternative synthesis.

IT **870552-97-9 870552-99-1**  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of substituted dibenzoxazepinones from trinitrobenzoic acid via nucleophilic displacement of nitro groups and subsequent N-alkylation)

RN 870552-97-9 CAPLUS  
 CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-(1-methylethoxy)-1-nitro- (9CI)  
 (CA INDEX NAME)




RN 870552-99-1 CAPLUS



10/785,120

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-(cyclohexyloxy)-1-nitro- (9CI)  
(CA INDEX NAME)




IT 309735-46-4P 447455-70-1P 728000-38-2P  
728003-32-5P 728884-28-4P 870552-93-5P  
870553-04-1P 870553-24-5P 870553-26-7P  
870553-27-8P 870553-29-0P 870553-31-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation of substituted dibenzoxazepinones from trinitrobenzoic acid via  
nucleophilic displacement of nitro groups and subsequent N-alkylation)


RN 309735-46-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,3-dinitro- (9CI) (CA INDEX NAME)




RN 447455-70-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,3-bis[(4-methylphenyl)thio]- (9CI)  
(CA INDEX NAME)




RN 728000-38-2 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,3-bis(butylthio)- (9CI) (CA INDEX  
NAME)




RN 728003-32-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-(butylthio)-1-nitro- (9CI) (CA INDEX NAME)



RN 728884-28-4 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,3-bis(3-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 870552-93-5 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-methoxy-1-nitro- (9CI) (CA INDEX NAME)

10/785,120




RN 870553-04-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1-nitro-3-phenoxy- (9CI) (CA INDEX NAME)




RN 870553-24-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,3-diphenoxy- (9CI) (CA INDEX NAME)



RN 870553-26-7 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-(butylthio)-1-phenoxy- (9CI) (CA INDEX NAME)



RN 870553-27-8 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1-(butylthio)-3-methoxy- (9CI) (CA INDEX NAME)

10/785,120




RN 870553-29-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-methoxy-1-[(phenylmethyl)thio]-  
(9CI) (CA INDEX NAME)



RN 870553-31-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1-[(4-methylphenyl)thio]-3-phenoxy-  
(9CI) (CA INDEX NAME)




IT 681845-18-1P 681850-38-4P 870552-94-6P  
870552-96-8P 870553-01-8P 870553-03-0P  
870553-05-2P 870553-07-4P 870553-09-6P  
870553-11-0P 870553-13-2P 870553-15-4P  
870553-19-8P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of substituted dibenzoxazepinones from trinitrobenzoic acid via  
nucleophilic displacement of nitro groups and subsequent N-alkylation)


RN 681845-18-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1-nitro-3-(phenylthio)- (9CI) (CA  
INDEX NAME)




RN 681850-38-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1-nitro-3-[(phenylmethyl)thio]-  
(9CI) (CA INDEX NAME)




RN 870552-94-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-ethoxy-1-nitro- (9CI) (CA INDEX  
NAME)



RN 870552-96-8 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1-nitro-3-propoxy- (9CI) (CA INDEX  
NAME)



RN 870553-01-8 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-(2-hydroxyethoxy)-1-nitro- (9CI)  
(CA INDEX NAME)

10/785,120




RN 870553-03-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1-nitro-3-(phenylmethoxy)- (9CI)  
(CA INDEX NAME)




RN 870553-05-2 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-(3-methylphenoxy)-1-nitro- (9CI)  
(CA INDEX NAME)




RN 870553-07-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-(4-methylphenoxy)-1-nitro- (9CI)  
(CA INDEX NAME)




RN 870553-09-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-(2-methoxyphenoxy)-1-nitro- (9CI)  
(CA INDEX NAME)




RN 870553-11-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-(4-methoxyphenoxy)-1-nitro- (9CI)  
(CA INDEX NAME)




RN 870553-13-2 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-(2-bromophenoxy)-1-nitro- (9CI)  
(CA INDEX NAME)



RN 870553-15-4 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-(4-bromophenoxy)-1-nitro- (9CI)  
(CA INDEX NAME)



RN 870553-19-8 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-[(4-methylphenyl)thio]-1-nitro- (9CI)  
(CA INDEX NAME)


10/785,120



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L10 ANSWER 2 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2005:1051145 CAPLUS  
 DN 144:6772  
 TI Intramolecular Carbonylation Reactions with Recyclable Palladium-Complexed Dendrimers on Silica: Synthesis of Oxygen, Nitrogen, or Sulfur-Containing Medium Ring Fused Heterocycles  
 AU Lu, Shui-Ming; Alper, Howard  
 CS Centre for Catalysis Research and Innovation, Department of Chemistry, University of Ottawa, Ottawa, ON, K1N 6N5, Can.  
 SO Journal of the American Chemical Society (2005), 127(42), 14776-14784  
 CODEN: JACSAT; ISSN: 0002-7863  
 PB American Chemical Society  
 DT Journal  
 LA English  
 OS CASREACT 144:6772  
 GI




AB Palladium-complexed dendrimers supported on silica were evaluated as catalysts for intramol. carbonylation reactions. The results showed that dendritic catalysts display high activity, affording oxygen, nitrogen, or sulfur-containing seven- or eight-membered ring fused heterocycles, e.g. I (X = O, S, MeN; Y = nothing, CH<sub>2</sub>; R<sub>1</sub> = H, Me, MeO, MeCO, CN, F<sub>3</sub>C, etc.; R<sub>2</sub> = H, Me, MeO<sub>2</sub>C, Cl, F, etc.), from aminophenyl ethers, thioethers or amines, e.g. II (R<sub>3</sub> = Br, iodo), in excellent yields. Moreover, these catalysts have competitive advantages in that they can be easily recovered by simple filtration in air and reused for up to eight cycles with only a slight loss of activity.

IT **869790-73-8P 869790-74-9P 869790-75-0P**  
**869790-76-1P 869790-77-2P 869790-78-3P**  
**869790-79-4P 869790-80-7P 869790-81-8P**  
**869790-83-0P 869790-84-1P 869790-85-2P**  
**869790-86-3P 869790-87-4P 869791-14-0P**  
**869791-15-1P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of oxygen, nitrogen, or sulfur-containing medium ring fused heterocycles via intramol. carbonylation reactions of aminophenyl ethers, thioethers or amines using recyclable Pd-complexed dendrimers on silica)

RN 869790-73-8 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-methyl-8-(trifluoromethyl)- (9CI)  
 (CA INDEX NAME)



10/785,120


RN 869790-74-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carbonitrile, 10,11-dihydro-2-methyl-11-oxo-  
(9CI) (CA INDEX NAME)




RN 869790-75-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8-acetyl-2-methyl- (9CI) (CA INDEX  
NAME)




RN 869790-76-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro-8-(trifluoromethyl)- (9CI)  
(CA INDEX NAME)



RN 869790-77-2 CAPLUS


CN Dibenz[b,f][1,4]oxazepine-8-carbonitrile, 2-chloro-10,11-dihydro-11-oxo-  
(9CI) (CA INDEX NAME)



RN 869790-78-3 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8-acetyl-2-chloro- (9CI) (CA INDEX  
NAME)

10/785,120




RN 869790-79-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-2-carboxylic acid, 10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 869790-80-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-2-carboxylic acid, 10,11-dihydro-11-oxo-8-(trifluoromethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 869790-81-8 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-2-carboxylic acid, 8-cyano-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 869790-83-0 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,4-difluoro- (9CI) (CA INDEX NAME)



10/785,120


RN 869790-84-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carbonitrile, 2-fluoro-10,11-dihydro-11-oxo-  
(9CI) (CA INDEX NAME)




RN 869790-85-2 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carbonitrile, 3-fluoro-10,11-dihydro-11-oxo-  
(9CI) (CA INDEX NAME)




RN 869790-86-3 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8-acetyl-2-fluoro- (9CI) (CA INDEX  
NAME)



RN 869790-87-4 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8-acetyl-3-fluoro- (9CI) (CA INDEX  
NAME)



RN 869791-14-0 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8,8'-sulfonylbis[2-methyl- (9CI)  
(CA INDEX NAME)]

10/785,120



RN 869791-15-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8,8'-sulfonylbis[2-chloro- (9CI)  
(CA INDEX NAME)




RE.CNT 112 THERE ARE 112 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/785,120

L10 ANSWER 3 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:633268 CAPLUS  
DN 143:133408  
TI Preparation of tricyclic compounds with NOS activity  
IN Rakhit, Suman; Ramnauth, Jailall; Bratovanov, Svetoslav; Maddaford, Shawn  
PA Neuraxon Inc., Can.  
SO U.S., 17 pp.  
CODEN: USXXAM  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6919328	B1	20050719	US 2002-265624	20021008
PRAI	US 2001-327317P	P	20011009		
OS	MARPAT 143:133408				
GI					



I




II

AB The title compds. I [R1 = CO(alkenyl), CONHR2, CONHCOR2, CSNH2, etc.; R2 = (un)substituted (hetero)aryl; X = O, NH, N(alkyl), S] and their pharmaceutically acceptable salts, useful as neuroprotectants, in particular, for treating stroke, were prepared E.g., a 3-step synthesis of II, starting from Me 2-chloro-4-nitrobenzoate and 1,2-diaminobenzene, was given. The compound II showed IC50 of 400  $\mu$ M and of 500  $\mu$ M against nNOS and iNOS, resp. The pharmaceutical composition comprising the compound I is disclosed.

IT **859158-37-5P 859158-38-6P 859158-44-4P**  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of dibenzo[b,e][1,4]diazepin-11-one and dibenzo[b,f][1,4]oxazepin-11-one derivs. with NOS activity for treating stroke)


RN 859158-37-5 CAPLUS  
CN Benzamide, N-[[ (10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-2-yl)amino]thioxomethyl]- (9CI) (CA INDEX NAME)



RN 859158-38-6 CAPLUS  
CN Thiourea, (10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-2-yl)- (9CI)


10/785,120

(CA INDEX NAME)



RN 859158-44-4 CAPLUS

CN Benzamide, N-[[ (10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)amino]thioxomethyl]- (9CI) (CA INDEX NAME)



IT 359644-13-6P 859158-36-4P 859158-39-7P

859158-40-0P 859158-41-1P 859158-42-2P

859158-43-3P 859158-45-5P 859158-46-6P


859158-47-7P 859158-48-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of dibenzo[b,e][1,4]diazepin-11-one and dibenzo[b,f][1,4]oxazepin-11-one derivs. with NOS activity for treating stroke)


RN 359644-13-6 CAPLUS

CN Thiourea, N-(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-N'-phenyl- (9CI) (CA INDEX NAME)



RN 859158-36-4 CAPLUS


CN Acetamide, N-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-2-yl)- (9CI) (CA INDEX NAME)



10/785,120


RN 859158-39-7 CAPLUS

CN Carbamimidothioic acid, (10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-2-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 859158-40-0 CAPLUS


CN Ethanimidamide, N-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-2-yl)-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr


RN 859158-41-1 CAPLUS

CN Carbamimidothioic acid, (10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-2-yl)-, 2-naphthalenylmethyl ester (9CI) (CA INDEX NAME)



RN 859158-42-2 CAPLUS

CN Carbamimidothioic acid, (10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-2-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)






10/785,120


RN 859158-43-3 CAPLUS

CN Ethanimidamide, N-(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-  
(9CI) (CA INDEX NAME)




RN 859158-45-5 CAPLUS

CN Thiourea, (10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)- (9CI) (CA  
INDEX NAME)



RN 859158-46-6 CAPLUS


CN 2-Thiophenecarboximidamide, N-(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-, monohydrobromide (9CI) (CA INDEX  
NAME)



● HBr

RN 859158-47-7 CAPLUS

CN 2-Thiophenecarboximidamide, N-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-2-yl)-, monohydrobromide (9CI) (CA INDEX NAME)




● HBr

10/785,120

RN 859158-48-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-(2-thiazolylamino)-  
(9CI) (CA INDEX NAME)




IT 16398-16-6P 23474-66-0P 54255-81-1P  
213208-07-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of dibenzo[b,e][1,4]diazepin-11-one and  
dibenzo[b,f][1,4]oxazepin-11-one derivs. with NOS activity for treating  
stroke)


RN 16398-16-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-nitro- (8CI, 9CI) (CA INDEX NAME)




RN 23474-66-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino- (8CI, 9CI) (CA INDEX NAME)



RN 54255-81-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-nitro- (9CI) (CA  
INDEX NAME)



RN 213208-07-2 CAPLUS

10/785,120

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-amino-5,10-dihydro- (9CI) (CA  
INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:612094 CAPLUS

DN 143:133403

TI Amino-substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists, their preparation and use in the treatment of neuropsychiatric disorders

IN Ek, Fredrik; Olsson, Roger; Ohlsson, Joergen

PA Acadia Pharmaceuticals Inc., USA

SO PCT Int. Appl., 129 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005063254	A2	20050714	WO 2004-US43224	20041221
	WO 2005063254	A3	20050915		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005192268	A1	20050901	US 2004-19555	20041221
PRAI	US 2003-531927P	P	20031222		
	US 2004-548090P	P	20040224		
	US 2004-548604P	P	20040227		
OS	MARPAT 143:133403				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention relates to a group of novel amino-substituted dibenzazepines I, benzazepines II and related clozapine analogs, which are agonists of muscarinic receptors. In compds. I and II, W is N, CH, O, or S; Y is N, O, or CH; R1, R6, and R7 are independently absent or selected from H, halo, amino, (un)substituted C1-20 alkyl, (un)substituted C3-8 cycloalkyl, (un)substituted aryl, etc., or R1R6 is -CH2CH2-; each R2, R3, R4, and R5 is independently selected from H, halo, (un)substituted C1-6 alkyl, (un)substituted C1-6 alkoxy, cyano, etc., or R2 and R3, or R3 and R4, or R4 and R5 taken together, along with the ring carbons to which they are attached, form a 5- or 6-membered cycloalkyl, heterocyclyl or heteroaryl ring, or a 6-membered aryl ring; Z is (un)substituted NH, O, S, or CH2; and R8 and R9 are independently selected from H, halo, (un)substituted C1-6 alkyl, (un)substituted C1-6 alkoxy, cyano, etc., or R8 and R9 taken together, along with the ring carbons to which they are attached, form a 5- or 6-membered cycloalkyl, heterocyclyl or heteroaryl ring, or a 6-membered aryl ring; including pharmaceutically acceptable salts, esters, amides or prodrugs of these, provided that compound I is not clozapine or N-desmethylozapine. The invention also relates to the preparation of I, preparation of a combinatorial library of compds. I, pharmaceutical compns. containing compound I with a physiol. acceptable carrier, diluent, or excipient, optionally including a neuropsychiatric agent as well as to the use of the

compns. for treating neuropsychiatric disorders. Substitution of 4-chloro-2-fluoronitrobenzene with 2-amino-5-chlorobenzoic acid followed by reduction of the nitro group, ring-closing coupling, and condensation with piperazine gave dibenzodiazepine III. The compds. of the invention express efficacy (eff) at muscarinic M1 receptors in the range of -11 to 92 and potency (expressed as pEC50) of 5.5 to 7.2; the compds. had eff at M2 receptors of -14 to 187 and pEC50 of 5.4 to 6.6.


IT **858670-39-0P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of amino-substituted diarylcycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders)

RN 858670-39-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-bromo-8-chloro-5,10-dihydro- (9CI)  
(CA INDEX NAME)




IT **67104-22-7**

RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; preparation of amino-substituted diarylcycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders)

RN 67104-22-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-2-methoxy- (9CI) (CA INDEX NAME)



L10 ANSWER 5 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2005:76302 CAPLUS  
 DN 142:170068  
 TI Small molecule toll-like receptor (TLR) antagonists  
 IN Lipford, Grayson B.; Forsbach, Alexandra; Zepp, Charles M.  
 PA Coley Pharmaceutical G.m.b.H., Germany; Coley Pharmaceutical Group, Inc.  
 SO PCT Int. Appl., 193 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005007672	A2	20050127	WO 2004-US19714	20040618
	WO 2005007672	A3	20050915		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2005119273	A1	20050602	US 2004-872196	20040618
PRAI	US 2003-480588P	P	20030620		
	US 2004-556007P	P	20040323		

OS MARPAT 142:170068

AB The invention provides methods and compns. useful for modulating signaling through Toll-like receptors (TLR). The methods involve contacting a TLR-expressing cell with a small mol. having a core structure including at least two rings. Certain of the compds. are 4-primary amino quinolines. Many of the compds. and methods are useful specifically for inhibiting immune stimulation involving at least one of TLR9, TLR8, TLR7, and TLR3. The methods may have use in the treatment of autoimmunity, inflammation, allergy, asthma, graft rejection, graft vs. host disease, infection, sepsis, cancer, and immunodeficiency.


IT 16398-16-6

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(small mol. toll-like receptor antagonists such as 4-primary amino quinolines to inhibit immunostimulatory signaling in response to antigens such as nucleic acids for treatment of autoimmune disorders)

RN 16398-16-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-nitro- (8CI, 9CI) (CA INDEX NAME)



10/785,120

L10 ANSWER 6 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:1082026 CAPLUS

DN 142:38288

TI Preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer

IN Hasvold, Lisa A.; Hexamer, Laura; Li, Gaoquan; Lin, Nan-horng; Sham, Hing; Sullivan, Gerard M.; Wang, Le; Xia, Ping

PA USA

SO U.S. Pat. Appl. Publ., 137 pp.



CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004254159	A1	20041216	US 2004-785120	20040225
	CA 2515790	AA	20040910	CA 2004-2515790	20040226
	WO 2004076424	A1	20040910	WO 2004-US5728	20040226
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1606268	A1	20051221	EP 2004-715097	20040226
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2003-450476P	P	20030227		
	US 2003-375412	A	20030227		
	US 2004-785120	A	20040225		
	WO 2004-US5728	W	20040226		
OS	MARPAT 142:38288				
GI					



AB Title heterocycles and analogs I [wherein A1 = CR1, N; A2 = CR8, N; R1, R8 = independently H, alkoxy, (hydroxy)alkyl, amino(alkyl), CN, halo, OH,


NO<sub>2</sub>; R<sub>2</sub>-R<sub>5</sub> = independently H, alkenyl, (alkoxy)alkoxy(alkoxy), (alkoxy)alkyl, alkoxycarbonyl(alkyl), alkylcarbonyl(alkyl), amino(alkoxy), aminoalkyl, aminocarbonyl(alkyl), aminosulfonyl, aryl(alkoxy), aryl(oxy)alkyl, carboxy(alkyl), cyano(alkyl), cycloalkyl(alkyl), halo(alkoxy), haloalkyl, heterocyclyl(alkoxy), heterocyclyl(carbonyl)alkyl, heterocycliloxyalkyl, hydroxy(alkoxy), hydroxyalkyl, nitro(alkyl), carbamoyl(alkyl); one of R<sub>6</sub> and R<sub>7</sub> = H and the other = H, aryl, cycloalkyl, halo, heterocyclyl, XR<sub>13</sub>; R<sub>13</sub> = aryl, cycloalkyl, heterocyclyl; X = O, NR<sub>14</sub>, CO, S, SO<sub>2</sub>, (CH<sub>2</sub>)<sub>n</sub>, CONR<sub>14</sub>, NR<sub>14</sub>CO, SO<sub>2</sub>NR<sub>14</sub>, NR<sub>14</sub>SO<sub>2</sub>, O(CH<sub>2</sub>)<sub>m</sub>, (CH<sub>2</sub>)<sub>m</sub>O, CH=CH, C.tplbond.C; R<sub>14</sub> = H, alkenyl, (amino)alkyl, hydroxyalkyl; Y = NR<sub>15</sub>, O; R<sub>15</sub> = H, alkoxycarbonyl, (cyclo)alkyl, alkylcarbonyl, arylalkyl, cycloalkylalkyl; m = 0-3; n = 1-3; and therapeutically acceptable salts thereof] were prepared as protein kinase inhibitors. For example, N-alkylation of Me 3,4-diaminobenzoate with Me 4-chloro-2-iodobenzoate using Cu and K<sub>2</sub>CO<sub>3</sub> in PhCl gave Me 2-[[2-amino-4-(methoxycarbonyl)phenyl]amino]-4-chlorobenzoate (68%), which was cyclized with 37% HCl in MeOH to provide II (87%). In enzymic assays using recombinant Chk1 kinase domain protein and human cdc25c peptide substrate, compds. of the invention inhibited Chk1 at IC<sub>50</sub> values between about 0.2 nM and about 280 μM. Thus, I and their pharmaceutical compns. are useful for treatment of cancer (no data).

IT **755035-60-0P**, 7-Methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylic acid  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (intermediate, kinase inhibitor; preparation of

dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)

RN 755035-60-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



IT **755026-94-9P 755026-98-3P 755027-01-1P**, 8-(3-Aminophenyl)-3-chloro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-03-3P**, 3-Chloro-8-(3-hydroxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-05-5P**, 3-Chloro-8-(pyridin-3-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-07-7P**, 3-Chloro-8-(1H-pyrrol-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-13-5P**, 3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-33-9P**, 3-(2-Fluoropyridin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-35-1P**, Methyl 3-(2-fluoro-4-pyridinyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylate **755027-36-2P**, 3-(2-Fluoro-4-pyridinyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylic acid **755027-38-4P**, 755028-00-3P **755028-37-6P**, 8-Amino-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-44-5P**, **755028-45-6P**, 3-Chloro-8-(2-oxopyrrolidin-1-yl)-5,10-dihydro-11H-



dibenzo[b,e][1,4]diazepin-11-one **755028-47-8P**  
**755028-48-9P**, 3-Chloro-8-(2-oxopiperidin-1-yl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755028-50-3P**  
**755028-68-3P**, 7-Amino-3-chloro-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755028-80-9P**,  
 3-Chloro-8-(1-hydroxy-1-methylethyl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755028-82-1P**,  
 3-Chloro-8-(1-ethyl-1-hydroxypropyl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755028-96-7P**  
**755028-97-8P 755029-00-6P**, 3-Chloro-8-(2-hydroxyethyl)-  
 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-02-8P**  
**755029-06-2P**, 3-Chloro-8-(2-hydroxy-2-methylpropyl)-5,10-dihydro-  
 11H-dibenzo[b,e][1,4]diazepin-11-one **755029-12-0P**,  
 8-Acetyl-3-chloro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755029-21-1P**, 3-Chloro-8-[2-(pyridin-2-yloxy)ethyl]-5,10-dihydro-  
 11H-dibenzo[b,e][1,4]diazepin-11-one **755029-32-4P**,  
 7-Bromo-3-chloro-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-  
 one **755029-33-5P 755029-35-7P 755029-37-9P**,  
 3-Chloro-7-(3-hydroxy-3-methylbutyl)-8-methoxy-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755029-50-6P**  
**755029-52-8P**, 3-Chloro-8-(3-hydroxy-3-methylbutyl)-5,10-dihydro-  
 11H-dibenzo[b,e][1,4]diazepin-11-one **755029-71-1P**,  
 3-Chloro-8-(3-hydroxypropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-  
 one **755029-73-3P 755029-76-6P 755029-81-3P**  
**755029-98-2P 755030-00-3P**, 3-Chloro-7-(2-hydroxy-2-  
 methylpropyl)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755030-03-6P**, 3-Chloro-7-(2-hydroxyethyl)-8-methoxy-5,10-dihydro-  
 11H-dibenzo[b,e][1,4]diazepin-11-one **755030-05-8P**,  
 3-Chloro-8-methoxy-7-(2-oxopropyl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755030-13-8P**  
**755030-14-9P**, 3-Chloro-7-(2-hydroxy-1,1-dimethylethyl)-8-methoxy-  
 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-22-9P**,  
 7-Bromo-3-chloro-8-(trifluoromethoxy)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755030-24-1P**  
**755030-25-2P 755030-26-3P**, 3-Chloro-7-(3-hydroxypropyl)-  
 8-(trifluoromethoxy)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755030-29-6P**, 3-Chloro-7-(3-hydroxy-3-methylbutyl)-8-  
 (trifluoromethoxy)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755030-41-2P**, 7-Bromo-3-chloro-8-methyl-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755030-43-4P**  
**755030-45-6P 755030-47-8P**, 3-Chloro-7-(3-hydroxy-3-  
 methylbutyl)-8-methyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755030-51-4P**, 3-Chloro-8-[(E)-2-(pyridin-4-yl)ethenyl]-5,10-  
 dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-52-5P**,  
 3-Chloro-8-[2-(pyridin-4-yl)ethyl]-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755030-55-8P**,  
 3-Chloro-8-[(E)-2-(pyridin-2-yl)ethenyl]-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755030-57-0P**,  
 3-Chloro-8-[2-(pyridin-2-yl)ethyl]-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755030-87-6P**  
**755030-88-7P 755030-90-1P 755030-96-7P**  
**755031-23-3P 755031-29-9P 755031-30-2P**  
**755031-40-4P 755031-41-5P**, 3-Chloro-7-(3-hydroxypropyl)-  
 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-44-8P**,  
 3-Chloro-7-(3-hydroxy-3-methylbutyl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755031-46-0P**,  
 3-Chloro-8-(2-hydroxy-1,1-dimethylethyl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755031-48-2P**,  
 3-Chloro-8-(2-hydroxy-1,1,2-trimethylpropyl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755031-50-6P**,  
 3-Chloro-8-(1,1-dimethyl-2-oxopropyl)-5,10-dihydro-11H-


dibenzo[b,e][1,4]diazepin-11-one **755031-59-5P**,  
 3-Chloro-8-[2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755031-63-1P**  
**755031-64-2P**, 3-Chloro-8-[2-[[4-(morpholin-4-  
 yl)phenyl]amino]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755031-72-2P**, 3-Chloro-8-[1,1-dimethyl-2-(pyridin-2-yloxy)ethyl]-  
 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-74-4P**,  
 3-Chloro-8-[1,1-dimethyl-2-(4-nitrophenoxy)ethyl]-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755031-75-5P**,  
 8-[2-(4-Aminophenoxy)-1,1-dimethylethyl]-3-chloro-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755031-76-6P**,  
 3-Chloro-8-[1,1-dimethyl-2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-  
 dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-16-7P**  
**755032-64-5P 755032-66-7P 755032-68-9P**,  
 3-(2-Fluoropyridin-4-yl)-8-[2-(morpholin-4-yl)-2-oxoethyl]-5,10-dihydro-  
 11H-dibenzo[b,e][1,4]diazepin-11-one **755032-70-3P**  
**755033-33-1P**, 3-Chloro-8-methoxy-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755033-42-2P**,  
 3-Chloro-7-(piperidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-  
 one **755033-45-5P**, (S)-3-Chloro-7-[2-(hydroxymethyl)pyrrolidin-1-  
 yl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-47-7P**  
 , 3-Chloro-7-(morpholin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-  
 11-one **755033-51-3P**, 3-Chloro-7-(4-hydroxypiperidin-1-yl)-5,10-  
 dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-62-6P**,  
 3-Chloro-8-(2-ethyl-2-hydroxybutyl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755033-72-8P**  
**755033-85-3P**, 3-Chloro-8-(2-oxopropyl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755033-95-5P**  
**755034-06-1P**, Methyl 3-chloro-11-oxo-10,11-dihydro-5H-  
 dibenzo[b,e][1,4]diazepine-7-carboxylate **755034-10-7P**,  
 3-Chloro-7-(1-hydroxy-1-methylethyl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755034-27-6P**,  
 3-Chloro-8-methoxy-7-[[2-(trimethylsilyl)ethoxy]methoxy]-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755034-28-7P**,  
 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[[2-(trimethylsilyl)ethoxy]methoxy]  
 ]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-36-7P**  
 , 3-Chloro-7-methoxy-8-[[2-(trimethylsilyl)ethoxy]methoxy]-5,10-dihydro-  
 11H-dibenzo[b,e][1,4]diazepin-11-one **755034-37-8P**,  
 7-Methoxy-3-(3-methoxy-4-nitrophenyl)-8-[[2-(trimethylsilyl)ethoxy]methoxy]  
 ]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-66-3P**  
 , 3-Chloro-7-hydroxy-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-  
 11-one **755034-67-4P 755034-68-5P 755034-75-4P**  
 , 3-Chloro-7-ethoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-77-6P**, 3-Chloro-7-hydroxy-5-[[2-  
 (trimethylsilyl)ethoxy]methyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-  
 11-one **755034-78-7P 755034-90-3P**, 3-Chloro-7-  
 (methoxymethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-92-5P**, 7-(Bromomethyl)-3-chloro-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755034-94-7P**,  
 3-Chloro-7-[[2-(dimethylamino)ethyl](methyl)amino]methyl]-5,10-dihydro-  
 11H-dibenzo[b,e][1,4]diazepin-11-one **755034-96-9P**,  
 3-Chloro-7-[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]-5,10-dihydro-  
 11H-dibenzo[b,e][1,4]diazepin-11-one **755034-99-2P**,  
 3-Chloro-8-hydroxy-7-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-  
 one **755035-00-8P 755035-02-0P**, 3-Chloro-7-methoxy-8-  
 vinyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-03-1P**, 3-Chloro-8-ethyl-7-methoxy-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755035-05-3P**  
**755035-06-4P**, 3-Chloro-8-methoxy-7-vinyl-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755035-10-0P**,  
 8-Bromo-3-chloro-7-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-

one **755035-11-1P** **755035-12-2P** **755035-13-3P**,  
 3-Chloro-8-(3-hydroxypropyl)-7-methoxy-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755035-15-5P**,  
 3-Chloro-7-methoxy-8-[3-[(2-methylpyridin-3-yl)oxy]propyl]-5,10-dihydro-  
 11H-dibenzo[b,e][1,4]diazepin-11-one **755035-18-8P**,  
 3-Chloro-7-methoxy-8-[3-[[4-(morpholin-4-yl)phenyl]oxy]propyl]-5,10-  
 dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-24-6P**,  
 Methyl 3-chloro-7-methoxy-11-oxo-10,11-dihydro-5H-  
 dibenzo[b,e][1,4]diazepine-8-carboxylate **755035-41-7P**  
**755035-81-5P**, 3-Chloro-8-[(4-methylpiperazin-1-yl)methyl]-5,10-  
 dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-83-7P**,  
 8-[(4-Methylpiperazin-1-yl)methyl]-3-(4,4,5,5-tetramethyl-1,3,2-  
 dioxaborolan-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-90-6P**, 3-Chloro-8-(hydroxymethyl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755035-97-3P**,  
 3-Chloro-8-(morpholin-4-ylmethyl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)

(intermediate; preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase  
 inhibitors for treatment of cancer)


RN 755026-94-9 CAPLUS

CN Methanesulfonamide, N-(3-chloro-10,11-dihydro-11-oxo-5H-  
 dibenzo[b,e][1,4]diazepin-8-yl)- (9CI) (CA INDEX NAME)



RN 755026-98-3 CAPLUS


CN Acetamide, N-(3-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-  
 yl)- (9CI) (CA INDEX NAME)



RN 755027-01-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(3-aminophenyl)-3-chloro-5,10-  
 dihydro- (9CI) (CA INDEX NAME)

10/785,120




RN 755027-03-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 755027-05-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 755027-07-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(1H-pyrrrol-2-yl)- (9CI) (CA INDEX NAME)



RN 755027-13-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-11-oxo-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755027-16-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- (9CI) (CA INDEX NAME)




RN 755027-33-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(2-fluoro-4-pyridinyl)-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 755027-35-1 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755027-36-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 755027-38-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 3-(2-fluoro-4-pyridinyl)-  
10,11-dihydro-11-oxo-N-[3-(1-pyrrolidinyl)propyl]-, mono(trifluoroacetate)  
(9CI) (CA INDEX NAME)

CM 1

CRN 755027-37-3


CMF C26 H26 F N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 755028-00-3 CAPLUS

CN Carbamic acid, [(1S)-1-[[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-  
5H-dibenzo[b,e][1,4]diazepin-8-yl]amino]carbonyl]-3-methylbutyl]-,  
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/785,120




RN 755028-37-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-5,10-dihydro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- (9CI) (CA INDEX NAME)




RN 755028-44-5 CAPLUS

CN Butanamide, 4-chloro-N-(3-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl)- (9CI) (CA INDEX NAME)



RN 755028-45-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



10/785,120


RN 755028-47-8 CAPLUS

CN Pentanamide, 5-chloro-N-(3-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl)- (9CI) (CA INDEX NAME)




RN 755028-48-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(2-oxo-1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 755028-50-3 CAPLUS

CN Butanamide, 4-chloro-N-[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-68-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-amino-3-chloro-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755028-80-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(1-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)







RN 755028-82-1 CAPLUS  
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-(1-ethyl-1-hydroxypropyl)-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 755028-96-7 CAPLUS  
 CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-chloro-10,11-dihydro- $\alpha,\alpha$ -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755028-97-8 CAPLUS  
 CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-chloro-10,11-dihydro- $\alpha,\alpha$ -dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-00-6 CAPLUS  
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

OCCc1ccc2c(c1)c(=O)[nH]c3cc(Cl)ccc3n2


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro- $\alpha,\alpha$ -dimethyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(2-hydroxy-2-methylpropyl)- (9CI) (CA INDEX NAME)




CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-acetyl-3-chloro-5,10-dihydro-  
(9CI) (CA INDEX NAME)




CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-(2-pyridinyloxy)ethyl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755029-32-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-bromo-3-chloro-5,10-dihydro-8-methoxy- (9CI) (CA INDEX NAME)




RN 755029-33-5 CAPLUS

CN 2-Propenoic acid, 3-(3-chloro-10,11-dihydro-8-methoxy-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl)-, methyl ester (9CI) (CA INDEX NAME)



RN 755029-35-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanoic acid, 3-chloro-10,11-dihydro-8-methoxy-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755029-37-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-8-methoxy- (9CI) (CA INDEX NAME)

10/785,120




RN 755029-50-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 3-chloro-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-52-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(3-hydroxy-3-methylbutyl)- (9CI) (CA INDEX NAME)



RN 755029-71-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(3-hydroxypropyl)- (9CI) (CA INDEX NAME)



RN 755029-73-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 10,11-dihydro-11-oxo-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755029-76-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-81-3 CAPLUS

CN Ethanimidamide, N-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropoxy]- (9CI) (CA INDEX NAME)



RN 755029-98-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetic acid, 3-chloro-10,11-dihydro-8-methoxy-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755030-00-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(2-hydroxy-2-methylpropyl)-8-methoxy- (9CI) (CA INDEX NAME)

10/785,120




RN 755030-03-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(2-hydroxyethyl)-8-methoxy- (9CI) (CA INDEX NAME)




RN 755030-05-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-methoxy-7-(2-oxopropyl)- (9CI) (CA INDEX NAME)



RN 755030-13-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetic acid, 3-chloro-10,11-dihydro-8-methoxy-α,α-dimethyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755030-14-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(2-hydroxy-1,1-dimethylethyl)-8-methoxy- (9CI) (CA INDEX NAME)

10/785,120




RN 755030-22-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-bromo-3-chloro-5,10-dihydro-8-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 755030-24-1 CAPLUS

CN 2-Propenoic acid, 3-[3-chloro-10,11-dihydro-11-oxo-8-(trifluoromethoxy)-5H-dibenzo[b,e][1,4]diazepin-7-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 755030-25-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanoic acid, 3-chloro-10,11-dihydro-11-oxo-8-(trifluoromethoxy)-, methyl ester (9CI) (CA INDEX NAME)



RN 755030-26-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(3-hydroxypropyl)-8-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

10/785,120




RN 755030-29-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-8-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



RN 755030-41-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-bromo-3-chloro-5,10-dihydro-8-methyl- (9CI) (CA INDEX NAME)



RN 755030-43-4 CAPLUS

CN 2-Propenoic acid, 3-(3-chloro-10,11-dihydro-8-methyl-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl)-, methyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 755030-45-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanoic acid, 3-chloro-10,11-dihydro-8-methyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




10/785,120



RN 755030-47-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-8-methyl- (9CI) (CA INDEX NAME)



RN 755030-51-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[(1E)-2-(4-pyridinyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 755030-52-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755030-55-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[(1E)-2-(2-pyridinyl)ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

10/785,120




RN 755030-57-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755030-87-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-chloro-10,11-dihydro-α,α-dimethyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755030-88-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755030-90-1 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 755030-96-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-α,α-dimethyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755031-23-3 CAPLUS

CN Cyclopropanecarboxylic acid, 1-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755031-29-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetic acid, 3-chloro-10,11-dihydro-α,α-dimethyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755031-30-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755031-40-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanoic acid, 3-chloro-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755031-41-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(3-hydroxypropyl)- (9CI) (CA INDEX NAME)




RN 755031-44-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(3-hydroxy-3-methylbutyl)- (9CI) (CA INDEX NAME)




RN 755031-46-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 755031-48-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(2-hydroxy-1,1,2-trimethylpropyl)- (9CI) (CA INDEX NAME)




RN 755031-50-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-(1,1-dimethyl-2-oxopropyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755031-59-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755031-63-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-[[4-methylphenyl)sulfonyl]oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755031-64-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-[[4-(4-morpholinyl)phenyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 755031-72-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-[1,1-dimethyl-2-(2-pyridinyloxy)ethyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755031-74-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-[1,1-dimethyl-2-(4-nitrophenoxy)ethyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755031-75-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-(4-aminophenoxy)-1,1-dimethylethyl]-3-chloro-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755031-76-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-[1,1-dimethyl-2-[4-(4-morpholinyl)phenoxy]ethyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755032-16-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro- $\alpha,\alpha$ -dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)

RN 755032-64-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755032-66-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 755032-68-9 CAPLUS

CN Morpholine, 4-[[3-(2-fluoro-4-pyridinyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-70-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755033-33-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-methoxy- (9CI) (CA INDEX NAME)




RN 755033-42-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(1-piperidinyl)- (9CI) (CA INDEX NAME)




10/785,120



RN 755033-45-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755033-47-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 755033-51-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(4-hydroxy-1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 755033-62-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-(2-ethyl-2-hydroxybutyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755033-72-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-11-oxo-3-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 755033-85-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(2-oxopropyl)- (9CI) (CA INDEX NAME)



RN 755033-95-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-α,α-dimethyl-3-[(2-methyl-4-pyridinyl)amino]-11-oxo- (9CI) (CA INDEX NAME)



RN 755034-06-1 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-carboxylic acid, 3-chloro-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755034-10-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(1-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 755034-27-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-methoxy-7-[[2-(trimethylsilyl)ethoxy]methoxy]- (9CI) (CA INDEX NAME)




RN 755034-28-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[[2-(trimethylsilyl)ethoxy]methoxy]- (9CI) (CA INDEX NAME)




RN 755034-36-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-methoxy-8-[[2-(trimethylsilyl)ethoxy]methoxy]- (9CI) (CA INDEX NAME)




RN 755034-37-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-8-[[2-(trimethylsilyl)ethoxy]methoxy]- (9CI) (CA INDEX NAME)




RN 755034-66-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-hydroxy-8-methoxy- (9CI) (CA INDEX NAME)



RN 755034-67-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-7-[4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]butoxy]-5,10-dihydro-8-methoxy- (9CI) (CA INDEX NAME)



RN 755034-68-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-[4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]butoxy]-5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-methoxy- (9CI) (CA INDEX NAME)

10/785,120




RN 755034-75-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-7-ethoxy-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755034-77-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-hydroxy-5-[[2-(trimethylsilyl)ethoxy]methyl]- (9CI) (CA INDEX NAME)



RN 755034-78-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-7-[4-[[[1,1-dimethylethyl]dimethylsilyl]oxy]butoxy]-5,10-dihydro-5-[[2-(trimethylsilyl)ethoxy]methyl]- (9CI) (CA INDEX NAME)



RN 755034-90-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(methoxymethyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755034-92-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(bromomethyl)-3-chloro-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755034-94-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-7-[[[2-(dimethylamino)ethyl]methylamino]methyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755034-96-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-[[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 755034-99-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-hydroxy-7-methoxy- (9CI) (CA INDEX NAME)




RN 755035-00-8 CAPLUS

CN Methanesulfonic acid, trifluoro-, 3-chloro-10,11-dihydro-7-methoxy-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl ester (9CI) (CA INDEX NAME)




RN 755035-02-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-ethenyl-5,10-dihydro-7-methoxy- (9CI) (CA INDEX NAME)



RN 755035-03-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-ethyl-5,10-dihydro-7-methoxy- (9CI) (CA INDEX NAME)



RN 755035-05-3 CAPLUS


CN Methanesulfonic acid, trifluoro-, 3-chloro-10,11-dihydro-8-methoxy-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755035-06-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-7-ethenyl-5,10-dihydro-8-methoxy- (9CI) (CA INDEX NAME)




RN 755035-10-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-bromo-3-chloro-5,10-dihydro-7-methoxy- (9CI) (CA INDEX NAME)



RN 755035-11-1 CAPLUS


CN 2-Propenoic acid, 3-(3-chloro-10,11-dihydro-7-methoxy-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 755035-12-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 3-chloro-10,11-dihydro-7-methoxy-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)






RN 755035-13-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(3-hydroxypropyl)-7-methoxy- (9CI) (CA INDEX NAME)




RN 755035-15-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-methoxy-8-[(2-methyl-3-pyridinyl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 755035-18-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-methoxy-8-[3-[4-(4-morpholinyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)




RN 755035-24-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 3-chloro-10,11-dihydro-7-methoxy-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755035-41-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanoic acid, 10,11-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755035-81-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 755035-83-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[(4-methyl-1-piperazinyl)methyl]-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- (9CI) (CA INDEX NAME)




RN 755035-90-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(hydroxymethyl)- (9CI) (CA INDEX NAME)



RN 755035-97-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)




IT 755026-34-7P, Methyl 3-chloro-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylate 755026-36-9P, 8-Bromo-3-chloro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755026-38-1P, 3-Chloro-8-nitro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755026-40-5P, 3-Chloro-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carbonitrile 755026-45-0P 755026-53-0P, 3-Bromo-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755026-56-3P, Methyl 3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylate 755026-57-4P, 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylic acid 755026-72-3P 755026-73-4P 755026-74-5P 755027-09-9P 755027-12-4P 755027-23-7P 755027-24-8P 755027-25-9P 755027-41-9P 755027-43-1P 755027-44-2P 755027-96-4P, 8-Amino-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one trifluoroacetate 755028-36-5P 755028-41-2P, 8-Amino-3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755028-51-4P 755028-57-0P 755028-65-0P, 7-Amino-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755028-69-4P 755029-08-4P 755029-13-1P 755029-56-2P 755029-58-4P 755029-69-7P, 8-(2-Hydroxyethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755029-70-0P, 8-(3-Hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755030-02-5P, 7-(2-Hydroxyethyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-18-6P 755032-40-7P 755032-41-8P 755032-44-1P 755032-47-4P 755032-56-5P 755032-58-7P 755033-90-0P 755034-22-1P, 7-Hydroxy-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755034-60-7P, 7-(2-Chloroethoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic)

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(kinase inhibitor; preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)


RN 755026-34-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 3-chloro-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755026-36-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-bromo-3-chloro-5,10-dihydro- (9CI)  
(CA INDEX NAME)




RN 755026-38-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-nitro- (9CI)  
(CA INDEX NAME)



RN 755026-40-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carbonitrile, 3-chloro-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-45-0 CAPLUS


10/785,120

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-chloro-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755026-53-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-bromo-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755026-56-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755026-57-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-72-3 CAPLUS


CN 2-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755026-73-4 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 755026-74-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 755027-09-9 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755027-12-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755027-23-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755027-24-8 CAPLUS

CN Benzoic acid, 4-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-2-methoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 755027-25-9 CAPLUS


CN Benzoic acid, 4-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)



RN 755027-41-9 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(2-fluoro-5-methyl-4-pyridinyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755027-43-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755027-44-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-96-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 755027-95-3

CMF C20 H16 N4 O4




CM 2




10/785,120


CRN 76-05-1  
CMF C2 H F3 O2




RN 755028-36-5 CAPLUS  
CN Benzonitrile, 4-(8-amino-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)



RN 755028-41-2 CAPLUS  
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-3-(4-chloro-3-methoxyphenyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755028-51-4 CAPLUS  
CN 1-Propanesulfonamide, 3-chloro-N-[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-57-0 CAPLUS  
CN 1-Propanesulfonamide, 3-chloro-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-65-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-amino-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755028-69-4 CAPLUS

CN 1-Propanesulfonamide, 3-chloro-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 755029-08-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[(2-chloro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755029-13-1 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[(2-chloro-4-pyridinyl)amino]-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 755029-56-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-58-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-69-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxyethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755029-70-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(3-hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755030-02-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxyethyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-18-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-α,α-dimethyl-11-oxo-3-(4-pyrimidinylamino)-, methyl ester (9CI) (CA INDEX NAME)



RN 755032-40-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-41-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-acetyl-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755032-44-1 CAPLUS

CN Carbamic acid, [1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 755032-47-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-56-5 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 755032-58-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 755033-90-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro- $\alpha,\alpha$ -dimethyl-3-[(2-methyl-4-pyridinyl)amino]-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755034-22-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-hydroxy-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755034-60-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(2-chloroethoxy)-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



IT 755026-42-7P, 3-Chloro-8-(trifluoromethyl)-5,10-dihydro-11H-

dibenzo[b,e][1,4]diazepin-11-one 755026-48-3P,

8-Amino-3-chloro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one

755026-50-7P, 3-Chloro-8-hydroxy-5,10-dihydro-11H-

dibenzo[b,e][1,4]diazepin-11-one 755026-54-1P,

3-(4-Hydroxy-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-

11-one 755026-55-2P 755026-58-5P, 3-(4-Hydroxy-3-

methoxyphenyl)-11-oxo-N-[3-(1-pyrrolidinyl)propyl]-10,11-dihydro-5H-

dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-59-6P**  
**755026-60-9P**, N-[3-(Dimethylamino)propyl]-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-61-0P 755026-62-1P**,  
 3-(4-Hydroxy-3-methoxyphenyl)-N-[3-(4-morpholinyl)propyl]-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-63-2P**  
**755026-64-3P**, 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-65-4P 755026-66-5P**,  
 N-(2-Hydroxyethyl)-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-67-6P**,  
 N-(2,3-Dihydroxypropyl)-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-68-7P**,  
 N-[2-(Acetylamino)ethyl]-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-69-8P**  
 , 3-(4-Hydroxy-3-methoxyphenyl)-8-[(3-hydroxy-1-pyrrolidinyl)carbonyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755026-70-1P**,  
 (S)-3-(4-Hydroxy-3-methoxyphenyl)-8-[[2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755026-71-2P**, 3-(4-Hydroxy-3-methoxyphenyl)-8-[[2-(hydroxymethyl)-1-piperidinyl]carbonyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755026-75-6P**, 3-(4-Hydroxy-3-methoxyphenyl)-8-[(3-hydroxy-1-piperidinyl)carbonyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755026-76-7P**, 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-N-[(3-pyridinyl)methyl]-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-77-8P 755026-78-9P**,  
 3-(4-Hydroxy-3-methoxyphenyl)-N-[4-(methylsulfonyl)benzyl]-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-79-0P**  
 , N-(2-Fluorobenzyl)-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-80-3P**,  
 3-(4-Hydroxy-3-methoxyphenyl)-N-(2-methoxybenzyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-81-4P**,  
 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-N-[(2-pyridinyl)methyl]-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-82-5P**  
**755026-83-6P**, 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-N-[(4-pyridinyl)methyl]-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-84-7P 755026-85-8P**,  
 3-(4-Hydroxy-3-methoxyphenyl)-N-[2-(4-methoxyphenyl)ethyl]-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-86-9P**  
**755026-87-0P 755026-88-1P 755026-89-2P**  
**755026-90-5P**, 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carbonitrile **755026-91-6P**,  
 3-(4-Hydroxy-3-methoxyphenyl)-8-nitro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755026-92-7P**,  
 8-Amino-3-(4-hydroxy-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one hydrochloride **755026-93-8P**  
**755026-95-0P 755026-97-2P 755026-99-4P**  
**755027-00-0P**, 8-(3-Aminophenyl)-3-(4-hydroxy-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-02-2P**,  
 3-(4-Hydroxy-3-methoxyphenyl)-8-(3-hydroxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-04-4P**,  
 3-(4-Hydroxy-3-methoxyphenyl)-8-(pyridin-3-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-06-6P**,  
 3-(4-Hydroxy-3-methoxyphenyl)-8-(1H-pyrrol-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-08-8P**,  
 3-(3-Methoxy-4-nitrophenyl)-8-(1H-pyrrol-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-10-2P**  
**755027-11-3P 755027-14-6P**, 3-(3-Methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-15-7P**,  
 3-(4-Chloro-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-17-9P**, 3-(4-Bromo-3-methoxyphenyl)-5,10-dihydro-11H-

dibenzo[b,e][1,4]diazepin-11-one **755027-19-1P**  
**755027-20-4P**, 3-(4-Acetyl-3-methoxyphenyl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755027-22-6P**  
**755027-26-0P 755027-27-1P 755027-28-2P**  
**755027-29-3P 755027-32-8P**, 3-(2-Methoxypyridin-4-yl)-  
 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-34-0P**,  
 3-(2-Methoxy-4-pyridinyl)-11-oxo-N-[3-(1-pyrrolidinyl)propyl]-10,11-  
 dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755027-39-5P**  
 , 11-Oxo-3-(2-oxo-1,2-dihydro-4-pyridinyl)-N-[3-(1-pyrrolidinyl)propyl]-  
 10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide  
**755027-40-8P 755027-45-3P 755027-46-4P**  
**755027-47-5P**, 8-[2-(3-Hydroxy-1-piperidinyl)-2-oxoethyl]-3-(3-  
 methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755027-48-6P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(4-methyl-1,4-  
 diazepan-1-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-  
 one **755027-50-0P 755027-51-1P**, 8-[2-(4-Hydroxy-1-  
 piperidinyl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755027-52-2P**  
**755027-53-3P 755027-54-4P 755027-55-5P**  
**755027-56-6P 755027-57-7P 755027-58-8P**  
**755027-59-9P 755027-60-2P 755027-61-3P**  
**755027-62-4P 755027-63-5P 755027-66-8P**  
**755027-67-9P 755027-68-0P 755027-69-1P**  
**755027-71-5P 755027-72-6P 755027-73-7P**  
**755027-74-8P 755027-75-9P 755027-76-0P**  
**755027-77-1P 755027-78-2P**, 8-[2-(4-Ethyl-1-piperazinyl)-  
 2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755027-79-3P**,  
 8-[2-[4-(2-Hydroxyethyl)-1-piperazinyl]-2-oxoethyl]-3-(3-methoxy-4-  
 nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755027-80-6P 755027-81-7P**, 3-(3-Methoxy-4-nitrophenyl)-8-  
 [2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755027-82-8P**,  
 3-(3-Methoxy-4-nitrophenyl)-8-[2-oxo-2-[4-(pyridin-2-yl)-1-  
 piperazinyl]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755027-83-9P 755027-84-0P 755027-85-1P**  
**755027-86-2P 755027-87-3P 755027-88-4P**  
**755027-89-5P 755027-90-8P 755027-91-9P**  
**755027-92-0P 755027-93-1P 755027-94-2P**,  
 (S)-8-[2-[2-(Hydroxymethyl)-1-pyrrolidinyl]-2-oxoethyl]-3-(3-methoxy-4-  
 nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755027-95-3P**, 8-Amino-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755027-97-5P**  
**755027-98-6P 755027-99-7P 755028-01-4P**  
**755028-02-5P 755028-03-6P 755028-04-7P**  
**755028-05-8P 755028-06-9P 755028-07-0P**  
**755028-08-1P 755028-09-2P 755028-10-5P**  
**755028-11-6P 755028-12-7P 755028-13-8P**  
**755028-14-9P 755028-15-0P 755028-16-1P**  
**755028-19-4P 755028-21-8P 755028-22-9P**  
**755028-24-1P 755028-25-2P 755028-26-3P**  
**755028-27-4P 755028-28-5P 755028-29-6P**  
**755028-30-9P 755028-31-0P 755028-32-1P**  
**755028-33-2P 755028-34-3P 755028-35-4P**  
**755028-38-7P 755028-39-8P 755028-40-1P**  
**755028-42-3P 755028-43-4P**, 3-(3-Methoxy-4-nitrophenyl)-8-  
 (2-oxopyrrolidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755028-46-7P**, 3-(3-Methoxy-4-nitrophenyl)-8-(2-oxopiperidin-1-yl)-  
 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-49-0P**,  
 3-(4-Chloro-3-methoxyphenyl)-8-(2-oxopyrrolidin-1-yl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755028-52-5P**



**755028-53-6P**, 3-(4-Chloro-3-methoxyphenyl)-8-(1,1-dioxidoisothiazolidin-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755028-54-7P 755028-55-8P 755028-56-9P**  
**755028-58-1P**, 8-(1,1-Dioxidoisothiazolidin-2-yl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755028-59-2P 755028-60-5P 755028-61-6P**  
**755028-62-7P 755028-63-8P 755028-64-9P**  
**755028-70-7P 755028-71-8P 755028-72-9P**  
**755028-73-0P 755028-74-1P 755028-75-2P**  
**755028-76-3P 755028-77-4P 755028-78-5P**  
**755028-79-6P**, 8-(1-Hydroxy-1-methylethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755028-81-0P**, 8-(1-Ethyl-1-hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755028-83-2P**, 8-(1-Hydroxy-1-methylethyl)-3-[(pyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755028-84-3P**, 3-[(2-Chloropyridin-4-yl)amino]-8-(1-hydroxy-1-methylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755028-86-5P**  
**755028-87-6P**, 8-(1-Hydroxy-1-methylethyl)-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755028-88-7P**, 8-(1-Hydroxy-1-methylethyl)-3-[(2,3,5,6-tetrafluoropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755028-89-8P**, 8-(1-Ethyl-1-hydroxypropyl)-3-[(pyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755028-90-1P**, 3-[(2-Aminopyrimidin-4-yl)amino]-8-(1-hydroxy-1-methylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755028-91-2P**, 3-[(2-Chloropyridin-4-yl)amino]-8-(1-ethyl-1-hydroxypropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755028-92-3P**, 8-(1-Hydroxy-1-methylethyl)-3-[(2,3,6-trifluoropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755028-93-4P**, 3-[[2-[(2-Chloropyridin-4-yl)amino]pyridin-4-yl]amino]-8-(1-hydroxy-1-methylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755028-94-5P**  
**755028-95-6P 755028-98-9P 755028-99-0P**, 3-[(2,6-Difluoropyridin-4-yl)amino]-8-(2-hydroxyethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755029-01-7P**  
**755029-03-9P**, 3-[(2,6-Difluoropyridin-4-yl)amino]-7-(morpholin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755029-04-0P**, 7-(Morpholin-4-yl)-3-[(2,3,6-trifluoropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755029-05-1P**, 3-[(2,6-Difluoropyridin-4-yl)amino]-8-(2-hydroxy-2-methylpropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755029-07-3P**  
**755029-09-5P 755029-10-8P**, 3-[(2-Chloropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755029-11-9P**, 8-Acetyl-3-[(2-chloropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755029-14-2P**, 3-[(2-Chloropyridin-4-yl)amino]-8-isopropenyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755029-15-3P**  
**755029-16-4P**, 3-[(2-Chloropyridin-4-yl)amino]-8-(2-hydroxy-2-methylpropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755029-17-5P 755029-18-6P**, 3-[(2-Chloropyridin-4-yl)amino]-8-(2-oxopyrrolidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755029-19-7P**  
**755029-20-0P**, 8-[2-(Pyridin-2-yloxy)ethyl]-3-[(2,3,6-trifluoropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755029-22-2P**, 8-(2-Hydroxy-2-methylpropyl)-3-[(2,3,5-trifluorophenyl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755029-23-3P**, 3-[(3,5-Difluorophenyl)amino]-7-(3-hydroxy-3-methylbutyl)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755029-39-1P**, 7-(3-Hydroxy-3-methylbutyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one


**755029-41-5P**, 3-[(2,6-Difluoropyridin-4-yl)amino]-7-(3-hydroxypropyl)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755029-43-7P**, 3-Chloro-7-(3-hydroxypropyl)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-44-8P**,  
 7-(3-Hydroxypropyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-46-0P**,  
 3-[(2,6-Difluoropyridin-4-yl)amino]-8-(3-hydroxy-3-methylbutyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-54-0P**,  
 8-(3-Hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-60-8P**  
**755029-61-9P 755029-63-1P**, 8-[3-(Azetidin-1-yl)-3-oxopropyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-64-2P**,  
 3-(3-Methoxy-4-nitrophenyl)-8-[3-oxo-3-(pyrrolidin-1-yl)propyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-65-3P**,  
 3-(3-Methoxy-4-nitrophenyl)-8-[3-(morpholin-4-yl)-3-oxopropyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-66-4P**  
**755029-67-5P**, 8-[3-(4-Hydroxypiperidin-1-yl)-3-oxopropyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755029-68-6P 755029-72-2P 755029-74-4P**  
**755029-78-8P**, 3-(4-Chloro-3-methoxyphenyl)-8-(3-hydroxy-3-methylbutyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755029-80-2P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755029-83-5P 755029-85-7P**, 7-(2-Hydroxy-2-methylpropyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-04-7P**,  
 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-(2-oxopropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-06-9P**,  
 7-(2-Hydroxy-1,1-dimethylethyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-15-0P**,  
 7-(3-Hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-8-(trifluoromethoxy)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-28-5P**,  
 7-(3-Hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-8-(trifluoromethoxy)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755030-31-0P**, 7-(3-Hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-8-methyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755030-48-9P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(pyridin-4-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755030-53-6P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(pyridin-2-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755030-60-5P 755030-62-7P 755030-63-8P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(kinase inhibitor; preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)

RN 755026-42-7 CAPIUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(trifluoromethyl)- (9CI) (CA INDEX NAME)



10/785,120


RN 755026-48-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-3-chloro-5,10-dihydro- (9CI)  
(CA INDEX NAME)




RN 755026-50-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-hydroxy- (9CI) (CA INDEX NAME)




RN 755026-54-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 755026-55-2 CAPLUS


CN Benzonitrile, 3-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)- (9CI) (CA INDEX NAME)



RN 755026-58-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755026-59-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-[3-(1-pyrrolidinyl)propyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 755026-58-5


CMF C28 H30 N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 755026-60-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, N-[3-(dimethylamino)propyl]-10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-61-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, N-[3-(dimethylamino)propyl]-10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

10/785,120

CM 1

CRN 755026-60-9


CMF C26 H28 N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 755026-62-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-N-[3-(4-morpholinyl)propyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-63-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-N-[3-(4-morpholinyl)propyl]-11-oxo-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 755026-62-1

CMF C28 H30 N4 O5


10/785,120



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 755026-64-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 755026-65-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 755026-64-3


CMF C28 H28 N4 O5




CM 2

10/785,120


CRN 76-05-1  
CMF C2 H F3 O2




RN 755026-66-5 CAPLUS  
CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-N-(2-hydroxyethyl)-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755026-67-6 CAPLUS  
CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, N-(2,3-dihydroxypropyl)-10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-68-7 CAPLUS  
CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, N-[2-(acetylamino)ethyl]-10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755026-69-8 CAPLUS  
CN 3-Pyrrolidinol, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 755026-70-1 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755026-71-2 CAPLUS

CN 2-Piperidinemethanol, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 755026-75-6 CAPLUS

CN 3-Piperidinol, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 755026-76-7 CAPLUS



10/785,120

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755026-77-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(3-pyridinylmethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 755026-76-7


CMF C27 H22 N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 755026-78-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-N-[[4-(methylsulfonyl)phenyl]methyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755026-79-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, N-[(2-fluorophenyl)methyl]-10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755026-80-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-N-[(2-methoxyphenyl)methyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-81-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 755026-82-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(2-pyridinylmethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

10/785,120

CM 1

CRN 755026-81-4


CMF C27 H22 N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 755026-83-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 755026-84-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(4-pyridinylmethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 755026-83-6

CMF C27 H22 N4 O4


10/785,120



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 755026-85-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-N-[2-(4-methoxyphenyl)ethyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755026-86-9 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 755026-87-0 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 755026-88-1 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI)  
(CA INDEX NAME)




RN 755026-89-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-, 2-[(1,1-dimethylethoxy)carbonyl]hydrazide (9CI) (CA INDEX NAME)



RN 755026-90-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carbonitrile, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-91-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-nitro- (9CI) (CA INDEX NAME)

10/785,120



RN 755026-92-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 755026-93-8 CAPLUS

CN Methanesulfonamide, N-[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755026-95-0 CAPLUS


CN Methanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755026-97-2 CAPLUS


CN Acetamide, N-[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755026-99-4 CAPLUS

CN Acetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755027-00-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(3-aminophenyl)-5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 755027-02-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 755027-04-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-(3-pyridinyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755027-06-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-(1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)




RN 755027-08-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-(1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)



RN 755027-10-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755027-11-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




10/785,120




RN 755027-14-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755027-15-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755027-17-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-bromo-3-methoxyphenyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755027-19-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-bromo-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755027-20-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-acetyl-3-methoxyphenyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755027-22-6 CAPLUS

CN Benzonitrile, 4-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 755027-26-0 CAPLUS

CN Benzanide, 4-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-N-[(3,4-dihydroxyphenyl)methyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 755027-27-1 CAPLUS

CN Benzanide, 4-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-N-[(3,4-dihydroxyphenyl)methyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 755027-28-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(5-methoxy-2-methyl-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755027-29-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-cyano-5-methoxy-2-methylphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755027-32-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(2-methoxy-4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 755027-34-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(2-methoxy-4-pyridinyl)-11-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 755027-39-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 3-(1,2-dihydro-2-oxo-4-methoxy-5-pyridinyl)-10,11-dihydro-11-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 755027-40-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-11-oxo-N-[3-(1-pyrrolidinyl)propyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 755027-39-5


CMF C26 H27 N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 755027-45-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-


10/785,120

nitrophenyl)-11-oxo-N-[3-(1-pyrrolidiny)propyl]- (9CI) (CA INDEX NAME)




RN 755027-46-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-(dimethylamino)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-methyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-47-5 CAPLUS

CN 3-Piperidinol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755027-48-6 CAPLUS


CN 1H-1,4-Diazepine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)



RN 755027-50-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 755027-51-1 CAPLUS

CN 4-Piperidinol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755027-52-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755027-53-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755027-54-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755027-55-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-3-quinolinyl- (9CI) (CA INDEX NAME)




RN 755027-56-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-6-quinolinyl- (9CI) (CA INDEX NAME)



RN 755027-57-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-58-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/785,120



RN 755027-59-9 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[(1R)-1-(hydroxymethyl)-2-methylpropyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



RN 755027-60-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(3-ethoxypropyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-61-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-(diethylamino)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)






RN 755027-62-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[(1R)-1-(hydroxymethyl)-3-methylbutyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 755027-63-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[(1S)-1-(hydroxymethyl)-3-methylbutyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 755027-66-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[3-(1H-imidazol-1-yl)propyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 755027-67-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-(3-hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-68-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[3-(diethylamino)propyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-69-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[(1S)-2-hydroxy-1-phenylethyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755027-71-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[(1R)-2-hydroxy-1-phenylethyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755027-72-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(3,4-difluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-73-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-(4-hydroxybutyl)-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-74-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[1-(phenylmethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)



10/785,120


RN 755027-75-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[4-(dimethylamino)butyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-76-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-77-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-(2-hydroxyethyl)-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-propyl- (9CI) (CA INDEX NAME)



RN 755027-78-2 CAPLUS


CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-4-ethyl- (9CI) (CA INDEX NAME)



RN 755027-79-3 CAPLUS


10/785,120

CN 1-Piperazineethanol, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755027-80-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-methyl-11-oxo-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755027-81-7 CAPLUS

CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 755027-82-8 CAPLUS


CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)



10/785,120


RN 755027-83-9 CAPLUS

CN	5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)
----	--




RN 755027-84-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755027-85-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755027-86-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-(dimethylamino)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-87-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[3-(dimethylamino)propyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-88-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(1-pyrrolidiny)ethyl]- (9CI) (CA INDEX NAME)




RN 755027-89-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(1-piperidiny)ethyl]- (9CI) (CA INDEX NAME)



RN 755027-90-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[3-(1-piperidiny)propyl]- (9CI) (CA INDEX NAME)



RN 755027-91-9 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[2-(4-morpholinyl)ethyl]-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 755027-92-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[3-(4-morpholinyl)propyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-93-1 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[2-(4-methyl-1-piperazinyl)ethyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-94-2 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






10/785,120


RN 755027-95-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755027-97-5 CAPLUS

CN Urea, [10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755027-98-6 CAPLUS


CN Acetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 755027-99-7 CAPLUS


CN Pentanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-(dimethylamino)-4-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755028-01-4 CAPLUS

CN Butanamide, 4-amino-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-02-5 CAPLUS

CN Propanamide, 3-amino-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-03-6 CAPLUS

CN 1H-Imidazole-5-acetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 755028-04-7 CAPLUS

CN 1H-Imidazole-4-acetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-05-8 CAPLUS

CN 3-Thiophenecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-06-9 CAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-07-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 755028-08-1 CAPLUS

CN 4-Thiazolecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-09-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-10-5 CAPLUS

CN 1H-Pyrazole-4-carboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-11-6 CAPLUS


CN 4-Pyridinecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-12-7 CAPLUS


CN 1-Pyrrolidinepropanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-13-8 CAPLUS

CN 1-Piperidinepropanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-14-9 CAPLUS


CN 4-Morpholinepropanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-15-0 CAPLUS

CN Benzenebutamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-α-hydroxy-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755028-16-1 CAPLUS


CN Propanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-

dibenzo[b,e][1,4]diazepin-8-yl]-3-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 755028-19-4 CAPLUS

CN Acetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-[(4-methylphenyl)sulfonyl]amino]- (9CI)  
(CA INDEX NAME)




RN 755028-21-8 CAPLUS

CN 2-Pyridinecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-22-9 CAPLUS


CN 3-Pyridinecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



10/785,120


RN 755028-24-1 CAPLUS

CN 3-Pyridineacetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-25-2 CAPLUS

CN 1-Piperazineacetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-4-methyl- (9CI) (CA INDEX NAME)



RN 755028-26-3 CAPLUS


CN Propanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-3-ethoxy- (9CI) (CA INDEX NAME)



RN 755028-27-4 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-5-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755028-28-5 CAPLUS


CN Cyclohexanecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 755028-29-6 CAPLUS

CN Benzeneacetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- $\alpha$ -methoxy-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755028-30-9 CAPLUS

CN Benzeneacetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- $\alpha$ -methoxy-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 755028-31-0 CAPLUS

CN 2-Furancarboxamide, N-[2-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 755028-32-1 CAPLUS

CN 4-Piperidinecarboxamide, 1-acetyl-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-33-2 CAPLUS


CN Pentanediamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-N'-phenyl- (9CI) (CA INDEX NAME)



RN 755028-34-3 CAPLUS

10/785,120


CN Benzeneacetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 755028-35-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-5-oxo-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755028-38-7 CAPLUS

CN Benzeneacetamide, N-[3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-α-methoxy-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755028-39-8 CAPLUS


CN 1-Piperidinepropanamide, N-[3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-40-1 CAPLUS

CN Methanesulfonamide, N-[3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-42-3 CAPLUS

CN 1-Piperidinepropanamide, N-[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-43-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-(2-oxo-1-pyrrolidiny)- (9CI) (CA INDEX NAME)



RN 755028-46-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-(2-oxo-1-piperidiny)- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-49-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-8-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 755028-52-5 CAPLUS

CN Benzenemesulfonamide, N-[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-53-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-8-(1,1-dioxido-2-isothiazolidinyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755028-54-7 CAPLUS

CN Ethanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)




RN 755028-55-8 CAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 755028-56-9 CAPLUS

CN Benzenemethanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-58-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(1,1-dioxido-2-isothiazolidinyl)-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755028-59-2 CAPLUS


CN 4-Morpholinepropanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-60-5 CAPLUS

CN 1-Piperidinepropanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-61-6 CAPLUS

CN 1-Propanesulfonamide, 3-(diethylamino)-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-62-7 CAPLUS


CN 1-Propanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-3-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 755028-63-8 CAPLUS


CN Methanesulfonamide, 1-chloro-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-64-9 CAPLUS

CN Benzanide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 755028-70-7 CAPLUS

CN Benzenemethanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755028-71-8 CAPLUS

CN Benzenemethanesulfonamide, 4-chloro-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755028-72-9 CAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 755028-73-0 CAPLUS

CN Methanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755028-74-1 CAPLUS

CN 4-Morpholinepropanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 755028-75-2 CAPLUS


CN 1-Piperidinepropanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 755028-76-3 CAPLUS


CN 1-Propanesulfonamide, 3-(diethylamino)-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)






RN 755028-77-4 CAPLUS

CN 1-Propanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]-3-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 755028-78-5 CAPLUS

CN 2H-Pyran-4-carboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]tetrahydro- (9CI) (CA INDEX NAME)



RN 755028-79-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(1-hydroxy-1-methylethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755028-81-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(1-ethyl-1-hydroxypropyl)-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-83-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(1-hydroxy-1-methylethyl)-3-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 755028-84-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(1-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 755028-86-5 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[[[10,11-dihydro-8-(1-hydroxy-1-methylethyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl]amino]- (9CI) (CA INDEX NAME)




RN 755028-87-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(1-hydroxy-1-methylethyl)-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755028-88-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(1-hydroxy-1-methylethyl)-3-[(2,3,5,6-tetrafluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755028-89-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(1-ethyl-1-hydroxypropyl)-5,10-dihydro-3-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 755028-90-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-amino-4-pyrimidinyl)amino]-5,10-dihydro-8-(1-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)



RN 755028-91-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-8-(1-ethyl-1-hydroxypropyl)-5,10-dihydro- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-92-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(1-hydroxy-1-methylethyl)-3-[(2,3,6-trifluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755028-93-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[[2-[(2-chloro-4-pyridinyl)amino]-4-pyridinyl]amino]-5,10-dihydro-8-(1-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 755028-94-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-α,α-dimethyl-11-oxo-3-[(2,3,6-trifluoro-4-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 755028-95-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo-3-[(2,3,6-trifluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755028-98-9 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro- $\alpha,\alpha$ -dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)

RN 755028-99-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 755029-01-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro- $\alpha,\alpha$ -dimethyl-11-oxo- (9CI) (CA INDEX NAME)

RN 755029-03-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755029-04-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-morpholinyl)-3-[(2,3,6-trifluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755029-05-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxy-2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 755029-07-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-11-oxo-3-(4-pyridinylamino)-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-09-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-[(2-methyl-4-pyridinyl)amino]-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-10-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755029-11-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-acetyl-3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755029-14-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(1-methylethenyl)- (9CI) (CA INDEX NAME)




RN 755029-15-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2-chloro-4-pyridinyl)amino]-10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-16-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxy-2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 755029-17-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2-chloro-4-pyridinyl)amino]-10,11-dihydro-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755029-18-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 755029-19-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetic acid, 3-[(2-chloro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)






RN 755029-20-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[2-(2-pyridinyloxy)ethyl]-3-[(2,3,6-trifluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755029-22-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-2-methylpropyl)-3-[(2,3,5-trifluorophenyl)amino]- (9CI) (CA INDEX NAME)




RN 755029-23-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(3,5-difluorophenyl)amino]-5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-8-methoxy- (9CI) (CA INDEX NAME)




RN 755029-39-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755029-41-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-7-(3-hydroxypropyl)-8-methoxy- (9CI) (CA INDEX NAME)




RN 755029-43-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(3-hydroxypropyl)-8-methoxy- (9CI) (CA INDEX NAME)




RN 755029-44-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxypropyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755029-46-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-(3-hydroxy-3-methylbutyl)- (9CI) (CA INDEX NAME)




RN 755029-54-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(3-hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755029-60-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-61-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-63-1 CAPLUS

CN Azetidine, 1-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755029-64-2 CAPLUS

CN Pyrrolidine, 1-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755029-65-3 CAPLUS

CN Morpholine, 4-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755029-66-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, N,N-diethyl-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-67-5 CAPLUS

CN 4-Piperidinol, 1-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755029-68-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-2-thiazolyl- (9CI) (CA INDEX NAME)




RN 755029-72-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755029-74-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755029-78-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-8-(3-hydroxy-3-methylbutyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755029-80-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 755029-83-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanoic acid, 10,11-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-85-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxy-2-methylpropyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755030-04-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-(2-oxopropyl)- (9CI) (CA INDEX NAME)




RN 755030-06-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxy-1,1-dimethylethyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755030-15-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-8-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



RN 755030-28-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-8-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



RN 755030-31-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-8-methyl- (9CI) (CA INDEX NAME)

10/785,120




RN 755030-48-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755030-53-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 755030-60-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(2-oxo-1(2H)-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 755030-62-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-(5-fluoro-2-oxo-1(2H)-pyridinyl)ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)





RN 755030-63-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(6-oxo-1(6H)-pyridazinyl)ethyl]- (9CI) (CA INDEX NAME)



IT 755030-65-0P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(pyridin-2-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
 755030-66-1P, 8-[2-[(5-Chloropyridin-3-yl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
 755030-67-2P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-[(pyridin-3-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
 755030-69-4P 755030-71-8P 755030-73-0P  
 755030-75-2P 755030-77-4P 755030-80-9P  
 755030-91-2P 755030-97-8P 755030-99-0P  
 755031-01-7P 755031-03-9P 755031-05-1P  
 755031-07-3P 755031-10-8P 755031-12-0P  
 755031-15-3P 755031-16-4P 755031-17-5P  
 755031-19-7P 755031-20-0P 755031-24-4P  
 755031-31-3P 755031-33-5P 755031-35-7P  
 755031-36-8P, 7-(3-Hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-43-7P,  
 7-(3-Hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-45-9P,  
 8-(2-Hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-47-1P,  
 8-(2-Hydroxy-1,1,2-trimethylpropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-49-3P,  
 8-(1,1-Dimethyl-2-oxopropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-51-7P,  
 7-(2-Hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-52-8P,  
 8-[1-(Hydroxymethyl)cyclopropyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-53-9P,  
 3-[(2-Chloropyridin-4-yl)amino]-8-(2-hydroxy-1,1-dimethylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-54-0P,  
 3-[(2,6-Difluoropyridin-4-yl)amino]-8-(2-hydroxy-1,1-dimethylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-55-1P,  
 3-[(2,6-Difluoropyridin-4-yl)amino]-8-(2-hydroxy-1,1,2-trimethylpropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-57-3P,  
 3-(4-Chloro-3-methoxyphenyl)-8-(2-hydroxy-1,1-dimethylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-58-4P,

3-(3-Methoxy-4-nitrophenyl)-8-[2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-60-8P**,  
 3-(4-Chloro-3-methoxyphenyl)-8-[2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-61-9P**  
**755031-62-0P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[[4-(morpholin-4-yl)phenyl]amino]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755031-65-3P 755031-67-5P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[[5-methylpyridin-2-yl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-68-6P**  
**755031-69-7P**, 8-[2-(Isoquinolin-3-yloxy)ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755031-70-0P 755031-71-1P**, 8-[1,1-Dimethyl-2-(pyridin-2-yloxy)ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-73-3P**,  
 8-[1,1-Dimethyl-2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755031-77-7P 755031-78-8P**, 8-(2-Hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)-7-methyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-79-9P**  
**755031-87-9P 755031-89-1P 755031-91-5P**, 8-(2-Hydroxy-1,1-dimethylethyl)-3-[(2-methylpyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-92-6P**,  
 8-(2-Hydroxy-1,1,2-trimethylpropyl)-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-93-7P**  
**755031-94-8P 755031-95-9P 755031-96-0P**  
**755031-97-1P 755031-98-2P 755031-99-3P**  
**755032-00-9P 755032-01-0P 755032-02-1P**  
**755032-03-2P 755032-04-3P 755032-05-4P**  
**755032-06-5P 755032-07-6P 755032-08-7P**  
**755032-09-8P 755032-10-1P 755032-11-2P**  
**755032-12-3P 755032-13-4P 755032-14-5P**  
**755032-15-6P 755032-17-8P 755032-18-9P**,  
 8-[1,1-Dimethyl-2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755032-19-0P 755032-20-3P**, 8-[1,1-Dimethyl-2-(morpholin-4-yl)-2-oxoethyl]-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-21-4P**  
**755032-22-5P 755032-23-6P 755032-24-7P**  
**755032-25-8P 755032-26-9P 755032-27-0P**  
**755032-28-1P 755032-29-2P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(quinolin-2-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-30-5P 755032-31-6P 755032-32-7P**  
**755032-33-8P 755032-34-9P 755032-35-0P**,  
 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(4-methylpyridin-2-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-36-1P**,  
 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(3-methoxypyridin-2-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-37-2P**  
**755032-38-3P**, 8-[2-[(6-Chloropyridin-2-yl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755032-39-4P**, 8-[2-[(5-Chloropyridin-2-yl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755032-42-9P 755032-43-0P 755032-45-2P**,  
 8-[2-(3-Aminopyrrolidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-46-3P**,  
 8-[2-(3-Aminopyrrolidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one trifluoroacetate  
**755032-48-5P 755032-49-6P**, (S)-8-[2-2-(Hydroxymethyl)pyrrolidin-1-yl]-2-oxoethyl]-3-(2-methoxy-5-methylpyridin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-50-9P**  
**755032-51-0P 755032-52-1P 755032-53-2P**,  
 3-(4-Chloro-3-methoxyphenyl)-8-[2-(3-hydroxypiperidin-1-yl)-2-oxoethyl]-

5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-54-3P**,  
 (S)-3-(4-Chloro-3-methoxyphenyl)-8-[2-(2-(hydroxymethyl)pyrrolidin-1-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755032-55-4P 755032-57-6P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-oxo-2-(piperazin-1-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-59-8P 755032-60-1P 755032-61-2P**,  
 3-(3-Methoxy-4-nitrophenyl)-8-[2-(morpholin-4-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-62-3P**,  
 3-(2-Methoxy-5-methylpyridin-4-yl)-8-[2-(morpholin-4-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-63-4P**  
**755032-65-6P 755032-67-8P**, 8-[2-(Morpholin-4-yl)-2-oxoethyl]-3-(2-oxo-1,2-dihydropyridin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-69-0P**  
**755032-71-4P 755032-75-8P**, 3-(3-Methoxy-4-nitrophenyl)-7-[2-(morpholin-4-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-76-9P 755032-77-0P 755032-78-1P**  
**755032-79-2P**, 7-[2-(4-Hydroxypiperidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755032-80-5P**, 7-[2-(3-Hydroxypiperidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755032-81-6P 755032-82-7P 755032-83-8P**  
**755032-84-9P**, 7-[2-(Azetidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755032-85-0P 755032-86-1P 755032-87-2P**,  
 (R)-7-[2-[2-(Hydroxymethyl)pyrrolidin-1-yl]-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755032-88-3P 755032-89-4P 755032-90-7P**  
**755032-91-8P 755032-92-9P**, (S)-7-[2-[2-(Hydroxymethyl)pyrrolidin-1-yl]-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-93-0P**,  
 7-[2-(3-Aminopyrrolidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-94-1P**,  
 3-(3-Methoxy-4-nitrophenyl)-7-[2-oxo-2-(piperazin-1-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-95-2P**  
**755032-96-3P 755032-97-4P 755032-99-6P**  
**755033-01-3P**, 3-(3-Methoxy-4-nitrophenyl)-7-[2-oxo-2-(4-thiomorpholinyl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755033-03-5P 755033-04-6P 755033-05-7P**  
**755033-06-8P 755033-07-9P 755033-08-0P**  
**755033-09-1P 755033-10-4P**, 7-[2-(1,4-Dioxo-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-11-5P**,  
 7-[2-(2,6-Dimethylmorpholin-4-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-12-6P**,  
 7-[2-(4-Acetylpiperazin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-13-7P**,  
 3-(3-Methoxy-4-nitrophenyl)-7-[2-oxo-2-[4-(pyridin-2-yl)piperazin-1-yl]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755033-14-8P 755033-15-9P 755033-16-0P**  
**755033-17-1P 755033-18-2P 755033-19-3P**  
**755033-20-6P 755033-21-7P 755033-22-8P**  
**755033-23-9P 755033-24-0P 755033-25-1P**  
**755033-26-2P 755033-27-3P 755033-28-4P**  
**755033-29-5P**, 8-Hydroxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-30-8P**,  
 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-34-2P**,  
 8-Ethoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-35-3P**,  
 3-(3-Methoxy-4-nitrophenyl)-8-[2-(4-methyl-1,3-thiazol-5-yl)ethoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-37-5P**,


8-[3-(Dimethylamino)propoxy]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-38-6P**,  
 3-(3-Methoxy-4-nitrophenyl)-8-[2-(morpholin-4-yl)ethoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-39-7P**,  
 3-(3-Methoxy-4-nitrophenyl)-8-[2-[4-(morpholin-4-yl)phenyl]ethoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-41-1P**,  
 3-(3-Methoxy-4-nitrophenyl)-7-(piperidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-43-3P**,  
 (S)-7-[2-(Hydroxymethyl)pyrrolidin-1-yl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-46-6P**,  
 3-(3-Methoxy-4-nitrophenyl)-7-(morpholin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-48-8P**,  
 7-(4-Hydroxypiperidin-1-yl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-54-6P**  
**755033-59-1P**, 8-(2-Ethyl-2-hydroxybutyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755033-65-9P**, 3-[(2-Chloropyridin-4-yl)amino]-8-(2-ethyl-2-hydroxybutyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755033-68-2P 755033-75-1P 755033-79-5P**,  
 8-(2-Hydroxy-2-methylpropyl)-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-81-9P**,  
 8-(2-Hydroxy-2-methylpropyl)-3-[(2-methylpyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-83-1P**,  
 3-(3-Methoxy-4-nitrophenyl)-8-(2-oxopropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-87-5P**,  
 3-[(2-Chloropyridin-4-yl)amino]-8-(2-oxopropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-89-7P**,  
 3-[[2-[(2-Chloropyridin-4-yl)amino]pyridin-4-yl]amino]-8-(2-oxopropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-92-2P**  
**755033-93-3P 755033-96-6P**, 3-[[3-(2-Hydroxyethyl)pyridin-4-yl]amino]-8-(1-hydroxy-1-methylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-00-5P**,  
 8-(2-Hydroxy-2-methylpropyl)-3-[(2-methoxypyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-02-7P**, Methyl  
 11-oxo-3-(pyrimidin-4-ylamino)-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-7-carboxylate **755034-08-3P**, 7-(1-Hydroxy-1-methylethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-11-8P**, 7-(1-Hydroxy-1-methylethyl)-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-12-9P 755034-14-1P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[[6-(morpholin-4-yl)pyridin-3-yl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-18-5P**,  
 3-(4-Hydroxy-3-methoxyphenyl)-8-[2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-20-9P**,  
 3-[(2,6-Difluoropyridin-4-yl)amino]-8-[2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-29-8P**, 8-Hydroxy-7-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-38-9P**,  
 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(tetrahydro-2H-pyran-2-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-39-0P**, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(1-methylpiperidin-3-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-40-3P**, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(pyridin-2-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-41-4P**, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(pyridin-3-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-42-5P**, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(pyridin-4-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-43-6P 755034-44-7P 755034-45-8P**,  
 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2-methyl-1,3-thiazol-4-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one

**755034-46-9P**, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2-oxo-1,3-oxazolidin-5-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-48-1P**, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(tetrahydrofuran-2-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-49-2P**, 7-[(2,2-Dimethyl-1,3-dioxolan-4-yl)methoxy]-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-50-5P**, (R)-8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(pyrrolidin-2-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-51-6P**  
**755034-52-7P**, 7,8-Dimethoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-53-8P**, 8-Methoxy-7-[2-(2-methoxyethoxy)ethoxy]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-54-9P**, 7-(2,3-Dihydroxypropoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-55-0P**, 7-[3-Hydroxy-2,2-bis(hydroxymethyl)propoxy]-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-56-1P** **755034-57-2P**, 7-(3-Aminopropoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-58-3P**, 7-(3-Aminopropoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one trifluoroacetate **755034-59-4P**, 7-[2-(Dimethylamino)ethoxy]-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-61-8P**, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-(pyrrolidin-1-yl)ethoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-63-0P**, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-(morpholin-4-yl)ethoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-64-1P**, 7-(4-Hydroxybutoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-65-2P**, 7-(4-Hydroxybutoxy)-3-(4-hydroxy-3-methoxyphenyl)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-69-6P**, 7-(4-Hydroxybutoxy)-8-methoxy-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(kinase inhibitor; preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)


RN 755030-65-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(2-pyridinyloxy)ethyl]- (9CI) (CA INDEX NAME)




RN 755030-66-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(5-chloro-3-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755030-67-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-(3-pyridinyloxy)ethyl]- (9CI) (CA INDEX NAME)




RN 755030-69-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(5-isoquinolinyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755030-71-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(8-nitro-5-isoquinolinyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



10/785,120


RN 755030-73-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 3-(4-formyl-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755030-75-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 10,11-dihydro-3-[4-(hydroxymethyl)-3-methoxyphenyl]-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755030-77-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 10,11-dihydro-3-[3-methoxy-4-(1-oxopropyl)phenyl]-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755030-80-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755030-91-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(4-cyano-3-methoxyphenyl)-

10/785,120


10,11-dihydro- $\alpha,\alpha$ -dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo-  
(9CI) (CA INDEX NAME)



RN 755030-97-8 CAPLUS  
CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(4-chloro-3-methoxyphenyl)-  
10,11-dihydro- $\alpha,\alpha$ -dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo-  
(9CI) (CA INDEX NAME)




RN 755030-99-0 CAPLUS  
CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-  
nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-N-2-pyridinyl- (9CI) (CA  
INDEX NAME)




RN 755031-01-7 CAPLUS  
CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-  
nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-N-3-pyridinyl- (9CI) (CA  
INDEX NAME)






RN 755031-03-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 755031-05-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 755031-07-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-[(tetrahydro-3-furanyl)methyl]- (9CI) (CA INDEX NAME)



10/785,120


RN 755031-10-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-N-2-thiazolyl- (9CI) (CA INDEX NAME)




RN 755031-12-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-N-[[6-(trifluoromethyl)-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)




RN 755031-15-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(4-fluorophenyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755031-16-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(2,5-difluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755031-17-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro- $\alpha,\alpha$ -dimethyl-11-oxo-3-(4-pyrimidinylamino)-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 755031-19-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro- $\alpha,\alpha$ -dimethyl-11-oxo-3-(4-pyrimidinylamino)-N-[[3-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 755031-20-0 CAPLUS

CN Cyclopropanecarboxamide, 1-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 755031-24-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755031-31-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755031-33-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 755031-35-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(cyclopropylmethyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI)  
(CA INDEX NAME)




RN 755031-36-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755031-43-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755031-45-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755031-47-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-1,1,2-trimethylpropyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-49-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(1,1-dimethyl-2-oxopropyl)-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-51-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-52-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[1-(hydroxymethyl)cyclopropyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-53-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 755031-54-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 755031-55-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxy-1,1,2-trimethylpropyl)- (9CI) (CA INDEX NAME)



RN 755031-57-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755031-58-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755031-60-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 755031-61-9 CAPLUS


CN Benzonitrile, 4-[10,11-dihydro-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 755031-62-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[[4-(4-morpholinyl)phenyl]amino]ethyl]- (9CI) (CA INDEX NAME)






RN 755031-65-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-methyl-2-oxo-1(2H)-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755031-67-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(5-methyl-2-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755031-68-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(4-methyl-2-oxo-1(2H)-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755031-69-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[2-(3-isoquinolinyl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-70-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-(5-chloro-2-oxo-1(2H)-pyridinyl)ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-71-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[1,1-dimethyl-2-(2-pyridinyloxy)ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755031-73-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[1,1-dimethyl-2-[4-(4-morpholinyl)phenoxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755031-77-7 CAPLUS


10/785,120

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 755031-78-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)-7-methyl- (9CI) (CA INDEX NAME)




RN 755031-79-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-2-methyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755031-87-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[4-(aminomethyl)-3-methoxyphenyl]-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755031-89-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(2-methoxy-5-

10/785,120


methyl-4-pyridinyl)- $\alpha,\alpha$ -dimethyl-N-[4-(4-morpholinyl)phenyl]-  
11-oxo-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 755031-91-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)-3-[(2-methyl-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755031-92-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-1,1,2-trimethylpropyl)-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755031-93-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-methyl-11-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 755031-94-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)


RN 755031-95-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)

RN 755031-96-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-N-(4-methyl-2-thiazolyl)-11-oxo- (9CI) (CA INDEX NAME)


RN 755031-97-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

10/785,120


RN 755031-98-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(3-fluorophenyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo- (9CI)  
(CA INDEX NAME)




RN 755031-99-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-N-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 755032-00-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 755032-01-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-N-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 755032-02-1 CAPLUS


10/785,120

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-03-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(2-fluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-04-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(3-fluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-05-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(4-fluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo- (9CI) (CA INDEX NAME)



10/785,120


RN 755032-06-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-N-[[4-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 755032-07-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 755032-08-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 755032-09-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-N-[[3-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)






10/785,120


RN 755032-10-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-(2-fluorophenyl)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-(9CI) (CA INDEX NAME)




RN 755032-11-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-(3-fluorophenyl)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-(9CI) (CA INDEX NAME)




RN 755032-12-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(2,4-difluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-(9CI) (CA INDEX NAME)




RN 755032-13-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(2,6-difluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-(9CI) (CA INDEX NAME)




RN 755032-14-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(cyclopropylmethyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI)  
(CA INDEX NAME)




RN 755032-15-6 CAPLUS .

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(3-ethoxypropyl)-10,11-dihydro-α,α-dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755032-17-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(3,4-difluorophenyl)methyl]-10,11-dihydro-α,α-dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755032-18-9 CAPLUS


CN Piperazine, 1-[2-[10,11-dihydro-11-oxo-3-(4-pyrimidinylamino)-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 755032-19-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-cyclopentyl-10,11-dihydro-  
α,α-dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX  
NAME)

RN 755032-20-3 CAPLUS


CN Morpholine, 4-[2-[10,11-dihydro-11-oxo-3-(4-pyrimidinylamino)-5H-  
dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX  
NAME)

RN 755032-21-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-α,α-  
dimethyl-11-oxo-3-(4-pyrimidinylamino)-N-[(tetrahydro-3-furanyl)methyl]-  
(9CI) (CA INDEX NAME)


RN 755032-22-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(cyclopentylmethyl)-10,11-  
dihydro-α,α-dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA  
INDEX NAME)




RN 755032-23-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(cyclopropylmethyl)-10,11-dihydro- $\alpha,\alpha$ -dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755032-24-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro- $\alpha,\alpha$ -dimethyl-11-oxo-3-(4-pyrimidinylamino)-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 755032-25-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro- $\alpha,\alpha$ -dimethyl-11-oxo-3-(4-pyrimidinylamino)-N-2-thiazolyl- (9CI) (CA INDEX NAME)




RN 755032-26-9 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[(2,5-difluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-27-0 CAPLUS  
 CN 5H-Dibenzo[b,e][1,4]diazepine-7-  
 3-(3-methoxy-4-nitrophenyl)-α,α-  
 INDEX NAME)




RN 755032-28-1 CAPLUS  
 CN 5H-Dibenzo[b,e][1,4]diazepine-7-  
 dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-  
 (CA INDEX NAME)




RN 755032-29-2 CAPLUS  
 CN 11H-Dibenzo[b,e][1,4]diazepin-11  
 nitrophenyl)-8-[2-(2-quinolinyl)ethoxy]




RN 755032-30-5 CAPLUS  
 CN 11H-Dibenzo[b,e][1,4]diazepin-11




acetamide, N-(4-fluorophenyl)-10,11-  
 yl)- $\alpha,\alpha$ -dimethyl-11-oxo- (9CI)



-one, 5,10-dihydro-3-(3-methoxy-4-  
 oxy)ethyl]- (9CI) (CA INDEX NAME)




-one, 5,10-dihydro-3-(3-methoxy-4-



acetamide, N-(2-ethoxyethyl)-10,11-dihydro-  
 dimethyl-11-oxo- (9CI) (CA


10/785,120

nitrophenyl)-8-[2-(5-methyl-2-oxo-1(2H)-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755032-31-6 CAPLUS

CN 3-Pyridinecarbonitrile, 2-[2-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]ethoxy]-6-methyl- (9CI) (CA INDEX NAME)




RN 755032-32-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(1-oxo-2(1H)-isoquinolinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 755032-33-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[2-oxo-5-(trifluoromethyl)-1(2H)-pyridinyl]ethyl]- (9CI) (CA INDEX NAME)



10/785,120


RN 755032-34-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-methoxy-2-oxo-1(2H)-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755032-35-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(4-methyl-2-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755032-36-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(3-methoxy-2-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 755032-37-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-oxo-2(3H)-isoquinolinyl)ethyl]- (9CI) (CA INDEX NAME)






10/785,120


RN 755032-38-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(6-chloro-2-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755032-39-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(5-chloro-2-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755032-42-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-acetyl-3-methoxyphenyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-43-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-45-2 CAPLUS

CN 3-Pyrrolidinamine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-

10/785,120

dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-46-3 CAPLUS

CN 3-Pyrrolidinamine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 755032-45-2


CMF C26 H25 N5 O5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 755032-48-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




10/785,120

RN 755032-49-6 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[[10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-, (2S)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 755032-50-9 CAPLUS

CN Carbamic acid, [1-[[[10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 755032-51-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-52-1 CAPLUS


CN Carbamic acid, [1-[[[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/785,120



RN 755032-53-2 CAPLUS


CN 3-Piperidinol, 1-[[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755032-54-3 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755032-55-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-57-6 CAPLUS


10/785,120

CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-59-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-60-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-methyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-61-2 CAPLUS


CN Morpholine, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755032-62-3 CAPLUS


CN Morpholine, 4-[[10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755032-63-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-65-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-67-8 CAPLUS

CN Morpholine, 4-[[3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-69-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-71-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755032-75-8 CAPLUS

CN Morpholine, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-76-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-2-pyridinyl- (9CI) (CA INDEX NAME)




RN 755032-77-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 755032-78-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 755032-79-2 CAPLUS

CN 4-Piperidinol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755032-80-5 CAPLUS


CN 3-Piperidinol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755032-81-6 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)






RN 755032-82-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755032-83-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 755032-84-9 CAPLUS


CN Azetidine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755032-85-0 CAPLUS


10/785,120

CN 3-Piperidinecarboxamide, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755032-86-1 CAPLUS


CN 4-Piperidinecarboxamide, 1-[[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755032-87-2 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755032-88-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)

10/785,120



RN 755032-89-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N,N-bis(2-methoxyethyl)-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-90-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[[ (2S)-tetrahydro-2-furanyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755032-91-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(2-propoxyethyl)- (9CI) (CA INDEX NAME)




10/785,120

RN 755032-92-9 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755032-93-0 CAPLUS

CN 3-Pyrrolidinamine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-94-1 CAPLUS

CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-95-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-(3-methoxypropyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-96-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(cyanomethyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-97-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(cyclopropylmethyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-99-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(1,3-dioxolan-2-ylmethyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-methyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-01-3 CAPLUS

CN Thiomorpholine, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755033-03-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755033-04-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 755033-05-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[2-(2,3-dimethoxyphenyl)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-06-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[2-(1,3-benzodioxol-5-


10/785,120

yl)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-07-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 755033-08-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(5-thiazolylmethyl)- (9CI) (CA INDEX NAME)




RN 755033-09-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[2-(1H-imidazol-4-yl)ethyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-10-4 CAPLUS

CN 1,4-Dioxa-8-azaspiro[4.5]decane, 8-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755033-11-5 CAPLUS

CN Morpholine, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]-2,6-dimethyl- (9CI) (CA INDEX NAME)




RN 755033-12-6 CAPLUS

CN Piperazine, 1-acetyl-4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755033-13-7 CAPLUS

CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 755033-14-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[3-(aminocarbonyl)phenyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




10/785,120




RN 755033-15-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755033-16-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-6-quinolinyl- (9CI) (CA INDEX NAME)



RN 755033-17-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/785,120

RN 755033-18-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[(1S)-1-(aminocarbonyl)-3-methylbutyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755033-19-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[(1S)-2-hydroxy-1-phenylethyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755033-20-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(2,3-dihydroxypropyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-21-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[3-(1H-imidazol-1-yl)propyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-22-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 755033-23-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[(2,6-difluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755033-24-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-25-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[(1R)-1-(hydroxymethyl)-2-methylpropyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

10/785,120


Absolute stereochemistry.



RN 755033-26-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[(1R)-2-hydroxy-1-phenylethyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755033-27-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(3-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 755033-28-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[4-(aminocarbonyl)-3-methoxyphenyl]-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755033-29-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-hydroxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755033-30-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755033-34-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-ethoxy-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755033-35-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(4-methyl-5-thiazolyl)ethoxy]- (9CI) (CA INDEX NAME)

10/785,120




RN 755033-37-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[3-(dimethylamino)propoxy]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755033-38-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 755033-39-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[4-(4-morpholinyl)phenyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 755033-41-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-7-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 755033-43-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755033-46-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 755033-48-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxy-1-piperidinyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755033-54-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-[3-methoxy-4-


10/785,120

(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755033-59-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(2-ethyl-2-hydroxybutyl)-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755033-65-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-8-(2-ethyl-2-hydroxybutyl)-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 755033-68-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N,N-dimethyl-11-oxo-3-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 755033-75-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo-3-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




10/785,120




RN 755033-79-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-2-methylpropyl)-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755033-81-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-2-methylpropyl)-3-[(2-methyl-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)



RN 755033-83-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-(2-oxopropyl)- (9CI) (CA INDEX NAME)



RN 755033-87-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(2-oxopropyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755033-89-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[[2-[(2-chloro-4-pyridinyl)amino]-4-pyridinyl]amino]-5,10-dihydro-8-(2-oxopropyl)- (9CI) (CA INDEX NAME)




RN 755033-92-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)



RN 755033-93-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-α,α-dimethyl-3-[(2-methyl-4-pyridinyl)amino]-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755033-96-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-[[3-(2-hydroxyethyl)-4-pyridinyl]amino]-8-(1-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755034-00-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-2-methylpropyl)-3-[(2-methoxy-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755034-02-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-carboxylic acid, 10,11-dihydro-11-oxo-3-(4-pyrimidinylamino)-, methyl ester (9CI) (CA INDEX NAME)



RN 755034-08-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(1-hydroxy-1-methylethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755034-11-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(1-hydroxy-1-methylethyl)-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)

10/785,120




RN 755034-12-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-[(6-methoxy-4-pyrimidinyl)amino]-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755034-14-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[[6-(4-morpholinyl)-3-pyridinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 755034-18-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)



10/785,120


RN 755034-20-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755034-29-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-hydroxy-7-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-38-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(tetrahydro-2H-pyran-2-yl)methoxy]- (9CI) (CA INDEX NAME)




RN 755034-39-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(1-methyl-3-piperidiny)methoxy]- (9CI) (CA INDEX NAME)




RN 755034-40-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-(2-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 755034-41-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 755034-42-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-(4-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 755034-43-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(5-methyl-3-isoxazolyl)methoxy]- (9CI) (CA INDEX NAME)




RN 755034-44-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(1-methyl-1H-imidazol-5-yl)methoxy]- (9CI) (CA INDEX NAME)




RN 755034-45-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2-methyl-4-thiazolyl)methoxy]- (9CI) (CA INDEX NAME)




RN 755034-46-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2-oxo-5-oxazolidinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 755034-48-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(tetrahydro-2-furanyl)methoxy]- (9CI) (CA INDEX NAME)



RN 755034-49-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)


10/785,120



RN 755034-50-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2R)-2-pyrrolidinylmethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755034-51-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2R)-2-pyrrolidinylmethoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 755034-50-5

CMF C26 H26 N4 O6

Absolute stereochemistry.




CM 2

CRN 76-05-1


CMF C2 H F3 O2






RN 755034-52-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7,8-dimethoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-53-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-7-[2-(2-methoxyethoxy)ethoxy]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755034-54-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(2,3-dihydroxypropoxy)-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755034-55-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755034-56-1 CAPLUS

CN 1-Propanesulfonic acid, 3-[[[10,11-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]oxy]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 755034-57-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(3-aminopropoxy)-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-58-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(3-aminopropoxy)-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 755034-57-2

CMF C24 H24 N4 O6




10/785,120

CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 755034-59-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-[2-(dimethylamino)ethoxy]-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-61-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 755034-63-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 755034-64-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxybutoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-65-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxybutoxy)-3-(4-hydroxy-3-methoxyphenyl)-8-methoxy- (9CI) (CA INDEX NAME)



RN 755034-69-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxybutoxy)-8-methoxy-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)



IT **755034-70-9P 755034-71-0P**, 3-[(2,6-Difluoropyridin-4-yl)amino]-7-(4-hydroxybutoxy)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-72-1P**, 7-(4-Hydroxybutoxy)-8-methoxy-3-[(2,3,6-trifluoropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-73-2P**, 7-Ethoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-76-5P**, 7-(4-Hydroxybutoxy)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-80-1P**, 7-(2-Hydroxyethoxy)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-82-3P**, 7-(2,3-Dihydroxypropoxy)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-83-4P**, 7-[2-(2-Methoxyethoxy)ethoxy]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-84-5P**, 7-(Methoxymethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-91-4P**, 7-[(3-Methoxy-4-nitrobenzyl)-3-(3-methoxy-4-nitrophenyl)]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-93-6P**, 7-[[[2-(Dimethylamino)ethyl](methyl)amino]methyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-95-8P**, 3-(3-Methoxy-4-nitrophenyl)-7-[[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-

11-one **755034-97-0P**, 8-Ethyl-7-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-04-2P**, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-vinyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-07-5P**,  
 8-(3-Hydroxypropyl)-7-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-14-4P**,  
 7-Methoxy-3-(3-methoxy-4-nitrophenyl)-8-[3-[(2-methylpyridin-3-yl)oxy]propyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-16-6P**, 8-[3-[(2-Chloropyridin-3-yl)oxy]propyl]-7-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-17-7P**, 7-Methoxy-3-(3-methoxy-4-nitrophenyl)-8-[3-[[4-(morpholin-4-yl)phenyl]oxy]propyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-19-9P**,  
 8-[3-(Isoquinolin-3-yloxy)propyl]-7-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-20-2P**  
**755035-22-4P**, Methyl 7-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylate  
**755035-25-7P**, Methyl 7-methoxy-11-oxo-3-(pyrimidin-4-ylamino)-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylate  
**755035-26-8P**, 3-[(2,6-Difluoropyridin-4-yl)amino]-8-[1,1-dimethyl-2-(morpholin-4-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-27-9P** **755035-28-0P** **755035-30-4P**  
**755035-31-5P** **755035-33-7P**, 3-[(2,6-Difluoropyridin-4-yl)amino]-8-[2-(4-hydroxypiperidin-1-yl)-1,1-dimethyl-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-34-8P**,  
 (S)-3-[(2,6-Difluoropyridin-4-yl)amino]-8-[2-(2-(hydroxymethyl)pyrrolidin-1-yl)-1,1-dimethyl-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-35-9P**, 3-[(2,6-Difluoropyridin-4-yl)amino]-8-[1,1-dimethyl-2-oxo-2-(pyrrolidin-1-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-36-0P**  
**755035-37-1P** **755035-38-2P** **755035-39-3P**, (R)-3-[(2,6-Difluoropyridin-4-yl)amino]-8-[2-(2-(hydroxymethyl)pyrrolidin-1-yl)-1,1-dimethyl-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-40-6P**, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[3-(morpholin-4-yl)-3-oxopropyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-42-8P** **755035-44-0P** **755035-45-1P**,  
 8-[3-(3-Hydroxypiperidin-1-yl)-3-oxopropyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-46-2P**  
**755035-47-3P** **755035-48-4P** **755035-49-5P** **755035-50-8P**, 8-[2-[(6-Chloropyridin-3-yl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-51-9P**, 8-[2-[(2-Chloropyridin-3-yl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-52-0P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(6-methylpyridin-3-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-53-1P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(2-methylpyridin-3-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-54-2P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(pyridin-3-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-56-4P**, 8-[2-[(2,6-Dimethylpyridin-3-yl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-57-5P**, 8-[2-[[2-[(Dimethylamino)methyl]pyridin-3-yl]oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-58-6P**,  
 8-[2-(Isoquinolin-7-yloxy)ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-59-7P**,  
 7-Methoxy-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755035-61-1P**,  
 7-[2-[(2-Chloropyridin-3-yl)oxy]ethyl]-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-63-3P**, 8-[2-(Isoquinolin-5-yloxy)ethyl]-3-(3-methoxy-4-


nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-64-4P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(quinolin-5-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-65-5P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(4-methoxyphenoxy)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-67-7P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(3-methoxyphenoxy)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-68-8P 755035-69-9P**, 3-(3-Methoxy-4-nitrophenyl)-8-[3-[[4-(morpholin-4-yl)phenyl]oxy]propyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-70-2P**, 3-(3-Methoxy-4-nitrophenyl)-8-[3-[(pyridin-3-yl)oxy]propyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-71-3P**, 8-[2-(3-Aminophenoxy)ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-72-4P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(2-methyl-1,3-benzothiazol-7-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-73-5P 755035-74-6P**, 8-(2-Hydroxy-2-methylpropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-75-7P**, 3-(3-Methoxy-4-nitrophenyl)-8-[(4-methylpiperazin-1-yl)methyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-82-6P**, 3-(4-Chloro-3-methoxyphenyl)-8-[(4-methylpiperazin-1-yl)methyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-84-8P 755035-86-0P**, 3-(4-Hydroxy-3-methoxyphenyl)-8-(hydroxymethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-91-7P**, 3-(3-Methoxy-4-nitrophenyl)-8-[(morpholin-4-yl)methyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-99-5P**, (R)-8-[[2-(Hydroxymethyl)pyrrolidin-1-yl)methyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755036-00-1P**, 7-(2-Hydroxyethoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755036-01-2P**, 8-[3-[2-(Hydroxymethyl)pyrrolidin-1-yl]-3-oxopropyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755036-02-3P 755036-04-5P**, 8-Amino-3-(4-hydroxy-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755036-06-7P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(kinase inhibitor; preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)


RN 755034-70-9 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[[10,11-dihydro-7-(4-hydroxybutoxy)-8-methoxy-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl]amino]- (9CI) (CA INDEX NAME)




RN 755034-71-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-7-(4-hydroxybutoxy)-8-methoxy- (9CI) (CA INDEX NAME)




RN 755034-72-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxybutoxy)-8-methoxy-3-[(2,3,6-trifluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755034-73-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-ethoxy-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-76-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxybutoxy)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-80-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxyethoxy)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-82-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(2,3-dihydroxypropoxy)-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-83-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-[2-(2-methoxyethoxy)ethoxy]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755034-84-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(methoxymethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-91-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-7-[(3-methoxy-4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)




10/785,120




RN 755034-93-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-[[[2-(dimethylamino)ethyl]methylamino]methyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-95-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-7-[[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 755034-97-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-ethyl-5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755035-04-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-ethenyl-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755035-07-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(3-hydroxypropyl)-7-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-14-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-8-[3-[(2-methyl-3-pyridinyl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 755035-16-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[3-[(2-chloro-3-pyridinyl)oxy]propyl]-5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-17-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-8-[3-[4-(4-morpholinyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)




RN 755035-19-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[3-(3-isoquinolinylloxy)propyl]-7-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-20-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-8-[3-(3-oxo-2(3H)-isoquinolinyl)propyl]- (9CI) (CA INDEX NAME)




RN 755035-22-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755035-25-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-7-methoxy-11-oxo-3-(4-pyrimidinylamino)-, methyl ester (9CI) (CA INDEX NAME)




RN 755035-26-8 CAPLUS

CN Morpholine, 4-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755035-27-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-N,N,α,α-tetramethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755035-28-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-α,α-dimethyl-11-oxo-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 755035-30-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-α,α-dimethyl-11-oxo-N-2-


10/785,120

thiazolyl- (9CI) (CA INDEX NAME)




RN 755035-31-5 CAPLUS

CN 3-Piperidinol, 1-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 755035-33-7 CAPLUS


CN 4-Piperidinol, 1-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 755035-34-8 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/785,120


RN 755035-35-9 CAPLUS

CN Pyrrolidine, 1-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755035-36-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro- $\alpha,\alpha$ -dimethyl-11-oxo-N-2-pyridinyl- (9CI) (CA INDEX NAME)




RN 755035-37-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro- $\alpha,\alpha$ -dimethyl-11-oxo-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 755035-38-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-N-(4-fluorophenyl)-10,11-dihydro- $\alpha,\alpha$ -dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755035-39-3 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755035-40-6 CAPLUS

CN Morpholine, 4-[3-[10,11-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 755035-42-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-3-pyridinyl- (9CI) (CA INDEX NAME)



10/785,120


RN 755035-44-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 755035-45-1 CAPLUS

CN 3-Piperidinol, 1-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755035-46-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, N-(4-fluorophenyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755035-47-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 755035-48-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-




10/785,120

nitrophenyl)-N-methyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755035-49-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanamide, 10,11-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755035-50-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(6-chloro-3-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755035-51-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(2-chloro-3-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755035-52-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(6-methyl-3-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755035-53-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(2-methyl-3-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755035-54-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-pyridinyloxy)ethyl]- (9CI) (CA INDEX NAME)




RN 755035-56-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(2,6-dimethyl-3-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-57-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[[2-[(dimethylamino)methyl]-3-pyridinyl]oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-58-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[2-(7-isoquinolinyloxy)ethyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-59-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755035-61-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-[2-[(2-chloro-3-pyridinyl)oxy]ethyl]-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-63-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[2-(5-isoquinolinyloxy)ethyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-64-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(5-quinolinyloxy)ethyl]- (9CI) (CA INDEX NAME)



RN 755035-65-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(4-methoxyphenoxy)ethyl]- (9CI) (CA INDEX NAME)



RN 755035-67-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-methoxyphenoxy)ethyl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755035-68-8 CAPLUS

CN 2-Pyridinecarboxamide, 3-[2-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]ethoxy]- (9CI) (CA INDEX NAME)




RN 755035-69-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[3-[4-(4-morpholinyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)



RN 755035-70-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[3-(3-pyridinyloxy)propyl]- (9CI) (CA INDEX NAME)



RN 755035-71-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-(3-aminophenoxy)ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755035-72-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(2-methyl-7-benzothiazolyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755035-73-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755035-74-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-2-methylpropyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-75-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 755035-82-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-8-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 755035-84-8 CAPLUS


CN Benzonitrile, 4-[10,11-dihydro-8-[(4-methyl-1-piperazinyl)methyl]-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 755035-86-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-(hydroxymethyl)- (9CI) (CA INDEX NAME)

10/785,120



RN 755035-91-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)



RN 755035-99-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[[ (2R)-2-(hydroxymethyl)-1-pyrrolidinyl]methyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755036-00-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxyethoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755036-01-2 CAPLUS



10/785,120


CN 2-Pyrrolidinemethanol, 1-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 755036-02-3 CAPLUS


CN Cyclohexanecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]-4-hydroxy-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 755036-04-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 755036-06-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)- $\alpha,\alpha$ -dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




IT 755031-66-4P

RL: BYP (Byproduct); PREP (Preparation)

(preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)

RN 755031-66-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(3-methyl-2-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)



10/785,120

L10 ANSWER 7 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:967765 CAPLUS

DN 142:129218

TI Identification of a novel non-carbohydrate molecule that binds to the ribosomal A-site RNA

AU Maddaford, Shawn P.; Motamed, Mina; Turner, Kevin B.; Choi, Min Soo K.; Ramnauth, Jailall; Rakhit, Suman; Hudgins, Robert R.; Fabris, Daniele; Johnson, Philip E.

CS MCR Research Inc., Toronto, ON, M3J 1P3, Can.

SO Bioorganic & Medicinal Chemistry Letters (2004), 14(24), 5987-5990  
CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier B.V.

DT Journal

LA English

OS CASREACT 142:129218

AB We report the identification of a novel compound that binds to the Escherichia coli 16S ribosomal A-site. Binding by the compound was observed using NMR and mass spectrometry techniques. We show that the compound binds in the same position in the A-site RNA as occupied by the aminoglycoside class of antibiotics.


IT **16398-16-6P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(novel non-carbohydrate mol. MCR13 that binds to the ribosomal A-site RNA)

RN 16398-16-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-nitro- (8CI, 9CI) (CA INDEX NAME)



RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/785,120

L10 ANSWER 8 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:740305 CAPLUS

DN 141:260782

TI Preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer

IN Hasvold, Lisa A.; Hexamer, Laura; Li, Gaoquan; Lin, Nan-horng; Sham, Hing; Sowin, Tom; Sullivan, Gerard M.; Wang, Le; Xia, Ping Xia

PA Abbott Laboratories, USA

SO PCT Int. Appl., 382 pp.


CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004076424	A1	20040910	WO 2004-US5728	20040226
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004254159	A1	20041216	US 2004-785120	20040225
	CA 2515790	AA	20040910	CA 2004-2515790	20040226
	EP 1606268	A1	20051221	EP 2004-715097	20040226
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2003-375412	A	20030227		
	US 2004-785120	A	20040225		
	US 2003-450476P	P	20030227		
	WO 2004-US5728	W	20040226		
OS	MARPAT 141:260782				
GI					



I




II

AB Title heterocycles and analogs I [wherein A1 = CR1, N; A2 = CR8, N; R1, R8 = independently H, alkoxy, (hydroxy)alkyl, amino(alkyl), CN, halo, OH,

NO<sub>2</sub>; R<sub>2</sub>-R<sub>5</sub> = independently H, alkenyl, (alkoxy)alkoxy(alkoxy), (alkoxy)alkyl, alkoxycarbonyl(alkyl), alkylcarbonyl(alkyl), amino(alkoxy), aminoalkyl, aminocarbonyl(alkyl), aminosulfonyl, aryl(alkoxy), aryl(oxy)alkyl, carboxy(alkyl), cyano(alkyl), cycloalkyl(alkyl), halo(alkoxy), haloalkyl, heterocyclyl(alkoxy), heterocyclyl(carbonyl)alkyl, heterocyclyloxyalkyl, hydroxy(alkoxy), hydroxyalkyl, nitro(alkyl), carbamoyl(alkyl); one of R<sub>6</sub> and R<sub>7</sub> = H and the other = H, aryl, cycloalkyl, halo, heterocyclyl, XR<sub>13</sub>; R<sub>13</sub> = aryl, cycloalkyl, heterocyclyl; X = O, NR<sub>14</sub>, CO, S, SO<sub>2</sub>, (CH<sub>2</sub>)<sub>n</sub>, CONR<sub>14</sub>, NR<sub>14</sub>CO, SO<sub>2</sub>NR<sub>14</sub>, NR<sub>14</sub>SO<sub>2</sub>, O(CH<sub>2</sub>)<sub>m</sub>, (CH<sub>2</sub>)<sub>m</sub>O, CH=CH, C.tplbond.C; R<sub>14</sub> = H, alkenyl, (amino)alkyl, hydroxyalkyl; Y = NR<sub>15</sub>, O; R<sub>15</sub> = H, alkoxycarbonyl, (cyclo)alkyl, alkylcarbonyl, arylalkyl, cycloalkylalkyl; m = 0-3; n = 1-3; and therapeutically acceptable salts thereof] were prepared as protein kinase inhibitors. For example, N-alkylation of Me 3,4-diaminobenzoate with Me 4-chloro-2-iodobenzoate using Cu and K<sub>2</sub>CO<sub>3</sub> in PhCl gave Me 2-[[2-amino-4-(methoxycarbonyl)phenyl]amino]-4-chlorobenzoate (68%), which was cyclized with 37% HCl in MeOH to provide II (87%). In enzymic assays using recombinant Chk1 kinase domain protein and human cdc25c peptide substrate, compds. of the invention inhibited Chk1 at IC<sub>50</sub> values between about 0.2 nM and about 280 μM. Thus, I and their pharmaceutical compns. are useful for treatment of cancer (no data).

- IT **755035-60-0P**, 7-Methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylic acid  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (intermediate, kinase inhibitor; preparation of  
 dibenzo[b,e][1,4]diazepin-11-  
 ones as kinase inhibitors for treatment of cancer)  
 RN 755035-60-0 CAPLUS  
 CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



- IT **755026-94-9P 755026-98-3P 755027-01-1P**,  
 8-(3-Aminophenyl)-3-chloro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-03-3P**, 3-Chloro-8-(3-hydroxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-05-5P**,  
 3-Chloro-8-(pyridin-3-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-07-7P**, 3-Chloro-8-(1H-pyrrol-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-13-5P**  
**755027-16-8P**, 3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-33-9P**,  
 3-(2-Fluoropyridin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-35-1P**, Methyl 3-(2-fluoro-4-pyridinyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylate **755027-36-2P**,  
 3-(2-Fluoro-4-pyridinyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylic acid **755027-38-4P**  
**755028-00-3P 755028-37-6P**, 8-Amino-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-44-5P**  
**755028-45-6P**, 3-Chloro-8-(2-oxopyrrolidin-1-yl)-5,10-dihydro-11H-

dibenzo[b,e][1,4]diazepin-11-one **755028-47-8P**  
**755028-48-9P**, 3-Chloro-8-(2-oxopiperidin-1-yl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755028-50-3P**  
**755028-68-3P**, 7-Amino-3-chloro-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755028-80-9P**,  
 3-Chloro-8-(1-hydroxy-1-methylethyl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755028-82-1P**,  
 3-Chloro-8-(1-ethyl-1-hydroxypropyl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755028-96-7P**  
**755028-97-8P** **755029-00-6P**, 3-Chloro-8-(2-hydroxyethyl)-  
 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-02-8P**  
**755029-06-2P**, 3-Chloro-8-(2-hydroxy-2-methylpropyl)-5,10-dihydro-  
 11H-dibenzo[b,e][1,4]diazepin-11-one **755029-12-0P**,  
 8-Acetyl-3-chloro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755029-21-1P**, 3-Chloro-8-[2-(pyridin-2-yloxy)ethyl]-5,10-dihydro-  
 11H-dibenzo[b,e][1,4]diazepin-11-one **755029-32-4P**,  
 7-Bromo-3-chloro-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-  
 one **755029-33-5P** **755029-35-7P** **755029-37-9P**,  
 3-Chloro-7-(3-hydroxy-3-methylbutyl)-8-methoxy-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755029-50-6P**  
**755029-52-8P**, 3-Chloro-8-(3-hydroxy-3-methylbutyl)-5,10-dihydro-  
 11H-dibenzo[b,e][1,4]diazepin-11-one **755029-71-1P**,  
 3-Chloro-8-(3-hydroxypropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-  
 one **755029-73-3P** **755029-76-6P** **755029-81-3P**  
**755029-98-2P** **755030-00-3P**, 3-Chloro-7-(2-hydroxy-2-  
 methylpropyl)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755030-03-6P**, 3-Chloro-7-(2-hydroxyethyl)-8-methoxy-5,10-dihydro-  
 11H-dibenzo[b,e][1,4]diazepin-11-one **755030-05-8P**,  
 3-Chloro-8-methoxy-7-(2-oxopropyl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755030-13-8P**  
**755030-14-9P**, 3-Chloro-7-(2-hydroxy-1,1-dimethylethyl)-8-methoxy-  
 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-22-9P**,  
 7-Bromo-3-chloro-8-(trifluoromethoxy)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755030-24-1P**  
**755030-25-2P** **755030-26-3P**, 3-Chloro-7-(3-hydroxypropyl)-  
 8-(trifluoromethoxy)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755030-29-6P**, 3-Chloro-7-(3-hydroxy-3-methylbutyl)-8-  
 (trifluoromethoxy)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755030-41-2P**, 7-Bromo-3-chloro-8-methyl-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755030-43-4P**  
**755030-45-6P** **755030-47-8P**, 3-Chloro-7-(3-hydroxy-3-  
 methylbutyl)-8-methyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755030-51-4P**, 3-Chloro-8-[(E)-2-(pyridin-4-yl)ethenyl]-5,10-  
 dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-52-5P**,  
 3-Chloro-8-[2-(pyridin-4-yl)ethyl]-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755030-55-8P**,  
 3-Chloro-8-[(E)-2-(pyridin-2-yl)ethenyl]-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755030-57-0P**,  
 3-Chloro-8-[2-(pyridin-2-yl)ethyl]-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755030-87-6P**  
**755030-88-7P** **755030-90-1P** **755030-96-7P**  
**755031-23-3P** **755031-29-9P** **755031-30-2P**  
**755031-40-4P** **755031-41-5P**, 3-Chloro-7-(3-hydroxypropyl)-  
 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-44-8P**,  
 3-Chloro-7-(3-hydroxy-3-methylbutyl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755031-46-0P**,  
 3-Chloro-8-(2-hydroxy-1,1-dimethylethyl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755031-48-2P**,  
 3-Chloro-8-(2-hydroxy-1,1,2-trimethylpropyl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755031-50-6P**,  
 3-Chloro-8-(1,1-dimethyl-2-oxopropyl)-5,10-dihydro-11H-

dibenzo[b,e][1,4]diazepin-11-one **755031-59-5P**,  
 3-Chloro-8-[2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755031-63-1P**  
**755031-64-2P**, 3-Chloro-8-[2-[[4-(morpholin-4-  
 yl)phenyl]amino]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755031-72-2P**, 3-Chloro-8-[1,1-dimethyl-2-(pyridin-2-yloxy)ethyl]-  
 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-74-4P**,  
 3-Chloro-8-[1,1-dimethyl-2-(4-nitrophenoxy)ethyl]-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755031-75-5P**,  
 8-[2-(4-Aminophenoxy)-1,1-dimethylethyl]-3-chloro-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755031-76-6P**,  
 3-Chloro-8-[1,1-dimethyl-2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-  
 dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-16-7P**  
**755032-64-5P** **755032-66-7P** **755032-68-9P**,  
 3-(2-Fluoropyridin-4-yl)-8-[2-(morpholin-4-yl)-2-oxoethyl]-5,10-dihydro-  
 11H-dibenzo[b,e][1,4]diazepin-11-one **755032-70-3P**  
**755033-33-1P**, 3-Chloro-8-methoxy-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755033-42-2P**,  
 3-Chloro-7-(piperidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-  
 one **755033-45-5P**, (S)-3-Chloro-7-[2-(hydroxymethyl)pyrrolidin-1-  
 yl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-47-7P**  
 , 3-Chloro-7-(morpholin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-  
 11-one **755033-51-3P**, 3-Chloro-7-(4-hydroxypiperidin-1-yl)-5,10-  
 dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-62-6P**,  
 3-Chloro-8-(2-ethyl-2-hydroxybutyl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755033-72-8P**  
**755033-85-3P**, 3-Chloro-8-(2-oxopropyl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755033-95-5P**  
**755034-06-1P**, Methyl 3-chloro-11-oxo-10,11-dihydro-5H-  
 dibenzo[b,e][1,4]diazepine-7-carboxylate **755034-10-7P**,  
 3-Chloro-7-(1-hydroxy-1-methylethyl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755034-27-6P**,  
 3-Chloro-8-methoxy-7-[[2-(trimethylsilyl)ethoxy]methoxy]-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755034-28-7P**,  
 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[[2-(trimethylsilyl)ethoxy]methoxy]  
 ]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-36-7P**  
 , 3-Chloro-7-methoxy-8-[[2-(trimethylsilyl)ethoxy]methoxy]-5,10-dihydro-  
 11H-dibenzo[b,e][1,4]diazepin-11-one **755034-37-8P**,  
 7-Methoxy-3-(3-methoxy-4-nitrophenyl)-8-[[2-(trimethylsilyl)ethoxy]methoxy]  
 ]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-66-3P**  
 , 3-Chloro-7-hydroxy-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-  
 11-one **755034-67-4P** **755034-68-5P** **755034-75-4P**  
 , 3-Chloro-7-ethoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-77-6P**, 3-Chloro-7-hydroxy-5-[[2-  
 (trimethylsilyl)ethoxy]methyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-  
 11-one **755034-78-7P** **755034-90-3P**, 3-Chloro-7-  
 (methoxymethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-92-5P**, 7-(Bromomethyl)-3-chloro-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755034-94-7P**,  
 3-Chloro-7-[[[2-(dimethylamino)ethyl](methyl)amino]methyl]-5,10-dihydro-  
 11H-dibenzo[b,e][1,4]diazepin-11-one **755034-96-9P**,  
 3-Chloro-7-[[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]-5,10-dihydro-  
 11H-dibenzo[b,e][1,4]diazepin-11-one **755034-99-2P**,  
 3-Chloro-8-hydroxy-7-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-  
 one **755035-00-8P** **755035-02-0P**, 3-Chloro-7-methoxy-8-  
 vinyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-03-1P**, 3-Chloro-8-ethyl-7-methoxy-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755035-05-3P**  
**755035-06-4P**, 3-Chloro-8-methoxy-7-vinyl-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755035-10-0P**,  
 8-Bromo-3-chloro-7-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-


one **755035-11-1P** **755035-12-2P** **755035-13-3P**,  
 3-Chloro-8-(3-hydroxypropyl)-7-methoxy-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755035-15-5P**,  
 3-Chloro-7-methoxy-8-[3-[(2-methylpyridin-3-yl)oxy]propyl]-5,10-dihydro-  
 11H-dibenzo[b,e][1,4]diazepin-11-one **755035-18-8P**,  
 3-Chloro-7-methoxy-8-[3-[[4-(morpholin-4-yl)phenyl]oxy]propyl]-5,10-  
 dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-24-6P**,  
 Methyl 3-chloro-7-methoxy-11-oxo-10,11-dihydro-5H-  
 dibenzo[b,e][1,4]diazepine-8-carboxylate **755035-41-7P**  
**755035-81-5P**, 3-Chloro-8-[(4-methylpiperazin-1-yl)methyl]-5,10-  
 dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-83-7P**,  
 8-[(4-Methylpiperazin-1-yl)methyl]-3-(4,4,5,5-tetramethyl-1,3,2-  
 dioxaborolan-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-90-6P**, 3-Chloro-8-(hydroxymethyl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one **755035-97-3P**,  
 3-Chloro-8-(morpholin-4-ylmethyl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)

(intermediate; preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase  
 inhibitors for treatment of cancer)


RN 755026-94-9 CAPLUS

CN Methanesulfonamide, N-(3-chloro-10,11-dihydro-11-oxo-5H-  
 dibenzo[b,e][1,4]diazepin-8-yl)- (9CI) (CA INDEX NAME)



RN 755026-98-3 CAPLUS

CN Acetamide, N-(3-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-  
 yl)- (9CI) (CA INDEX NAME)




RN 755027-01-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(3-aminophenyl)-3-chloro-5,10-  
 dihydro- (9CI) (CA INDEX NAME)




10/785,120




RN 755027-03-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 755027-05-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 755027-07-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)



RN 755027-13-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-11-oxo-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755027-16-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- (9CI) (CA INDEX NAME)




RN 755027-33-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(2-fluoro-4-pyridinyl)-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 755027-35-1 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755027-36-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 755027-38-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-11-oxo-N-[3-(1-pyrrolidinyl)propyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 755027-37-3


CMF C26 H26 F N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 755028-00-3 CAPLUS

CN Carbamic acid, [(1S)-1-[[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]amino]carbonyl]-3-methylbutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/785,120




RN 755028-37-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-5,10-dihydro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- (9CI) (CA INDEX NAME)




RN 755028-44-5 CAPLUS

CN Butanamide, 4-chloro-N-(3-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl)- (9CI) (CA INDEX NAME)



RN 755028-45-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



10/785,120


RN 755028-47-8 CAPLUS

CN Pentanamide, 5-chloro-N-(3-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl)- (9CI) (CA INDEX NAME)




RN 755028-48-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(2-oxo-1-piperidiny)- (9CI) (CA INDEX NAME)




RN 755028-50-3 CAPLUS

CN Butanamide, 4-chloro-N-[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-68-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-amino-3-chloro-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 755028-80-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(1-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-82-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-(1-ethyl-1-hydroxypropyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755028-96-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-chloro-10,11-dihydro-α,α-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755028-97-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-chloro-10,11-dihydro-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755029-00-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755029-02-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-α,α-dimethyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-06-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(2-hydroxy-2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 755029-12-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-acetyl-3-chloro-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 755029-21-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-(2-pyridinyloxy)ethyl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755029-32-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-bromo-3-chloro-5,10-dihydro-8-methoxy- (9CI) (CA INDEX NAME)




RN 755029-33-5 CAPLUS

CN 2-Propenoic acid, 3-(3-chloro-10,11-dihydro-8-methoxy-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl)-, methyl ester (9CI) (CA INDEX NAME)



RN 755029-35-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanoic acid, 3-chloro-10,11-dihydro-8-methoxy-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-37-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-8-methoxy- (9CI) (CA INDEX NAME)




10/785,120




RN 755029-50-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 3-chloro-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-52-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(3-hydroxy-3-methylbutyl)- (9CI) (CA INDEX NAME)



RN 755029-71-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(3-hydroxypropyl)- (9CI) (CA INDEX NAME)



RN 755029-73-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 10,11-dihydro-11-oxo-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755029-76-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-81-3 CAPLUS

CN Ethanimidamide, N-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropoxy]- (9CI) (CA INDEX NAME)



RN 755029-98-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetic acid, 3-chloro-10,11-dihydro-8-methoxy-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755030-00-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(2-hydroxy-2-methylpropyl)-8-methoxy- (9CI) (CA INDEX NAME)

10/785,120




RN 755030-03-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(2-hydroxyethyl)-8-methoxy- (9CI) (CA INDEX NAME)




RN 755030-05-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-methoxy-7-(2-oxopropyl)- (9CI) (CA INDEX NAME)



RN 755030-13-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetic acid, 3-chloro-10,11-dihydro-8-methoxy-α,α-dimethyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755030-14-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(2-hydroxy-1,1-dimethylethyl)-8-methoxy- (9CI) (CA INDEX NAME)

10/785,120




RN 755030-22-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-bromo-3-chloro-5,10-dihydro-8-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 755030-24-1 CAPLUS

CN 2-Propenoic acid, 3-[3-chloro-10,11-dihydro-11-oxo-8-(trifluoromethoxy)-5H-dibenzo[b,e][1,4]diazepin-7-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 755030-25-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanoic acid, 3-chloro-10,11-dihydro-11-oxo-8-(trifluoromethoxy)-, methyl ester (9CI) (CA INDEX NAME)



RN 755030-26-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(3-hydroxypropyl)-8-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

10/785,120




RN 755030-29-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-8-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



RN 755030-41-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-bromo-3-chloro-5,10-dihydro-8-methyl- (9CI) (CA INDEX NAME)



RN 755030-43-4 CAPLUS

CN 2-Propenoic acid, 3-(3-chloro-10,11-dihydro-8-methyl-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl)-, methyl ester, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 755030-45-6 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanoic acid, 3-chloro-10,11-dihydro-8-methyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120



RN 755030-47-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-8-methyl- (9CI) (CA INDEX NAME)



RN 755030-51-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[(1E)-2-(4-pyridinyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 755030-52-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755030-55-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[(1E)-2-(2-pyridinyl)ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

10/785,120




RN 755030-57-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755030-87-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-chloro-10,11-dihydro-α,α-dimethyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755030-88-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755030-90-1 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 755030-96-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-α,α-dimethyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755031-23-3 CAPLUS

CN Cyclopropanecarboxylic acid, 1-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755031-29-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetic acid, 3-chloro-10,11-dihydro-α,α-dimethyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755031-30-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




10/785,120




RN 755031-40-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanoic acid, 3-chloro-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755031-41-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(3-hydroxypropyl)- (9CI) (CA INDEX NAME)




RN 755031-44-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(3-hydroxy-3-methylbutyl)- (9CI) (CA INDEX NAME)




RN 755031-46-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 755031-48-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(2-hydroxy-1,1,2-trimethylpropyl)- (9CI) (CA INDEX NAME)




RN 755031-50-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-(1,1-dimethyl-2-oxopropyl)-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 755031-59-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 755031-63-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-[[4-methylphenyl)sulfonyl]oxy]ethyl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755031-64-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-[[4-(4-morpholinyl)phenyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 755031-72-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-[1,1-dimethyl-2-(2-pyridinyloxy)ethyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 755031-74-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-[1,1-dimethyl-2-(4-nitrophenoxy)ethyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 755031-75-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-(4-aminophenoxy)-1,1-dimethylethyl]-3-chloro-5,10-dihydro- (9CI) (CA INDEX NAME)

10/785,120




RN 755031-76-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-[1,1-dimethyl-2-[4-(4-morpholinyl)phenoxy]ethyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755032-16-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-α,α-dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)



RN 755032-64-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755032-66-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 755032-68-9 CAPLUS

CN Morpholine, 4-[[3-(2-fluoro-4-pyridinyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-70-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755033-33-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-methoxy- (9CI) (CA INDEX NAME)



RN 755033-42-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(1-piperidinyl)- (9CI) (CA INDEX NAME)


10/785,120



RN 755033-45-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755033-47-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 755033-51-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(4-hydroxy-1-piperidiny)- (9CI) (CA INDEX NAME)



RN 755033-62-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-(2-ethyl-2-hydroxybutyl)-5,10-dihydro- (9CI) (CA INDEX NAME)

10/785,120




RN 755033-72-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-11-oxo-3-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 755033-85-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(2-oxopropyl)- (9CI) (CA INDEX NAME)



RN 755033-95-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro- $\alpha,\alpha$ -dimethyl-3-[(2-methyl-4-pyridinyl)amino]-11-oxo- (9CI) (CA INDEX NAME)



RN 755034-06-1 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-carboxylic acid, 3-chloro-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755034-10-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(1-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 755034-27-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-methoxy-7-[[2-(trimethylsilyl)ethoxy]methoxy]- (9CI) (CA INDEX NAME)



RN 755034-28-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[[2-(trimethylsilyl)ethoxy]methoxy]- (9CI) (CA INDEX NAME)




RN 755034-36-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-methoxy-8-[[2-(trimethylsilyl)ethoxy]methoxy]- (9CI) (CA INDEX NAME)




10/785,120




RN 755034-37-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-8-[[2-(trimethylsilyl)ethoxy]methoxy]- (9CI) (CA INDEX NAME)




RN 755034-66-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-hydroxy-8-methoxy- (9CI) (CA INDEX NAME)



RN 755034-67-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-7-[4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]butoxy]-5,10-dihydro-8-methoxy- (9CI) (CA INDEX NAME)



RN 755034-68-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-[4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]butoxy]-5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-methoxy- (9CI) (CA INDEX NAME)

10/785,120




RN 755034-75-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-7-ethoxy-5,10-dihydro-  
(9CI) (CA INDEX NAME)




RN 755034-77-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-hydroxy-5-  
[[2-(trimethylsilyl)ethoxy]methyl]- (9CI) (CA INDEX NAME)



RN 755034-78-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-7-[4-[[[(1,1-  
dimethylethyl)dimethylsilyl]oxy]butoxy]-5,10-dihydro-5-[[2-  
(trimethylsilyl)ethoxy]methyl]- (9CI) (CA INDEX NAME)



RN 755034-90-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-  
(methoxymethyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755034-92-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(bromomethyl)-3-chloro-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755034-94-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-7-[[[2-(dimethylamino)ethyl]methylamino]methyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 755034-96-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-[[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 755034-99-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-hydroxy-7-methoxy- (9CI) (CA INDEX NAME)

10/785,120




RN 755035-00-8 CAPLUS

CN Methanesulfonic acid, trifluoro-, 3-chloro-10,11-dihydro-7-methoxy-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl ester (9CI) (CA INDEX NAME)




RN 755035-02-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-ethenyl-5,10-dihydro-7-methoxy- (9CI) (CA INDEX NAME)



RN 755035-03-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-ethyl-5,10-dihydro-7-methoxy- (9CI) (CA INDEX NAME)



RN 755035-05-3 CAPLUS


CN Methanesulfonic acid, trifluoro-, 3-chloro-10,11-dihydro-8-methoxy-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755035-06-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-7-ethenyl-5,10-dihydro-8-methoxy- (9CI) (CA INDEX NAME)




RN 755035-10-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-bromo-3-chloro-5,10-dihydro-7-methoxy- (9CI) (CA INDEX NAME)



RN 755035-11-1 CAPLUS


CN 2-Propenoic acid, 3-(3-chloro-10,11-dihydro-7-methoxy-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 755035-12-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 3-chloro-10,11-dihydro-7-methoxy-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755035-13-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(3-hydroxypropyl)-7-methoxy- (9CI) (CA INDEX NAME)




RN 755035-15-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-methoxy-8-[(2-methyl-3-pyridinyl)oxy]propyl- (9CI) (CA INDEX NAME)



RN 755035-18-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-methoxy-8-[3-[4-(4-morpholinyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)



RN 755035-24-6 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 3-chloro-10,11-dihydro-7-methoxy-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755035-41-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanoic acid, 10,11-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755035-81-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 755035-83-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[(4-methyl-1-piperazinyl)methyl]-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- (9CI) (CA INDEX NAME)




RN 755035-90-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(hydroxymethyl)- (9CI) (CA INDEX NAME)



RN 755035-97-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)



IT 755026-34-7P, Methyl 3-chloro-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylate 755026-36-9P, 8-Bromo-3-chloro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755026-38-1P, 3-Chloro-8-nitro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755026-40-5P, 3-Chloro-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carbonitrile 755026-45-0P 755026-53-0P, 3-Bromo-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755026-56-3P, Methyl 3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylate 755026-57-4P, 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylic acid 755026-72-3P 755026-73-4P 755026-74-5P 755027-09-9P 755027-12-4P 755027-23-7P 755027-24-8P 755027-25-9P 755027-41-9P 755027-43-1P 755027-44-2P 755027-96-4P, 8-Amino-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one trifluoroacetate 755028-36-5P 755028-41-2P, 8-Amino-3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755028-51-4P 755028-57-0P 755028-65-0P, 7-Amino-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755028-69-4P 755029-08-4P 755029-13-1P 755029-56-2P 755029-58-4P 755029-69-7P, 8-(2-Hydroxyethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755029-70-0P, 8-(3-Hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755030-02-5P, 7-(2-Hydroxyethyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-18-6P 755032-40-7P 755032-41-8P 755032-44-1P 755032-47-4P 755032-56-5P 755032-58-7P 755033-90-0P 755034-22-1P, 7-Hydroxy-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755034-60-7P, 7-(2-Chloroethoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic




10/785,120

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(kinase inhibitor; preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)


RN 755026-34-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 3-chloro-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755026-36-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-bromo-3-chloro-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755026-38-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-nitro- (9CI) (CA INDEX NAME)



RN 755026-40-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carbonitrile, 3-chloro-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-45-0 CAPLUS


10/785,120

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-chloro-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755026-53-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-bromo-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755026-56-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755026-57-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-72-3 CAPLUS


CN 2-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755026-73-4 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 755026-74-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 755027-09-9 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755027-12-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755027-23-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755027-24-8 CAPLUS

CN Benzoic acid, 4-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-2-methoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 755027-25-9 CAPLUS


CN Benzoic acid, 4-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)



RN 755027-41-9 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(2-fluoro-5-methyl-4-pyridinyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755027-43-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755027-44-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-96-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 755027-95-3


CMF C20 H16 N4 O4




CM 2

10/785,120


CRN 76-05-1  
CMF C2 H F3 O2




RN 755028-36-5 CAPLUS  
CN Benzonitrile, 4-(8-amino-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)



RN 755028-41-2 CAPLUS  
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-3-(4-chloro-3-methoxyphenyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755028-51-4 CAPLUS  
CN 1-Propanesulfonamide, 3-chloro-N-[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-57-0 CAPLUS  
CN 1-Propanesulfonamide, 3-chloro-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-65-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-amino-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755028-69-4 CAPLUS

CN 1-Propanesulfonamide, 3-chloro-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 755029-08-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[(2-chloro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755029-13-1 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[(2-chloro-4-pyridinyl)amino]-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 755029-56-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-58-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755029-69-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxyethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755029-70-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(3-hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




10/785,120




RN 755030-02-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxyethyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-18-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-α,α-dimethyl-11-oxo-3-(4-pyrimidinylamino)-, methyl ester (9CI) (CA INDEX NAME)



RN 755032-40-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-41-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-acetyl-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755032-44-1 CAPLUS

CN Carbamic acid, [1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 755032-47-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-56-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 755032-58-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-90-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro- $\alpha,\alpha$ -dimethyl-3-[(2-methyl-4-pyridinyl)amino]-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755034-22-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-hydroxy-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755034-60-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(2-chloroethoxy)-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



IT **755026-42-7P**, 3-Chloro-8-(trifluoromethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755026-48-3P**,

8-Amino-3-chloro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one

**755026-50-7P**, 3-Chloro-8-hydroxy-5,10-dihydro-11H-

dibenzo[b,e][1,4]diazepin-11-one **755026-54-1P**,

3-(4-Hydroxy-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-

11-one **755026-55-2P** **755026-58-5P**, 3-(4-Hydroxy-3-

methoxyphenyl)-11-oxo-N-[3-(1-pyrrolidinyl)propyl]-10,11-dihydro-5H-

dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-59-6P**  
**755026-60-9P**, N-[3-(Dimethylamino)propyl]-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-61-0P 755026-62-1P**,  
 3-(4-Hydroxy-3-methoxyphenyl)-N-[3-(4-morpholinyl)propyl]-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-63-2P**  
**755026-64-3P**, 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-65-4P 755026-66-5P**,  
 N-(2-Hydroxyethyl)-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-67-6P**,  
 N-(2,3-Dihydroxypropyl)-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-68-7P**,  
 N-[2-(Acetylaminomethyl)-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-69-8P**  
 , 3-(4-Hydroxy-3-methoxyphenyl)-8-[(3-hydroxy-1-pyrrolidinyl)carbonyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755026-70-1P**,  
 (S)-3-(4-Hydroxy-3-methoxyphenyl)-8-[(2-(hydroxymethyl)-1-pyrrolidinyl)carbonyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755026-71-2P**, 3-(4-Hydroxy-3-methoxyphenyl)-8-[(2-(hydroxymethyl)-1-piperidinyl)carbonyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755026-75-6P**, 3-(4-Hydroxy-3-methoxyphenyl)-8-[(3-hydroxy-1-piperidinyl)carbonyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755026-76-7P**, 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-N-[(3-pyridinyl)methyl]-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-77-8P 755026-78-9P**,  
 3-(4-Hydroxy-3-methoxyphenyl)-N-[4-(methylsulfonyl)benzyl]-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-79-0P**  
 , N-(2-Fluorobenzyl)-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-80-3P**,  
 3-(4-Hydroxy-3-methoxyphenyl)-N-(2-methoxybenzyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-81-4P**,  
 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-N-[(2-pyridinyl)methyl]-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-82-5P**  
**755026-83-6P**, 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-N-[(4-pyridinyl)methyl]-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-84-7P 755026-85-8P**,  
 3-(4-Hydroxy-3-methoxyphenyl)-N-[2-(4-methoxyphenyl)ethyl]-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-86-9P**  
**755026-87-0P 755026-88-1P 755026-89-2P**  
**755026-90-5P**, 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carbonitrile **755026-91-6P**,  
 3-(4-Hydroxy-3-methoxyphenyl)-8-nitro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755026-92-7P**,  
 8-Amino-3-(4-hydroxy-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one hydrochloride **755026-93-8P**  
**755026-95-0P 755026-97-2P 755026-99-4P**  
**755027-00-0P**, 8-(3-Aminophenyl)-3-(4-hydroxy-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-02-2P**,  
 3-(4-Hydroxy-3-methoxyphenyl)-8-(3-hydroxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-04-4P**,  
 3-(4-Hydroxy-3-methoxyphenyl)-8-(pyridin-3-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-06-6P**,  
 3-(4-Hydroxy-3-methoxyphenyl)-8-(1H-pyrrol-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-08-8P**,  
 3-(3-Methoxy-4-nitrophenyl)-8-(1H-pyrrol-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-10-2P**  
**755027-11-3P 755027-14-6P**, 3-(3-Methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-15-7P**,  
 3-(4-Chloro-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-17-9P**, 3-(4-Bromo-3-methoxyphenyl)-5,10-dihydro-11H-

dibenzo[b,e][1,4]diazepin-11-one 755027-19-1P  
 755027-20-4P, 3-(4-Acetyl-3-methoxyphenyl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one 755027-22-6P  
 755027-26-0P 755027-27-1P 755027-28-2P  
 755027-29-3P 755027-32-8P, 3-(2-Methoxypyridin-4-yl)-  
 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755027-34-0P,  
 3-(2-Methoxy-4-pyridinyl)-11-oxo-N-[3-(1-pyrrolidinyl)propyl]-10,11-  
 dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide 755027-39-5P  
 , 11-Oxo-3-(2-oxo-1,2-dihydro-4-pyridinyl)-N-[3-(1-pyrrolidinyl)propyl]-  
 10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide  
 755027-40-8P 755027-45-3P 755027-46-4P  
 755027-47-5P, 8-[2-(3-Hydroxy-1-piperidinyl)-2-oxoethyl]-3-(3-  
 methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
 755027-48-6P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(4-methyl-1,4-  
 diazepan-1-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-  
 one 755027-50-0P 755027-51-1P, 8-[2-(4-Hydroxy-1-  
 piperidinyl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one 755027-52-2P  
 755027-53-3P 755027-54-4P 755027-55-5P  
 755027-56-6P 755027-57-7P 755027-58-8P  
 755027-59-9P 755027-60-2P 755027-61-3P  
 755027-62-4P 755027-63-5P 755027-66-8P  
 755027-67-9P 755027-68-0P 755027-69-1P  
 755027-71-5P 755027-72-6P 755027-73-7P  
 755027-74-8P 755027-75-9P 755027-76-0P  
 755027-77-1P 755027-78-2P, 8-[2-(4-Ethyl-1-piperazinyl)-  
 2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one 755027-79-3P,  
 8-[2-(4-(2-Hydroxyethyl)-1-piperazinyl)-2-oxoethyl]-3-(3-methoxy-4-  
 nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
 755027-80-6P 755027-81-7P, 3-(3-Methoxy-4-nitrophenyl)-8-  
 [2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one 755027-82-8P,  
 3-(3-Methoxy-4-nitrophenyl)-8-[2-oxo-2-(4-(pyridin-2-yl)-1-  
 piperazinyl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
 755027-83-9P 755027-84-0P 755027-85-1P  
 755027-86-2P 755027-87-3P 755027-88-4P  
 755027-89-5P 755027-90-8P 755027-91-9P  
 755027-92-0P 755027-93-1P 755027-94-2P,  
 (S)-8-[2-[2-(Hydroxymethyl)-1-pyrrolidinyl]-2-oxoethyl]-3-(3-methoxy-4-  
 nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
 755027-95-3P, 8-Amino-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one 755027-97-5P  
 755027-98-6P 755027-99-7P 755028-01-4P  
 755028-02-5P 755028-03-6P 755028-04-7P  
 755028-05-8P 755028-06-9P 755028-07-0P  
 755028-08-1P 755028-09-2P 755028-10-5P  
 755028-11-6P 755028-12-7P 755028-13-8P  
 755028-14-9P 755028-15-0P 755028-16-1P  
 755028-19-4P 755028-21-8P 755028-22-9P  
 755028-24-1P 755028-25-2P 755028-26-3P  
 755028-27-4P 755028-28-5P 755028-29-6P  
 755028-30-9P 755028-31-0P 755028-32-1P  
 755028-33-2P 755028-34-3P 755028-35-4P  
 755028-38-7P 755028-39-8P 755028-40-1P  
 755028-42-3P 755028-43-4P, 3-(3-Methoxy-4-nitrophenyl)-8-  
 (2-oxopyrrolidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
 755028-46-7P, 3-(3-Methoxy-4-nitrophenyl)-8-(2-oxopiperidin-1-yl)-  
 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755028-49-0P,  
 3-(4-Chloro-3-methoxyphenyl)-8-(2-oxopyrrolidin-1-yl)-5,10-dihydro-11H-  
 dibenzo[b,e][1,4]diazepin-11-one 755028-52-5P

**755028-53-6P**, 3-(4-Chloro-3-methoxyphenyl)-8-(1,1-dioxidoisothiazolidin-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-54-7P** **755028-55-8P** **755028-56-9P**  
**755028-58-1P**, 8-(1,1-Dioxidoisothiazolidin-2-yl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755028-59-2P** **755028-60-5P** **755028-61-6P**  
**755028-62-7P** **755028-63-8P** **755028-64-9P**  
**755028-70-7P** **755028-71-8P** **755028-72-9P**  
**755028-73-0P** **755028-74-1P** **755028-75-2P**  
**755028-76-3P** **755028-77-4P** **755028-78-5P**  
**755028-79-6P**, 8-(1-Hydroxy-1-methylethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755028-81-0P**, 8-(1-Ethyl-1-hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755028-83-2P**, 8-(1-Hydroxy-1-methylethyl)-3-[(pyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-84-3P**, 3-[(2-Chloropyridin-4-yl)amino]-8-(1-hydroxy-1-methylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-86-5P**  
**755028-87-6P**, 8-(1-Hydroxy-1-methylethyl)-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755028-88-7P**, 8-(1-Hydroxy-1-methylethyl)-3-[(2,3,5,6-tetrafluoropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-89-8P**, 8-(1-Ethyl-1-hydroxypropyl)-3-[(pyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755028-90-1P**, 3-[(2-Aminopyrimidin-4-yl)amino]-8-(1-hydroxy-1-methylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755028-91-2P**, 3-[(2-Chloropyridin-4-yl)amino]-8-(1-ethyl-1-hydroxypropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755028-92-3P**, 8-(1-Hydroxy-1-methylethyl)-3-[(2,3,6-trifluoropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-93-4P**, 3-[[2-[(2-Chloropyridin-4-yl)amino]pyridin-4-yl)amino]-8-(1-hydroxy-1-methylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-94-5P**  
**755028-95-6P** **755028-98-9P** **755028-99-0P**, 3-[(2,6-Difluoropyridin-4-yl)amino]-8-(2-hydroxyethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-01-7P**  
**755029-03-9P**, 3-[(2,6-Difluoropyridin-4-yl)amino]-7-(morpholin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-04-0P**, 7-(Morpholin-4-yl)-3-[(2,3,6-trifluoropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-05-1P**, 3-[(2,6-Difluoropyridin-4-yl)amino]-8-(2-hydroxy-2-methylpropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-07-3P**  
**755029-09-5P** **755029-10-8P**, 3-[(2-Chloropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755029-11-9P**, 8-Acetyl-3-[(2-chloropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-14-2P**, 3-[(2-Chloropyridin-4-yl)amino]-8-isopropenyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-15-3P**  
**755029-16-4P**, 3-[(2-Chloropyridin-4-yl)amino]-8-(2-hydroxy-2-methylpropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755029-17-5P** **755029-18-6P**, 3-[(2-Chloropyridin-4-yl)amino]-8-(2-oxopyrrolidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-19-7P**  
**755029-20-0P**, 8-[2-(Pyridin-2-yloxy)ethyl]-3-[(2,3,6-trifluoropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-22-2P**, 8-(2-Hydroxy-2-methylpropyl)-3-[(2,3,5-trifluorophenyl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755029-23-3P**, 3-[(3,5-Difluorophenyl)amino]-7-(3-hydroxy-3-methylbutyl)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755029-39-1P**, 7-(3-Hydroxy-3-methylbutyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one


**755029-41-5P**, 3-[(2,6-Difluoropyridin-4-yl)amino]-7-(3-hydroxypropyl)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755029-43-7P**, 3-Chloro-7-(3-hydroxypropyl)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-44-8P**,  
 7-(3-Hydroxypropyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-46-0P**,  
 3-[(2,6-Difluoropyridin-4-yl)amino]-8-(3-hydroxy-3-methylbutyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-54-0P**,  
 8-(3-Hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-60-8P**  
**755029-61-9P 755029-63-1P**, 8-[3-(Azetidin-1-yl)-3-oxopropyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-64-2P**,  
 3-(3-Methoxy-4-nitrophenyl)-8-[3-oxo-3-(pyrrolidin-1-yl)propyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-65-3P**,  
 3-(3-Methoxy-4-nitrophenyl)-8-[3-(morpholin-4-yl)-3-oxopropyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-66-4P**  
**755029-67-5P**, 8-[3-(4-Hydroxypiperidin-1-yl)-3-oxopropyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755029-68-6P 755029-72-2P 755029-74-4P**  
**755029-78-8P**, 3-(4-Chloro-3-methoxyphenyl)-8-(3-hydroxy-3-methylbutyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755029-80-2P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755029-83-5P 755029-85-7P**, 7-(2-Hydroxy-2-methylpropyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-04-7P**,  
 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-(2-oxopropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-06-9P**,  
 7-(2-Hydroxy-1,1-dimethylethyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-15-0P**,  
 7-(3-Hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-8-(trifluoromethoxy)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-28-5P**,  
 7-(3-Hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-8-(trifluoromethoxy)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755030-31-0P**, 7-(3-Hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-8-methyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755030-48-9P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(pyridin-4-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755030-53-6P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(pyridin-2-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755030-60-5P 755030-62-7P 755030-63-8P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(kinase inhibitor; preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)

RN 755026-42-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(trifluoromethyl)- (9CI) (CA INDEX NAME)



10/785,120


RN 755026-48-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-3-chloro-5,10-dihydro- (9CI)  
(CA INDEX NAME)




RN 755026-50-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-hydroxy- (9CI) (CA INDEX NAME)




RN 755026-54-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 755026-55-2 CAPLUS

CN Benzonitrile, 3-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 755026-58-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



10/785,120




RN 755026-59-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-[3-(1-pyrrolidinyl)propyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 755026-58-5


CMF C28 H30 N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 755026-60-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, N-[3-(dimethylamino)propyl]-10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-61-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, N-[3-(dimethylamino)propyl]-10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

10/785,120

CM 1

CRN 755026-60-9


CMF C26 H28 N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 755026-62-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-N-[3-(4-morpholinyl)propyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-63-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-N-[3-(4-morpholinyl)propyl]-11-oxo-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 755026-62-1

CMF C28 H30 N4 O5


10/785,120



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 755026-64-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-[3-(2-oxo-1-pyrrolidiny)propyl]- (9CI) (CA INDEX NAME)




RN 755026-65-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-[3-(2-oxo-1-pyrrolidiny)propyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 755026-64-3


CMF C28 H28 N4 O5




CM 2

10/785,120


CRN 76-05-1  
CMF C2 H F3 O2




RN 755026-66-5 CAPLUS  
CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-N-(2-hydroxyethyl)-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-67-6 CAPLUS  
CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, N-(2,3-dihydroxypropyl)-10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755026-68-7 CAPLUS  
CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, N-[2-(acetylamino)ethyl]-10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-69-8 CAPLUS  
CN 3-Pyrrolidinol, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI) (CA INDEX NAME)


10/785,120



RN 755026-70-1 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755026-71-2 CAPLUS

CN 2-Piperidinemethanol, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 755026-75-6 CAPLUS


CN 3-Piperidinol, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 755026-76-7 CAPLUS

10/785,120

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755026-77-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(3-pyridinylmethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 755026-76-7


CMF C27 H22 N4 O4



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 755026-78-9 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-N-[[4-(methylsulfonyl)phenyl]methyl]-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 755026-79-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, N-[(2-fluorophenyl)methyl]-10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755026-80-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-N-[(2-methoxyphenyl)methyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-81-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 755026-82-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(2-pyridinylmethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

10/785,120

CM 1

CRN 755026-81-4


CMF C27 H22 N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 755026-83-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 755026-84-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(4-pyridinylmethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 755026-83-6

CMF C27 H22 N4 O4




10/785,120



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 755026-85-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-N-[2-(4-methoxyphenyl)ethyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-86-9 CAPLUS


CN 2-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 755026-87-0 CAPLUS


CN 3-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755026-88-1 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI)  
(CA INDEX NAME)




RN 755026-89-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-, 2-[(1,1-dimethylethoxy)carbonyl]hydrazide (9CI) (CA INDEX NAME)



RN 755026-90-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carbonitrile, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-91-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-nitro- (9CI) (CA INDEX NAME)

10/785,120



RN 755026-92-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 755026-93-8 CAPLUS

CN Methanesulfonamide, N-[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755026-95-0 CAPLUS


CN Methanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755026-97-2 CAPLUS


CN Acetamide, N-[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755026-99-4 CAPLUS

CN Acetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755027-00-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(3-aminophenyl)-5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 755027-02-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 755027-04-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-(3-pyridinyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755027-06-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-(1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)




RN 755027-08-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-(1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)



RN 755027-10-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755027-11-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755027-14-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755027-15-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 755027-17-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-bromo-3-methoxyphenyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755027-19-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-bromo-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)


10/785,120




RN 755027-20-4 CAPLUS  
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-acetyl-3-methoxyphenyl)-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 755027-22-6 CAPLUS  
CN Benzonitrile, 4-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 755027-26-0 CAPLUS  
CN Benzanide, 4-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-N-[(3,4-dihydroxyphenyl)methyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 755027-27-1 CAPLUS  
CN Benzanide, 4-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-N-[(3,4-dihydroxyphenyl)methyl]-2-methoxy- (9CI) (CA INDEX NAME)

10/785,120




RN 755027-28-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(5-methoxy-2-methyl-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755027-29-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-cyano-5-methoxy-2-methylphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755027-32-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(2-methoxy-4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 755027-34-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(2-methoxy-4-pyridinyl)-11-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




10/785,120



RN 755027-39-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-11-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 755027-40-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-11-oxo-N-[3-(1-pyrrolidinyl)propyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 755027-39-5


CMF C26 H27 N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 755027-45-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-


10/785,120

nitrophenyl)-11-oxo-N-[3-(1-pyrrolidiny)propyl]- (9CI) (CA INDEX NAME)




RN 755027-46-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-(dimethylamino)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-methyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-47-5 CAPLUS

CN 3-Piperidinol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755027-48-6 CAPLUS


CN 1H-1,4-Diazepine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)



RN 755027-50-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 755027-51-1 CAPLUS

CN 4-Piperidinol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755027-52-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 755027-53-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755027-54-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


10/785,120




RN 755027-55-5 CAPLUS  
CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-3-quinolinyl- (9CI) (CA INDEX NAME)



RN 755027-56-6 CAPLUS  
CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-6-quinolinyl- (9CI) (CA INDEX NAME)




RN 755027-57-7 CAPLUS  
CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-58-8 CAPLUS  
CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/785,120



RN 755027-59-9 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[(1R)-1-(hydroxymethyl)-2-methylpropyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 755027-60-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(3-ethoxypropyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-61-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-(diethylamino)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-67-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-(3-hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-68-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[3-(diethylamino)propyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-69-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[(1S)-2-hydroxy-1-phenylethyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755027-71-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[(1R)-2-hydroxy-1-phenylethyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755027-72-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(3,4-difluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-73-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-(4-hydroxybutyl)-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-74-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



10/785,120


RN 755027-75-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[4-(dimethylamino)butyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-76-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-77-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-(2-hydroxyethyl)-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-propyl- (9CI) (CA INDEX NAME)



RN 755027-78-2 CAPLUS

CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-4-ethyl- (9CI) (CA INDEX NAME)




RN 755027-79-3 CAPLUS




10/785,120

CN 1-Piperazineethanol, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755027-80-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-methyl-11-oxo-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755027-81-7 CAPLUS

CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 755027-82-8 CAPLUS


CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)



10/785,120


RN 755027-83-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755027-84-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755027-85-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 755027-86-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-(dimethylamino)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



10/785,120


RN 755027-87-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[3-(dimethylamino)propyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-88-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755027-89-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 755027-90-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 755027-91-9 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[2-(4-morpholinyl)ethyl]-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 755027-92-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[3-(4-morpholinyl)propyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-93-1 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[2-(4-methyl-1-piperazinyl)ethyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-94-2 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/785,120


RN 755027-95-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755027-97-5 CAPLUS

CN Urea, [10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755027-98-6 CAPLUS


CN Acetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 755027-99-7 CAPLUS


CN Pentanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-(dimethylamino)-4-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755028-01-4 CAPLUS

CN Butanamide, 4-amino-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-02-5 CAPLUS

CN Propanamide, 3-amino-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-03-6 CAPLUS

CN 1H-Imidazole-5-acetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 755028-04-7 CAPLUS

CN 1H-Imidazole-4-acetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 755028-05-8 CAPLUS

CN 3-Thiophenecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-06-9 CAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-07-0 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 755028-08-1 CAPLUS


CN 4-Thiazolecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-09-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-10-5 CAPLUS

CN 1H-Pyrazole-4-carboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-11-6 CAPLUS

CN 4-Pyridinecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-12-7 CAPLUS

CN 1-Pyrrolidinepropanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




10/785,120




RN 755028-13-8 CAPLUS

CN 1-Piperidinepropanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-14-9 CAPLUS


CN 4-Morpholinepropanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-15-0 CAPLUS

CN Benzenebutanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-α-hydroxy-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755028-16-1 CAPLUS


CN Propanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-

dibenzo[b,e][1,4]diazepin-8-yl]-3-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 755028-19-4 CAPLUS

CN Acetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-[(4-methylphenyl)sulfonyl]amino]- (9CI)  
(CA INDEX NAME)




RN 755028-21-8 CAPLUS

CN 2-Pyridinecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-22-9 CAPLUS


CN 3-Pyridinecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



10/785,120


RN 755028-24-1 CAPLUS

CN 3-Pyridineacetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-25-2 CAPLUS

CN 1-Piperazineacetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-4-methyl- (9CI) (CA INDEX NAME)



RN 755028-26-3 CAPLUS


CN Propanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-3-ethoxy- (9CI) (CA INDEX NAME)



RN 755028-27-4 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-5-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755028-28-5 CAPLUS


CN Cyclohexanecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 755028-29-6 CAPLUS

CN Benzeneacetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-α-methoxy-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755028-30-9 CAPLUS


CN Benzeneacetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-α-methoxy-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755028-31-0 CAPLUS

CN 2-Furancarboxamide, N-[2-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 755028-32-1 CAPLUS

CN 4-Piperidinecarboxamide, 1-acetyl-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-33-2 CAPLUS


CN Pentanediamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-N'-phenyl- (9CI) (CA INDEX NAME)



RN 755028-34-3 CAPLUS

10/785,120


CN Benzeneacetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 755028-35-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-5-oxo-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755028-38-7 CAPLUS

CN Benzeneacetamide, N-[3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-α-methoxy-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755028-39-8 CAPLUS


CN 1-Piperidinepropanamide, N-[3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-40-1 CAPLUS

CN Methanesulfonamide, N-[3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-42-3 CAPLUS

CN 1-Piperidinepropanamide, N-[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-43-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 755028-46-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-(2-oxo-1-piperidinyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-49-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-8-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 755028-52-5 CAPLUS

CN Benzenemethanesulfonamide, N-[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-53-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-8-(1,1-dioxido-2-isothiazolidinyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755028-54-7 CAPLUS

CN Ethanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)




10/785,120




RN 755028-55-8 CAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 755028-56-9 CAPLUS

CN Benzenemethanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-58-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(1,1-dioxido-2-isothiazolidinyl)-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755028-59-2 CAPLUS


CN 4-Morpholinepropanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-60-5 CAPLUS

CN 1-Piperidinepropanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-61-6 CAPLUS

CN 1-Propanesulfonamide, 3-(diethylamino)-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-62-7 CAPLUS


CN 1-Propanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-3-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 755028-63-8 CAPLUS


CN Methanesulfonamide, 1-chloro-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-64-9 CAPLUS

CN Benamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 755028-70-7 CAPLUS

CN Benzenemethanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755028-71-8 CAPLUS

CN Benzenemethanesulfonamide, 4-chloro-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755028-72-9 CAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 755028-73-0 CAPLUS

CN Methanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755028-74-1 CAPLUS

CN 4-Morpholinepropanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755028-75-2 CAPLUS

CN 1-Piperidinepropanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755028-76-3 CAPLUS

CN 1-Propanesulfonamide, 3-(diethylamino)-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755028-77-4 CAPLUS

CN 1-Propanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]-3-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 755028-78-5 CAPLUS

CN 2H-Pyran-4-carboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]tetrahydro- (9CI) (CA INDEX NAME)



RN 755028-79-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(1-hydroxy-1-methylethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755028-81-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(1-ethyl-1-hydroxypropyl)-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-83-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(1-hydroxy-1-methylethyl)-3-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 755028-84-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(1-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 755028-86-5 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[[10,11-dihydro-8-(1-hydroxy-1-methylethyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl]amino]- (9CI) (CA INDEX NAME)




RN 755028-87-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(1-hydroxy-1-methylethyl)-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755028-88-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(1-hydroxy-1-methylethyl)-3-[(2,3,5,6-tetrafluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755028-89-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(1-ethyl-1-hydroxypropyl)-5,10-dihydro-3-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 755028-90-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-amino-4-pyrimidinyl)amino]-5,10-dihydro-8-(1-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)



RN 755028-91-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-8-(1-ethyl-1-hydroxypropyl)-5,10-dihydro- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-92-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(1-hydroxy-1-methylethyl)-3-[(2,3,6-trifluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755028-93-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[[2-[(2-chloro-4-pyridinyl)amino]-4-pyridinyl]amino]-5,10-dihydro-8-(1-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)



RN 755028-94-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-α,α-dimethyl-11-oxo-3-[(2,3,6-trifluoro-4-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 755028-95-6 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo-3-[(2,3,6-trifluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)






RN 755028-98-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755028-99-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 755029-01-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-α,α-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-03-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 755029-04-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-morpholinyl)-3-[(2,3,6-trifluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755029-05-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxy-2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 755029-07-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-11-oxo-3-(4-pyridinylamino)-, methyl ester (9CI) (CA INDEX NAME)



RN 755029-09-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-[(2-methyl-4-pyridinyl)amino]-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755029-10-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755029-11-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-acetyl-3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755029-14-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(1-methylethenyl)- (9CI) (CA INDEX NAME)




RN 755029-15-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2-chloro-4-pyridinyl)amino]-10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-16-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxy-2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 755029-17-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2-chloro-4-pyridinyl)amino]-10,11-dihydro-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755029-18-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 755029-19-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetic acid, 3-[(2-chloro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755029-20-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[2-(2-pyridinyloxy)ethyl]-3-[(2,3,6-trifluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755029-22-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-2-methylpropyl)-3-[(2,3,5-trifluorophenyl)amino]- (9CI) (CA INDEX NAME)




RN 755029-23-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(3,5-difluorophenyl)amino]-5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-8-methoxy- (9CI) (CA INDEX NAME)




RN 755029-39-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755029-41-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-7-(3-hydroxypropyl)-8-methoxy- (9CI) (CA INDEX NAME)




RN 755029-43-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(3-hydroxypropyl)-8-methoxy- (9CI) (CA INDEX NAME)



RN 755029-44-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxypropyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755029-46-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-(3-hydroxy-3-methylbutyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755029-54-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(3-hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755029-60-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755029-61-9 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755029-63-1 CAPLUS


CN Azetidine, 1-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755029-64-2 CAPLUS

CN Pyrrolidine, 1-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755029-65-3 CAPLUS

CN Morpholine, 4-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 755029-66-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, N,N-diethyl-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755029-67-5 CAPLUS


CN 4-Piperidinol, 1-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)






RN 755029-68-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-2-thiazolyl- (9CI) (CA INDEX NAME)




RN 755029-72-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755029-74-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755029-78-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-8-(3-hydroxy-3-methylbutyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755029-80-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 755029-83-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanoic acid, 10,11-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-85-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxy-2-methylpropyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755030-04-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-(2-oxopropyl)- (9CI) (CA INDEX NAME)




RN 755030-06-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxy-1,1-dimethylethyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755030-15-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-8-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



RN 755030-28-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-8-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



RN 755030-31-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-8-methyl- (9CI) (CA INDEX NAME)

10/785,120




RN 755030-48-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755030-53-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755030-60-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(2-oxo-1(2H)-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755030-62-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-(5-fluoro-2-oxo-1(2H)-pyridinyl)ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755030-63-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(6-oxo-1(6H)-pyridazinyl)ethyl]- (9CI) (CA INDEX NAME)



IT **755030-65-0P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(pyridin-2-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755030-66-1P**, 8-[2-[(5-Chloropyridin-3-yl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755030-67-2P**, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-[(pyridin-3-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755030-69-4P** **755030-71-8P** **755030-73-0P**  
**755030-75-2P** **755030-77-4P** **755030-80-9P**  
**755030-91-2P** **755030-97-8P** **755030-99-0P**  
**755031-01-7P** **755031-03-9P** **755031-05-1P**  
**755031-07-3P** **755031-10-8P** **755031-12-0P**  
**755031-15-3P** **755031-16-4P** **755031-17-5P**  
**755031-19-7P** **755031-20-0P** **755031-24-4P**  
**755031-31-3P** **755031-33-5P** **755031-35-7P**  
**755031-36-8P**, 7-(3-Hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-43-7P**,  
7-(3-Hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-45-9P**,  
8-(2-Hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-47-1P**,  
8-(2-Hydroxy-1,1,2-trimethylpropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-49-3P**,  
8-(1,1-Dimethyl-2-oxopropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-51-7P**,  
7-(2-Hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-52-8P**,  
8-[1-(Hydroxymethyl)cyclopropyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-53-9P**,  
3-[(2-Chloropyridin-4-yl)amino]-8-(2-hydroxy-1,1-dimethylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-54-0P**,  
3-[(2,6-Difluoropyridin-4-yl)amino]-8-(2-hydroxy-1,1-dimethylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-55-1P**,  
3-[(2,6-Difluoropyridin-4-yl)amino]-8-(2-hydroxy-1,1,2-trimethylpropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-57-3P**,  
3-(4-Chloro-3-methoxyphenyl)-8-(2-hydroxy-1,1-dimethylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-58-4P**,

3-(3-Methoxy-4-nitrophenyl)-8-[2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-60-8P**,  
 3-(4-Chloro-3-methoxyphenyl)-8-[2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-61-9P**  
**755031-62-0P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[[4-(morpholin-4-yl)phenyl]amino]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755031-65-3P 755031-67-5P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[[5-methylpyridin-2-yl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-68-6P**  
**755031-69-7P**, 8-[2-(Isoquinolin-3-yloxy)ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755031-70-0P 755031-71-1P**, 8-[1,1-Dimethyl-2-(pyridin-2-yloxy)ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-73-3P**,  
 8-[1,1-Dimethyl-2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755031-77-7P 755031-78-8P**, 8-(2-Hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)-7-methyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-79-9P**  
**755031-87-9P 755031-89-1P 755031-91-5P**, 8-(2-Hydroxy-1,1-dimethylethyl)-3-[(2-methylpyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-92-6P**,  
 8-(2-Hydroxy-1,1,2-trimethylpropyl)-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-93-7P**  
**755031-94-8P 755031-95-9P 755031-96-0P**  
**755031-97-1P 755031-98-2P 755031-99-3P**  
**755032-00-9P 755032-01-0P 755032-02-1P**  
**755032-03-2P 755032-04-3P 755032-05-4P**  
**755032-06-5P 755032-07-6P 755032-08-7P**  
**755032-09-8P 755032-10-1P 755032-11-2P**  
**755032-12-3P 755032-13-4P 755032-14-5P**  
**755032-15-6P 755032-17-8P 755032-18-9P**,  
 8-[1,1-Dimethyl-2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755032-19-0P 755032-20-3P**, 8-[1,1-Dimethyl-2-(morpholin-4-yl)-2-oxoethyl]-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-21-4P**  
**755032-22-5P 755032-23-6P 755032-24-7P**  
**755032-25-8P 755032-26-9P 755032-27-0P**  
**755032-28-1P 755032-29-2P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(quinolin-2-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-30-5P 755032-31-6P 755032-32-7P**  
**755032-33-8P 755032-34-9P 755032-35-0P**,  
 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(4-methylpyridin-2-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-36-1P**,  
 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(3-methoxypyridin-2-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-37-2P**  
**755032-38-3P**, 8-[2-[(6-Chloropyridin-2-yl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755032-39-4P**, 8-[2-[(5-Chloropyridin-2-yl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755032-42-9P 755032-43-0P 755032-45-2P**,  
 8-[2-(3-Aminopyrrolidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-46-3P**,  
 8-[2-(3-Aminopyrrolidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one trifluoroacetate  
**755032-48-5P 755032-49-6P**, (S)-8-[2-[2-(Hydroxymethyl)pyrrolidin-1-yl]-2-oxoethyl]-3-(2-methoxy-5-methylpyridin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-50-9P**  
**755032-51-0P 755032-52-1P 755032-53-2P**,  
 3-(4-Chloro-3-methoxyphenyl)-8-[2-(3-hydroxypiperidin-1-yl)-2-oxoethyl]-

5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-54-3P**,  
 (S)-3-(4-Chloro-3-methoxyphenyl)-8-[2-[2-(hydroxymethyl)pyrrolidin-1-yl]-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755032-55-4P 755032-57-6P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-oxo-2-(piperazin-1-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-59-8P 755032-60-1P 755032-61-2P**,  
 3-(3-Methoxy-4-nitrophenyl)-8-[2-(morpholin-4-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-62-3P**,  
 3-(2-Methoxy-5-methylpyridin-4-yl)-8-[2-(morpholin-4-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-63-4P**  
**755032-65-6P 755032-67-8P**, 8-[2-(Morpholin-4-yl)-2-oxoethyl]-3-(2-oxo-1,2-dihydropyridin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-69-0P**  
**755032-71-4P 755032-75-8P**, 3-(3-Methoxy-4-nitrophenyl)-7-[2-(morpholin-4-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-76-9P 755032-77-0P 755032-78-1P**  
**755032-79-2P**, 7-[2-(4-Hydroxypiperidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-80-5P**,  
 7-[2-(3-Hydroxypiperidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-81-6P 755032-82-7P 755032-83-8P**  
**755032-84-9P**, 7-[2-(Azetidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-85-0P 755032-86-1P 755032-87-2P**,  
 (R)-7-[2-[2-(Hydroxymethyl)pyrrolidin-1-yl]-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-88-3P 755032-89-4P 755032-90-7P**  
**755032-91-8P 755032-92-9P**, (S)-7-[2-[2-(Hydroxymethyl)pyrrolidin-1-yl]-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-93-0P**,  
 7-[2-(3-Aminopyrrolidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-94-1P**,  
 3-(3-Methoxy-4-nitrophenyl)-7-[2-oxo-2-(piperazin-1-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-95-2P**  
**755032-96-3P 755032-97-4P 755032-99-6P**  
**755033-01-3P**, 3-(3-Methoxy-4-nitrophenyl)-7-[2-oxo-2-(4-thiomorpholinyl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-03-5P 755033-04-6P 755033-05-7P**  
**755033-06-8P 755033-07-9P 755033-08-0P**  
**755033-09-1P 755033-10-4P**, 7-[2-(1,4-Dioxo-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-11-5P**,  
 7-[2-(2,6-Dimethylmorpholin-4-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-12-6P**,  
 7-[2-(4-Acetylpiperazin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-13-7P**,  
 3-(3-Methoxy-4-nitrophenyl)-7-[2-oxo-2-[4-(pyridin-2-yl)piperazin-1-yl]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-14-8P 755033-15-9P 755033-16-0P**  
**755033-17-1P 755033-18-2P 755033-19-3P**  
**755033-20-6P 755033-21-7P 755033-22-8P**  
**755033-23-9P 755033-24-0P 755033-25-1P**  
**755033-26-2P 755033-27-3P 755033-28-4P**  
**755033-29-5P**, 8-Hydroxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-30-8P**,  
 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-34-2P**,  
 8-Ethoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-35-3P**,  
 3-(3-Methoxy-4-nitrophenyl)-8-[2-(4-methyl-1,3-thiazol-5-yl)ethoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-37-5P**,

8-[3-(Dimethylamino)propoxy]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-38-6P**,  
 3-(3-Methoxy-4-nitrophenyl)-8-[2-(morpholin-4-yl)ethoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-39-7P**,  
 3-(3-Methoxy-4-nitrophenyl)-8-[2-[4-(morpholin-4-yl)phenyl]ethoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-41-1P**,  
 3-(3-Methoxy-4-nitrophenyl)-7-(piperidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-43-3P**,  
 (S)-7-[2-(Hydroxymethyl)pyrrolidin-1-yl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-46-6P**,  
 3-(3-Methoxy-4-nitrophenyl)-7-(morpholin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-48-8P**,  
 7-(4-Hydroxypiperidin-1-yl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-54-6P**  
**755033-59-1P**, 8-(2-Ethyl-2-hydroxybutyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755033-65-9P**, 3-[(2-Chloropyridin-4-yl)amino]-8-(2-ethyl-2-hydroxybutyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755033-68-2P 755033-75-1P 755033-79-5P**,  
 8-(2-Hydroxy-2-methylpropyl)-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-81-9P**,  
 8-(2-Hydroxy-2-methylpropyl)-3-[(2-methylpyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-83-1P**,  
 3-(3-Methoxy-4-nitrophenyl)-8-(2-oxopropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-87-5P**,  
 3-[(2-Chloropyridin-4-yl)amino]-8-(2-oxopropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-89-7P**,  
 3-[[2-[(2-Chloropyridin-4-yl)amino]pyridin-4-yl]amino]-8-(2-oxopropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-92-2P**  
**755033-93-3P 755033-96-6P**, 3-[[3-(2-Hydroxyethyl)pyridin-4-yl]amino]-8-(1-hydroxy-1-methylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-00-5P**,  
 8-(2-Hydroxy-2-methylpropyl)-3-[(2-methoxypyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-02-7P**, Methyl  
 11-oxo-3-(pyrimidin-4-ylamino)-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-7-carboxylate **755034-08-3P**, 7-(1-Hydroxy-1-methylethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-11-8P**, 7-(1-Hydroxy-1-methylethyl)-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-12-9P 755034-14-1P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[[6-(morpholin-4-yl)pyridin-3-yl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-18-5P**,  
 3-(4-Hydroxy-3-methoxyphenyl)-8-[2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-20-9P**,  
 3-[(2,6-Difluoropyridin-4-yl)amino]-8-[2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-29-8P**, 8-Hydroxy-7-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-38-9P**,  
 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(tetrahydro-2H-pyran-2-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-39-0P**, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(1-methylpiperidin-3-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-40-3P**, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(pyridin-2-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-41-4P**, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(pyridin-3-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-42-5P**, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(pyridin-4-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-43-6P 755034-44-7P 755034-45-8P**,  
 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2-methyl-1,3-thiazol-4-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one




**755034-46-9P**, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2-oxo-1,3-oxazolidin-5-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-48-1P**, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(tetrahydrofuran-2-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-49-2P**, 7-[(2,2-Dimethyl-1,3-dioxolan-4-yl)methoxy]-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-50-5P**, (R)-8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(pyrrolidin-2-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-51-6P**  
**755034-52-7P**, 7,8-Dimethoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-53-8P**, 8-Methoxy-7-[2-(2-methoxyethoxy)ethoxy]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-54-9P**, 7-(2,3-Dihydroxypropoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-55-0P**, 7-[3-Hydroxy-2,2-bis(hydroxymethyl)propoxy]-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-56-1P** **755034-57-2P**, 7-(3-Aminopropoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-58-3P**, 7-(3-Aminopropoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-59-4P**, 7-[2-(Dimethylamino)ethoxy]-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-61-8P**, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-(pyrrolidin-1-yl)ethoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-63-0P**, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-(morpholin-4-yl)ethoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-64-1P**, 7-(4-Hydroxybutoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-65-2P**, 7-(4-Hydroxybutoxy)-3-(4-hydroxy-3-methoxyphenyl)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755034-69-6P**, 7-(4-Hydroxybutoxy)-8-methoxy-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(kinase inhibitor; preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)

RN 755030-65-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(2-pyridinyloxy)ethyl]- (9CI) (CA INDEX NAME)



RN 755030-66-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(5-chloro-3-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755030-67-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-(3-pyridinyloxy)ethyl]- (9CI) (CA INDEX NAME)




RN 755030-69-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(5-isoquinolinyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755030-71-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(8-nitro-5-isoquinolinyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



10/785,120


RN 755030-73-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 3-(4-formyl-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755030-75-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 10,11-dihydro-3-[4-(hydroxymethyl)-3-methoxyphenyl]-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755030-77-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 10,11-dihydro-3-[3-methoxy-4-(1-oxopropyl)phenyl]-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755030-80-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755030-91-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(4-cyano-3-methoxyphenyl)-


10/785,120

10,11-dihydro- $\alpha,\alpha$ -dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo-  
(9CI) (CA INDEX NAME)




RN 755030-97-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(4-chloro-3-methoxyphenyl)-  
10,11-dihydro- $\alpha,\alpha$ -dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo-  
(9CI) (CA INDEX NAME)




RN 755030-99-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-  
nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-N-2-pyridinyl- (9CI) (CA  
INDEX NAME)




RN 755031-01-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-  
nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-N-3-pyridinyl- (9CI) (CA  
INDEX NAME)




RN 755031-03-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 755031-05-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 755031-07-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-[(tetrahydro-3-furanyl)methyl]- (9CI) (CA INDEX NAME)




10/785,120

RN 755031-10-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-N-2-thiazolyl- (9CI) (CA INDEX NAME)






RN 755031-17-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro- $\alpha,\alpha$ -dimethyl-11-oxo-3-(4-pyrimidinylamino)-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 755031-19-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro- $\alpha,\alpha$ -dimethyl-11-oxo-3-(4-pyrimidinylamino)-N-[[3-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 755031-20-0 CAPLUS

CN Cyclopropanecarboxamide, 1-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 755031-24-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755031-31-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 755031-33-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)






RN 755031-35-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(cyclopropylmethyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI)  
(CA INDEX NAME)




RN 755031-36-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-43-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-45-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-47-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-1,1,2-trimethylpropyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-49-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(1,1-dimethyl-2-oxopropyl)-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-51-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-52-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[1-(hydroxymethyl)-cyclopropyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-53-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 755031-54-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 755031-55-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxy-1,1,2-trimethylpropyl)- (9CI) (CA INDEX NAME)



RN 755031-57-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755031-58-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755031-60-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 755031-61-9 CAPLUS


CN Benzonitrile, 4-[10,11-dihydro-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 755031-62-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[4-(4-morpholinyl)phenyl]amino]ethyl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755031-65-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-methyl-2-oxo-1(2H)-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755031-67-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(5-methyl-2-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755031-68-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(4-methyl-2-oxo-1(2H)-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755031-69-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[2-(3-isoquinolinyl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-70-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-(5-chloro-2-oxo-1(2H)-pyridinyl)ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-71-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[1,1-dimethyl-2-(2-pyridinyloxy)ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755031-73-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[1,1-dimethyl-2-[4-(4-morpholinyl)phenoxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755031-77-7 CAPLUS


10/785,120

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 755031-78-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)-7-methyl- (9CI) (CA INDEX NAME)




RN 755031-79-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-2-methyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755031-87-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[4-(aminomethyl)-3-methoxyphenyl]-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755031-89-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(2-methoxy-5-

10/785,120


methyl-4-pyridinyl)- $\alpha,\alpha$ -dimethyl-N-[4-(4-morpholinyl)phenyl]-  
11-oxo-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 755031-91-5 CAPLUS

11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)-3-[(2-methyl-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755031-92-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-1,1,2-trimethylpropyl)-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755031-93-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-methyl-11-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)







RN 755031-94-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)


RN 755031-95-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)

RN 755031-96-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-N-(4-methyl-2-thiazolyl)-11-oxo- (9CI) (CA INDEX NAME)


RN 755031-97-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

10/785,120


RN 755031-98-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(3-fluorophenyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo- (9CI)  
(CA INDEX NAME)




RN 755031-99-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-N-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 755032-00-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 755032-01-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-N-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 755032-02-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-03-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(2-fluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-04-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(3-fluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-05-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(4-fluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo- (9CI) (CA INDEX NAME)



10/785,120


RN 755032-06-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-N-[[4-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 755032-07-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 755032-08-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 755032-09-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-N-[[3-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



10/785,120


RN 755032-10-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-(2-fluorophenyl)ethyl]-  
10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-  
(9CI) (CA INDEX NAME)




RN 755032-11-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-(3-fluorophenyl)ethyl]-  
10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-  
(9CI) (CA INDEX NAME)




RN 755032-12-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(2,4-difluorophenyl)methyl]-  
10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-  
(9CI) (CA INDEX NAME)




RN 755032-13-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(2,6-difluorophenyl)methyl]-  
10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo-  
(9CI) (CA INDEX NAME)




RN 755032-14-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(cyclopropylmethyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI)  
(CA INDEX NAME)




RN 755032-15-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(3-ethoxypropyl)-10,11-dihydro-α,α-dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755032-17-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(3,4-difluorophenyl)methyl]-10,11-dihydro-α,α-dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755032-18-9 CAPLUS

CN Piperazine, 1-[2-[10,11-dihydro-11-oxo-3-(4-pyrimidinylamino)-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 755032-19-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-cyclopentyl-10,11-dihydro- $\alpha,\alpha$ -dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)

RN 755032-20-3 CAPLUS

CN Morpholine, 4-[2-[10,11-dihydro-11-oxo-3-(4-pyrimidinylamino)-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755032-21-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro- $\alpha,\alpha$ -dimethyl-11-oxo-3-(4-pyrimidinylamino)-N-[(tetrahydro-3-furanyl)methyl]- (9CI) (CA INDEX NAME)


RN 755032-22-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(cyclopentylmethyl)-10,11-dihydro- $\alpha,\alpha$ -dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755032-23-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(cyclopropylmethyl)-10,11-dihydro- $\alpha,\alpha$ -dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755032-24-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro- $\alpha,\alpha$ -dimethyl-11-oxo-3-(4-pyrimidinylamino)-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)



RN 755032-25-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro- $\alpha,\alpha$ -dimethyl-11-oxo-3-(4-pyrimidinylamino)-N-2-thiazolyl- (9CI) (CA INDEX NAME)



RN 755032-26-9 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[(2,5-difluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- $\alpha,\alpha$ -dimethyl-11-oxo- (9CI) (CA INDEX NAME)






RN 755032-27-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(2-ethoxyethyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-28-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(4-fluorophenyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-29-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(2-quinolinylloxy)ethyl]- (9CI) (CA INDEX NAME)




RN 755032-30-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-


10/785,120

nitrophenyl)-8-[2-(5-methyl-2-oxo-1(2H)-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755032-31-6 CAPLUS

CN 3-Pyridinecarbonitrile, 2-[2-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]ethoxy]-6-methyl- (9CI) (CA INDEX NAME)




RN 755032-32-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(1-oxo-2(1H)-isoquinolinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 755032-33-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[2-oxo-5-(trifluoromethyl)-1(2H)-pyridinyl]ethyl]- (9CI) (CA INDEX NAME)



10/785,120


RN 755032-34-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-methoxy-2-oxo-1(2H)-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755032-35-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(4-methyl-2-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755032-36-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(3-methoxy-2-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 755032-37-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-oxo-2(3H)-isoquinolinyl)ethyl]- (9CI) (CA INDEX NAME)



10/785,120


RN 755032-38-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(6-chloro-2-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755032-39-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(5-chloro-2-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755032-42-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-acetyl-3-methoxyphenyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-43-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-45-2 CAPLUS

CN 3-Pyrrolidinamine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-

10/785,120

dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-46-3 CAPLUS

CN 3-Pyrrolidinamine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 755032-45-2


CMF C26 H25 N5 O5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 755032-48-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




10/785,120

RN 755032-49-6 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-, (2S)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 755032-50-9 CAPLUS

CN Carbamic acid, [1-[[10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 755032-51-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-52-1 CAPLUS


CN Carbamic acid, [1-[[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/785,120



RN 755032-53-2 CAPLUS


CN 3-Piperidinol, 1-[[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755032-54-3 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755032-55-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-57-6 CAPLUS


10/785,120

CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-59-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-60-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-methyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-61-2 CAPLUS


CN Morpholine, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755032-62-3 CAPLUS


CN Morpholine, 4-[[10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)






RN 755032-63-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-65-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-67-8 CAPLUS

CN Morpholine, 4-[[3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-69-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-71-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755032-75-8 CAPLUS

CN Morpholine, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-76-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-2-pyridinyl- (9CI) (CA INDEX NAME)




RN 755032-77-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 755032-78-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 755032-79-2 CAPLUS

CN 4-Piperidinol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-80-5 CAPLUS

CN 3-Piperidinol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-81-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755032-82-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755032-83-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 755032-84-9 CAPLUS


CN Azetidine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755032-85-0 CAPLUS


10/785,120

CN 3-Piperidinecarboxamide, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755032-86-1 CAPLUS


CN 4-Piperidinecarboxamide, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755032-87-2 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755032-88-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)

10/785,120



RN 755032-89-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N,N-bis(2-methoxyethyl)-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-90-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[[ (2S)-tetrahydro-2-furanyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755032-91-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(2-propoxyethyl)- (9CI) (CA INDEX NAME)




10/785,120

RN 755032-92-9 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755032-93-0 CAPLUS

CN 3-Pyrrolidinamine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-94-1 CAPLUS

CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-95-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-(3-methoxypropyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-96-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(cyanomethyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-97-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(cyclopropylmethyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-99-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(1,3-dioxolan-2-ylmethyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-methyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-01-3 CAPLUS

CN Thiomorpholine, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




10/785,120




RN 755033-03-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755033-04-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 755033-05-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[2-(2,3-dimethoxyphenyl)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-06-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[2-(1,3-benzodioxol-5-


10/785,120

yl)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-07-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 755033-08-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(5-thiazolylmethyl)- (9CI) (CA INDEX NAME)




RN 755033-09-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[2-(1H-imidazol-4-yl)ethyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-10-4 CAPLUS

CN 1,4-Dioxa-8-azaspiro[4.5]decane, 8-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755033-11-5 CAPLUS

CN Morpholine, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]-2,6-dimethyl- (9CI) (CA INDEX NAME)




RN 755033-12-6 CAPLUS

CN Piperazine, 1-acetyl-4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755033-13-7 CAPLUS


CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 755033-14-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[3-(aminocarbonyl)phenyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 755033-15-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755033-16-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-6-quinolinyl- (9CI) (CA INDEX NAME)



RN 755033-17-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/785,120

RN 755033-18-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[(1S)-1-(aminocarbonyl)-3-methylbutyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755033-19-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[(1S)-2-hydroxy-1-phenylethyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755033-20-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(2,3-dihydroxypropyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-21-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[3-(1H-imidazol-1-yl)propyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-22-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 755033-23-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[(2,6-difluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755033-24-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-25-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[(1R)-1-(hydroxymethyl)-2-methylpropyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

10/785,120


Absolute stereochemistry.



RN 755033-26-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[(1R)-2-hydroxy-1-phenylethyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755033-27-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(3-thienylmethyl)- (9CI) (CA INDEX NAME)



RN 755033-28-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[4-(aminocarbonyl)-3-methoxyphenyl]-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755033-29-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-hydroxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755033-30-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755033-34-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-ethoxy-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755033-35-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(4-methyl-5-thiazolyl)ethoxy]- (9CI) (CA INDEX NAME)




10/785,120




RN 755033-37-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[3-(dimethylamino)propoxy]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755033-38-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 755033-39-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[4-(4-morpholinyl)phenyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 755033-41-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-7-(1-piperidinyl)- (9CI) (CA INDEX NAME)


10/785,120



RN 755033-43-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755033-46-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 755033-48-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxy-1-piperidiny)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755033-54-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-[3-methoxy-4-


10/785,120

(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755033-59-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(2-ethyl-2-hydroxybutyl)-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755033-65-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-8-(2-ethyl-2-hydroxybutyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755033-68-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N,N-dimethyl-11-oxo-3-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 755033-75-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo-3-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 755033-79-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-2-methylpropyl)-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755033-81-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-2-methylpropyl)-3-[(2-methyl-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)



RN 755033-83-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-(2-oxopropyl)- (9CI) (CA INDEX NAME)



RN 755033-87-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(2-oxopropyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755033-89-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[[2-[(2-chloro-4-pyridinyl)amino]-4-pyridinyl]amino]-5,10-dihydro-8-(2-oxopropyl)- (9CI) (CA INDEX NAME)




RN 755033-92-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)



RN 755033-93-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-α,α-dimethyl-3-[(2-methyl-4-pyridinyl)amino]-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755033-96-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-[[3-(2-hydroxyethyl)-4-pyridinyl]amino]-8-(1-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755034-00-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-2-methylpropyl)-3-[(2-methoxy-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755034-02-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-carboxylic acid, 10,11-dihydro-11-oxo-3-(4-pyrimidinylamino)-, methyl ester (9CI) (CA INDEX NAME)




RN 755034-08-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(1-hydroxy-1-methylethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-11-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(1-hydroxy-1-methylethyl)-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755034-12-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-[(6-methoxy-4-pyrimidinyl)amino]-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755034-14-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[[6-(4-morpholinyl)-3-pyridinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 755034-18-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)



10/785,120


RN 755034-20-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755034-29-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-hydroxy-7-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-38-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(tetrahydro-2H-pyran-2-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 755034-39-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(1-methyl-3-piperidinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 755034-40-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-(2-pyridinylmethoxy)- (9CI) (CA INDEX NAME)






RN 755034-41-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 755034-42-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-(4-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 755034-43-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(5-methyl-3-isoxazolyl)methoxy]- (9CI) (CA INDEX NAME)




RN 755034-44-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(1-methyl-1H-imidazol-5-yl)methoxy]- (9CI) (CA INDEX NAME)




RN 755034-45-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2-methyl-4-thiazolyl)methoxy]- (9CI) (CA INDEX NAME)




RN 755034-46-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2-oxo-5-oxazolidinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 755034-48-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(tetrahydro-2-furanyl)methoxy]- (9CI) (CA INDEX NAME)



RN 755034-49-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)


10/785,120



RN 755034-50-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2R)-2-pyrrolidinylmethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755034-51-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2R)-2-pyrrolidinylmethoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 755034-50-5

CMF C26 H26 N4 O6


Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 755034-52-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7,8-dimethoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-53-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-7-[2-(2-methoxyethoxy)ethoxy]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755034-54-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(2,3-dihydroxypropoxy)-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755034-55-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755034-56-1 CAPLUS

CN 1-Propanesulfonic acid, 3-[[10,11-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]oxy]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 755034-57-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(3-aminopropoxy)-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-58-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(3-aminopropoxy)-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 755034-57-2

CMF C24 H24 N4 O6




10/785,120

CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 755034-59-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-[2-(dimethylamino)ethoxy]-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-61-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 755034-63-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 755034-64-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxybutoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-65-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxybutoxy)-3-(4-hydroxy-3-methoxyphenyl)-8-methoxy- (9CI) (CA INDEX NAME)



RN 755034-69-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxybutoxy)-8-methoxy-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)



IT **755034-70-9P 755034-71-0P**, 3-[(2,6-Difluoropyridin-4-yl)amino]-7-(4-hydroxybutoxy)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-72-1P**, 7-(4-Hydroxybutoxy)-8-methoxy-3-[(2,3,6-trifluoropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-73-2P**, 7-Ethoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-76-5P**, 7-(4-Hydroxybutoxy)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-80-1P**, 7-(2-Hydroxyethoxy)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-82-3P**, 7-(2,3-Dihydroxypropoxy)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-83-4P**, 7-[2-(2-Methoxyethoxy)ethoxy]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-84-5P**, 7-(Methoxymethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-91-4P**, 7-(3-Methoxy-4-nitrobenzyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-93-6P**, 7-[[[2-(Dimethylamino)ethyl](methyl)amino]methyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-95-8P**, 3-(3-Methoxy-4-nitrophenyl)-7-[[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-

11-one **755034-97-0P**, 8-Ethyl-7-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-04-2P**, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-vinyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-07-5P**,  
 8-(3-Hydroxypropyl)-7-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-14-4P**,  
 7-Methoxy-3-(3-methoxy-4-nitrophenyl)-8-[3-[(2-methylpyridin-3-yl)oxy]propyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-16-6P**, 8-[3-[(2-Chloropyridin-3-yl)oxy]propyl]-7-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-17-7P**, 7-Methoxy-3-(3-methoxy-4-nitrophenyl)-8-[3-[[4-(morpholin-4-yl)phenyl]oxy]propyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-19-9P**,  
 8-[3-(Isoquinolin-3-yloxy)propyl]-7-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-20-2P**  
**755035-22-4P**, Methyl 7-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylate  
**755035-25-7P**, Methyl 7-methoxy-11-oxo-3-(pyrimidin-4-ylamino)-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylate  
**755035-26-8P**, 3-[(2,6-Difluoropyridin-4-yl)amino]-8-[1,1-dimethyl-2-(morpholin-4-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-27-9P** **755035-28-0P** **755035-30-4P**  
**755035-31-5P** **755035-33-7P**, 3-[(2,6-Difluoropyridin-4-yl)amino]-8-[2-(4-hydroxypiperidin-1-yl)-1,1-dimethyl-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-34-8P**,  
 (S)-3-[(2,6-Difluoropyridin-4-yl)amino]-8-[2-[2-(hydroxymethyl)pyrrolidin-1-yl]-1,1-dimethyl-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-35-9P**, 3-[(2,6-Difluoropyridin-4-yl)amino]-8-[1,1-dimethyl-2-oxo-2-(pyrrolidin-1-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-36-0P**  
**755035-37-1P** **755035-38-2P** **755035-39-3P**, (R)-3-[(2,6-Difluoropyridin-4-yl)amino]-8-[2-[2-(hydroxymethyl)pyrrolidin-1-yl]-1,1-dimethyl-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-40-6P**, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[3-(morpholin-4-yl)-3-oxopropyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-42-8P** **755035-44-0P** **755035-45-1P**,  
 8-[3-(3-Hydroxypiperidin-1-yl)-3-oxopropyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-46-2P**  
**755035-47-3P** **755035-48-4P** **755035-49-5P**, 8-[2-[(6-Chloropyridin-3-yl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-51-9P**, 8-[2-[(2-Chloropyridin-3-yl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-52-0P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(6-methylpyridin-3-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-53-1P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(2-methylpyridin-3-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-54-2P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(pyridin-3-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-56-4P**, 8-[2-[(2,6-Dimethylpyridin-3-yl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-57-5P**, 8-[2-[[2-[(Dimethylamino)methyl]pyridin-3-yl]oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-58-6P**,  
 8-[2-(Isoquinolin-7-yloxy)ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-59-7P**,  
 7-Methoxy-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755035-61-1P**,  
 7-[2-[(2-Chloropyridin-3-yl)oxy]ethyl]-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-63-3P**, 8-[2-(Isoquinolin-5-yloxy)ethyl]-3-(3-methoxy-4-




nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-64-4P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(quinolin-5-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-65-5P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(4-methoxyphenoxy)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-67-7P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(3-methoxyphenoxy)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-68-8P 755035-69-9P**, 3-(3-Methoxy-4-nitrophenyl)-8-[3-[[4-(morpholin-4-yl)phenyl]oxy]propyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-70-2P**,  
 3-(3-Methoxy-4-nitrophenyl)-8-[3-[(pyridin-3-yl)oxy]propyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-71-3P**,  
 8-[2-(3-Aminophenoxy)ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-72-4P**,  
 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(2-methyl-1,3-benzothiazol-7-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-73-5P 755035-74-6P**, 8-(2-Hydroxy-2-methylpropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-75-7P**, 3-(3-Methoxy-4-nitrophenyl)-8-[(4-methylpiperazin-1-yl)methyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-82-6P**, 3-(4-Chloro-3-methoxyphenyl)-8-[(4-methylpiperazin-1-yl)methyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-84-8P 755035-86-0P**, 3-(4-Hydroxy-3-methoxyphenyl)-8-(hydroxymethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-91-7P**, 3-(3-Methoxy-4-nitrophenyl)-8-[(morpholin-4-yl)methyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755035-99-5P**, (R)-8-[[2-(Hydroxymethyl)pyrrolidin-1-yl]methyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755036-00-1P**, 7-(2-Hydroxyethoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755036-01-2P**, 8-[3-[2-(Hydroxymethyl)pyrrolidin-1-yl]-3-oxopropyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755036-02-3P 755036-04-5P**, 8-Amino-3-(4-hydroxy-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
**755036-06-7P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(kinase inhibitor; preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)


RN 755034-70-9 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[[[10,11-dihydro-7-(4-hydroxybutoxy)-8-methoxy-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl]amino]- (9CI) (CA INDEX NAME)




RN 755034-71-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-7-(4-hydroxybutoxy)-8-methoxy- (9CI) (CA INDEX NAME)




RN 755034-72-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxybutoxy)-8-methoxy-3-[(2,3,6-trifluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755034-73-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-ethoxy-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-76-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxybutoxy)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-80-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxyethoxy)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-82-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(2,3-dihydroxypropoxy)-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-83-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-[2-(2-methoxyethoxy)ethoxy]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755034-84-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(methoxymethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755034-91-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-7-[(3-methoxy-4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755034-93-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-[[[2-(dimethylamino)ethyl]methylamino]methyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-95-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-7-[[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 755034-97-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-ethyl-5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-04-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-ethenyl-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-07-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(3-hydroxypropyl)-7-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-14-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-8-[3-[(2-methyl-3-pyridinyl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 755035-16-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[3-[(2-chloro-3-pyridinyl)oxy]propyl]-5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-17-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-8-[3-[4-(4-morpholinyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)




RN 755035-19-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[3-(3-  
isoquinolinyl)oxy)propyl]-7-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA  
INDEX NAME)




RN 755035-20-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-methoxy-3-(3-methoxy-  
4-nitrophenyl)-8-[3-(3-oxo-2(3H)-isoquinolinyl)propyl]- (9CI) (CA INDEX  
NAME)




RN 755035-22-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-7-methoxy-3-  
(3-methoxy-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755035-25-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-7-methoxy-  
11-oxo-3-(4-pyrimidinylamino)-, methyl ester (9CI) (CA INDEX NAME)




RN 755035-26-8 CAPLUS

CN Morpholine, 4-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755035-27-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-N,N,α,α-tetramethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755035-28-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-α,α-dimethyl-11-oxo-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 755035-30-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-α,α-dimethyl-11-oxo-N-2-


10/785,120

thiazolyl- (9CI) (CA INDEX NAME)




RN 755035-31-5 CAPLUS

CN 3-Piperidinol, 1-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 755035-33-7 CAPLUS


CN 4-Piperidinol, 1-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 755035-34-8 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






10/785,120


RN 755035-35-9 CAPLUS

CN Pyrrolidine, 1-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755035-36-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro- $\alpha,\alpha$ -dimethyl-11-oxo-N-2-pyridinyl- (9CI) (CA INDEX NAME)




RN 755035-37-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro- $\alpha,\alpha$ -dimethyl-11-oxo-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 755035-38-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-N-(4-fluorophenyl)-10,11-dihydro- $\alpha,\alpha$ -dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755035-39-3 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755035-40-6 CAPLUS

CN Morpholine, 4-[3-[10,11-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755035-42-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 755035-44-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 755035-45-1 CAPLUS

CN 3-Piperidinol, 1-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755035-46-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, N-(4-fluorophenyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755035-47-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 755035-48-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-


10/785,120

nitrophenyl)-N-methyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755035-49-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanamide, 10,11-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755035-50-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(6-chloro-3-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-51-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(2-chloro-3-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-52-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(6-methyl-3-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755035-53-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(2-methyl-3-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755035-54-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-pyridinyloxy)ethyl]- (9CI) (CA INDEX NAME)




RN 755035-56-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(2,6-dimethyl-3-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-57-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[[2-[(dimethylamino)methyl]-3-pyridinyl]oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-58-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[2-(7-isoquinolinylloxy)ethyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-59-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755035-61-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-[2-[(2-chloro-3-pyridinyl)oxy]ethyl]-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755035-63-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[2-(5-isoquinolinylloxy)ethyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755035-64-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(5-quinolinyl)oxy]ethyl- (9CI) (CA INDEX NAME)




RN 755035-65-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(4-methoxyphenoxy)ethyl]- (9CI) (CA INDEX NAME)




RN 755035-67-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-methoxyphenoxy)ethyl]- (9CI) (CA INDEX NAME)




RN 755035-68-8 CAPLUS

CN 2-Pyridinecarboxamide, 3-[2-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]ethoxy]- (9CI) (CA INDEX NAME)




RN 755035-69-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[3-[4-(4-morpholinyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)



RN 755035-70-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[3-(3-pyridinyloxy)propyl]- (9CI) (CA INDEX NAME)




RN 755035-71-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-(3-aminophenoxy)ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




10/785,120




RN 755035-72-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(2-methyl-7-benzothiazolyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755035-73-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755035-74-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-2-methylpropyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-75-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 755035-82-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-8-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 755035-84-8 CAPLUS


CN Benzonitrile, 4-[10,11-dihydro-8-[(4-methyl-1-piperazinyl)methyl]-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 755035-86-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-(hydroxymethyl)- (9CI) (CA INDEX NAME)

10/785,120



RN 755035-91-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)



RN 755035-99-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[[ (2R)-2-(hydroxymethyl)-1-pyrrolidinyl]methyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755036-00-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxyethoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755036-01-2 CAPLUS

10/785,120


CN 2-Pyrrolidinemethanol, 1-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 755036-02-3 CAPLUS


CN Cyclohexanecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]-4-hydroxy-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 755036-04-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 755036-06-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




IT 755031-66-4P

RL: BYP (Byproduct); PREP (Preparation)

(preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)

RN 755031-66-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(3-methyl-2-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 9 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:634064 CAPLUS

DN 141:167757

TI Farnesyl dibenzodiazepinones, their production with microorganisms, and their use as antitumor, antibacterial, and antiinflammatory agents

IN Bachmann, Brian O.; Mcalpine, James B.; Zazopoulos, Emmanuel; Farnet, Chris M.; Pirae, Mahmood

PA Ecopia Biosciences Inc., Can.

SO PCT Int. Appl., 269 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004065591	A1	20040805	WO 2004-CA69	20040121
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
	CA 2466340	AA	20040809	CA 2004-2466340	20040121
	EP 1585814	A1	20051019	EP 2004-703733	20040121
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2003-441126P	P	20030121		
	US 2003-492997P	P	20030807		
	US 2003-518286P	P	20031110		
	WO 2004-CA69	W	20040121		

OS MARPAT 141:167757

AB This invention relates to a novel farnesylated dibenzodiazepinone, named ECO-04601, its pharmaceutically acceptable salts and derivs., and to methods for obtaining such compds. One method of obtaining the ECO-04601 compound is by cultivation of a novel strain of Micromonospora sp., 046-ECO11; another method involves expression of biosynthetic pathway genes in transformed host cells. The present invention further relates to Micromonospora sp. strain 046-ECO11, to the use of ECO-04601 and its pharmaceutically acceptable salts and derivs. as pharmaceuticals, in particular to their use as inhibitors of cancer cell growth, bacterial cell growth, mammalian lipoxxygenase, and to pharmaceutical compns. comprising ECO-04601 or a pharmaceutically acceptable salt or derivative thereof. Finally, the invention relates to novel polynucleotide sequences and their encoded proteins, which are involved in the biosynthesis of ECO-04601.

IT 733011-09-1DP, derivs.


RL: BMF (Bioindustrial manufacture); BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(farnesyl dibenzodiazepinones, their production with microorganisms, and their use as antitumor, antibacterial, and antiinflammatory agents)

RN 733011-09-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy- (9CI)  
(CA INDEX NAME)

10/785,120



RE.CNT 2      THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 10 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:546376 CAPLUS

DN 141:84051

TI Preparation of dibenzo(hetero)azepine derivatives as insecticides, acaricides and nematocides

IN Steiner, Gerd; Schmidt, Thomas; Kordes, Markus; Von Deyn, Wolfgang; Goetz, Norbert; Hofmann, Michael; De Kramer, Jacobus Jan; Heffernan, Gavin; Culbertson, Deborah L.; Treacy, Michael F.; Oloumi-Sadeghi, Hassan; Ebuenga, Cecille; Tedeschi, Livio; Bucci, Toni; Parra, Rapado Liliana; Rack, Michael; Baumann, Ernst; Puhl, Michael

PA BASF Aktiengesellschaft, Germany

SO PCT Int. Appl., 91 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004056182	A1	20040708	WO 2003-EP14443	20031218
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1578198	A1	20050928	EP 2003-782439	20031218
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003017528	A	20051122	BR 2003-17528	20031218
PRAI	US 2002-434801P	P	20021220		
	WO 2003-EP14443	W	20031218		
OS	MARPAT 141:84051				
GI					



AB The dibenzo(hetero)azepine derivs. I [X = S, O, SO or SO<sub>2</sub>, NH, CH<sub>2</sub>, etc.; R<sub>1</sub>, R<sub>2</sub> = halo, OH, SH, NH<sub>2</sub>, CN, NO<sub>2</sub>, alkyl, alkoxy, alkylamino, dialkylamino, alkylthio, alkenyl, alkenyloxy, alkenylamino, alkenylthio, alkynyl, alkynyloxy, alkynlamino, alkynylthio, alkylsulfonyl, alkylsulfoxyl, alkenylsulfonyl, alkynylsulfoxyl, formyl, alkylcarbonyl, hydroxycarbonyl, alkoxy carbonyl, carbonyloxy, alkylcarbonyloxy, phenyloxy, alkylcarbonylamino, etc.; R<sub>3</sub>, R<sub>4</sub> = H, (halo)alkyl, alkylamino, alkoxy, cycloalkyl, etc.; m, n = 0, 1-4] are prepared as insecticides, acaricides and nematocides.

IT **167997-02-6P 714221-44-0P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate in preparation of dibenzothiazepine derivative as insecticide,




10/785,120

acaricide and nematocide)


RN 167997-02-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-methoxy- (9CI) (CA INDEX NAME)




RN 714221-44-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro-7-methyl- (9CI) (CA INDEX NAME)




RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 11 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:202759 CAPLUS  
DN 142:176726  
TI Product class 5: seven-membered hetarenes with two or more heteroatoms  
AU Herr, R. J.  
CS Medicinal Chemistry Dept., Albany Molecular Research, Inc., Albany, NY,  
12212-5098, USA  
SO Science of Synthesis (2004), 17, 929-977  
CODEN: SSCYJ9  
PB Georg Thieme Verlag  
DT Journal; General Review  
LA English  
AB A review. Methods for preparing diazepines are reviewed including  
cyclization, ring transformation, and substituent modification.  
IT **183583-25-7**  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(review prepn of diazepines via cyclization, ring transformation, and  
substituent modification)  
RN 183583-25-7 CAPLUS  
CN Methanesulfonic acid, trifluoro-, 10,11-dihydro-11-oxo-5H-  
dibenzo[b,e][1,4]diazepin-2-yl ester (9CI) (CA INDEX NAME)




IT **162930-70-3P 167996-99-8P**  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(review prepn of diazepines via cyclization, ring transformation, and  
substituent modification)  
RN 162930-70-3 CAPLUS  
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4-nitro- (9CI) (CA  
INDEX NAME)



RN 167996-99-8 CAPLUS  
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 4-chloro-5,10-dihydro- (9CI) (CA  
INDEX NAME)


10/785,120



RE.CNT 157 THERE ARE 157 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/785,120


L10 ANSWER 12 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2003:795028 CAPLUS  
DN 140:5028  
TI Solid-phase synthesis of dibenzoxazepinones  
AU Hone, Neal D.; Salter, James I.; Reader, John C.  
CS Millennium Pharmaceuticals Ltd, Cambridge, CB1 6ET, UK  
SO Tetrahedron Letters (2003), 44(44), 8169-8172  
CODEN: TELEAY; ISSN: 0040-4039  
PB Elsevier Science B.V.  
DT Journal  
LA English  
OS CASREACT 140:5028  
GI



AB Two solid-phase routes to the pharmaceutically relevant dibenzoxazepinones, e.g., I, are described. In one, a key cyclization step involves intramol. phenolate displacement of an activated aryl fluoride. In the second, the tricyclic nucleus is prepared in solution prior to derivatization on a resin.

IT **627546-00-3DP**, amide derivs.  
RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)  
(solid-phase preparation of combinatorial dibenzoxazepinone libraries via ester hydrolysis of dibenzoxazepinonecarboxylates followed by coupling to oxime resin, N-deprotection, alkylation with alkyl halides followed by resin cleavage with amines)


RN 627546-00-3 CAPLUS  
CN Dibenz[b,f][1,4]oxazepine-8-carboxamide, 10,11-dihydro-2-nitro-11-oxo- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/785,120

L10 ANSWER 13 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2003:555345 CAPLUS  
DN 139:350712  
TI Synthesis of substituted dibenzoxazepines and dibenzthiazepine using of  
4-bromo-5-nitrophthalonitrile  
AU Abramov, Igor' G.; Smirnov, Alexey V.; Kalandadze, Levan S.; Sakharov,  
Vladimir N.; Plakhtinskii, Vladimir V.  
CS Yaroslavl State Technical University, Yaroslavl, 150023, Russia  
SO Heterocycles (2003), 60(7), 1611-1614  
CODEN: HTCYAM; ISSN: 0385-5414  
PB Japan Institute of Heterocyclic Chemistry  
DT Journal  
LA English  
OS CASREACT 139:350712  
AB Proposed a method of synthesis of new cyano containing compds. of oxazepine  
and thiazepine series based on activated aromatic nucleophilic substitution  
reaction of bromine atom and nitro group in 4-bromo-5-nitrophthalonitrile  
(I) by various bifunctional O-, N-, S-nucleophiles. For example, reaction  
of I with 2-(5-phenyl-4H-1,2,4-triazol-3-yl)phenol in DMF at 90°  
for 2 h gave 79% 3-phenylbenzo[b]-1,2,4-triazolo[4,3-d][1,4]benzoxazepine-  
6,7-dicarbonitrile.  
IT **619261-38-0P**  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(synthesis of substituted dibenzoxazepines and dibenzthiazepine using  
4-bromo-5-nitrophthalonitrile)  
RN 619261-38-0 CAPLUS  
CN Dibenz[b,f][1,4]oxazepine-7,8-dicarbonitrile, 2-bromo-10,11-dihydro-11-oxo-  
(9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/785,120

L10 ANSWER 14 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:551518 CAPLUS

DN 139:101151

TI Preparation of dibenzodiazepine derivates and use as inhibitors of  
poly(ADP-ribose) polymerase

IN Lubisch, Wilfried; Grandel, Roland; Braje, Wilfried; Subkowski, Thomas;  
Mueller, Reinhold; Wernet, Wolfgang; Drescher, Karla

PA Abbott G.m.b.H. & Co. K.-G., Germany

SO PCT Int. Appl., 40 pp.


CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2003057699	A1	20030717	WO 2003-EP192	20030110
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003139394	A1	20030724	US 2002-41556	20020110
	CA 2472107	AA	20030717	CA 2003-2472107	20030110
	AU 2003235806	A1	20030724	AU 2003-235806	20030110
	EP 1463731	A1	20041006	EP 2003-729243	20030110
	EP 1463731	B1	20050928		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005516031	T2	20050602	JP 2003-558014	20030110
	AT 305472	E	20051015	AT 2003-729243	20030110
PRAI	US 2002-41556	A	20020110		
	WO 2003-EP192	W	20030110		
OS	CASREACT 139:101151; MARPAT 139:101151				
GI					




I



III



IV



V

AB The invention relates to compds. I [A = (un)saturated or partially unsatd. C6-ring, unsatd. or partially unsatd. ring containing 3 - 5 C, 1 - 3 N, 1 O and/or 1 S; B = (un)saturated or partially unsatd. mono- bi- or tricyclic ring containing 3 - 15 C or 3 - 14 C, 0 - 5 N, 0 - 2 O and/or 0 - 2 S, etc.; R1 = H, Cl, Br, F, I, (un)branched C1-6-alkyl, OH, NO2, CF3, CN, NR11R12, NHCOR13, O-(C1-6-alkyl) R11, R12 = H, C1-4-alkyl; R13 = H, C1-4-alkyl, (C1-4-alkyl)phenyl, Ph ; X1 = S, O, NH] and their tautomeric forms, possible enantiomeric and diastereomeric forms and their prodrugs, and to their preparation and use. Their preparation comprises: condensing aldehyde,

BCHO

(II) with benzodiazepine III; III is prepared by reaction nitrobenzoic esters IV [R2 = (un)branched, (un)saturated C1-6-alkyl, Z = leaving group] with diamines V in a polar solvent and in the presence of a base, and with subsequent hydrogenation. Thus, I (B = Ph) was prepared from IV (R1 = H, R2 = Me, Z = Cl) via cyclization with 1,2-C6H4(NH2)2 in DMF containing K2CO3, hydrogenation over Pd/C in DMF and cyclocondensation with PhCHO in MeOH containing AcOH. Inhibition of the enzyme, poly(ADP-ribose) polymerase (PARP) by I was tested (no data).

IT **561054-28-2P**, 4-Amino-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one dihydrochloride


RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and condensation of, with aldehydes; preparation of dibenzodiazepine

derivates and use as inhibitors of poly(ADP-ribose) polymerase)


RN 561054-28-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 4-amino-5,10-dihydro-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

IT **162930-70-3P**, 4-Nitro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one  
 RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and hydrogenation of; preparation of dibenzodiazepine derivatives and  
 use as inhibitors of poly(ADP-ribose) polymerase)  
 RN 162930-70-3 CAPLUS  
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4-nitro- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT



L10 ANSWER 15 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:391737 CAPLUS

DN 136:386147

TI Preparation of [3-(naphthyridinylethoxy)dibenzoxazepin-10-yl]acetic acid  
av integrin receptor antagonists

IN Patane, Michael A.

PA Merck &amp; Co., Inc., USA

SO PCT Int. Appl., 44 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002040505	A2	20020523	WO 2001-US45499	20011019
	WO 2002040505	A3	20020808		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2425117	AA	20020523	CA 2001-2425117	20011019
	AU 2002039435	A5	20020527	AU 2002-39435	20011019
	EP 1331937	A2	20030806	EP 2001-987196	20011019
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2004513953	T2	20040513	JP 2002-543513	20011019
	US 2004019035	A1	20040129	US 2003-415032	20030423
	US 6943156	B2	20050913		
	PRAI	US 2000-242829P	P	20001024	
US 2000-242929P		P	20001024		
WO 2001-US45499		W	20011019		

GI



AB The dibenzoxazepine (I) was prepared as an  $\alpha_v\beta_3$  or  $\alpha_v\beta_5$  integrin receptor antagonist. Thus, 2-fluoronitrobenzene was coupled with Me 4-methoxysalicylate, the nitro group reduced using Pd/C, the amine cyclized with NaH, and the ketone reduced with LiAlH<sub>4</sub> to give 3-methoxy-10,11-dihydrodibenzo[1,4]oxazepine. N-alkylation with BrCH<sub>2</sub>CO<sub>2</sub>Et and NaH, conversion to the alc., coupling with 2-(5,6,7,8-tetrahydro[1,8]naphthyridin-2-yl)ethanol in the presence of PPh<sub>3</sub> and di-Et azodicarboxylate, and saponification afforded I. The latter is useful for inhibiting bone resorption, treating and/or preventing

osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory arthritis, cancer and metastatic tumor growth (no data). Examples also include detailed syntheses of two radioligands for SPAV3 and SPAV5 assays.


IT **54584-61-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of dibenzoxazepine  $\alpha$  integrin receptor antagonists from salicylates, nitrobenzenes, bromoacetates, and naphthyridineethanol for treatment of osteoporosis, cancer, and other diseases)


RN 54584-61-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-methoxy- (9CI) (CA INDEX NAME)



10/785,120


L10 ANSWER 16 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2001:461681 CAPLUS  
DN 135:257221  
TI Synthesis of nitro-substituted benzoannelated seven-membered heterocycles  
from trinitrotoluene  
AU Chernysheva, Natalya B.; Samet, Alexander V.; Marshalkin, Viktor N.;  
Polukeev, Valery A.; Semenov, Victor V.  
CS N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences,  
Moscow, 119992, Russia  
SO Mendeleev Communications (2001), (3), 109-110  
CODEN: MENCEX; ISSN: 0959-9436  
PB Russian Academy of Sciences  
DT Journal  
LA English  
OS CASREACT 135:257221  
AB 1,3-Dinitrodibenz[b,f]oxepin, 1,3-dinitrobenzo[f]naphth[2,1-  
b][1,4]oxazepine and 1,3-dinitrodibenz[b,f][1,4]oxazepin-11(10H)-one were  
prepared starting from TNT (2-methyl-1,3,5-trinitrobenzene) and  
2-hydroxybenzaldehyde, 1-nitroso-2-naphthalenol and N-(2-hydroxyphenyl)-  
2,4,6-trinitrobenzamide.  
IT **309735-46-4P**  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of nitro-substituted benzoannelated seven-membered heterocycles  
from trinitrotoluene)  
RN 309735-46-4 CAPLUS  
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,3-dinitro- (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 17 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2000:592558 CAPLUS  
 DN 133:193180  
 TI Preparation of dibenzooxazepinones and related compounds as  
 $\alpha\text{v}\beta 3$ ,  $\alpha\text{v}\beta 5$ , and/or  $\alpha\text{v}\beta 6$  integrin receptor  
 antagonists.  
 IN Patane, Michael A.; Newton, Randall C.  
 PA Merck and Co., Inc., USA  
 SO PCT Int. Appl., 81 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000048603	A1	20000824	WO 2000-US3796	20000214
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2362334	AA	20000824	CA 2000-2362334	20000214
	EP 1169042	A1	20020109	EP 2000-911811	20000214
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	AU 750584	B2	20020725	AU 2000-33643	20000214
	JP 2002537260	T2	20021105	JP 2000-599395	20000214
PRAI	US 1999-120564P	P	19990217		
	WO 2000-US3796	W	20000214		
OS	MARPAT 133:193180				
GI					



AB Title compds. [I; U, V = N, CR6;  $\leq 1$  U = N,  $\leq 1$  V = N; W CO, SO<sub>2</sub>, CR<sub>1</sub>R<sub>2</sub>; X = O, S, SO, SO<sub>2</sub>, NR<sub>4</sub>, CR<sub>1</sub>R<sub>2</sub>; Y = (substituted) (CH<sub>2</sub>)<sub>0-4</sub>, (CH<sub>2</sub>)<sub>0-4</sub>O(CH<sub>2</sub>)<sub>1-4</sub>, (CH<sub>2</sub>)<sub>0-4</sub>NR<sub>4</sub>(CH<sub>2</sub>)<sub>1-4</sub>, (CH<sub>2</sub>)<sub>0-4</sub>SO(CH<sub>2</sub>)<sub>1-4</sub>, (CH<sub>2</sub>)<sub>0-4</sub>SO<sub>2</sub>(CH<sub>2</sub>)<sub>1-4</sub>, etc.; Z = (substituted) 5-6 membered monocyclic aromatic or nonarom. ring system having 1-4 N, O, S atoms, 9-14 membered polycyclic ring system, wherein  $\geq 1$  of the rings is aromatic; R<sub>1</sub>, R<sub>2</sub> = H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, cycloalkylalkyl, cycloheteroalkylalkyl, aryl, aralkyl, aminoalkyl, acylaminoalkyl, alkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, alkylthioalkyl, carboxyalkyl, alkoxyalkyl, CF<sub>3</sub>; R<sub>4</sub> = H, alkyl, alkenyl, alkynyl, aralkyl, alkoxyalkyl, cycloalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl,

alkoxycarbonyl, aryloxycarbonyl, arylalkoxycarbonyl, alkylcarbonyl, arylcarbonyl, etc.; R5 = H, alkyl, aryl, aralkyl, alkylcarbonyloxyalkyl, alkylaminocarbonylmethylene, etc.; R6 = H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, amino, etc.], were prepared. A solution of 2-fluoronitrobenzene, Me 4-methoxysalicylate, and K<sub>2</sub>CO<sub>3</sub> in DMF was warmed to 50°C overnight to give Me 4-methoxy-2-(2-nitrophenoxy)-benzoate. The latter in MeOH was added to a suspension of 10% Pd/C in EtOH and treated with H<sub>2</sub> at room temperature and pressure for 3 h to give Me

2-(2-aminophenoxy)-4-

methoxybenzoate. This was stirred with NaH in THF to give 3-methoxy-10H-dibenzo[1,4]oxazepin-11-one, which was converted in several steps to [11-oxo-3-[3-(pyridin-2-ylamino)-1-propoxy]-11H-dibenzo[1,4]oxazepin-10-yl]acetic acid. Tested I at 1 μM gave ≥50% inhibition of attachment of αvβ5-expressing cells to vitronectin-coated plates.


IT **54584-61-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of dibenzooxazepinones and related compds. as αvβ3, αvβ5, and/or αvβ6 integrin receptor antagonists)

RN 54584-61-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-methoxy- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 18 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:221253 CAPLUS

DN 133:38104

TI In vitro and in vivo m2 muscarinic subtype selectivity of some dibenzodiazepinones and pyridobenzodiazepinones

AU Cohen, V. I.; Jin, B.; McRee, R. C.; Boulay, S. F.; Cohen, E. I.; Sood, V. K.; Zeeberg, B. R.; Reba, R. C.

CS N.W., 2300 Eye St., Walter G. Ross Hall, Section of Radiopharmaceutical Chemistry, George Washington University Medical Center, Washington, DC, USA

SO Brain Research (2000), 861(2), 305-315

CODEN: BRREAP; ISSN: 0006-8993

PB Elsevier Science B.V.

DT Journal

LA English

AB Alzheimer's disease (AD) involves selective loss of muscarinic m2, but not m1, subtype receptors in cortical and hippocampal regions of the human brain. Emission tomog. study of the loss of m2 receptors in AD has been limited by the absence of available m2-selective radioligands, which can penetrate the blood-brain barrier. We now report on the in vitro and in vivo m2 muscarinic subtype selectivity of a series of dibenzodiazepinones and pyridobenzodiazepinones determined by competition studies against (R)-3-quinuclidinyl (S)-4-iodobenzilate ((R,S)-[125I]IQNB or [3H]QNB. Of the compds. examined, three of the 5-[[4-[(4-dialkylamino)butyl]-1-piperidinyl]acetyl]-10,11-dihydro-5-H-dibenzo[b,e][1,4]diazepin-11-ones (including DIBA) and three of the 11-[[4-[4-(dialkylamino)butyl]-1-phenyl]acetyl]-5,11-dihydro-6H-pyrido [2,3-b][1,4]benzodiazepin-6-ones (including PBID) exhibited both high binding affinity for the m2 subtype ( $\leq 5$  nM) and high m2/m1 selectivity ( $\geq 10$ ). In vivo rat brain dissection studies of the competition of PBID or DIBD against (R,S)[125I]IQNB or [3H]QNB exhibited a dose-dependent preferential decrease in the binding of the radiotracer in brain regions that are enriched in the m2 muscarinic subtype. In vivo rat brain autoradiog. studies of the competition of PBID, BIBN 99, or DIBD against (R,S)[125I]IQNB exhibited an insignificant effect of BIBN 99 and confirmed the effect of PBID and DIBD in decreasing the binding of (R,S)[125I]IQNB in brain regions that are enriched in the m2 muscarinic subtype. We conclude that PBID and DIBD are potentially useful parent compds. from which in vivo m2 selective derivs. may be prepared for potential use in positron emission tomog. (PET) study of the loss of m2 receptors in AD.

IT 213208-22-1 213208-23-2 213208-24-3

213208-25-4 213208-33-4 213208-35-6


213208-41-4 213208-42-5

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(In vitro and in vivo m2 muscarinic subtype selectivity of dibenzodiazepinones and pyridobenzodiazepinones for potential use in tomog. brain imaging)


RN 213208-22-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-(diethylamino)butyl]phenyl]acetyl]-3-fluoro-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 213208-23-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-[bis(1-methylethyl)amino]butyl]phenyl]acetyl]-3-fluoro-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 213208-24-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-[bis(2-methylpropyl)amino]butyl]phenyl]acetyl]-3-fluoro-5,10-dihydro- (9CI) (CA INDEX NAME)


10/785,120



(i-Bu)<sub>2</sub>N-(CH<sub>2</sub>)<sub>4</sub>

RN 213208-25-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5-[[4-[3-(ethylamino)propyl]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




EtNH-(CH<sub>2</sub>)<sub>3</sub>

RN 213208-33-4 CAPLUS


CN Pentanamide, N-[3-[4-[2-(2-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]phenyl]propyl]-N-ethyl-2,2-dimethyl- (9CI) (CA INDEX NAME)






RN 213208-35-6 CAPLUS

CN Pentanamide, N-[4-[4-[2-(2-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]phenyl]butyl]-N-ethyl-2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 213208-41-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-[bis(2-methylpropyl)amino]butyl]phenyl]acetyl]-5,10-dihydro-2-iodo- (9CI) (CA INDEX NAME)



(i-Bu)<sub>2</sub>N-(CH<sub>2</sub>)<sub>4</sub>

RN 213208-42-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-[bis(2-methylpropyl)amino]butyl]phenyl]acetyl]-5,10-dihydro-4-iodo- (9CI) (CA INDEX NAME)



(i-Bu)<sub>2</sub>N-(CH<sub>2</sub>)<sub>4</sub>

RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 19 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1999:331933 CAPLUS

DN 131:124930

TI New (Sulfonyloxy)piperazinyldibenzazepines as Potential Atypical Antipsychotics: Chemistry and Pharmacological Evaluation

AU Liao, Yi; Venhuis, Bastiaan J.; Rodenhuis, Nienke; Timmerman, Wia; Wikstroem, Hkan; Meier, Eddie; Bartoszyk, Gerd D.; Boettcher, Henning; Seyfried, Christoph A.; Sundell, Staffan

CS Department of Medicinal Chemistry, University of Groningen, Groningen, 9713 AV, Neth.

SO Journal of Medicinal Chemistry (1999), 42(12), 2235-2244  
CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

AB A series of 2- or 8-trifluoromethylsulfonyloxy (TfO) and 2- or 8-methylsulfonyloxy (MsO) 11-piperazinyldibenzodiazepines, -oxazepines, and -thiazepines were synthesized and evaluated in pharmacol. models for their potential clozapine-like properties. In receptor binding assays, the 2-TfO analogs (GMC2-83, GMC3-06, and previously reported GMC1-169) of the dibenzazepines have profiles comparable to that of clozapine, acting on a variety of CNS receptors except they lack M1 receptor affinity. Introduction of 2-TfO to clozapine leads to compound GMC61-39 which has a similar binding profile as that of clozapine including having M1 receptor affinity. Interestingly, the MsO analogs, as well as the 8-TfO analogs, have no or weak dopaminergic and serotonergic affinities, but all 8-sulfonyloxy analogs do have M1 affinities. In behavioral studies performed to indicate the potential antipsychotic efficacy and the propensity to induce EPS, 2-TfO analogs blocked effectively the apomorphine-induced climbing in mice in a dose-dependent manner with ED50 values (mg/kg) of 2.1 s.c. for GMC1-169, 1.3 po for GMC2-83, 2.6 s.c. for GMC3-06, and 8.2 s.c. for GMC61-39. On the other hand, they showed a clear dose separation with regard to their ED50 values (mg/kg) for indicating catalepsy in rats (>44 s.c. for GMC1-169, 28 po for GMC2-83, 30 s.c. for GMC3-06, and >50 s.c. for GMC61-39, resp.), thus implicating a more favorable therapeutic ratio (K/A, ED50 climbing/ED50 catalepsy) in comparison with typical neuroleptics such as haloperidol and isoclozapine. Furthermore, compound GMC2-83 was also demonstrated to be an orally potent DA antagonist with an ED50 value of 0.7 mg/kg po in the ex vivo L-DOPA accumulation model. The present study contributes to the SAR of 11-piperazinyldibenzazepines, and the 2-TfO analogs of 11-piperazinyldibenzazepines are promising candidates as clozapine-like atypical antipsychotics with low propensity to induce EPS.

IT 60287-08-3P 60287-33-4P 67104-22-7P

167997-02-6P 183583-24-6P 183583-25-7P

183583-27-9P 183583-29-1P 234113-90-7P

234113-92-9P 234113-95-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of (sulfonyloxy)piperazinyldibenzazepines as potential clozapine-like antipsychotics)

RN 60287-08-3 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-hydroxy- (9CI) (CA INDEX NAME)

10/785,120




RN 60287-33-4 CAPLUS

CN Dibenzo[b,f][1,4]oxazepin-11(10H)-one, 2-methoxy- (9CI) (CA INDEX NAME)




RN 67104-22-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-2-methoxy- (9CI) (CA INDEX NAME)



RN 167997-02-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-methoxy- (9CI) (CA INDEX NAME)



RN 183583-24-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-hydroxy- (9CI) (CA INDEX NAME)

10/785,120




RN 183583-25-7 CAPLUS

CN Methanesulfonic acid, trifluoro-, 10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-2-yl ester (9CI) (CA INDEX NAME)




RN 183583-27-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-[(methanesulfonyl)oxy]-(9CI) (CA INDEX NAME)



RN 183583-29-1 CAPLUS


CN Methanesulfonic acid, trifluoro-, 10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl ester (9CI) (CA INDEX NAME)



RN 234113-90-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-2-hydroxy-(9CI) (CA INDEX NAME)

10/785,120




RN 234113-92-9 CAPLUS

CN Methanesulfonic acid, trifluoro-, 8-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-2-yl ester (9CI) (CA INDEX NAME)



RN 234113-95-2 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-[(methanesulfonyl)oxy]- (9CI) (CA INDEX NAME)



RE.CNT 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/785,120

L10 ANSWER 20 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1999:184239 CAPLUS

DN 130:209728

TI Integrin receptor antagonists

IN Heerding, Dirk A.; Samanen, James M.

PA SmithKline Beecham Corporation, USA

SO PCT Int. Appl., 39 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9911626	A1	19990311	WO 1998-US18379	19980903
	W: CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	IL 119820	A1	20000217	IL 1996-119820	19961212
	CA 2304117	AA	19990311	CA 1998-2304117	19980903
	EP 1027337	A1	20000816	EP 1998-944735	19980903
	R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
	JP 2001514253	T2	20010911	JP 2000-508666	19980903
PRAI	US 1997-57529P	P	19970904		
	US 1997-63520P	P	19971029		
	WO 1998-US18379	W	19980903		
OS	MARPAT 130:209728				
GI					




AB This invention relates to seven-membered tricyclic heterocycles containing at least one N atom which bind to integrins such as the vitronectin receptor and fibrinogen receptor. Such compds. are useful for inhibiting platelet aggregation and osteoclast attachment to bone. Thus, dibenzoxazepineacetic acid I was prepared in nine steps starting from 1-fluoro-2-nitrobenzene and Me 2-hydroxy-4-methoxybenzoate.

IT **54584-61-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and reduction of)

RN 54584-61-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-methoxy- (9CI) (CA INDEX NAME)




10/785,120


RE.CNT 3      THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT




L10 ANSWER 21 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1999:176508 CAPLUS  
DN 130:296672  
TI Solid support synthesis of 2-substituted dibenz[b,f]oxazepin-11(10H)-ones  
via SNAr methodology on AMEBA resin  
AU Ouyang, Xiaohu; Tamayo, Nuria; Kiselyov, Alexander S.  
CS Small Molecule Drug Discovery, Amgen Inc., Thousand Oaks, CA, 91320, USA  
SO Tetrahedron (1999), 55(10), 2827-2834  
CODEN: TETRAB; ISSN: 0040-4020  
PB Elsevier Science Ltd.  
DT Journal  
LA English  
AB Efficient assembly of dibenz[b,f]oxazepin-11(10H)-ones utilizing the SNAr  
of fluorine in 2-fluoro-5-nitrobenzoic acid with the OH of various  
2-aminophenols on solid support is reported. The flexibility of this  
synthesis, as well as the excellent purity (>90%) of the final products  
are the distinctive characteristics of the resulting library.  
IT **16398-16-6P 16398-19-9P 135810-39-8P**  
**223261-47-0P**  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(solid support synthesis of dibenzoxazepinones)  
RN 16398-16-6 CAPLUS  
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-nitro- (8CI, 9CI) (CA INDEX NAME)



RN 16398-19-9 CAPLUS  
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8-methyl-2-nitro- (8CI, 9CI) (CA INDEX NAME)




RN 135810-39-8 CAPLUS  
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 7-methyl-2-nitro- (9CI) (CA INDEX NAME)



RN 223261-47-0 CAPLUS

10/785,120

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 9-methyl-2-nitro- (9CI) (CA INDEX NAME)




IT 223261-48-1P 223261-49-2P 223261-50-5P  
223261-51-6P 223261-52-7P 223261-53-8P  
223261-54-9P 223261-55-0P 223261-56-1P  
223261-57-2P 223261-58-3P 223261-59-4P  
223261-60-7P 223261-61-8P 223261-62-9P  
223261-63-0P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(solid support synthesis of dibenzoxazepinones)


RN 223261-48-1 CAPLUS

CN Acetamide, N-(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)- (9CI)  
(CA INDEX NAME)




RN 223261-49-2 CAPLUS

CN Benzamide, N-(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-4-fluoro-  
(9CI) (CA INDEX NAME)



RN 223261-50-5 CAPLUS

CN Benzamide, N-(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-4-methyl-  
(9CI) (CA INDEX NAME)




RN 223261-51-6 CAPLUS

CN Benzamide, N-(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-4-methoxy-


10/785,120

(9CI) (CA INDEX NAME)




RN 223261-52-7 CAPLUS

CN Acetamide, N-(10,11-dihydro-7-methyl-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-  
(9CI) (CA INDEX NAME)




RN 223261-53-8 CAPLUS

CN Benzamide, N-(10,11-dihydro-7-methyl-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-  
4-fluoro- (9CI) (CA INDEX NAME)



RN 223261-54-9 CAPLUS


CN Benzamide, N-(10,11-dihydro-7-methyl-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-  
4-methyl- (9CI) (CA INDEX NAME)



RN 223261-55-0 CAPLUS


CN Benzamide, N-(10,11-dihydro-7-methyl-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-  
4-methoxy- (9CI) (CA INDEX NAME)

10/785,120




RN 223261-56-1 CAPLUS

CN Acetamide, N-(10,11-dihydro-8-methyl-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-(9CI) (CA INDEX NAME)




RN 223261-57-2 CAPLUS

CN Benzamide, N-(10,11-dihydro-8-methyl-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-4-fluoro- (9CI) (CA INDEX NAME)




RN 223261-58-3 CAPLUS

CN Benzamide, N-(10,11-dihydro-8-methyl-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-4-methyl- (9CI) (CA INDEX NAME)



RN 223261-59-4 CAPLUS


CN Benzamide, N-(10,11-dihydro-8-methyl-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-4-methoxy- (9CI) (CA INDEX NAME)



10/785,120


RN 223261-60-7 CAPLUS

CN Acetamide, N-(10,11-dihydro-9-methyl-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-  
(9CI) (CA INDEX NAME)




RN 223261-61-8 CAPLUS

CN Benzamide, N-(10,11-dihydro-9-methyl-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-  
4-fluoro- (9CI) (CA INDEX NAME)




RN 223261-62-9 CAPLUS

CN Benzamide, N-(10,11-dihydro-9-methyl-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-  
4-methyl- (9CI) (CA INDEX NAME)



RN 223261-63-0 CAPLUS

CN Benzamide, N-(10,11-dihydro-9-methyl-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-  
4-methoxy- (9CI) (CA INDEX NAME)



RE.CNT 46

THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/785,120

L10 ANSWER 22 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:816103 CAPLUS

DN 130:52440

TI Preparation of tricyclic benzazepine vasopressin antagonists

IN Albright, Jay D.; Venkatesan, Aranapakam M.; Delos Santos, Efren G.

PA American Cyanamid Company, USA

SO U.S., 82 pp., Cont.-in-part of U.S. Ser. No. 373,169, abandoned.


CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5849735	A	19981215	US 1995-548805	19951222
	ZA 9600300	A	19970715	ZA 1996-300	19960115
	CA 2210688	AA	19960725	CA 1996-2210688	19960116
	WO 9622282	A1	19960725	WO 1996-US1051	19960116
	W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, AZ, BY, KG, KZ, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9649042	A1	19960807	AU 1996-49042	19960116
	BR 9606977	A	19971104	BR 1996-6977	19960116
	EP 804420	A1	19971105	EP 1996-905227	19960116
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV				
	CN 1190391	A	19980812	CN 1996-192568	19960116
	JP 10512865	T2	19981208	JP 1996-522448	19960116
	IL 116777	A1	20001121	IL 1996-116777	19960116
	TW 449584	B	20010811	TW 1996-85100462	19960116
PRAI	US 1995-373169	B2	19950117		
	US 1995-548805	A	19951222		
	WO 1996-US1051	W	19960116		
OS	MARPAT 130:52440				
GI					



AB The title compds. [I; Y = NH, N(Ac), N(C1-3 alkyl); AB = CH<sub>2</sub>N(R<sub>3</sub>), N(R<sub>3</sub>)CH<sub>2</sub>; R<sub>1</sub> = H, halo, OH, etc.; R<sub>2</sub> = H, OH, halo, etc.; R<sub>3</sub> = C(O)Ar; Ar = (un)substituted thienyl, furanyl, Ph, etc.; Z together with two carbon atoms attached = (un)substituted Ph, 5-membered aromatic (un)saturated heterocyclic ring having one heteroatom selected from O, N or S, etc.],

10/785,120


which exhibit antagonist activity at V1 and/or V2 receptors, in vivo vasopressin antagonist activity, and oxytocin antagonist activity, and therefore are useful in treating diseases characterized by excess renal reabsorption of water as well as congestive heart failure, liver cirrhosis, nephrotic syndrome, CNS injuries, lung disease and hyponatremia, were prepared. Thus, reaction of 10,11-dihydrodibenz[b,f][1,4]oxazepine with 6-[(5-fluoro-2-methylbenzoyl)amino]pyridine-3-carbonyl in the presence of Et3N in CH2Cl2 afforded the title compound II which showed IC50 of 0.24  $\mu$ M and 0.054  $\mu$ M against rat hepatic V1 receptors binding and rat kidney medullary V2 receptors binding, resp.

IT 22361-77-9

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of tricyclic benzazepine vasopressin antagonists)

RN 22361-77-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-2-sulfonamide, 10,11-dihydro-N,N-dimethyl-11-oxo-  
(8CI, 9CI) (CA INDEX NAME)





RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/785,120


L10 ANSWER 23 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1998:735045 CAPLUS  
DN 129:343507  
TI Preparation of piperazinooxazepines as dopamine D4 receptor antagonists  
IN Fu, Jian-Min  
PA Allelix Biopharmaceuticals Inc., Can.  
SO U.S., 10 pp., Cont.-in-part of U.S. 5,602,121.  
CODEN: USXXAM  
DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5834459	A	19981110	US 1996-754014	19960401
	US 5602121	A	19970211	US 1994-354793	19941212
	CA 2207771	AA	19960620	CA 1995-2207771	19951208
PRAI	US 1994-354793	A2	19941212		
OS	MARPAT 129:343507				
GI					



AB Title compds. [I; A,B = atoms to complete (un)saturated (heterocyclic) rings; R = (heteroatom-interrupted) (un)substituted alkyl; R1 = H or 1 or 2 alkyl substituents; X1 = O, NH, CO, CH2, etc.; X2 = N, CH, CH2, CO; Z = CH2 or CH2CH2; dashed line = addnl. bond when X2 = N or CH] were prepared. Thus, 2-(OHC)C6H4OK was etherified by 2-ClC6H4NO2 and the product cyclized in 3 steps to give, after piperazine condensation, dibenzoxazepine II (R = H) which was N-alkylated by BuCH2CH2Br to give II (R = CH2CH2Bu). Data for biol. activity of I were given.

IT **3158-94-9**  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of piperazinooxazepines as dopamine D4 receptor antagonists)  
RN 3158-94-9 CAPLUS  
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD



10/785,120

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 24 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:682355 CAPLUS

DN 129:302376

TI Preparation of arylalkylamine as calcilytic compounds

IN Barmore, Robert M.; Bhatnagar, Pradip Kumar; Bryan, William M.; Burgess, Joelle Lorraine; Callahan, James Francis; Calvo, Raul Rolando; Del Mar, Eric G.; et al.

PA Smithkline Beecham Corporation, USA; Nps Pharmaceuticals, Inc.

SO PCT Int. Appl., 102 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9845255	A1	19981015	WO 1998-US6928	19980408
	W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	ZA 9802951	A	19990316	ZA 1998-2951	19980407
	CA 2286454	AA	19981015	CA 1998-2286454	19980408
	AU 9868900	A1	19981030	AU 1998-68900	19980408
	AU 721910	B2	20000720		
	EP 973730	A1	20000126	EP 1998-914581	19980408
	EP 973730	B1	20040616		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI				
	TR 9902516	T2	20000221	TR 1999-9902516	19980408
	BR 9808491	A	20000523	BR 1998-8491	19980408
	JP 2001523223	T2	20011120	JP 1998-543055	19980408
	AT 269300	E	20040715	AT 1998-914581	19980408
	ES 2223126	T3	20050216	ES 1998-914581	19980408
	TW 407144	B	20001001	TW 1998-87105217	19980722
	US 6294531	B1	20010925	US 1999-402310	19991001
	NO 9904877	A	19991007	NO 1999-4877	19991007
PRAI	US 1997-42724P	P	19970408		
	US 1997-61327P	P	19971008		
	US 1997-61329P	P	19971008		
	US 1997-61330P	P	19971008		
	US 1997-61331P	P	19971008		
	US 1997-61333P	P	19971008		
	WO 1998-US6928	W	19980408		

OS MARPAT 129:302376

AB Title compds. XZY1CR7R8Y2NHCR3R4GABR5 [Y1 = covalent bond, alkylene, alkenylene, alkyl; Y2 = methylene, alkyl, CF3; Z = O, S, NH, alkyl, etc.; R3 = CH3, CH3CH2; R4 = CH3, CH3CH2; R3-R4 = cyclopropyl; R5 = C6H5, naphthyl, OH, alkoxy, cycloalkyl, CN, NO2, etc.; G = electron pair, COH, CH, CO; R7 = H, OH, alkoxy; R8 = H, alkyl; R7-R8 = carbonyl moiety; AB = CH2CH2, CH:CH, CC, covalent bond; X = (un)substituted phenylaminosulfonyl, phenylaminocarbonylalkyl, phenylcarbonylamino, phenylsulfonylamino, etc.] exhibiting calcilytic properties are prepared of treating abnormal bone or mineral homeostasis (no data).

IT 214623-53-7P 214625-44-2P 214625-45-3P

214625-46-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


10/785,120

(preparation of arylalkylamine as calcilytic compds.)

RN 214623-53-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-[(2R)-3-[[1,1-dimethyl-2-(2-naphthalenyl)ethyl]amino]-2-hydroxypropoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 214625-44-2 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-[(2R)-2-hydroxy-3-[[2-(4-methoxyphenyl)-1,1-dimethylethyl]amino]propoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 214625-45-3 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-[(2R)-3-[(1,1-dimethyl-4-phenylbutyl)amino]-2-hydroxypropoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 214625-46-4 CAPLUS

CN Dibenzo[b,f][1,4]oxazepin-11(10H)-one, 3-[(2R)-3-[[1,1-dimethyl-2-(1-methyl-1-phenylethoxy)ethyl]amino]-2-hydroxypropoxy]-, monohydrochloride (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




● HCl

IT 54584-61-1P 60287-50-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of arylalkylamine as calcilytic compds.)

RN 54584-61-1 CAPLUS


CN Dibenzo[b,f][1,4]oxazepin-11(10H)-one, 3-methoxy- (9CI) (CA INDEX NAME)



RN 60287-50-5 CAPLUS

CN Dibenzo[b,f][1,4]oxazepin-11(10H)-one, 3-hydroxy- (9CI) (CA INDEX NAME)

10/785,120



RE.CNT 3      THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 25 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:517394 CAPLUS

DN 129:245121

TI Synthesis of some substituted dibenzodiazepinones and pyridobenzodiazepinones

AU Cohen, Victor I.; Jin, Biyun; Cohen, Emil I.; Zeeberg, Barry R.; Reba, Richard C.

CS Section Radiopharmaceutical Chem., George Washington Univ. Medical Center, Washington, DC, 20037, USA

SO Journal of Heterocyclic Chemistry (1998), 35(3), 675-686

CODEN: JHTCAD; ISSN: 0022-152X

PB HeteroCorporation

DT Journal

LA English

AB Fluoro- and iodo-derivs. of 5-[[4-[(4-diisobutylamino)butyl]-1-phenyl]acetyl]-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-11-one and 11-[[4-[(dialkylamino)butyl]-1-phenyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-ones and their analogs were synthesized. The synthesis of dibenzodiazepinones was based on the reaction between 1,4-phenylenediamine and substituted benzoic acids. The intermediate pyridobenzodiazepinones were prepared by condensation of 2-chloro-3-aminopyridine with Me anthranilate and its chlorine derivative. The condensation of 4-[(halo)alkyl]phenylacetyl chloride with dibenzodiazepinones and pyridobenzodiazepinones followed by the reaction of mono- or dialkyl- or dialkenylamine provided 11-[[4-[(dialkylamino)butyl]-1-phenyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-ones.

IT 54255-81-1P 82096-44-4P 162930-70-3P

162930-73-6P 213208-06-1P 213208-07-2P

213208-08-3P 213208-09-4P 213208-11-8P

213208-12-9P 213208-13-0P 213208-14-1P

213208-18-5P 213208-19-6P 213208-22-1P

213208-23-2P 213208-24-3P 213208-25-4P


213208-33-4P 213208-39-0P 213208-40-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of dibenzodiazepinone and pyridobenzodiazepinone derivs.)

RN 54255-81-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-nitro- (9CI) (CA INDEX NAME)



RN 82096-44-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro- (7CI, 9CI) (CA INDEX NAME)

10/785,120




RN 162930-70-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4-nitro- (9CI) (CA INDEX NAME)




RN 162930-73-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 4-amino-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 213208-06-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-fluoro-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 213208-07-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-amino-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 213208-08-3 CAPLUS

CN Carbamic acid, (10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-2-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 213208-09-4 CAPLUS

CN Carbamic acid, (10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-4-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 213208-11-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(4-bromobutyl)phenyl]acetyl]-3-fluoro-5,10-dihydro- (9CI) (CA INDEX NAME)




10/785,120




RN 213208-12-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5-[[4-(3-chloropropyl)phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 213208-13-0 CAPLUS

CN Carbamic acid, [5-[[4-(4-bromobutyl)phenyl]acetyl]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-2-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 213208-14-1 CAPLUS

CN Carbamic acid, [5-[[4-(4-bromobutyl)phenyl]acetyl]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-4-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 213208-18-5 CAPLUS


CN Carbamic acid, [5-[[4-[4-[bis(2-methylpropyl)amino]butyl]phenyl]acetyl]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-2-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



(i-Bu)<sub>2</sub>N-(CH<sub>2</sub>)<sub>4</sub>

RN 213208-19-6 CAPLUS

CN Carbamic acid, [5-[[4-[4-[bis(2-methylpropyl)amino]butyl]phenyl]acetyl]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-4-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




(i-Bu)<sub>2</sub>N-(CH<sub>2</sub>)<sub>4</sub>

RN 213208-22-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-(diethylamino)butyl]phenyl]acetyl]-3-fluoro-5,10-dihydro- (9CI) (CA INDEX NAME)

10/785,120



RN 213208-23-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-[bis(1-methylethyl)amino]butyl]phenyl]acetyl]-3-fluoro-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 213208-24-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-[bis(2-methylpropyl)amino]butyl]phenyl]acetyl]-3-fluoro-5,10-dihydro- (9CI) (CA INDEX NAME)

10/785,120



RN 213208-25-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5-[[4-[3-(ethylamino)propyl]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 213208-33-4 CAPLUS


CN Pentanamide, N-[3-[4-[2-(2-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]phenyl]propyl]-N-ethyl-2,2-dimethyl- (9CI) (CA INDEX NAME)

CC(C)C(C)(C)C(=O)N(CCCc1ccc(cc1)CC2C(=O)Nc3ccccc3C2)c4ccc(Cl)cc4

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-amino-5-[[4-[4-[bis(2-methylpropyl)amino]butyl]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 4-amino-5-[[4-[4-[bis(2-methylpropyl)amino]butyl]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



(i-Bu)<sub>2</sub>N-(CH<sub>2</sub>)<sub>4</sub>


IT 213208-35-6P 213208-41-4P 213208-42-5P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of dibenzodiazepinone and pyridobenzodiazepinone derivs.)


RN 213208-35-6 CAPLUS

CN Pentanamide, N-[4-[4-[2-(2-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]phenyl]butyl]-N-ethyl-2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 213208-41-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-[bis(2-methylpropyl)amino]butyl]phenyl]acetyl]-5,10-dihydro-2-iodo- (9CI) (CA INDEX NAME)



(i-Bu)<sub>2</sub>N-(CH<sub>2</sub>)<sub>4</sub>

RN 213208-42-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-[bis(2-methylpropyl)amino]butyl]phenyl]acetyl]-5,10-dihydro-4-iodo- (9CI) (CA INDEX NAME)




(i-Bu)<sub>2</sub>N-(CH<sub>2</sub>)<sub>4</sub>

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT




L10 ANSWER 26 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1998:366893 CAPLUS  
 DN 129:54301  
 TI Preparation of tricyclic benzazepine vasopressin antagonists  
 IN Albright, Jay Donald; Reich, Marvin Fred  
 PA American Cyanamid Co., USA  
 SO U.S., 103 pp., Cont.-in-part of U. S. 5,512,563.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5760031	A	19980602	US 1996-637911	19960425
	US 5512563	A	19960430	US 1994-254823	19940613
	NZ 299340	A	20000825	NZ 1994-299340	19940728
PRAI	US 1993-100003	B2	19930729		
	US 1994-254823	A2	19940613		
	NZ 1994-264116	A1	19940728		
OS	MARPAT 129:54301				
GI					



I



II

AB The title compds. [I; R1 = H, Cl, F, etc.; R2 = H, Cl, Br, etc.; R1R2 = methylenedioxy, ethylenedioxy; R5 = H, Me, Et, etc.; R6 = N(Ra)COAr', CON(Ra)Ar', etc. (Ra = H, Me, Et; Ar' = (un)substituted Ph, thienyl, etc.); R7 = H, Me, Et, etc.; Z = (un)substituted fused oxazole, Ph], which exhibit antagonist activity at V1 and/or V2 receptors and in vivo vasopressin antagonist activity as well as antagonist activity at oxytocin receptors, and as such useful in treating diseases characterized by excess renal reabsorption of water (e.g., congestive heart failure, nephrotic syndrome, hyponatremia, coronary vasospasm, cardiac ischemia, renal vasospasm, liver cirrhosis, brain edema, cerebral ischemia, cerebral hemorrhage-stroke), were prepared Thus, reaction of 4-[(2-methylbenzoyl)amino]benzoyl chloride with 10,11-dihydro-5H-dibenz[b,f]azepine in the presence of 4-(dimethylamino)pyridine in pyridine at 80° for 18 h followed by the addition of NaH afforded the compound II which showed IC50 of 2.5  $\mu$ M against rat hepatic V1 receptor binding and IC50 of 0.86  $\mu$ M against rat kidney medullary V2 receptor binding.

IT 22361-77-9

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of tricyclic benzazepine vasopressin antagonists)

RN 22361-77-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-2-sulfonamide, 10,11-dihydro-N,N-dimethyl-11-oxo-


10/785,120

(8CI, 9CI) (CA INDEX NAME)




RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 27 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1998:336533 CAPLUS  
DN 128:313007  
TI HPLC determination of clozapine and its related substances  
AU Li, Li-Xin  
CS Shanghai Institute of Pharmaceutical Industry, Shanghai, 200040, Peop.  
Rep. China  
SO Zhongguo Yiyao Gongye Zazhi (1998), 29(4), 173-174  
CODEN: ZYGZEA; ISSN: 1001-8255  
PB Zhongguo Yiyao Gongye Zazhi Bianjibu  
DT Journal  
LA Chinese  
AB Clozapine and its related substances (ACA, CDD) was defected on Spherisorb  
C8 column with DAD at 230 nm. The mobile phase was 0.02 mol/L potassium  
dihydrogen phosphate solution (pH 5.9)-methanel (40:60). This method is  
simple, rapid accurate and reliable.  
IT **82096-44-4**  
RL: ANT (Analyte); ANST (Analytical study)  
(determination of clozapine by HPLC)  
RN 82096-44-4 CAPLUS  
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro- (7CI, 9CI)  
(CA INDEX NAME)




L10 ANSWER 28 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1998:289524 CAPLUS  
 DN 128:321569  
 TI Preparation of tricyclic benzazepine vasopressin antagonists  
 IN Albright, Jay Donald; Reich, Marvin Fred  
 PA American Cyanamid Co., USA  
 SO U.S., 101 pp., Cont.-in-part of U.S. Ser. No. 5,512,563.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5747487	A	19980505	US 1996-638067	19960425
	US 5512563	A	19960430	US 1994-254823	19940613
	NZ 299340	A	20000825	NZ 1994-299340	19940728
PRAI	US 1993-100003	B2	19930729		
	US 1994-254823	A2	19940613		
	NZ 1994-264116	A1	19940728		
OS	MARPAT 128:321569				
GI					



I



II

AB The title compds. [I; Y = a bond; AB = (CH<sub>2</sub>)<sub>2</sub>N(R<sub>3</sub>); R<sub>1</sub> = H, halo, OH, etc.; R<sub>2</sub> = H, halo, OH, etc.; R<sub>1</sub>R<sub>2</sub> = methylenedioxy, ethylenedioxy; R<sub>3</sub> = C(O)Ar (wherein Ar = (un)substituted Ph, thienyl, etc.); Z = (un)substituted fused benzo, thiazole, etc.], which exhibit antagonistic activity at V<sub>1</sub> and/or V<sub>2</sub> receptors, in vivo vasopressin antagonist activity, and antagonistic activity at oxytocin receptors, and therefore useful in treating diseases characterized by excess renal reabsorption of water such as congestive heart failure, nephrotic syndrome, hyponatremia, coronary vasospasm, cardiac ischemia, liver cirrhosis, brain edema, cerebral ischemia, or cerebral hemorrhage-stroke, were prepared Thus, reaction of 4-[(2-methylbenzoyl)amino]benzoyl chloride with 10,11-dihydro-5H-dibenz[b,f]azepine in the presence of 4-(dimethylamino)pyridine in pyridine afforded the title compound II which showed IC<sub>50</sub> of 2.5 μM against rat hepatic V<sub>1</sub> receptors binding and IC<sub>50</sub> of 0.86 μM against rat kidney medullary V<sub>2</sub> receptors binding.

IT **22361-77-9**


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of tricyclic benzazepine vasopressin antagonists)

RN 22361-77-9. CAPLUS

CN Dibenz[b,f][1,4]oxazepine-2-sulfonamide, 10,11-dihydro-N,N-dimethyl-11-oxo-(8CI, 9CI) (CA INDEX NAME)

10/785,120



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/785,120

L10 ANSWER 29 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:226808 CAPLUS

DN 128:282791

TI Preparation of tricyclic benzazepine vasopressin antagonists

IN Albright, Jay Donald; Reich, Marvin Fred; Sum, Fuk-wah; Du, Xuemei

PA American Cyanamid Co., USA

SO U.S., 104 pp., Cont.-in-part of U.S. 5,512,563.


CODEN: USXXAM

DT Patent

LA English

FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5739128	A	19980414	US 1996-637058	19960424
	US 5512563	A	19960430	US 1994-254823	19940613
	NZ 299340	A	20000825	NZ 1994-299340	19940728
	US 5786353	A	19980728	US 1997-893497	19970711
PRAI	US 1993-100003	B2	19930729		
	US 1994-254823	A2	19940613		
	NZ 1994-264116	A1	19940728		
	US 1996-637058	A3	19960424		
OS	MARPAT 128:282791				
GI					



AB The title compds. [I; Z-containing ring = (un)substituted fused Ph; Y = NH, NCOMe; N(Cl-3 alkyl); R1 = H, halo, OH, etc.; R2 = H, Cl, Br, I, F, OH, etc.; R1R2 = methylenedioxy, ethylenedioxy; R3 = C(O)Ar (wherein Ar = (un)substituted Ph, furanyl, thienyl, pyrrolyl)] which exhibit antagonist activity at V1 and/or V2 receptors, in vivo vasopressin antagonist activity, and antagonist activity at oxytocin receptors, and are therefore useful in treating diseases characterized by excess renal reabsorption of water, were prepared Thus, reaction of 4-[(2-methylbenzoyl)amino]benzoyl chloride with 10,11-dihydro-5H-dibenz[b,f]azepine in the presence of 4-(dimethylamino)pyridine and NaH in pyridine afforded compound II which showed IC50 of 2.5  $\mu$ M against rat hepatic V1 receptor binding and IC50 of 0.86  $\mu$ M against rat kidney medullary V2 receptor binding.

IT 22361-77-9


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of tricyclic benzazepine vasopressin antagonists)

RN 22361-77-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-2-sulfonamide, 10,11-dihydro-N,N-dimethyl-11-oxo-  
(8CI, 9CI) (CA INDEX NAME)

10/785,120



RE.CNT 14      THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 30 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:15699 CAPLUS

DN 128:88936

TI Preparation of (diazabicycloalkyl)dibenzoxepines and analogs as dopamine D4 receptor antagonists

IN Power, Patricia L.; Rakhit, Sumanas

PA Allelix Biopharmaceuticals, Can.

SO U.S., 14 pp., Cont.-in-part of U.S. 5,576,314.


CODEN: USXXAM

DT Patent


LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5703072	A	19971230	US 1996-625358	19960401
	US 5576314	A	19961119	US 1994-354906	19941212
	CA 2207546	AA	19960620	CA 1995-2207546	19951208
PRAI	US 1994-354906	A2	19941212		
OS	MARPAT 128:88936				
GI					



I



II

AB Title compds. [I; R1 = H, amino acid side chain residue; R2,R3= H, halo, alkyl, alkoxy, etc.; R4R5,R6R7 = atoms to complete a ring; Z = CH2 or CH2CH2; Z1 = O, SOO-2, CH2, CO, etc.; Z2 = N, CH2, CH, co, etc.; dashed line = optional addnl. bond] were prepared Thus, N-Fmoc-L-proline was condensed with H2NCH2CO2Me and the product converted in 2 steps to (S)-1,4-diazabicyclo[4.3.0]nonane which was condensed with the product of PC15 treatment of 8-chloro-10,11-dihydrobenz[b,f][1,4]oxazepin-11-one to give title compound II. Data for biol. activity of I were given.

IT 3158-94-9P 167997-03-7P 179458-05-0P

201037-63-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of (diazabicycloalkyl)dibenzoxepines and analogs as dopamine D4 receptor antagonists)

RN 3158-94-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)




10/785,120




RN 167997-03-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-nitro- (9CI) (CA INDEX NAME)




RN 179458-05-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-bromo- (9CI) (CA INDEX NAME)



RN 201037-63-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-amino- (9CI) (CA INDEX NAME)



L10 ANSWER 31 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:13962 CAPLUS

DN 128:75393

TI Preparation of tricyclic benzazepines as vasopressin antagonists

IN Albright, Jay Donald; Reich, Marvin Fred

PA American Cyanamid Company, USA

SO PCT Int. Appl., 289 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9747624	A1	19971218	WO 1997-US9548	19970603
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9732964	A1	19980107	AU 1997-32964	19970603
PRAI	US 1996-663400	A	19960613		
	WO 1997-US9548	W	19970603		
OS	MARPAT 128:75393				
GI					



AB The title compds. [I; Y = a bond, CH<sub>2</sub>; AB = (CH<sub>2</sub>)<sub>2</sub>NR<sub>3</sub>, NR<sub>3</sub>(CH<sub>2</sub>)<sub>2</sub>; R<sub>1</sub> = H, halo, OH, etc.; R<sub>2</sub> = H, halo, OH, etc.; R<sub>1</sub>R<sub>2</sub> = methylenedioxy, ethylenedioxy; R<sub>3</sub> = C(O)Ar; Ar = (un)substituted Ph, 5-indolyl, thienyl, etc.; Z = (un)substituted fused pyrazole, benzene, etc.] and their salts which exhibit vasopressin antagonist activity and are useful in treating diseases characterized by excess renal reabsorption of water, were prepared. Thus, reaction of 4-[(2-methylbenzoyl)amino]benzoyl chloride with 6,11-dihydro-5H-dibenz[b,e]azepine in the presence of Et<sub>3</sub>N in THF afforded the title compound II which showed IC<sub>50</sub> of 0.15 μM against rat hepatic V<sub>1</sub> receptor binding and IC<sub>50</sub> of 0.068 μM against rat kidney medullary V<sub>2</sub>-receptor binding. Compound II also showed 73% inhibition of oxytocin receptor binding at 10 μM.

IT 22361-77-9


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of tricyclic benzazepines as vasopressin antagonists)

10/785,120

RN 22361-77-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-2-sulfonamide, 10,11-dihydro-N,N-dimethyl-11-oxo-  
(8CI, 9CI) (CA INDEX NAME)



L10 ANSWER 32 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1997:772293 CAPLUS

DN 128:48246

TI Preparation of tricyclic benzazepines as vasopressin antagonists

IN Albright, Jay Donald; Reich, Marvin Fred

PA American Cyanamid Co., USA

SO U.S., 103 pp., Cont.-in-part of U.S. Ser. No. 639,014.



CODEN: USXXAM

DT Patent

LA English

FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5693635	A	19971202	US 1996-662546	19960613
	US 5512563	A	19960430	US 1994-254823	19940613
	NZ 299340	A	20000825	NZ 1994-299340	19940728
	US 5869483	A	19990209	US 1996-639014	19960424
	WO 9747625	A1	19971218	WO 1997-US9549	19970603
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9732965	A1	19980107	AU 1997-32965	19970603
PRAI	US 1993-100003	B2	19930729		
	US 1994-254823	A2	19940613		
	US 1996-639014	A2	19960424		
	NZ 1994-264116	A1	19940728		
	US 1996-662546	A	19960613		
	WO 1997-US9549	W	19970603		
OS	MARPAT 128:48246				
GI					



AB The title compds. [I; Y = a bond; AB= (CH<sub>2</sub>)<sub>2</sub>NR<sub>3</sub>, NR<sub>3</sub>(CH<sub>2</sub>)<sub>2</sub>; R<sub>1</sub> = H, halo, OH, etc.; R<sub>2</sub> = H, halo, OH, etc.; R<sub>1</sub>R<sub>2</sub> = methylenedioxy, ethylenedioxy; R<sub>3</sub> = COAr (wherein Ar = substituted Ph); Z with two carbon atoms attached represents a (un)substituted fused thiophene ring, Ph, etc.] which exhibit antagonist activity at V<sub>1</sub> and/or V<sub>2</sub> receptors, in vivo vasopressin antagonist activity, and also antagonist activity at oxytocin receptors, and are useful in treating diseases characterized by excess renal reabsorption of water, were prepared Thus, reaction of 4-[(2-methylbenzoyl)amino]benzoyl chloride with 10,11-dihydro-5H-dibenz[b,f]azepine in the presence of NaH and 4-(dimethylamino)pyridine in pyridine afforded II which showed IC<sub>50</sub> of 2.5 μM against rat hepatic V<sub>1</sub>

10/785,120

receptor binding and IC<sub>50</sub> of 0.86  $\mu$ M against rat kidney medullary V<sub>2</sub> receptor binding.


IT **22361-77-9**

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of tricyclic benzazepines as vasopressin antagonists)

RN 22361-77-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-2-sulfonamide, 10,11-dihydro-N,N-dimethyl-11-oxo-  
(8CI, 9CI) (CA INDEX NAME)



10/785,120

L10 ANSWER 33 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1997:735922 CAPLUS

DN 128:22824

TI Pyridobenzoxazepine and pyridobenzothiazepine vasopressin antagonists

IN Albright, Jay Donald; Du, Xuemei

PA American Cyanamid Co., USA

SO U.S., 107 pp., Cont.-in-part of U.S. 5,512,563.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5686445	A	19971111	US 1996-637908	19960425
	US 5512563	A	19960430	US 1994-254823	19940613
	NZ 299340	A	20000825	NZ 1994-299340	19940728
	US 5854236	A	19981229	US 1997-834706	19970401
PRAI	US 1993-100003	B2	19930729		
	US 1994-254823	A2	19940613		
	NZ 1994-264116	A1	19940728		
	US 1996-637908	A3	19960425		

OS MARPAT 128:22824


AB Approx. 80 title compds., primarily N-(substituted benzoylaminobenzoyl)dibenzazepines, were prepared by N-acylation of the azepine. E.g., acylation of 10,11-dihydro-5H-dibenz[b,f]azepine with o-MeC6H4CONHC6H4COCl-p gave N-[4-(10,11-dihydro-5H-dibenz[b,f]azepin-5-ylcarbonyl)phenyl]-2-methylbenzamide. The title compds. exhibit antagonist activity at V1 and/or V2 receptors and extensive data is given for vasopressin antagonist activity.

IT 22361-77-9



RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation and vasopressin antagonist activity of  
(benzoylaminobenzoyl)dibenzazepines)

RN 22361-77-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-2-sulfonamide, 10,11-dihydro-N,N-dimethyl-11-oxo-  
(8CI, 9CI) (CA INDEX NAME)



L10 ANSWER 34 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1997:727380 CAPLUS  
 DN 128:30304  
 TI Synthesis and Pharmacological Evaluation of Triflate-Substituted Analogs of Clozapine: Identification of a Novel Atypical Neuroleptic  
 AU Liao, Yi; DeBoer, Peter; Meier, Eddie; Wikstroem, Hkan  
 CS Department of Medicinal Chemistry, University of Groningen, Groningen, NL-9713 AV, Neth.  
 SO Journal of Medicinal Chemistry (1997), 40(25), 4146-4153  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PB American Chemical Society  
 DT Journal  
 LA English  
 GI



AB The trifluoromethanesulfonyloxy (TfO) analogs I and II (R = OSO<sub>2</sub>CF<sub>3</sub>) 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine (clozapine) (I; R = Cl) and its 2-chloro isomer (isoclozapine) (II; R = Cl) were prepared via their OMe and OH analogs with the conventional synthetic method of the tricyclic dibenzodiazepines and evaluated pharmacol. along with their parent drugs. The binding profile of the 2-OTf analog II (R = OSO<sub>2</sub>CF<sub>3</sub>) is comparable to the binding profile of I (R = Cl), although the affinity for the dopamine (DA) D<sub>2</sub> receptors is higher [IC<sub>50</sub> = 31 nM and 330 nM for II (R = OSO<sub>2</sub>CF<sub>3</sub>) and I (R = Cl), resp.]. Interestingly, no notable affinity for muscarinic receptors could be detected in II (R = OSO<sub>2</sub>CF<sub>3</sub>). On the contrary, the 8-OTf analog I (R = OSO<sub>2</sub>CF<sub>3</sub>) only displayed affinity for muscarinic M<sub>1</sub> receptors (IC<sub>50</sub> = 35 nM) and no affinity (IC<sub>50</sub> > 500 nM) for the other receptors tested. The 10 μmol/kg s.c. dose, but not the 10 μmol/kg po dose, of II (R = OSO<sub>2</sub>CF<sub>3</sub>) stimulated the output of DA. Increases of 80% and 35% in DOPAC output from the dorsal striatum were seen after s.c. and po administrations of 10 μmol/kg of II (R = OSO<sub>2</sub>CF<sub>3</sub>) resp. Doses up to 100 μmol/kg of I (R = OSO<sub>2</sub>CF<sub>3</sub>) had no effect on either parameter. Doses up to 100 μmol/kg of II (R = OSO<sub>2</sub>CF<sub>3</sub>) were not cataleptogenic, but significantly decreased apomorphine-induced locomotor activity. In conclusion, II (R = OSO<sub>2</sub>CF<sub>3</sub>) (GMC1-169) is a new clozapine-like neuroleptic candidate, which is lacking anticholinergic properties and displays a higher potency, as compared to clozapine itself.


IT 167997-02-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation and neuroleptic evaluation of clozapine triflate analogs)

RN 167997-02-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-methoxy- (9CI) (CA INDEX NAME)




IT 183583-24-6P 183583-25-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and neuroleptic evaluation of clozapine triflate analogs)


RN 183583-24-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-hydroxy- (9CI) (CA INDEX NAME)



RN 183583-25-7 CAPLUS

CN Methanesulfonic acid, trifluoro-, 10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-2-yl ester (9CI) (CA INDEX NAME)



RE.CNT 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



10/785,120

L10 ANSWER 35 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1997:623152 CAPLUS

DN 127:262691

TI Preparation of nitrogenous tricyclic compounds as allergy inhibitors

IN Miyamoto, Mitsuaki; Yoshiuchi, Tatsuya; Sato, Keizo; Kaino, Makoto;  
Tanaka, Masayuki; Soejima, Motohiro; Moriya, Katsuhiko; Sakuma, Yoshinori;  
Yamada, Koji; Harada, Kokichi; Nishizawa, Yukio; Kobayashi, Seiichi;  
Okita, Makoto; Katayama, Koichi

PA Eisai Co., Ltd., Japan

SO PCT Int. Appl., 175 pp.



CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9733871	A1	19970918	WO 1997-JP789	19970313
	W: AU, CA, CN, HU, JP, KR, MX, NO, NZ, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2248820	AA	19970918	CA 1997-2248820	19970313
	AU 9719399	A1	19971001	AU 1997-19399	19970313
	EP 889037	A1	19990107	EP 1997-907297	19970313
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	CN 1216982	A	19990519	CN 1997-194202	19970313
	NO 9804217	A	19981112	NO 1998-4217	19980911
	US 6333322	B1	20011225	US 1998-125451	19980921
	US 2002103189	A1	20020801	US 2001-985416	20011102
	US 6489336	B2	20021203		
	US 2003171367	A1	20030911	US 2002-201952	20020725
	US 6703388	B2	20040309		
PRAI	JP 1996-55628	A	19960313		
	WO 1997-JP789	W	19970313		
	US 1998-125451	A3	19980921		
	US 2001-985416	A3	20011102		
OS	MARPAT 127:262691				
GI					



AB The title compds. I [D = alkylene; R1 - R8 = hydrogen, hydroxy, cyano, nitro, optionally substituted carbamoyl, halogeno, lower alkyl optionally substituted by halogeno, etc.; Z = S, SO, etc. ; and Q represents, for example, NR20R21 (where R20, R21 = hydrogen, lower alkyl optionally substituted by halogeno, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl, or NR20R21 = three- to eight-membered ring)] are prepared I are effective in the prevention and treatment of diseases in which chemical transmitters such as histamine and leukotriene participate, for example, asthma, allergic rhinitis, atopic dermatitis, hives, hay fever, gastrointestinal allergy, and dietary allergy. In an in vitro test for inhibition of antigen-induced histamine release from basophils, the title compound II showed IC50 of 10 - 30  $\mu$ M.


IT **196098-27-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of nitrogenous tricyclic compds. as allergy inhibitors)

RN 196098-27-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3,4-dimethyl- (9CI)  
(CA INDEX NAME)



L10 ANSWER 36 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1997:145240 CAPLUS

DN 126:157525

TI Tricyclic inhibitors of protein farnesyltransferase

IN Bolton, Gary Louis; Doherty, Annette Marian; Kaltenbronn, James Stanley; Quin, John, III; Scholten, Jeffrey D.; Sebolt-Leopold, Judith; Zinnes, Harold

PA Warner-Lambert Company, USA; Bolton, Gary Louis; Doherty, Annette Marian; Kaltenbronn, James Stanley; Quin, John, III; Scholten, Jeffrey D.; Sebolt-Leopold, Judith; Zinnes, Harold

SO PCT Int. Appl., 82 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9700252	A1	19970103	WO 1996-US8528	19960604
	W: AU, BG, CA, CN, CZ, EE, GE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, US, UZ, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9660342	A1	19970115	AU 1996-60342	19960604
	US 5919780	A	19990706	US 1997-981505	19971211
PRAI	US 1995-913P	P	19950616		
	WO 1996-US8528	W	19960604		
OS	MARPAT 126:157525				
GI					



AB Title compds. I [wherein X = N or CR<sub>9</sub>; Y = NR<sub>10</sub>, CH<sub>2</sub>, O, S, SO, SO<sub>2</sub>, C:O, or CH(OH); R = H or alkyl; R<sub>1</sub> = heteroaryl; n = 1-5; R<sub>2</sub>-R<sub>10</sub> = H or various substituents] are useful as inhibitors of protein farnesyltransferase (PFT), and thus for the treatment of proliferative diseases including cancer, restenosis and psoriasis, and as antiviral agents. For example, condensation of 8-chloro-5,10-dihydrodibenzo[b,e][1,4]diazepine-11-one with 3-(aminomethyl)pyridine in refluxing EtOCH<sub>2</sub>CH<sub>2</sub>OH gave 80% title compound II. Eighteen I were prepared and tested for PFT inhibiting and anticancer activity. In two in vitro bioassays, II had IC<sub>50</sub> values of 3.7 and 5.0  $\mu$ M against PFT.

IT **186765-25-3P**, 7,8-Dichloro-2,3-dimethoxy-5,10-dihydrodibenzo[b,e][1,4]diazepin-11-one

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(intermediate; preparation of tricyclic inhibitors of protein farnesyltransferase)

RN 186765-25-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7,8-dichloro-5,10-dihydro-2,3-

10/785,120

dimethoxy- (9CI) (CA INDEX NAME)



L10 ANSWER 37 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1996:713039 CAPLUS

DN 126:8143

TI Preparation of sulfonyloxyisoclozapine derivatives as atypical neuroleptics.

PA Wikstroem, Haakan, Neth.; De Boer, Peter; Liao, Yi

SO PCT Int. Appl., 37 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9629316	A1	19960926	WO 1996-SE344	19960319
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
	AU 9651305	A1	19961008	AU 1996-51305	19960319
PRAI	SE 1995-998	A	19950319		
	WO 1996-SE344	W	19960319		
OS	MARPAT 126:8143				
GI					



AB Title compds. [I; R1 = H, alkyl, haloalkyl, hydroxyalkyl, alkenyl, alkynyl, cyclopropylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl; R2 = H, alkyl, alkenyl, alkynyl, cyclopropylalkyl, haloalkyl, hydroxylalkyl, hydroxyalkoxyalkyl, 1-(alkyl-2-imidazolidinonyl); X = NH, NR1, O, S, SO, SO2], were prepared. The compds. of this invention possess affinity to one or several receptor systems, e.g. DA (D1-D4),  $\alpha$ 1, muscarinic (M1-M4) and 5-HT (5-HT2A, 5-HT2C and 5-HT7). Thus, (I; X = NH; R1 = CF3; R2 = Me), prepared starting from 5-methoxy-2-aminobenzoic acid and 2-bromonitrobenzene via cyclization of 2-(2-aminophenyl)amino-5-methoxybenzoic acid, s.c. in rats gave a 94% increase in dopamine.

IT 60287-08-3P 167997-02-6P 183583-24-6P

183583-25-7P 183583-27-9P 183583-29-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of sulfonyloxyisoclozapine derivs. as atypical neuroleptics)

RN 60287-08-3 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-hydroxy- (9CI) (CA INDEX NAME)

10/785,120




RN 167997-02-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-methoxy- (9CI) (CA INDEX NAME)




RN 183583-24-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-hydroxy- (9CI) (CA INDEX NAME)



RN 183583-25-7 CAPLUS


CN Methanesulfonic acid, trifluoro-, 10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-2-yl ester (9CI) (CA INDEX NAME)



RN 183583-27-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-[(methanesulfonyl)oxy]- (9CI) (CA INDEX NAME)

10/785,120



RN 183583-29-1 CAPLUS

CN Methanesulfonic acid, trifluoro-, 10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl ester (9CI) (CA INDEX NAME)



L10 ANSWER 38 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1996:567275 CAPLUS

DN 125:221884

TI Preparation of tricyclic benzazepines and benzodiazepines as vasopressin antagonists

IN Albright, Jay Donald; Venkatesan, Aranapakam Mudumbai; Delos Santos, Efren Guillermo

PA American Cyanamid Company, USA

SO PCT Int. Appl., 357 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9622282	A1	19960725	WO 1996-US1051	19960116
	W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, AZ, BY, KG, KZ, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5849735	A	19981215	US 1995-548805	19951222
	AU 9649042	A1	19960807	AU 1996-49042	19960116
	BR 9606977	A	19971104	BR 1996-6977	19960116
	EP 804420	A1	19971105	EP 1996-905227	19960116
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV				
	JP 10512865	T2	19981208	JP 1996-522448	19960116
PRAI	US 1995-373169	A	19950117		
	US 1995-548805	A	19951222		
	WO 1996-US1051	W	19960116		
OS	MARPAT 125:221884				
GI					



AB The title compds. [I; Y = (CH<sub>2</sub>)<sub>n</sub> (wherein n = 0-2), O, S, etc.; AB = (N-substituted) (CH<sub>2</sub>)<sub>m</sub>NH, NH(CH<sub>2</sub>)<sub>m</sub> (wherein m = 1-2); R<sub>1</sub>, R<sub>2</sub> = H, halo, OH, etc.; Z = (substituted) fused Ph, 5-membered fused heteroaryl, etc.] which exhibit antagonist activity at V<sub>1</sub> and/or V<sub>2</sub> receptors and therefore useful as diuretics and antihypertensives, and in the treatment and/or prevention of congestive heart failure, liver cirrhosis, brain edema, cerebral ischemia, cerebral hemorrhage-stroke, thrombosis-bleeding, etc., were prepared. Thus, reaction of 10,11-dihydrodibenz[b,f][1,4]oxazine with 6-[(5-fluoro-2-methylbenzoyl)amino]pyridine-3-carbonyl chloride in the presence of Et<sub>3</sub>N in CH<sub>2</sub>Cl<sub>2</sub> afforded the desired product II which showed IC<sub>50</sub> of 0.24 μM against rat hepatic V<sub>1</sub> receptors and of 0.054 μM



10/785,120

against rat kidney medullary V2 receptors.


IT **22361-77-9**

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of tricyclic benzazepines and benzodiazepines as vasopressin antagonists)

RN 22361-77-9 CAPLUS


CN Dibenz[b,f][1,4]oxazepine-2-sulfonamide, 10,11-dihydro-N,N-dimethyl-11-oxo-  
(8CI, 9CI) (CA INDEX NAME)



10/785,120

L10 ANSWER 39 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1996:494734 CAPLUS  
DN 125:140671  
TI Compound produced by a Micromonospora strain  
IN Ohkuma, Hiroaki; Kobaru, Seikichi  
PA Bristol-Myers Squibb Company, USA  
SO U.S., 14 pp.  
CODEN: USXXAM  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5541181	A	19960730	US 1994-249518	19940526
PRAI	US 1994-249518		19940526		
OS	MARPAT 125:140671				
GI					



AB Disclosed is the novel compound BU-4664L (I) and derivs. thereof. The compound is produced by fermentation of Micromonospora sp. M990-6. The compound

possesses anti-inflammatory and/or anti-tumor activities.


IT **179981-41-0P 179981-42-1P**

RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(anti-inflammatory and anti-tumor compound BU-4664L from Micromonospora)

RN 179981-41-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 4,7,9-tris(acetyloxy)-5,10-dihydro-5-(3,7,11-trimethyl-2,6,10-dodecatrienyl)-, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 179981-42-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,7,9-trimethoxy-5-(3,7,11-trimethyl-2,6,10-dodecatrienyl)-, (E,E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 179981-43-2P

RL: BPN (Biosynthetic preparation); PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(anti-inflammatory and anti-tumor compound BU-4664L from Micromonospora)

RN 179981-43-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,7,9-trimethoxy- (9CI) (CA INDEX NAME)



10/785,120

L10 ANSWER 40 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1996:486143 CAPLUS  
DN 125:158639  
TI Dopamine receptor ligands  
IN Tehim, Ashok; Fu, Jian-min; Rakhit, Sumanas  
PA Allelix Biopharmaceuticals Inc., Can.  
SO U.S., 18 pp., Cont.-in-part of U.S. Ser. No. 172,208, abandoned.  
CODEN: USXXAM  
DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5538965	A	19960723	US 1994-355297	19941212
	CA 2179306	AA	19950629	CA 1994-2179306	19941214
	CA 2179306	C	20001107		
	US 5798350	A	19980825	US 1996-642264	19960503
	US 6103715	A	20000815	US 1998-139715	19980825
PRAI	US 1993-172208	B2	19931223		
	US 1994-355297	A3	19941212		
	US 1996-642264	A3	19960503		
OS	MARPAT 125:158639				
GI					



I


AB D4 receptor-selective compds. such as 11-(4-piperonyl)-1-piperazinyldibenz[b,f][1,4]oxazepine (I) and other dibenzoxazepine, dibenzodiazepine, dibenzothiazepine, and dibenzothiepine derivs. were prepared Their use as ligands for dopamine receptor identification and in a drug screening program, and as pharmaceuticals to treat indications in which the D4 receptor is implicated, such as schizophrenia, is also described.

IT **82096-44-4P 167996-99-8P**  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(dopamine receptor ligands)

RN 82096-44-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro- (7CI, 9CI)  
(CA INDEX NAME)

10/785,120



RN 167996-99-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 4-chloro-5,10-dihydro- (9CI) (CA  
INDEX NAME)



L10 ANSWER 41 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1996:476853 CAPLUS

DN 125:142798

TI Alkyl-substituted oxazepine compounds having dopamine receptor affinity

IN Fu, Jian-Min

PA Allelix Biopharmaceuticals Inc., Can.

SO PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9618621	A1	19960620	WO 1995-IB1108	19951208
	W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5602121	A	19970211	US 1994-354793	19941212
	CA 2207771	AA	19960620	CA 1995-2207771	19951208
	AU 9539345	A1	19960703	AU 1995-39345	19951208
PRAI	US 1994-354793	A	19941212		
	WO 1995-IB1108	W	19951208		

OS MARPAT 125:142798

GI For diagram(s), see printed CA Issue.

AB The compds. are I, wherein: A and B are independently selected, optionally substituted, unsatd. 5- or 6-membered, homo- or heterocyclic rings; X1 is selected from CH<sub>2</sub>, O, NH, S, C=O, CH-OH, CH-N(C1-4alkyl)<sub>2</sub>, C=CHCl, C=CHCN, N-C1-4alkyl, N-acetyl, SO<sub>2</sub> and SO; X2--- is selected from N-, CH<sub>2</sub>-, CH= and C(OH); Y is selected from N and CH; R1 represents C1-4alkyl; n is 0, 1 or 2; q is 1 or 2; and Z is C5-10alkyl optionally substituted with OH, halo, C1-4alkyl or C1-4alkoxy and optionally incorporating a heteroatom selected from O, N and S; and acid addition salts, solvates and hydrates thereof. Their use as ligands for dopamine receptor identification and in a drug screening program, and as pharmaceuticals to treat indications in which D4 receptor stimulation is implicated, such as schizophrenia, is also described.


IT 3158-94-9

RL: RCT (Reactant); RACT (Reactant or reagent)

(in manufacture of alkyl-substituted oxazepine compds. having dopamine receptor affinity)

RN 3158-94-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)



L10 ANSWER 42 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1996:476852 CAPLUS

DN 125:142797

TI Preparation of pyrrolo[1,2-a]pyrazine and pyrrolo[1,2-a][1,4]diazepine derivs. as dopamine agonists or antagonists

IN Power, Patricia L.; Rakhit, Sumanas

PA Allelix Biopharmaceuticals Inc., Can.

SO PCT Int. Appl., 41 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9618630	A1	19960620	WO 1995-IB1110	19951208
	W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5576314	A	19961119	US 1994-354906	19941212
	CA 2207546	AA	19960620	CA 1995-2207546	19951208
	AU 9539347	A1	19960703	AU 1995-39347	19951208
	EP 797577	A1	19971001	EP 1995-937148	19951208
	EP 797577	B1	20000726		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV				
	AT 194988	E	20000815	AT 1995-937148	19951208
PRAI	US 1994-354906	A	19941212		
	WO 1995-IB1110	W	19951208		
OS	MARPAT 125:142797				
GI					



AB Bicyclic nonane and decane compds., i.e., octahydropyrrolo[1,2-a]pyrazine and octahydro-1H-pyrrolo[1,2-a][1,4]diazepine derivs. I (A, B = ring-forming group; R1 = H,  $\alpha$ -carbon of amino acid side-chain; R2, R3 = H, hydroxy, amino, etc.; n = 1,2; X2 = O, S, methine, etc.; X2 = imino, methylene, carbonyl) were disclosed as D4 receptor-selective compds. The use of I as ligands for dopamine receptor identification and the use of I in drug screening programs and as pharmaceuticals to treat indications in which the D4 receptor is implicated, such as schizophrenia,

10/785,120

were also described. The target compds. I were analogs of clozapine. An example compound is (R)-11-(octahydropyrrolo[1,2-a]pyrazinyl-2-yl)dibenz[b,f][1,4]oxazepine (II).


IT **167997-03-7**

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrrolo[1,2-a]pyrazine and pyrrolo[1,2-a][1,4]diazepine derivs. as dopamine agonists or antagonists)

RN 167997-03-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-nitro- (9CI) (CA INDEX NAME)




IT **3158-94-9P 179458-05-0P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrrolo[1,2-a]pyrazine and pyrrolo[1,2-a][1,4]diazepine derivs. as dopamine agonists or antagonists)


RN 3158-94-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 179458-05-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-bromo- (9CI) (CA INDEX NAME)





10/785,120

L10 ANSWER 43 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1996:476645 CAPLUS

DN 125:142792

TI Substituted tetracyclic oxazepine and thiazepine derivatives with 5-HT2 receptor affinity.

IN Fernandez-Gadea, Francisco Javier; Sipido, Victor Karel; Andres-Gil, Jose Ignacio; Meert, Theo Frans

PA Janssen Pharmaceutica N.V., Belg.

SO PCT Int. Appl., 28 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9614321	A1	19960517	WO 1995-EP4197	19951025
	W: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	TW 449601	B	20010811	TW 1995-84111064	19951020
	CA 2203664	AA	19960517	CA 1995-2203664	19951025
	AU 9539250	A1	19960531	AU 1995-39250	19951025
	AU 699545	B2	19981203		
	EP 789702	A1	19970820	EP 1995-937007	19951025
	EP 789702	B1	20010207		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CN 1162314	A	19971015	CN 1995-195988	19951025
	CN 1065245	B	20010502		
	JP 10508309	T2	19980818	JP 1995-515010	19951025
	RU 2161159	C2	20001227	RU 1997-108688	19951025
	AT 199088	E	20010215	AT 1995-937007	19951025
	ES 2155899	T3	20010601	ES 1995-937007	19951025
	PT 789702	T	20010731	PT 1995-937007	19951025
	PL 183618	B1	20020628	PL 1995-319870	19951025
	ZA 9509216	A	19970430	ZA 1995-9216	19951031
	IL 115820	A1	19990620	IL 1995-115820	19951031
	US 5773433	A	19980630	US 1997-817989	19970425
	FI 9701855	A	19970430	FI 1997-1855	19970430
	FI 113270	B1	20040331		
	NO 9702018	A	19970430	NO 1997-2018	19970430
	NO 308036	B1	20000710		
	GR 3035666	T3	20010629	GR 2001-400516	20010329
PRAI	EP 1994-203177	A	19941102		
	US 1995-454993	A1	19950531		
	EP 1995-937007	A	19951025		
	WO 1995-EP4197	W	19951025		
OS	CASREACT 125:142792; MARPAT 125:142792				
GI					



AB The invention concerns title compds. I [R1, R2 = H, C1-6 alkyl or alkylcarbonyl, trihalomethylcarbonyl, C1-6 hydroxyalkyl, C1-6 alkoxy, CO2H, C1-6 alkylcarbonyloxy, C1-6 alkoxy carbonyl, or aryl; or R1 and R2 form various N heterocycles; R3-R10 = H, halo, cyano, OH, CF3, CF3O, CO2H, NO2, (di)(alkyl)amino, C1-6 alkylcarbonylamino, aminosulfonyl, (di)alkylaminosulfonyl, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylcarbonyl, C1-6 alkoxy carbonyl; R11 = H, C1-6 alkyl, CF3; R12 = H, C1-6 alkyl, cyano, or CF3; n = 0-6; and X = O, S, S(:O) or S(:O)2], and their pharmaceutically acceptable salts, stereoisomeric forms, and N-oxides. I show activity in 5-HT2 receptor binding tests in vitro (no data), and may be used as therapeutic agents in the treatment or the prevention of CNS disorders, cardiovascular disorders or gastrointestinal disorders. For example, 1,3-dipolar cycloaddn. of dibenzoxazepine oxide II with the corresponding allylic amine gave cis-isomeric title compound III [R = COCF3], which was hydrolyzed with K2CO3 in aqueous MeOH to give preferred title compound III [R = H], the latter isolated as its (2:3) oxalate salt in 47% yield. III was active in the "elevated and illuminated plus maze test" in rats, with a highest/lowest active dose ratio of  $\geq 4$ . I were also active as antagonists of mCPP-induced effects in rats. Examples include preps. of over 50 compds. I and several precursors, plus 4 formulations and the above bioassays.

IT **3158-88-1**


RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; preparation of tetracyclic oxazepine and thiazepine derivs. with 5-HT2 receptor affinity)

RN 3158-88-1 CAPLUS

CN Dibenz[*b,f*][1,4]oxazepin-11(10H)-one, 3-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)

10/785,120



L10 ANSWER 44 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1996:473239 CAPLUS

DN 125:142799

TI Preparation of (4-methyl-1-piperazinyl)dibenzo[b,e][1,4]diazepines and  
(4-methyl-1-piperazinyl)dibenzo[b,f]thiepins as dopaminergic  
neurotransmitter agonists or antagonists

IN Fu, Jian-Min; Rakhit, Sumanas

PA Allelix Biopharmaceuticals Inc., Can.

SO PCT Int. Appl., 31 pp.


CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9618622	A1	19960620	WO 1995-IB1109	19951208
	W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5700445	A	19971223	US 1994-354905	19941212
	CA 2207494	AA	19960620	CA 1995-2207494	19951208
	AU 9539346	A1	19960703	AU 1995-39346	19951208
	US 5968478	A	19991019	US 1997-948051	19971009
PRAI	US 1994-354905	A	19941212		
	WO 1995-IB1109	W	19951208		
OS	MARPAT 125:142799				
GI					



I



II



III

AB Piperazine derivs. I ( X1 = methine, amino group, O, S: X2 = methylene,


methine, imino; R1-R8 = H, alkyl, halo, cyano, nitro, etc.) were disclosed. I are dopaminergic D4 receptor agonists and/or antagonists. The use of I as ligands for dopamine receptor identification and their use in drug screening programs and as pharmaceuticals to treat indications in which the D4 receptor is implicated, such as schizophrenia, were described. Example compds. were 4-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine (II) and 10-(4-methyl-1-piperazinyl)-10-oxodibenzo[b,f]thiepin-2-carbonitrile (III).

IT 162930-70-3 167996-99-8, 4-Chloro-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine 167997-00-4 167997-01-5 167997-04-8 179385-64-9

RL: RCT (Reactant); RACT (Reactant or reagent)  
((piperazinyl)dibenzo[b,e][1,4]diazepines and  
(piperazinyl)dibenzo[b,f]thiepins as dopaminergic neurotransmitter  
agonists or antagonists)


RN 162930-70-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4-nitro- (9CI) (CA INDEX NAME)




RN 167996-99-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 4-chloro-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 167997-00-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 167997-01-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2,7,8-trichloro-5,10-dihydro- (9CI)


10/785,120

(CA INDEX NAME)




RN 167997-04-8 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-4-carbonitrile, 10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)



RN 179385-64-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 4,7,8-trichloro-5,10-dihydro- (9CI) (CA INDEX NAME)



L10 ANSWER 45 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1996:473238 CAPLUS

DN 125:142796

TI Preparation of (piperazinyl)dibenzoxazepines as 5-HT<sub>2</sub> receptor ligands

IN Tehim, Ashok; Fu, Jian-Min; Rakhit, Sumanas

PA Allelix Biopharmaceuticals Inc., Can.

SO PCT Int. Appl., 27 pp.


CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9618629	A1	19960620	WO 1995-IB1111	19951208
	W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5602124	A	19970211	US 1994-354765	19941212
	CA 2207613	AA	19960620	CA 1995-2207613	19951208
	AU 9539348	A1	19960703	AU 1995-39348	19951208
	US 5824676	A	19981020	US 1996-763255	19961210
PRAI	US 1994-354765	A	19941212		
	WO 1995-IB1111	W	19951208		
OS	MARPAT 125:142796				
GI					



I



II

AB The piperazine derivs, I (A, B = ring-forming group; X1 = O, S, etc.; X2 = imino, methine, carbonyl, etc.; R1 = alkyl, etc.; R2, R3, R4 = H, alkyl) were disclosed as 5-HT<sub>2</sub> receptor-selective compds. The compds. I are analogs of clozapine. The use of I in the serotonin 5-HT<sub>2</sub> receptor identification and use in drug screening programs and as pharmaceuticals to treat indications in which the 5-HT<sub>2</sub> receptor is implicated, such as hypertension, thrombosis, migraine, vasospasm, ischemia, depression, anxiety, schizophrenia, sleep disorders and appetite disorders were also described.

IT **3158-88-1**


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of (piperazinyl)dibenzoxazepines as serotonergic neurotransmitter agonists of antagonists)

RN 3158-88-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)

10/785,120





L10 ANSWER 46 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1995:927367 CAPLUS

DN 124:117270

TI Pictet-Spengler reaction in trifluoroacetic acid. Large scale synthesis of pyridoindolobenzodiazepine as an atypical antipsychotic agent

AU Zhang, Lin-hua; Meier, W.; Wats, E.; Costello, T. D.; Ma, P.; Ensinger, C. L.; Rodgers, J. M.; Jacobson, I. C.; Rajagopalan, P.

CS DuPont Merck Pharmaceutical Company, Deepwater, NJ, 08023-0999, USA

SO Tetrahedron Letters (1995), 36(46), 8387-90

CODEN: TELEAY; ISSN: 0040-4039


PB Elsevier

DT Journal

LA English

OS CASREACT 124:117270

GI



AB Traditional syntheses of benzodiazepines involve a Bischler-Napieralski reaction which is a three step process and gives low overall yields. An attractive alternative is to construct the diazepine ring under Pictet-Spengler conditions. This paper reports the synthesis of a novel pyridoindolobenzodiazepine, I, as a potent atypical antipsychotic agent. The key step in the synthesis is the ring formation of the diazepine ring from pyridoindole II in neat trifluoroacetic acid.

IT 90353-71-2P 90353-75-6P 154557-90-1P


173034-10-1P 173034-11-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyridoindolobenzodiazepines via Pictet-Spengler reaction in trifluoroacetic acid)

RN 90353-71-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-2-methyl-5-nitroso- (9CI) (CA INDEX NAME)



10/785,120


RN 90353-75-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-2-methyl-  
(9CI) (CA INDEX NAME)




RN 154557-90-1 CAPLUS

CN Benzo[b]pyrido[3',4':4,5]pyrrolo[3,2,1-jk][1,4]benzodiazepin-8(9H)-one,  
11-chloro-1,2,3,4-tetrahydro-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 173034-10-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-amino-8-chloro-5,10-dihydro-2-methyl-  
(9CI) (CA INDEX NAME)



RN 173034-11-2 CAPLUS

CN Pyrido[3',4':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,  
6-chloro-1,2,3,4-tetrahydro-2,11-dimethyl- (9CI) (CA INDEX NAME)

10/785,120



L10 ANSWER 47 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1995:898877 CAPLUS

DN 123:313792

TI Preparation of tricyclic benzazepine vasopressin antagonists

IN Albright, Jay D.; Reich, Marvin F.; Sum, Fuk-Wah; Du, Xuemei

PA American Cyanamid Co., USA

SO Can. Pat. Appl., 288 pp.



CODEN: CPXXEB

DT Patent


LA English

FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 2128955	AA	19950130	CA 1994-2128955	19940727
	EP 640592	A1	19950301	EP 1994-111040	19940715
	EP 640592	B1	19981230		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	AT 175198	E	19990115	AT 1994-111040	19940715
	ES 2125377	T3	19990301	ES 1994-111040	19940715
	SK 281194	B6	20010118	SK 1994-880	19940720
	IL 110436	A1	20031210	IL 1994-110436	19940725
	FI 9403542	A	19950130	FI 1994-3542	19940728
	FI 108433	B1	20020131		
	NO 9402817	A	19950130	NO 1994-2817	19940728
	NO 308601	B1	20001002		
	AU 9468776	A1	19950209	AU 1994-68776	19940728
	AU 676737	B2	19970320		
	ZA 9405604	A	19950309	ZA 1994-5604	19940728
	JP 07179430	A2	19950718	JP 1994-195886	19940728
	JP 3630449	B2	20050316		
	HU 71548	A2	19951228	HU 1994-2223	19940728
	RU 2149160	C1	20000520	RU 1994-27580	19940728
	NZ 299340	A	20000825	NZ 1994-299340	19940728
	CN 1106802	A	19950816	CN 1994-108768	19940729
	CN 1064354	B	20010411		
	PL 181918	B1	20011031	PL 1994-304496	19940729
	TW 402592	B	20000821	TW 1994-83108599	19940916
	HK 1011362	A1	20010727	HK 1998-112373	19981127
	FI 2001001100	A	20010525	FI 2001-1100	20010525
	FI 111077	B1	20030530		
	FI 2001001101	A	20010525	FI 2001-1101	20010525
	FI 111075	B1	20030530		
	FI 2001001102	A	20010525	FI 2001-1102	20010525
	FI 111076	B1	20030530		
PRAI	US 1993-100003	A	19930729		
OS	NZ 1994-264116	A1	19940728		
GI	MARPAT 123:313792				



- AB The title compds. [I; AB = (CH<sub>2</sub>)<sub>m</sub>NR<sub>3</sub>, (un)substituted R<sub>3</sub>N(CH<sub>2</sub>)<sub>m</sub>; R<sub>3</sub> = (un)substituted arylcarbonyl, (un)substituted 5-indolylcarbonyl, etc.; m = 1, 2; R<sub>1</sub> = H, halogen, OH, alkylthio, SH, acyl, etc.; R<sub>2</sub> = H, Cl, F, Br, I, alkyl, alkoxy; Z = (un)substituted fused Ph, (un)substituted 5-member heteroarom. ring, etc.], useful as vasopressin antagonists for diseases requiring diuretic application, are prepared Thus, dibenzazepine II was prepared and demonstrated a IC<sub>50</sub> for human V<sub>2</sub> receptors of 0.86 μM.
- IT **22361-77-9**  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of tricyclic benzazepine vasopressin antagonists from)
- RN 22361-77-9 CAPLUS
- CN Dibenz[b,f][1,4]oxazepine-2-sulfonamide, 10,11-dihydro-N,N-dimethyl-11-oxo-  
 (8CI, 9CI) (CA INDEX NAME)



L10 ANSWER 48 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1995:804461 CAPLUS

DN 123:198834

TI N-Heterobicycyl-piperazinyl or -piperidinyl tricyclic derivatives useful as dopamine receptor ligands

IN Tehim, Ashok; Fu, Jian-Min; Rakhit, Sumanas

PA Allelix Biopharmaceuticals Inc., Can.

SO PCT Int. Appl., 49 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9517400	A1	19950629	WO 1994-CA687	19941214
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN				
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2179306	AA	19950629	CA 1994-2179306	19941214
	CA 2179306	C	20001107		
	AU 9511899	A1	19950710	AU 1995-11899	19941214
	EP 736024	A1	19961009	EP 1995-902734	19941214
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 09506868	T2	19970708	JP 1994-517063	19941214
PRAI	US 1993-172208	A	19931223		
	WO 1994-CA687	W	19941214		
OS	CASREACT 123:198834; MARPAT 123:198834				
GI	For diagram(s), see printed CA Issue.				
AB	<p>Dopamine D4 receptor-selective compds. are disclosed, specifically I [rings A, B = (un)substituted, (un)saturated 5- or 6-membered, homo- or heterocyclic rings; X1 = CH2, O, NH, S, CO, CH(OH), CH[CH(C1-4-alkyl)2], C:CHCl, C:CHCN, N(C1-4-alkyl), NAc, SO2, SO; X2 = N:, CH2CH:, CO, O, S; R1 = C1-4 alkyl; Y = CH, N; n = 0-2; q = 1-2; R2 = C1-6 alkyl bridge optionally incorporating N, O and S; ring D = cyclohexane or benzene nucleus; ring E = (un)saturated 5- or 6-membered heterocycle incorporating 1-3 of O, N, and/or S and (un)substituted by 1-2 of halo, C1-4 alkyl, haloalkyl] and their acid addition salts, solvates, and hydrates. Their uses as ligands for dopamine receptor identification, in a drug screening program, and as pharmaceuticals for, e.g., schizophrenia, are also described. Eighteen compds. I were claimed, prepared, and/or tested. Various salts and precursors were also prepared For example, condensation of 8-chlorodibenz[b,f][1,4]oxazepin-11(10H)-one [preparation briefly described] with 1-piperonylpiperazine in refluxing PhMe in the presence of TiCl4 gave title compound II. As the most preferred embodiment of the invention, II exhibited better D4 affinity and selectivity than the standard D4 antagonist clozapine. For example, II had D4 receptor Ki of 4, vs. 23 for clozapine, and a D2/D4 ratio of 23.8, vs. 10 for clozapine.</p>				
IT	<p><b>3158-94-9</b>, 4-Chlorodibenz[b,f][1,4]oxazepin-11(10H)-one  <b>82096-44-4</b>, 2-Chloro-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-11-one  <b>90353-73-4</b>, 3-Chloro-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine  <b>167996-99-8</b>, 4-Chloro-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine  <b>167997-00-4</b>, 2-Trifluoromethyl-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine  <b>167997-01-5</b>, 2,7,8-Trichloro-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine  <b>167997-02-6</b>, 2-Methoxy-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine  <b>167997-03-7</b>, 4-Nitrodibenz[b,f][1,4]oxazepin-11(10H)-one  <b>167997-04-8</b>, 4-Cyanodibenz[b,f][1,4]oxazepin-11(10H)-one</p>				

10/785,120

RL: RCT (Reactant); RACT (Reactant or reagent)  
(starting material; preparation of piperazinyl and piperidinyl tricyclics as  
dopamine receptor ligands)


RN 3158-94-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-chloro- (7CI, 8CI, 9CI) (CA INDEX  
NAME)




RN 82096-44-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro- (7CI, 9CI)  
(CA INDEX NAME)




RN 90353-73-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro- (7CI, 9CI)  
(CA INDEX NAME)



RN 167996-99-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 4-chloro-5,10-dihydro- (9CI) (CA  
INDEX NAME)



10/785,120


RN 167997-00-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-(trifluoromethyl)-  
(9CI) (CA INDEX NAME)




RN 167997-01-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2,7,8-trichloro-5,10-dihydro- (9CI)  
(CA INDEX NAME)




RN 167997-02-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-methoxy- (9CI) (CA  
INDEX NAME)



RN 167997-03-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-nitro- (9CI) (CA INDEX NAME)




RN 167997-04-8 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-4-carbonitrile, 10,11-dihydro-11-oxo- (9CI) (CA  
INDEX NAME)



10/785,120



L10 ANSWER 49 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1995:570871 CAPLUS

DN 122:314588

TI Preparation of sulfonamide and sulfonic ester derivatives each having tricyclic heterocyclic ring as antitumor agents

IN Yoshino, Hiroshi; Ueda, Norihiro; Niijima, Jun; Haneda, Toru; Kotake, Yoshihiko; Yoshimatsu, Kentaro; Watanabe, Tatsuo; Nagasu, Takeshi; Tsukahara, Naoko; et al.

PA Eisai Co., Ltd., Japan

SO PCT Int. Appl., 84 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9503279	A1	19950202	WO 1994-JP1231	19940726
	W: CA, FI, NO, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2144854	AA	19950202	CA 1994-2144854	19940726
	EP 679641	A1	19951102	EP 1994-921819	19940726
	EP 679641	B1	20021002		
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
	JP 08081441	A2	19960326	JP 1994-174643	19940726
	JP 3690825	B2	20050831		
	AT 225334	E	20021015	AT 1994-921819	19940726
	NO 9501108	A	19950523	NO 1995-1108	19950323
	US 5834462	A	19981110	US 1995-397254	19950323
	FI 9501416	A	19950517	FI 1995-1416	19950324
	US 5854274	A	19981229	US 1996-760738	19961205
	US 5846969	A	19981208	US 1997-873033	19970611
PRAI	JP 1993-202466	A	19930726		
	JP 1994-158870	A	19940711		
	WO 1994-JP1231	W	19940726		
	US 1995-397254	A3	19950323		
	US 1996-760738	A3	19961205		

OS MARPAT 122:314588

GI For diagram(s), see printed CA Issue.

AB N-heterocyclarylarylsulfonamide and heterocyclaryl arylsulfonate derivs. each having a tricyclic hetero ring, represented by general formula G-SO<sub>2</sub>-L-M [G = a 5- or 6-membered aromatic ring; L = O or NR<sub>1</sub>, wherein R<sub>1</sub> = H or lower alkyl; M = a tricyclic structure selected from the members Q - Q<sub>5</sub>, wherein rings A and B represent each a 5 or 6-membered unsatd. ring; X = NR<sub>2</sub> (wherein R<sub>2</sub> = H or lower alkyl) or NHCO; Y = O, S(O)<sub>n</sub>, CR<sub>3</sub>R<sub>4</sub>, CO, NR<sub>5</sub>, CHR<sub>6</sub>CHR<sub>7</sub>, CR<sub>8</sub>:R<sub>9</sub>, NR<sub>10</sub>CO, N:CR<sub>11</sub>, OCHR<sub>12</sub>, S(O)<sub>n</sub>CH<sub>13</sub>, or NR<sub>14</sub>CHR<sub>15</sub>; Z = N or CR<sub>16</sub>, wherein n represents 0, 1 or 2; R<sub>3</sub> - R<sub>13</sub>, R<sub>15</sub>, R<sub>16</sub> = H or lower alkyl; R<sub>14</sub> = H, lower alkyl, or lower acyl] are prepared Thus, 107 mg 1-amino-10H-phenothiazine was dissolved in pyridine and a solution of 115 mg 4-methoxybenzenesulfonyl chloride in THF was added followed by stirring the mixture overnight at room temperature to give, after silica gel chromatog., a

title compound (I) (115 mg). I and phenothiazin-3-one derivative (II) showed IC<sub>50</sub> of 0.11 and 0.016 µg/mL against KB cells (human nasal cavity cancer). A total of 49 I were prepared

IT **163308-29-0P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(intermediate for preparation of N-heterocyclarylarylsulfonamide as antitumor agent)

RN 163308-29-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-amino-2-fluoro-5,10-dihydro- (9CI)

10/785,120

(CA INDEX NAME)




IT **163308-03-0P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of N-heterocyclaryl sulfonamide as antitumor agent)

RN 163308-03-0 CAPLUS

CN Benzenesulfonamide, N-(2-fluoro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-6-yl)-4-methoxy- (9CI) (CA INDEX NAME)



L10 ANSWER 50 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1995:380741 CAPLUS

DN 122:290829

TI Synthesis and Anti-HIV-1 Activity of 4,5,6,7-Tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one (TIBO) Derivatives. 3

AU Breslin, Henry J.; Kukla, Michael J.; Ludovici, Donald W.; Mohrbacher, Richard; Ho, Winston; Miranda, Milton; Rodgers, James D.; Hitchens, T. Kevin; Leo, Gregory; et al.

CS Janssen Research Foundation, Spring House, PA, 19477, USA

SO Journal of Medicinal Chemistry (1995), 38(5), 771-93


CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

GI



AB 4,5,6,7-Tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-ones (TIBO) (I, R = H, 5-Et, 7-Ph, etc.; X = S, O; Y = 8-Cl, 9-Cl; Z = H, 3,3-dimethylallyl, Pr, etc.) have been shown to significantly inhibit HIV-1 replication in vitro by interfering with the virus's reverse transcriptase enzyme. We describe our synthetic endeavors around 4, 5, and 7 mono- and disubstitutions of I and discuss HIV-1 inhibitory structure-activity relationships. On the basis of inhibition of HIV-1 replication in MT-4 cells, we found that 5-mono-Me-substituted analogs and 7-mono-Me-substituted analogs of I were comparable as being consistently the most active compds. Although generally less active, the 4,5,7-unsubstituted, 4-mono-substituted, cis- and trans-5,7-di-Me-substituted, and cis-4,5-di-Me-substituted analogs of I also exhibited significant activity. The remaining trans-4,5-di-Me-substituted, cis- and trans-4,7-di-Me-substituted, and all 4,5-, 5,6-, 6,7-, and 7,8-fused disubstituted analogs of I possessed no noticeable desired activity.


IT 162930-70-3P 162930-73-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis and anti-HIV-1 activity of imidazobenzodiazepinones)

RN 162930-70-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4-nitro- (9CI) (CA INDEX NAME)



10/785,120

RN 162930-73-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 4-amino-5,10-dihydro- (9CI) (CA  
INDEX NAME)



L10 ANSWER 51 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1994:534165 CAPLUS

DN 121:134165

TI Preparation of 1-,2-,3-,4-,5-,6-,7-,8- and/or 9 substituted dibenzox(thi)azepine compounds, and methods for treating pain

IN Husa, Robert K.; Rafferty, Michael F.; Hagen, Timothy J.; Hallinan, E. Ann

PA G. D. Searle and Co., USA

SO U.S., 27 pp.


CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5304644	A	19940419	US 1992-869563	19920415
	US 5461046	A	19951024	US 1993-126826	19930924
PRAI	US 1992-869563	A1	19920415		
OS	MARPAT 121:134165				
GI					



AB Title compds. I (R1 = H, HO, alkyl, haloalkyl, alkoxy, HO2C, alkoxy carbonyl, amino, aminocarbonyl, (alkyl)(dialkyl)amino, amido, halo, NC, O2N, F3C, etc.; R2 = H, halo; X = O, S, with the proviso that R1 is not Cl at position 8 when X is O and R2 is H) or a salt, ester or amide thereof, are prepared 4-Chloro-3-nitrobenzotrifluoride and salicylaldehyde K salt were were reacted to give 2-[2-nitro-4-(trifluoromethyl)phenoxy]benzaldehyde which in EtOH was hydrogenated over Raney Ni to give 8-(trifluoromethyl)-10,11-dihydrodiben[b,f]oxazepine to which was added phosgene in MePh followed by 2-[3-(ethylsulfonyl)-1-oxopropyl]hydrazide to give I (R1 = 8-F3C, R2 = H, X = O) which in a writhing assay at 30 mg/kg was the most potent. I were also tested for prostaglandin antagonism.


IT 3158-94-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of analgesics)

RN 3158-94-9 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)





L10 ANSWER 52 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1994:270470 CAPLUS  
 DN 120:270470  
 TI Pyridoindolobenzodiazepines and derivatives as antipsychotics  
 IN Rajagopalan, Parthasarathi  
 PA The Du Pont Merck Pharmaceutical Co., USA  
 SO PCT Int. Appl., 37 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9403455	A1	19940217	WO 1993-US6823	19930723
	W: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5321023	A	19940614	US 1992-921051	19920729
	AU 9346853	A1	19940303	AU 1993-46853	19930723
	EP 652878	A1	19950517	EP 1993-917295	19930723
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	HU 69393	A2	19950928	HU 1995-193	19930723
	JP 08500579	T2	19960123	JP 1993-505349	19930723
	BR 9306896	A	19981208	BR 1993-6896	19930723
	ZA 9305486	A	19950130	ZA 1993-5486	19930729
	CN 1100424	A	19950322	CN 1993-109416	19930729
	FI 9500303	A	19950124	FI 1995-303	19950124
	NO 9500327	A	19950127	NO 1995-327	19950127
PRAI	US 1992-921051	A	19920729		
	WO 1993-US6823	W	19930723		
OS	MARPAT 120:270470				
GI					



AB Pyrido[4',3':2,3]indolo-[1,7-ab][1,5]benzodiazepines [I; R = H, C1-10 alkyl, C3-7 cycloalkyl, hydroxyalkyl, amidoalkyl, aminoalkyl, (CH2)n-adamantyl, etc.; n = 1-8; R1, R2, R4, and R5 are independently selected from H, C1-3 alkyl, CF3, Cl, F, Br, OH, CN, OMe, S(O)pR7; P = 0-2; R7 = H, C1-3 alkyl, Ph; R3 = H, C1-3 alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, heteroarylalkyl, CO2Me, CO2Et; X = O, S, 2H], pharmaceutical compns. containing these compds., and methods of using these compds. to treat physiol. or drug induced psychosis and/or dyskinesia are claimed. In an example, I (R = R4 = Me, R1 = R3 = R5 = H, R2 = Cl, CF3, X = 2H, O) gave ED50 values of  $\leq 20$  mg/kg in overcoming catalepsy in rats.

IT 154557-90-1P 154557-91-2P 154557-92-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)




10/785,120

(preparation, antidyskinetic and antipsychotic activity, and reduction of)


RN 154557-90-1 CAPLUS

CN Benzo[b]pyrido[3',4':4,5]pyrrolo[3,2,1-jk][1,4]benzodiazepin-8(9H)-one,  
11-chloro-1,2,3,4-tetrahydro-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 154557-91-2 CAPLUS

CN Benzo[b]pyrido[3',4':4,5]pyrrolo[3,2,1-jk][1,4]benzodiazepin-8(9H)-one,  
11-chloro-1,2,3,4-tetrahydro-6-methyl- (9CI) (CA INDEX NAME)



RN 154557-92-3 CAPLUS

CN Benzo[b]pyrido[3',4':4,5]pyrrolo[3,2,1-jk][1,4]benzodiazepin-8(9H)-one,  
1,2,3,4-tetrahydro-3,6-dimethyl-11-(trifluoromethyl)- (9CI) (CA INDEX  
NAME)




IT 154557-99-0

RL: RCT (Reactant); RACT (Reactant or reagent)  
(reaction of, with methylpiperidone)


RN 154557-99-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-8-methyl-5-  
nitroso- (9CI) (CA INDEX NAME)


10/785,120



L10 ANSWER 53 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1992:407902 CAPLUS  
 DN 117:7902  
 TI Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 2.  
 Tricyclic pyridobenzoxazepinones and dibenzoxazepinones  
 AU Klunder, Janice M.; Hargrave, Karl D.; West, M.; Cullen, Ernest; Pal,  
 Kollol; Behnke, Mark L.; Kapadia, Suresh R.; McNeil, Daniel W.; Wu, Joe  
 C.; Chow, Grace C.  
 CS Boehringer Ingelheim Pharm., Ridgefield, CT, 06877, USA  
 SO Journal of Medicinal Chemistry (1992), 35(10), 1887-97  
 CODEN: JMCMAR; ISSN: 0022-2623  
 DT Journal  
 LA English  
 OS CASREACT 117:7902  
 GI




AB Dibenzo[b,f][1,4]oxazepin-11(10H)-ones, e.g., I, pyrido[2,3-  
 b][1,4]benzoxazepin-6(5H)-ones, e.g., II, and pyrido[2,3-  
 b][1,5]benzoxazepin-5(6)-ones (III) inhibited human immunodeficiency virus  
 type 1 reverse transcriptase with IC50 values as low as 19 nM. A-ring  
 substitution had a profound effect on activity, with appropriate  
 substituents at the positions ortho and para to the lactam N providing  
 dramatically enhanced potency. Substitution in the C-ring is generally  
 neutral or detrimental to activity. I-III are specific for HIV-1 RT,  
 showing no activity for other viral reverse transcriptase enzymes.  
 IT **140412-92-6P**  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and HIV-1 inhibition activity of)  
 RN 140412-92-6 CAPLUS  
 CN Dibenzo[b,f][1,4]oxazepin-11(10H)-one, 2-amino-9-methyl- (9CI) (CA INDEX  
 NAME)



IT **135810-39-8P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and alkylation of)  
 RN 135810-39-8 CAPLUS  
 CN Dibenzo[b,f][1,4]oxazepin-11(10H)-one, 7-methyl-2-nitro- (9CI) (CA INDEX  
 NAME)

10/785,120



L10 ANSWER 54 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1992:194275 CAPLUS

DN 116:194275

TI Reaction of tetrafluorodibenz[b,f][1,4]oxazepin-11(10H)-ones with nucleophiles

AU Konstantinova, A. V.; Yakovleva, O. D.; Gerasimova, T. N.

CS Novosib. Inst. Org. Khim., Novosibirsk, 630090, USSR


SO Khimiya Geterotsiklicheskikh Soedinenii (1991), (9), 1259-61

CODEN: KGSSAQ; ISSN: 0453-8234

DT Journal

LA Russian

GI




AB The nucleophilic substitution reactions of the title compound I (R = R2 = F; R1 = H) with NaOMe/MeOH or piperidine gave I (R2 = OMe or piperidino). In excess piperidine a 1,3-dipiperidino derivative was formed. I (R = R2 = H; R1 = F) did not react with NaOMe/MeOH or piperidine.

IT **140406-57-1P 140406-58-2P 140406-59-3P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 140406-57-1 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,2,4-trifluoro-3-methoxy- (9CI)  
(CA INDEX NAME)



RN 140406-58-2 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,2,4-trifluoro-3-(1-piperidinyl)-  
(9CI) (CA INDEX NAME)

10/785,120



RN 140406-59-3 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,4-difluoro-1,3-di-1-piperidinyl-  
(9CI) (CA INDEX NAME)




IT 123959-09-1

RL: RCT (Reactant); RACT (Reactant or reagent)  
(reaction of, with methoxide or piperidine)

RN 123959-09-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,2,3,4-tetrafluoro- (9CI) (CA  
INDEX NAME)



L10 ANSWER 55 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1991:583381 CAPLUS

DN 115:183381

TI Preparation of dibenz[b,f][1,4]oxazepin (and thiazepin)-11(10H)-ones and -thiones for prevention and treatment of AIDS

IN Hargrave, Karl D.; Schmidt, Guenther; Engel, Wolfhard; Schromm, Kurt

PA Boehringer Ingelheim Pharmaceuticals, Inc., USA; Thomae, Dr. Karl, G.m.b.H.

SO Can. Pat. Appl., 41 pp.


CODEN: CPXXEB

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<hr/>					
PI	CA 2024040	AA	19910301	CA 1990-2024040	19900827
	CA 2024040	C	20020219		
	EP 419861	A2	19910403	EP 1990-116339	19900827
	EP 419861	A3	19920610		
	EP 419861	B1	19951102		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 129637	E	19951115	AT 1990-116339	19900827
	JP 03163021	A2	19910715	JP 1990-226409	19900828
	JP 2862980	B2	19990303		
	HU 57589	A2	19911230	HU 1990-5511	19900828
	HU 211077	B	19951030		
	ZA 9006834	A	19920527	ZA 1990-6834	19900828
	KR 165108	B1	19990218	KR 1990-13273	19900828
	AU 9061916	A1	19910307	AU 1990-61916	19900829
	AU 639255	B2	19930722		
	US 5571806	A	19961105	US 1994-271350	19940706
PRAI	US 1989-400254	A	19890829		
	US 1990-582773	B1	19900803		
	US 1992-879652	B1	19920506		
	US 1993-53948	B1	19930428		
OS	MARPAT 115:183381				
GI					



AB The title compds. [I; X, Z = O, S; R1 = H, C1-6 alkyl, C2-6 alkenyl, alkynyl, C3-6 cycloalkyl, etc.; R2 = H, Me, halo; R3 = H, C1-4 alkyl, halo, OH, C1-3 alkoxy, etc.; R4 = H, Me, halo; R5 = H, C1-4 alkyl, OH, C1-3 alkoxy, alkylthio, etc.] are prepared, tested, and formulated. To a solution of I (R1-R5 = H, X = Z = O) in DMF was added a 50% dispersion of NaH in mineral oil, the resulting mixture was stirred with PrBr to give 87% I (R1 = Pr, R2-R5 = H, X = Z = O), which showed 100% reverse transcriptase inhibition at 10 µg/mL. Also prepared and tested were 49 addnl. I. Capsule, parenteral solution, and nasal solution formulations were given.

IT 135810-39-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of HIV inhibitor)

10/785,120

RN 135810-39-8 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 7-methyl-2-nitro- (9CI) (CA INDEX NAME)




IT 23474-55-7P 23474-59-1P 23474-63-7P  
23474-66-0P 135810-51-4P 135810-53-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as HIV inhibitor for prevention and treatment of AIDS)


RN 23474-55-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-chloro- (8CI, 9CI) (CA INDEX NAME)




RN 23474-59-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-methyl- (8CI, 9CI) (CA INDEX NAME)



RN 23474-63-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-amino- (8CI, 9CI) (CA INDEX NAME)




RN 23474-66-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino- (8CI, 9CI) (CA INDEX NAME)




10/785,120




RN 135810-51-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-(methylamino)- (9CI) (CA INDEX NAME)




RN 135810-53-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-7-methyl- (9CI) (CA INDEX NAME)



10/785,120

L10 ANSWER 56 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1991:247246 CAPLUS  
DN 114:247246  
TI Synthesis of fluorosubstituted 10,11-dihydrodibenz[b,f][1,4]oxazepines  
AU Konstantinova, A. V.; Zborovskaya, O. D.; Gerasimova, T. N.  
CS Novosib. Inst. Org. Khim., Novosibirsk, 630090, USSR  
SO Khimiya Geterotsiklicheskikh Soedinenii (1990), (12), 1679-82  
CODEN: KGSSAQ; ISSN: 0453-8234  
DT Journal  
LA Russian  
OS CASREACT 114:247246  
GI




AB Fluorinated dibenzoxazepinones I (X = F; Y = H and vice versa; R = H; Z = CO) were alkylated with Me<sub>2</sub>N(CH<sub>2</sub>)<sub>3</sub>Cl.HCl to give I [R = (CH<sub>2</sub>)<sub>3</sub>NMe<sub>2</sub>]. Also, the reaction of dibenzoxazepines I (R = H; X = CH<sub>2</sub>) with CO<sub>2</sub>Cl<sub>2</sub> and subsequent amination with NH<sub>3</sub> or Me<sub>2</sub>NH or reaction with NH<sub>2</sub>NH<sub>2</sub> followed by acetylation gave I (R = CONH<sub>2</sub>, CONMe<sub>2</sub>) or I (R = CONHNHAc), resp.

IT **123959-09-1**  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(alkylation of, with (dimethylamino)chloropropane hydrochloride)

RN 123959-09-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,2,3,4-tetrafluoro- (9CI) (CA INDEX NAME)



L10 ANSWER 57 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1989:632774 CAPLUS

DN 111:232774

TI Preparation of tricyclic lactams and analogs as muscarinic antagonists

IN Turconi, Marco; Donetti, Arturo; Cereda, Enzo; Quintero, Myrna Gil; Schiavi, Giovanni Battista; Micheletti, Rosamaria

PA Istituto De Angeli S.p.A., Italy

SO Eur. Pat. Appl., 46 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 309422	A2	19890329	EP 1988-830374	19880919
	EP 309422	A3	19900110		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	DD 282689	A5	19900919	DD 1988-319831	19880915
	DK 8805226	A	19890322	DK 1988-5226	19880920
	FI 8804305	A	19890322	FI 1988-4305	19880920
	NO 8804174	A	19890322	NO 1988-4174	19880920
	JP 01132567	A2	19890525	JP 1988-236178	19880920
	AU 8822380	A1	19890323	AU 1988-22380	19880921
PRAI	IT 1987-21978	A	19870921		

OS MARPAT 111:232774

GI For diagram(s), see printed CA Issue.

AB Title compds. I [R = H, halo; X = N, CH; W = NHCO, CH:CH, (CH<sub>2</sub>)<sub>2</sub>, O, S; R<sub>1</sub> = H, C1-4 alkyl; n = 0, 1; Y = S, CH; A = C, N; B = CH when A ≠ N, CO<sub>2</sub>, CO, CH<sub>2</sub>; m = 0-3; Z = NH, CO, CO<sub>2</sub>, CH, bond; p, q = 0, 1; Q = (homo)piperazinyl, piperidinyl, trotyl, tetrahydropyrimidinyl, the above groups may be substituted by a C1-4 alkyl or an amino; R = CR<sub>2</sub>:NR<sub>3</sub>; R<sub>2</sub> = H, C1-4 alkyl, (C1-4 alkyl- or Ph-substituted) amino; R<sub>3</sub> = C1-8 alkyl, H (provided that the bond of QR is a C-C bond or AB = C:CH); R<sub>2</sub>R<sub>3</sub> = atoms to form a 5-membered ring] are prepared for treatment of motility disorders of the gastrointestinal or urogenital tract and peptic ulcer disorders. A mixture of 5,10-dihydro-5-[2-piperazin-1-yl]acetyl-11H-dibenzo[b,e][1,4]-diazepin-11-one and H<sub>2</sub>NC(:NH)SMe.H<sub>2</sub>SO<sub>4</sub> in EtOH was refluxed to give the 4-guanylpiperazinyl analog isolated as its 2 HCl salt. The latter salt showed a dissociation constant (K<sub>D</sub>) of 6 nM for displacement of 3H-pirenzepine from cerebral cortex homogenate of rats. Tablets were formulated containing I 20, lactose 247, cornstarch 30, and Mg stearate 3 mg.

IT **122859-65-8P 122859-68-1P 122859-69-2P**  
**122860-39-3P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of muscarinic antagonists)

RN 122859-65-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4-methyl-5-(1-piperazinylacetyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 122859-68-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 122859-69-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-(chloroacetyl)-5,10-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 122860-39-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[imino(nitroamino)methyl]-1-piperazinyl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)




IT **122858-73-5P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as muscarinic antagonist)

RN 122858-73-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(aminoiminomethyl)-1-piperazinyl]acetyl]-5,10-dihydro-4-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

10/785,120

L10 ANSWER 58 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1989:632756 CAPLUS

DN 111:232756

TI 11-Substituted polyfluorinated dibenz[b,f][1,4]oxazepines

AU Konstantinova, A. V.; Gerasimova, T. N.; Kozlova, M. M.; Petrenko, N. I.

CS Novosib. Inst. Org. Khim., Novosibirsk, USSR

SO Khimiya Geterotsiklicheskikh Soedinenii (1989), (4), 539-42


CODEN: KGSSAQ; ISSN: 0453-8234

DT Journal


LA Russian

OS CASREACT 111:232756

GI



I



II


AB Tetrafluorodibenzoxazepinones I (X = F, Y = H; X = H, Y = F), prepared by oxidation of the corresponding dibenzoxazepinones with Na<sub>2</sub>Cr<sub>2</sub>O<sub>7</sub> in AcOH, were chlorinated with POCl<sub>3</sub> to give 73 and 95% chloro derivs. II (same X, Y), resp. Amination of the latter by piperidine gave the corresponding piperidine derivs.

IT 123959-09-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and chlorination of)

RN 123959-09-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,2,3,4-tetrafluoro- (9CI) (CA INDEX NAME)



L10 ANSWER 59 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1988:492960 CAPLUS

DN 109:92960

TI Synthesis and structure of 7,9-dinitro-5-phenyl-1,4-benzodiazepine derivatives and benzo[b] analogs

AU Dvorkin, A. A.; Simonov, Yu. A.; Ivanov, E. I.; Fedorova, G. V.; Ivanova, R. Yu.

CS Fiz. Khim. Inst., Odessa, USSR

SO Zhurnal Obshchei Khimii (1987), 57(11), 2613-17


CODEN: ZOKHA4; ISSN: 0044-460X

DT Journal

LA Russian

OS CASREACT 109:92960

GI



AB Cyclocondensation of o-H<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>NH<sub>2</sub> and H<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub> with benzoic acid derivs. I (R<sub>1</sub> = R<sub>3</sub> = NO<sub>2</sub>, R<sub>2</sub> = Ph, OMe) gave 65 and 72% benzodiazepines II and III and 68 and 79% benzo[b]-analogs IV and V.


IT **22177-14-6P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 22177-14-6 CAPLUS



CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2,4-dinitro- (8CI, 9CI)  
(CA INDEX NAME)

10/785,120





L10 ANSWER 60 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1987:489483 CAPLUS  
 DN 107:89483  
 TI 2-[10,11-Dihydro-11-oxodibenz[b,f][1,4]oxazepin-7 or 8-yl]propanoic acids  
 as potential anti-inflammatory agents  
 AU Chakrabarti, Jiban K.; Hicks, Terence A.  
 CS Lilly Res. Cent. Ltd., Windlesham/Surrey, GU20 6PH, UK  
 SO European Journal of Medicinal Chemistry (1987), 22(2), 161-3  
 CODEN: EJMCA5; ISSN: 0223-5234  
 DT Journal  
 LA English  
 OS CASREACT 107:89483  
 GI




AB I (R = o-Cl, o-O2N, o-H2N, or m-F) were prepared by the reaction of  
 appropriately substituted o-aminophenols with o-halobenzoyl chlorides in  
 the presence of 1 equivalent of aqueous NaOH and cyclization of the resulting

II  
 (R = 2-Cl, 2-NO2, 2-NH2 or 3-F, X = F or Cl) as di-Na salts followed by  
 neutralization. The compds. were administered in mice in oral doses up to  
 1600 mg/kg. The compds. were not potent inhibitors of adjuvant-induced  
 arthritis in rats and effects, where seen, were only moderate. I (R =  
 3-F; 7- or 8-CHMeCO2H) showed moderately weak in vitro reduction of  
 cyclooxygenase products of arachidonic acid in guinea pig peritoneal  
 polymorphonuclear leukocytes. The compds. were 300-fold less potent than  
 indomethacin.

IT **109790-28-5P 109790-29-6P 109790-30-9P**  
**109790-31-0P 109790-32-1P 109823-13-4P**  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, as antiinflammatory agent)


RN 109790-28-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-7-acetic acid, 3-fluoro-10,11-dihydro- $\alpha$ -  
 methyl-11-oxo- (9CI) (CA INDEX NAME)




RN 109790-29-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-acetic acid, 2-chloro-10,11-dihydro-α-methyl-11-oxo- (9CI) (CA INDEX NAME)




RN 109790-30-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-acetic acid, 10,11-dihydro-α-methyl-2-nitro-11-oxo- (9CI) (CA INDEX NAME)




RN 109790-31-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-acetic acid, 2-amino-10,11-dihydro-α-methyl-11-oxo- (9CI) (CA INDEX NAME)



RN 109790-32-1 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-fluoro- (9CI) (CA INDEX NAME)



10/785,120

RN 109823-13-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-acetic acid, 3-fluoro-10,11-dihydro- $\alpha$ -methyl-11-oxo- (9CI) (CA INDEX NAME)



L10 ANSWER 61 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1986:442760 CAPLUS

DN 105:42760

TI Synthesis of 10,11-dihydrodibenz[b,f][1,4]oxazepine derivatives as potential anticonvulsant and psychotropic agents

AU Nagarajan, K.; David, J.; Bhat, G. A.

CS Res. Cent., Hindustan Ciba-Geigy Ltd., Bombay, 400 063, India

SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1985), 24B(8), 840-4



CODEN: IJSBDB; ISSN: 0376-4699

DT Journal

LA English

OS CASREACT 105:42760

GI




AB Dihydrobenzoxazepines I (Z = O, S; R = H<sub>2</sub>N, MeNH, EtNH, PrNH, cyclohexylamino, PhNH, Me<sub>2</sub>N, H<sub>2</sub>NNH, EtO, Me, CF<sub>3</sub>, ClCH<sub>2</sub>, morpholinomethyl, Et<sub>2</sub>NCH<sub>2</sub>; R<sub>1</sub> = H, NO<sub>2</sub>, NH<sub>2</sub>, AcNH) and II (Z<sub>1</sub> = O, H<sub>2</sub>; R<sub>2</sub> = NH<sub>2</sub> NO<sub>2</sub>; R<sub>3</sub> = H, Me), most of them carrying either a nitro or amino group at position-2, have been synthesized as analogs of carbamazepine and evaluated as anticonvulsants associated with potential neuroleptic activity. I (Z, R, R<sub>1</sub> = O, AcNHNH, NO<sub>2</sub>; O, Me<sub>2</sub>N, NH<sub>2</sub>) have moderate activity in the electroshock test but are inactive against chemoshock. I (Z = S, R = NH<sub>2</sub>, R<sub>1</sub> = H) is active against electroshock as well as against strychnine-induced seizures, has some analgesic activity and also exhibits neuroleptic properties, but its overall profile does not present any advantages over carbamazepine.

IT 23474-59-1P 23474-66-0P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and anticonvulsant and psychotropic activities of)

RN 23474-59-1 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-methyl- (8CI, 9CI) (CA INDEX NAME)




RN 23474-66-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino- (8CI, 9CI) (CA INDEX NAME)

10/785,120



L10 ANSWER 62 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1986:435135 CAPLUS  
 DN 105:35135  
 TI Piperazinylnaphthoxazepines with CNS depressant properties  
 AU Nagarajan, Kuppuswamy; David, Joy; Kulkarni, Yashwant S.; Hendi, Shivakumar B.; Shenoy, Sharada J.; Upadhyaya, Pramod  
 CS Res. Cent., Hindustan Ciba-Geigy Ltd., Bombay, 400063, India  
 SO European Journal of Medicinal Chemistry (1986), 21(1), 21-6  
 CODEN: EJMCA5; ISSN: 0223-5234  
 DT Journal  
 LA English  
 OS CASREACT 105:35135  
 GI



AB Several piperazinylnaphthoxazepines were synthesized and tested for central nervous system (CNS)-depressant, anticonvulsant, and antimescaline (tranquilizing) activities in mice. 13-(4-Methyl-1-piperazinyl)benzo[b]naphth[2,3-f][1,4]oxazepine maleate (I maleate) [103086-38-0] and 13-(4-methyl-1-piperazinyl)benzo[b]naphth[1,2-f][1,4]oxazepine maleate (II maleate) [103086-50-6] had strong CNS-depressant and antimescaline activity, but provided little or no protection against electroshock convulsions. III [103086-33-5] had only moderate antimescaline and CNS-depressant action, but protected the animals against electroshock convulsions. Structure-activity relation of the psychoactive agents are discussed.


IT 103086-27-7P 103086-33-5P 103086-64-2P  
 103086-65-3P 103116-81-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation and central nervous system activity of)

RN 103086-27-7 CAPLUS


CN Benzo[f]naphth[1,2-b][1,4]oxazepin-8(7H)-one, 10-nitro- (9CI) (CA INDEX NAME)

10/785,120




RN 103086-33-5 CAPLUS

CN Benzo[f]naphth[2,1-b][1,4]oxazepin-12(13H)-one, 10-amino- (9CI) (CA INDEX NAME)




RN 103086-64-2 CAPLUS

CN Benzo[f]naphth[2,1-b][1,4]oxazepin-12(13H)-one, 10-nitro- (9CI) (CA INDEX NAME)



RN 103086-65-3 CAPLUS


CN Benzo[f]naphth[2,1-b][1,4]oxazepin-12(13H)-one, 10-chloro- (9CI) (CA INDEX NAME)



RN 103116-81-0 CAPLUS

CN Benzo[f]naphth[2,3-b][1,4]oxazepin-13(12H)-one, 2-chloro- (9CI) (CA INDEX NAME)


10/785,120






10/785,120

L10 ANSWER 63 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1986:148838 CAPLUS  
DN 104:148838  
TI A new facile synthesis of 11-oxo-10,11-dihydro-5H-  
dibenzo[b,e][1,4]diazepines  
AU Giani, R. P.; Borsa, M.; Parini, E.; Tonon, G. C.  
CS Res. Dev. Dep., Dompe Farm. S.p.A., Milan, I-20122, Italy  
SO Synthesis (1985), (5), 550-2  
CODEN: SYNTBF; ISSN: 0039-7881  
DT Journal  
LA English  
OS CASREACT 104:148838  
GI




AB The title compds. I (R = 3-NO<sub>2</sub>, 2-NO<sub>2</sub>, 3-Cl, H, 2-Cl; R<sub>1</sub> = H, 4-NO<sub>2</sub>; R<sub>2</sub> = H, 7-Me, 7-Cl; R<sub>3</sub> = H, 8-Me, 8-Cl) were prepared in 3-41% yield by heating chlorobenzoic acids II with phenylenediamines III in a PhCl suspension of Cu powder.  
IT 22177-14-6P 54255-81-1P 82096-44-4P  
90353-73-4P 101382-96-1P 101382-98-3P  
101382-99-4P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 22177-14-6 CAPLUS  
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2,4-dinitro- (8CI, 9CI)  
(CA INDEX NAME)




RN 54255-81-1 CAPLUS  
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-nitro- (9CI) (CA INDEX NAME)

10/785,120




RN 82096-44-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro- (7CI, 9CI)  
(CA INDEX NAME)




RN 90353-73-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro- (7CI, 9CI)  
(CA INDEX NAME)



RN 101382-96-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-nitro- (9CI) (CA  
INDEX NAME)



RN 101382-98-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7,8-dimethyl-2-nitro-  
(9CI) (CA INDEX NAME)

10/785,120



RN 101382-99-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7,8-dimethyl-  
(9CI) (CA INDEX NAME)



L10 ANSWER 64 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1985:166786 CAPLUS

DN 102:166786

TI Dibenzodiazepines

PA Hoechst-Roussel Pharmaceuticals, Inc., USA

SO Jpn. Kokai Tokkyo Koho, 47 pp.


CODEN: JKXXAF

DT Patent


LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 59219285	A2	19841210	JP 1984-97691	19840517
	US 4761411	A	19880802	US 1983-495569	19830518
	HU 37432	A2	19851228	HU 1984-1858	19840514
	HU 193010	B	19870828		
	EP 129692	A2	19850102	EP 1984-105509	19840515
	EP 129692	A3	19870729		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	FI 8401965	A	19841119	FI 1984-1965	19840516
	FI 77865	B	19890131		
	FI 77865	C	19890510		
	ES 532509	A1	19850801	ES 1984-532509	19840516
	DK 8402469	A	19841119	DK 1984-2469	19840517
	AU 8428347	A1	19841122	AU 1984-28347	19840517
	AU 575830	B2	19880811		
	ZA 8403722	A	19850130	ZA 1984-3722	19840517
	CA 1244414	A1	19881108	CA 1984-454542	19840517
	US 4663453	A	19870505	US 1985-770046	19850828
	US 4723003	A	19880202	US 1986-929697	19861112
	US 4723007	A	19880202	US 1986-929705	19861112
	US 4761412	A	19880802	US 1986-929700	19861112
	US 4764616	A	19880816	US 1986-929696	19861112
	FI 8800925	A	19880229	FI 1988-925	19880229
PRAI	US 1983-495569	A	19830518		
	FI 1984-1965	A	19840516		
	US 1984-639569	A2	19840810		
	US 1985-770046	A3	19850828		
OS	CASREACT 102:166786; MARPAT 102:166786				
GI					



I



II

AB Title compds. I (R, R4 = H, halo, CF3, alkyl, alkoxy, alkylthio, alkylsulfonyl; R1 = H, R2R3 = alkylene, CH:CH; R3 = H, R1R2 = alkylene, CH:CH; R5 = amino) and their salts were prepared Thus, treating 5-chloroindoline with 2-FC6H4CONH2 in Me2SO in the presence of NaH gave indoline II (R6 = H), which was nitrated and reduced to give II (R6 = NH2). The latter compound was cyclized with HCl-Et2O and condensed with

10/785,120


N-methylpiperazine to give I (R = R<sub>1</sub> = H, R<sub>2</sub>R<sub>3</sub> = CH:CH, R<sub>4</sub> = 4-Cl, R<sub>5</sub> = N-methylpiperazinyl). 9-Methyl-6-(4-methylpiperazinyl)-1,2-dihydrobenzo[b]pyrrolo[3,2,1-jk][1,4]benzodiazepine had antipsychotic ED<sub>50</sub> of 25.5 mg/kg orally in mice and analgesic ED<sub>50</sub> of 0.34 mg/kg s.c. in mice.

IT **96015-18-8P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 96015-18-8 CAPLUS


CN Benzo[b]pyrrolo[3,2,1-jk][1,4]benzodiazepin-6(7H)-one,  
4-chloro-1,2-dihydro- (9CI) (CA INDEX NAME)




10/785,120

L10 ANSWER 65 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1984:407218 CAPLUS  
DN 101:7218  
TI Pyridoindolobenzodiazepine tranquilizers  
IN Rajagopalan, Parthasarathi  
PA du Pont de Nemours, E. I., and Co. , USA  
SO U.S., 15 pp.  
CODEN: USXXAM  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4438120	A	19840320	US 1982-441376	19821112
PRAI	US 1982-441376		19821112		
OS	CASREACT 101:7218; MARPAT 101:7218				
GI					



I



III


AB Pyridoindolobenzodiazepines I [R = H, (un)substituted alkyl; R1, R2, R4, R5 = H, CF3, Me, Et, halo; R3 = H, alkyl; X = H2, O, S] and their trans-4a,14a dihydro derivs. (II) were prepared Thus, the dibenzodiazepinone III (R6 = H) was nitrosated to give III (R6 = NO) which was treated with Zn-HOAc and 4-piperidone to give I (R = R1 = R3 = R4 = R5 = H, R2 = Cl; X = O; IV). IV was acetylated to give I (R = Ac, R1 = R3 = R4 = R5 = H, R2 = Cl, X = O; IV) which was reduced by B2H6 in THF, then refluxed with 6N HCl to give II.2HCl (R = Et, R1 = R3 = R4 = R5 = H, R2 = Cl, X = H2; V). In the conditioned avoidance response test with mice, the ED50 for IV and V were 29 and 0.3 mg/kg orally, resp.

IT 82096-44-4 90353-73-4 90353-74-5  
90353-75-6

RL: RCT (Reactant); RACT (Reactant or reagent)  
(nitrosation of)

RN 82096-44-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro- (7CI, 9CI)  
(CA INDEX NAME)



10/785,120


RN 90353-73-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro- (7CI, 9CI)  
(CA INDEX NAME)




RN 90353-74-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-methyl- (9CI) (CA INDEX NAME)



RN 90353-75-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-2-methyl- (9CI) (CA INDEX NAME)




IT 90353-29-0P 90353-35-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and borane reduction of)


RN 90353-29-0 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,  
3-acetyl-11-chloro-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



RN 90353-35-8 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,  
6-chloro-1,2,3,4-tetrahydro-11-methyl-3-(1-oxohexyl)- (9CI) (CA INDEX  
NAME)




IT 90353-38-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and reduction of, by borane)

RN 90353-38-1 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,  
11-chloro-1,2,3,4-tetrahydro-3-(phenylacetyl)- (9CI) (CA INDEX NAME)



IT 90340-27-5P 90340-29-7P 90340-30-0P  
90340-33-3P 90340-34-4P 90340-35-5P




90340-37-7P 90340-38-8P 90340-40-2P

90340-55-9P 90340-56-0P 90340-57-1P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and tranquilizer activity of)


RN 90340-27-5 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,  
1,2,3,4-tetrahydro-11-methyl- (9CI) (CA INDEX NAME)




RN 90340-29-7 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,  
12-chloro-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



RN 90340-30-0 CAPLUS


CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,  
5-chloro-1,2,3,4-tetrahydro-11-methyl- (9CI) (CA INDEX NAME)




RN 90340-33-3 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,  
11-chloro-1,2,3,4-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)


10/785,120



RN 90340-34-4 CAPLUS  
CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,  
6-chloro-1,2,3,4-tetrahydro-3,11-dimethyl- (9CI) (CA INDEX NAME)




RN 90340-35-5 CAPLUS  
CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,  
6,11-dichloro-1,2,3,4-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)




RN 90340-37-7 CAPLUS  
CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,  
6-chloro-1,2,3,4-tetrahydro-11-methyl-3-(2-phenylethyl)- (9CI) (CA INDEX  
NAME)


10/785,120



RN 90340-38-8 CAPLUS  
CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,  
11-chloro-1,2,3,4-tetrahydro-3-methyl-6-(trifluoromethyl)- (9CI) (CA  
INDEX NAME)




RN 90340-40-2 CAPLUS  
CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,  
5-chloro-1,2,3,4-tetrahydro-3,11-dimethyl- (9CI) (CA INDEX NAME)




RN 90340-55-9 CAPLUS  
CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,  
5-chloro-3-hexyl-1,2,3,4-tetrahydro-11-methyl- (9CI) (CA INDEX NAME)


10/785,120



RN 90340-56-0 CAPLUS  
CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,  
6-chloro-3-hexyl-1,2,3,4-tetrahydro-11-methyl- (9CI) (CA INDEX NAME)




RN 90340-57-1 CAPLUS  
CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,  
11-chloro-3-hexyl-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




IT 90340-36-6P 90353-30-3P 90353-67-6P  
90353-68-7P 90353-70-1P 90353-71-2P  
90353-72-3P 90353-96-1P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 90340-36-6 CAPLUS  
CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,  
12-chloro-1,2,3,4-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)

10/785,120




RN 90353-30-3 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,  
3-acetyl-11-chloro-1,2,3,4-tetrahydro-6-(trifluoromethyl)- (9CI) (CA  
INDEX NAME)



RN 90353-67-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-nitroso-  
(9CI) (CA INDEX NAME)



RN 90353-68-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-5-nitroso-  
(9CI) (CA INDEX NAME)

10/785,120




RN 90353-70-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-methyl-5-nitroso-  
(9CI) (CA INDEX NAME)




RN 90353-71-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-2-methyl-5-  
nitroso- (9CI) (CA INDEX NAME)



RN 90353-72-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-nitroso-8-  
(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 90353-96-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-8-  
(trifluoromethyl)- (9CI) (CA INDEX NAME)

10/785,120




IT 90340-41-3P 90340-42-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation, acylation, and tranquilizer activity of)


RN 90340-41-3 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one, 6-chloro-1,2,3,4-tetrahydro-11-methyl- (9CI) (CA INDEX NAME)



RN 90340-42-4 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one, 11-chloro-1,2,3,4-tetrahydro-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




IT 90340-28-6P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation, borane reduction, and tranquilizer activity of)

RN 90340-28-6 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one, 11-chloro-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




IT 90353-67-6 90353-68-7 90353-70-1  
90353-71-2 90353-72-3 90353-78-9  
90353-79-0

RL: RCT (Reactant); RACT (Reactant or reagent)  
(reduction and reaction of, with piperidones, pyridoindolobenzodiazepines  
from)


RN 90353-67-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-nitroso-  
(9CI) (CA INDEX NAME)



RN 90353-68-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-5-nitroso-  
(9CI) (CA INDEX NAME)



RN 90353-70-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-methyl-5-nitroso-  
(9CI) (CA INDEX NAME)






RN 90353-71-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-2-methyl-5-nitroso- (9CI) (CA INDEX NAME)




RN 90353-72-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-nitroso-8-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 90353-78-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-chloro-5,10-dihydro-2-methyl-5-nitroso- (9CI) (CA INDEX NAME)



RN 90353-79-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2,8-dichloro-5,10-dihydro-5-nitroso- (9CI) (CA INDEX NAME)

10/785,120




IT 90353-92-7 90353-94-9

RL: RCT (Reactant); RACT (Reactant or reagent)  
(reduction of, by borane)


RN 90353-92-7 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,  
11-chloro-3-(cyclopropylcarbonyl)-1,2,3,4-tetrahydro- (9CI) (CA INDEX  
NAME)




RN 90353-94-9 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,  
6-chloro-1,2,3,4-tetrahydro-11-methyl-3-(phenylacetyl)- (9CI) (CA INDEX  
NAME)



10/785,120


L10 ANSWER 66 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1984:407128 CAPLUS  
DN 101:7128  
TI Synthesis of carbon-14-labeled 10-[3-(dimethylamino)propyl]-2-nitrodibenz[b,f][1,4]oxazepin-11(10H)one (nitroxazepine) hydrochloride  
AU Maller, R. K.; Nagarajan, K.  
CS Res. Cent., Ciba-Geigy, Bombay, 400 063, India  
SO Journal of Labelled Compounds and Radiopharmaceuticals (1983), 20(12), 1339-48  
CODEN: JLCRD4; ISSN: 0362-4803  
DT Journal  
LA English  
OS CASREACT 101:7128  
GI



AB The title antidepressant compound I was prepared labeled in the 11-position with <sup>14</sup>C in an overall yield of 12% and sp. activity 0.95  $\mu$ Ci/mg starting from Na<sup>14</sup>CN, and <sup>14</sup>C-labeled in one terminal Me group in 20% overall yield and sp. activity 1.84  $\mu$ Ci/mg starting from desmethylnitroxazepine. The 11-<sup>14</sup>C atom was introduced by treating diazotized 2-ClC<sub>6</sub>H<sub>4</sub>NH<sub>2</sub> with Cu<sub>2</sub>(<sup>14</sup>CN)<sub>2</sub>, prepared in situ from Cu<sub>2</sub>Cl<sub>2</sub> and K<sup>14</sup>CN, to give 2-ClC<sub>6</sub>H<sub>4</sub><sup>14</sup>CN.

IT **90425-08-4P**  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and condensation of, with (dimethylamino)propyl chloride)


RN 90425-08-4 CAPLUS  
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one-11-<sup>14</sup>C, 2-nitro- (9CI) (CA INDEX NAME)



10/785,120

L10 ANSWER 67 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1984:209889 CAPLUS  
DN 100:209889  
TI Dibenzoxazepine derivatives  
PA Chugai Pharmaceutical Co., Ltd., Japan  
SO Jpn. Kokai Tokkyo Koho, 4 pp.  
CODEN: JKXXAF  
DT Patent  
LA Japanese  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 58225074	A2	19831227	JP 1982-108516	19820625
	JP 03059068	B4	19910909		
PRAI	JP 1982-108516		19820625		
OS	CASREACT 100:209889				
GI					



AB Ten anti-ulcer (no data) dibenzoxazepine derivs. I [R<sub>1</sub> = H, halo, alkoxy, alkyl; n = 1, 2; NR<sub>2</sub>R<sub>3</sub> = NH(CH<sub>2</sub>)<sub>m</sub>NR<sub>4</sub>R<sub>5</sub> (R<sub>4</sub>, R<sub>5</sub> = alkyl; NR<sub>4</sub>R<sub>5</sub> may form a heterocyclic ring; m = 2, 3), 4-methyl(homo)piperazino] and their HCl salts were prepared by reaction of II with R<sub>2</sub>R<sub>3</sub>NH. Thus, refluxing 3.4 g II (R<sub>1</sub> = 2- and 4-Me<sub>2</sub>CH, n = 2) with 10 mL SOCl<sub>2</sub> in C<sub>6</sub>H<sub>6</sub> 3 h gave the chloride, which (in CHCl<sub>3</sub>) was added to a mixture of 3 g N-methylpiperazine and 15 mL 10% aqueous NaOH with ice cooling and the whole stirred 1 h with ice cooling and 2 h at room temperature to give 85.4% I (R<sub>1</sub> = 2- and 4-Me<sub>2</sub>CH, n =


2, NR<sub>2</sub>R<sub>3</sub> = 4-methylpiperazino).

IT **81679-38-1**

RL: RCT (Reactant); RACT (Reactant or reagent)  
(chlorination of)

RN 81679-38-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 10,11-dihydro-2,4-bis(1-methylethyl)-11-oxo- (9CI) (CA INDEX NAME)




IT **90174-23-5P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and amidation of)

RN 90174-23-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carbonyl chloride, 10,11-dihydro-2,4-bis(1-methylethyl)-11-oxo- (9CI) (CA INDEX NAME)




IT 90174-02-0P 90174-04-2P 90174-05-3P  
 90174-06-4P 90174-07-5P 90174-08-6P  
 90174-09-7P 90174-10-0P 90174-11-1P  
 90174-12-2P 90174-14-4P 90174-15-5P  
 90174-16-6P 90174-17-7P 90174-18-8P  
 90174-19-9P 90174-20-2P 90174-21-3P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)


RN 90174-02-0 CAPLUS

CN Piperazine, 1-[[10,11-dihydro-2,4-bis(1-methylethyl)-11-oxodibenz[b,f][1,4]oxazepin-8-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 90174-04-2 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxamide, N-[2-(dimethylamino)ethyl]-10,11-dihydro-2,4-bis(1-methylethyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 90174-05-3 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxamide, N-[3-(dimethylamino)propyl]-10,11-dihydro-2,4-bis(1-methylethyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 90174-06-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxamide, N-[2-(diethylamino)ethyl]-10,11-dihydro-4-methoxy-11-oxo- (9CI) (CA INDEX NAME)




RN 90174-07-5 CAPLUS

CN Piperazine, 1-[(10,11-dihydro-3-methyl-11-oxodibenz[b,f][1,4]oxazepin-8-yl)carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 90174-08-6 CAPLUS


CN Piperazine, 1-[(10,11-dihydro-4-methoxy-11-oxodibenz[b,f][1,4]oxazepin-8-yl)carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 90174-09-7 CAPLUS


CN 1H-1,4-Diazepine, 1-[[10,11-dihydro-2,4-bis(1-methylethyl)-11-oxodibenz[b,f][1,4]oxazepin-8-yl]carbonyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)

10/785,120




RN 90174-10-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxamide, 10,11-dihydro-2,4-bis(1-methylethyl)-11-oxo-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 90174-11-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxamide, 10,11-dihydro-2,4-bis(1-methylethyl)-N-[2-(4-morpholinyl)ethyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 90174-12-2 CAPLUS

CN Piperazine, 1-[[10,11-dihydro-2,4-bis(1-methylethyl)-11-oxodibenz[b,f][1,4]oxazepin-8-yl]carbonyl]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 90174-14-4 CAPLUS

10/785,120


CN Dibenzo[b,f][1,4]oxazepine-8-carboxamide, N-[2-(dimethylamino)ethyl]-10,11-dihydro-2,4-bis(1-methylethyl)-11-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 90174-15-5 CAPLUS


CN Dibenzo[b,f][1,4]oxazepine-8-carboxamide, N-[3-(dimethylamino)propyl]-10,11-dihydro-2,4-bis(1-methylethyl)-11-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 90174-16-6 CAPLUS

CN Dibenzo[b,f][1,4]oxazepine-8-carboxamide, N-[2-(diethylamino)ethyl]-10,11-dihydro-4-methoxy-11-oxo-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 90174-17-7 CAPLUS

CN Piperazine, 1-[(10,11-dihydro-3-methyl-11-oxodibenzo[b,f][1,4]oxazepin-8-yl)carbonyl]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




10/785,120




● HCl

RN 90174-18-8 CAPLUS  
CN Piperazine, 1-[(10,11-dihydro-4-methoxy-11-oxodibenz[b,f][1,4]oxazepin-8-yl)carbonyl]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 90174-19-9 CAPLUS  
CN 1H-1,4-Diazepine, 1-[[10,11-dihydro-2,4-bis(1-methylethyl)-11-oxodibenz[b,f][1,4]oxazepin-8-yl]carbonyl]hexahydro-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 90174-20-2 CAPLUS  
CN Dibenz[b,f][1,4]oxazepine-8-carboxamide, 10,11-dihydro-2,4-bis(1-methylethyl)-11-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

10/785,120



● HCl

RN 90174-21-3 CAPLUS  
CN Dibenzo[b,f][1,4]oxazepine-8-carboxamide, 10,11-dihydro-2,4-bis(1-methylethyl)-N-[2-(4-morpholinyl)ethyl]-11-oxo-, monohydrochloride (9CI)  
(CA INDEX NAME)



● HCl

10/785,120

L10 ANSWER 68 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1984:191915 CAPLUS

DN 100:191915

TI Dibenzoxazepinone derivatives

PA Chugai Pharmaceutical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 4 pp.


CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 58225073	A2	19831227	JP 1982-108515	19820625
	JP 03059067	B4	19910909		
PRAI	JP 1982-108515		19820625		
GI					




AB Sixteen anti-ulcer (no data) dibenzoxazepinones I (R1 = H, alkyl, alkoxy; n = 1, 2; R2 = alkyl, alkenyl, aralkyl; R3 = H, alkyl) were prepared by reaction of II with R2X (X = halo) optionally followed by hydrolysis. Thus, 3.86 g MeI and 5.6 g K2CO3 were added to 5 g II (R1 = 2- and 4-Me2CH, n = 2, R3 = Et) in Me2CO to give, after refluxing 30 h, 86% I (R1 = 2- and 4-Me2CH, n = 2, R2 = Me, R3 = Et). Treatment of the latter with refluxing 50 mL 10% aqueous NaOH in EtOH 2 h gave 92% I (R1 = 2- and 4-Me2CH, n = 2, R2 = Me, R3 = H).

IT 81679-30-3

RL: RCT (Reactant); RACT (Reactant or reagent)  
(methylation of)



RN 81679-30-3 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 10,11-dihydro-2,4-bis(1-methylethyl)-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)



L10 ANSWER 69 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1984:156648 CAPLUS  
 DN 100:156648  
 TI Dibenz[b,f][1,4]oxazepine derivatives  
 PA Chugai Pharmaceutical Co., Ltd., Japan  
 SO Jpn. Kokai Tokkyo Koho, 3 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 58208278	A2	19831203	JP 1982-91265	19820531
	JP 03059065	B4	19910909		
PRAI	JP 1982-91265		19820531		
GI					




AB Dibenz[b,f][1,4]oxazepine derivs. I [Rn = H, 3-Me, 4-Me, 2-Br, 2-Cl, 4-MeO, 2,4-(Me2CH)2, 2,4-Cl2, 2,4-Br2] were prepared by lactamization of II (R1 = alkyl) in the presence of strong bases. Thus, heating 1.5 g II [Rn = 4,6-(Me2CH)2, R1 = Et] with 145 mg 60% NaH in DMF 1 h at 70° gave 77% I [Rn = 2,4-(Me2CH)2].

IT **81679-23-4P 81679-24-5P 81679-25-6P**  
**81679-26-7P 81679-27-8P 81679-28-9P**  
**81679-29-0P 81679-30-3P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)


RN 81679-23-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 10,11-dihydro-3-methyl-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 81679-24-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 10,11-dihydro-4-methyl-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 81679-25-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 2-bromo-10,11-dihydro-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 81679-26-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 2-chloro-10,11-dihydro-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 81679-27-8 CAPLUS


CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 10,11-dihydro-4-methoxy-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 81679-28-9 CAPLUS


CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 2,4-dichloro-10,11-dihydro-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 81679-29-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 2,4-dibromo-10,11-dihydro-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 81679-30-3 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 10,11-dihydro-2,4-bis(1-methylethyl)-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)



L10 ANSWER 70 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1984:80806 CAPLUS

DN 100:80806

TI The fate of dibenz[b,f]-1,4-oxazepine (CR) in the rat. Part II.  
Metabolism in vitro

AU Furnival, B.; Harrison, J. M.; Newman, J.; Upshall, D. G.

CS Chem. Def. Establ., Salisbury/Wiltshire, SP4 0JQ, UK

SO Xenobiotica (1983), 13(6), 361-72

CODEN: XENOBH; ISSN: 0049-8254

DT Journal

LA English

AB Dibenz[b,f]-1,4-oxazepine (I) [257-07-8] is metabolized by rat liver fractions by (a) ring opening and reduction to 2-amino-2'-hydroxymethyldiphenyl ether [88373-14-2] and (b) oxidation at C11 to give a cyclic lactam [3158-85-8]. Reaction a is NADPH-dependent, decreased by dialysis and methylene blue, and reaction b is heat-resistant, inactivated by dialysis, inhibited by cyanide, p-chloromercuribenzoate, amytal and menadione, and stimulated by methylene blue, phenazine methosulfate and 2,6-dichlorophenol indophenol. Reaction a is similar to that of aldehyde reductase (EC 1.1.1.2) [9028-12-0] and reaction b to that of aldehyde oxidase (EC 1.2.3.1) [9029-07-6]. Reaction a is also catalyzed by an NADH-dependent enzyme in liver microsomes and subsequent hydroxylation of the lactam also occurs in this cell fraction. Some extrahepatic metabolism of I occurs via the same routes in kidney, small intestine, and lung, though the yield is limited. Digestive gland extract of *Helix pomatia* converts I to its lactam. The metabolism of I in vitro is similar to that predicted from observations in vivo.


IT 60287-09-4 88373-19-7

RL: FORM (Formation, nonpreparative)

(formation of, as dibenzoxazepine metabolite by liver in vitro)


RN 60287-09-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-hydroxy- (9CI) (CA INDEX NAME)



RN 88373-19-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-(sulfooxy)- (9CI) (CA INDEX NAME)



L10 ANSWER 71 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1984:30556 CAPLUS

DN 100:30556

TI The fate of dibenz[b,f]-1,4-oxazepine (CR) in the rat. Part III. The intermediary metabolites

AU French, M. C.; Harrison, J. M.; Newman, J.; Upshall, D. G.; Powell, G. M.

CS Chem. Def. Establ., Salisbury/Wiltshire, SP4 0JQ, UK

SO Xenobiotica (1983), 13(6), 373-81

CODEN: XENOBH; ISSN: 0049-8254

DT Journal

LA English

AB The fates of several intermediates of dibenz[b,f]-1,4-oxazepine (CR) [257-07-8] metabolism in vivo and in vitro in rats were examined to establish the metabolic and excretory sequence of CR. The ring-opened 2-amino-2'-hydroxymethyldiphenyl ether (amino alc.) [88373-14-2] added to isolated perfused rat liver was rapidly cleared in bile as a mixture of highly polar conjugates, whereas the major route of excretion in vivo was as the 4- [88373-19-7], 7- [88373-20-0] and 9-hydroxylactam sulfate [88373-18-6] in urine. The lactam of CR [3158-85-8] was eliminated exclusively in urine giving the same products as obtained for CR, but the distribution of metabolites of the C10-C11 dihydro derivative of CR [2244-60-2] was unlike that of the parent compound indicating that it occupies only a peripheral role in the fate of CR in vivo. A mixture of 7- [60287-11-8], 4- [60287-09-4] and 9-hydroxylactam [60287-13-0] derivs. derived from the enzymic hydrolysis of urinary sulfates was rapidly removed from blood, sulfated and secreted as sulfates into blood both in vivo and in isolated perfused liver. Little biliary excretion occurred. When the urinary sulfates of the hydroxylactams were administered i.v. to rats, 70% was eliminated in urine within 1 h; however, if the kidneys were ligated biliary excretion of sulfate was higher (58% in 5 h). After intraduodenal administration of the biliary conjugates of CR metabolism, all of the dose was resorbed to be resecreted in bile or excreted as sulfate in urine. Apparently, the major metabolite fate of CR in the rat is oxidation to lactam, followed by ring hydroxylation, sulfation and urinary excretion. However, a significant proportion of the dose is oxidized to the amino alc. which is conjugated for biliary secretion, intestinal resorption, and recycling.


IT 60287-09-4 88373-19-7

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(metabolism of, dibenzoxazepine metabolism in relation to)

RN 60287-09-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-hydroxy- (9CI) (CA INDEX NAME)




RN 88373-19-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-(sulfooxy)- (9CI) (CA INDEX NAME)



10/785,120



L10 ANSWER 72 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1984:30555 CAPLUS

DN 100:30555

TI The fate of dibenz[b,f]-1,4-oxazepine (CR) in the rat, rhesus monkey and guinea pig. Part I. Metabolism in vivo

AU French, M. C.; Harrison, J. M.; Inch, T. D.; Leadbeater, L.; Newman, J.; Upshall, D. G.

CS Chem. Def. Establ., Salisbury/Wiltshire, SP4 0JQ, UK

SO Xenobiotica (1983), 13(6), 345-59

CODEN: XENOBH; ISSN: 0049-8254

DT Journal

LA English

AB After i.v. or intragastric administration of dibenz[b,f]-1,4-oxazepine (I) [257-07-8] to rats, guinea pigs, or monkeys most (59-93%) was excreted via urine. The principal I metabolites were 9-hydroxylactam sulfate [88373-18-6], 7-hydroxylactam sulfate [88373-20-0], and 4-hydroxylactam sulfate [88373-19-7]. The bile of rats contained only small amts. of sulfate conjugates. The predominant metabolite of the bile was identified as the conjugates of the hydroxylactams and the amino alc. [88373-14-2]. This was not identified in the urine or blood of rats. In isolated and perfused rat liver preps. I was metabolized initially into lactam [3158-85-8] and later into 4- [60287-09-4], 7- [60287-11-8], and 9-hydroxylactam [60287-13-0]. Traces of amino alc. and I were also detected. In pregnant mice injected i.v. with [14C]I a rapid distribution of 14C to liver, lung, brain, brown fats, salivary gland and kidney was observed after 1 min. Little penetrated into the fetus. However, the 14C disappeared rapidly from the tissues. The toxicity of I (to rats) was greater than that of its metabolites except for the I lactam which was 3 times more toxic than I.


IT 60287-09-4 88373-19-7

RL: BIOL (Biological study)

(as dibenzoxepine metabolite, species-related differences in)


RN 60287-09-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-hydroxy- (9CI) (CA INDEX NAME)



RN 88373-19-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-(sulfooxy)- (9CI) (CA INDEX NAME)





L10 ANSWER 73 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1982:582469 CAPLUS

DN 97:182469

TI Dibenz[b,f][1,4]oxazepine derivatives and their pharmaceutical composition

IN Ito, Kiyohiko; Koizumi, Masuo; Murakami, Yasushi; Akima, Mitchitaka; Aono, Jinichiro; Ohba, Yasuhiro; Yamazaki, Tamotsu; Sakai, Kazushige; Hata, Shun-ichi; Takanashi, Shigeru

PA Chugai Pharmaceutical Co., Ltd. , Japan

SO Eur. Pat. Appl., 18 pp.



CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 54951	A1	19820630	EP 1981-110655	19811221
	EP 54951	B1	19841212		
	R: AT, BE, CH, DE, FR, GB, IT, NL, SE				
	JP 57106673	A2	19820702	JP 1980-181831	19801224
	US 4379150	A	19830405	US 1981-331897	19811217
	CA 1169059	A1	19840612	CA 1981-392733	19811218
	AT 10741	E	19841215	AT 1981-110655	19811221
PRAI	JP 1980-181831	A	19801224		
	EP 1981-110655	A	19811221		
OS	CASREACT 97:182469; MARPAT 97:182469				
GI					



AB Title compds. I (R = H, alkyl; R1 = alkyl; R2 = H, CO2H, CONH2, carbalkoxy, alkoxy; R3, R4 = alkyl; NR3R4 = heterocyclyl; Z = alkylene) were prepared, and showed effectiveness in the treatment of angina pectoris. II (R = H) reacted with ClCH2CH2NMe3.HCl and KOH to give II (R = CH2CH2NMe2).


IT **81679-30-3**

RL: RCT (Reactant); RACT (Reactant or reagent)

(N-alkylation of, by aminoethyl chloride derivative)

RN 81679-30-3 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 10,11-dihydro-2,4-bis(1-methylethyl)-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)



10/785,120

L10 ANSWER 74 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1982:472339 CAPLUS

DN 97:72339

TI Nonsteroidal antiinflammatory agents. 1. 10,11-Dihydro-11-oxodibenz[b,f]oxepinacetic acids and related compounds

AU Nagai, Yasutaka; Irie, Akira; Nakamura, Hideo; Hino, Katsuhiko; Uno, Hitoshi; Nishimura, Haruki

CS Res. Lab., Dainippon Pharm. Co., Ltd., Suita, Japan


SO Journal of Medicinal Chemistry (1982), 25(9), 1065-70

CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

GI




AB 10,11-Dihydro-11-oxodibenz[b,f]oxepinacetic acids and related compds. were synthesized as potential inflammation-inhibitors. Among them, 2-(8-methyl-10,11-dihydro-11-oxodibenz[b,f]oxepin-2-yl)propionic acid (I, X = O) and its thiepin analog I (X = S) showed excellent antipyretic activity together with potent inflammation-inhibiting and analgesic properties in conventional biol. tests. Structure and activity relationships are discussed.

IT **82341-22-8P 82341-23-9P 82341-24-0P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation and pharmacol. activity of)

RN 82341-22-8 CAPLUS


CN Dibenz[b,f][1,4]oxazepine-2-acetic acid, 10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)



RN 82341-23-9 CAPLUS


CN Dibenz[b,f][1,4]oxazepine-2-acetic acid, 10,11-dihydro- $\alpha$ -methyl-11-oxo- (9CI) (CA INDEX NAME)

10/785,120



RN 82341-24-0 CAPLUS

CN Dibenzo[b,f][1,4]oxazepine-3-acetic acid, 10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)




IT 82340-99-6P 82341-00-2P 82341-01-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and saponification of)


RN 82340-99-6 CAPLUS

CN Dibenzo[b,f][1,4]oxazepine-2-acetic acid, 10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 82341-00-2 CAPLUS


CN Dibenzo[b,f][1,4]oxazepine-2-acetic acid, 10,11-dihydro- $\alpha$ -methyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 82341-01-3 CAPLUS


CN Dibenzo[b,f][1,4]oxazepine-3-acetic acid, 10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




L10 ANSWER 75 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1982:423831 CAPLUS  
 DN 97:23831  
 TI Dibenzoxazepine derivatives  
 PA Chugai Pharmaceutical Co., Ltd., Japan  
 SO Jpn. Kokai Tokkyo Koho, 4 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 57002278	A2	19820107	JP 1980-74176	19800604
PRAI	JP 1980-74176	A	19800604		
GI					



I



II


AB Eighteen dibenzoxazepine derivs. I (R, R1 = H, halo, alkyl, alkoxy; R2 = H, Et) were prepared by cyclization of II (R3 = alkyl) optionally followed by hydrolysis. I had hypolipemic, antiulcer, and PGI2 production accelerating activities (no data). Thus, heating 10 g 2,4-H2N(EtO2C)C6H3OC6H4CO2Me-2 3 h at 175° gave 89% I (R = R1 = H, R2 = Et), which (5.65 g) was hydrolyzed (KOH in aqueous MeOH) to give 94% I (R = R1 = R2 = H).

IT **81679-23-4P 81679-24-5P 81679-25-6P**  
**81679-26-7P 81679-27-8P 81679-28-9P**  
**81679-29-0P 81679-30-3P 81679-31-4P**  
**81679-32-5P 81679-33-6P 81679-34-7P**  
**81679-35-8P 81679-36-9P 81679-37-0P**  
**81679-38-1P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation and pharmacol. activities of)

RN 81679-23-4 CAPLUS


CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 10,11-dihydro-3-methyl-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 81679-24-5 CAPLUS


CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 10,11-dihydro-4-methyl-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)






RN 81679-25-6 CAPLUS

CN Dibenzo[b,f][1,4]oxazepine-8-carboxylic acid, 2-bromo-10,11-dihydro-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 81679-26-7 CAPLUS

CN Dibenzo[b,f][1,4]oxazepine-8-carboxylic acid, 2-chloro-10,11-dihydro-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 81679-27-8 CAPLUS


CN Dibenzo[b,f][1,4]oxazepine-8-carboxylic acid, 10,11-dihydro-4-methoxy-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 81679-28-9 CAPLUS


CN Dibenzo[b,f][1,4]oxazepine-8-carboxylic acid, 2,4-dichloro-10,11-dihydro-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 81679-29-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 2,4-dibromo-10,11-dihydro-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 81679-30-3 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 10,11-dihydro-2,4-bis(1-methylethyl)-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 81679-31-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 10,11-dihydro-3-methyl-11-oxo- (9CI) (CA INDEX NAME)




RN 81679-32-5 CAPLUS


CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 10,11-dihydro-4-methyl-11-oxo- (9CI) (CA INDEX NAME)




RN 81679-33-6 CAPLUS  
 CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 2-bromo-10,11-dihydro-11-oxo-  
 (9CI) (CA INDEX NAME)



RN 81679-34-7 CAPLUS  
 CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 2-chloro-10,11-dihydro-11-oxo-  
 (9CI) (CA INDEX NAME)




RN 81679-35-8 CAPLUS  
 CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 10,11-dihydro-4-methoxy-11-  
 oxo- (9CI) (CA INDEX NAME)




RN 81679-36-9 CAPLUS  
 CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 2,4-dichloro-10,11-dihydro-11-  
 oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 81679-37-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 2,4-dibromo-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)



RN 81679-38-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 10,11-dihydro-2,4-bis(1-methylethyl)-11-oxo- (9CI) (CA INDEX NAME)



L10 ANSWER 76 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1982:423828 CAPLUS

DN 97:23828

TI 5-Substituted 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-ones and medicaments containing them

IN Schmidt, Guenther; Bergamaschi, Mario

PA Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.

SO Eur. Pat. Appl., 34 pp.


CODEN: EPXXDW

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 44989	A1	19820203	EP 1981-105421	19810711
	EP 44989	B1	19830525		
	R: AT, BE, CH, DE, FR, IT, LU, NL, SE				
	DE 3028001	A1	19820218	DE 1980-3028001	19800724
	AT 3548	E	19830615	AT 1981-105421	19810711
	US 4377576	A	19830322	US 1981-282501	19810713
	DD 202023	A5	19830824	DD 1981-231897	19810717
	JP 57056470	A2	19820405	JP 1981-113421	19810720
	DK 8103264	A	19820125	DK 1981-3264	19810722
	FI 8102321	A	19820125	FI 1981-2321	19810723
	FI 67697	B	19850131		
	FI 67697	C	19850510		
	NO 8102529	A	19820125	NO 1981-2529	19810723
	AU 8173370	A1	19820128	AU 1981-73370	19810723
	AU 543677	B2	19850426		
	GB 2081264	A	19820217	GB 1981-22782	19810723
	GB 2081264	B2	19840125		
	ES 504206	A1	19821116	ES 1981-504206	19810723
	ZA 8105043	A	19830330	ZA 1981-5043	19810723
	CA 1154763	A1	19831004	CA 1981-382372	19810723
	HU 28455	O	19831228	HU 1981-2160	19810723
	HU 187340	B	19851228		
PRAI	DE 1980-3028001	A	19800724		
	EP 1981-105421	A	19810711		
OS	CASREACT 97:23828; MARPAT 97:23828				
GI					



AB Dibenzodiazepinones I (R1 = H, Me, Et; R2, R3 = H, Cl; R4 = 1-pyrrolidinyl, piperidino, 2-methyl-, 2-ethyl-, 2,6-dimethylpiperidino, morpholino) and their physiol. tolerable salts, useful in inhibiting gastric secretion and gastric ulcers, were prepared Acylating 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one with Cl(CH2)2COCl in dioxane gave I (R1-R3 = H, R4 = Cl) which N-alkylated pyrrolidine in refluxing Me2CHOH in 45 min to give I (R2-R3 = H, R4 = 1-pyrrolidinyl)

(II). The ED50 for gastric secretion inhibition for II.HCl was 0.20 mg/kg (duodenum) in rats vs. 8.15 for the 5-(1-pyrrolidinylacetyl) analog.


IT **31265-85-7P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and N-alkylation by, of cyclic amines)

RN 31265-85-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5-(3-chloro-1-oxopropyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




IT **82096-30-8P 82097-68-5P 82097-71-0P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 82096-30-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-[3-(2-methyl-1-piperidiny)-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 82097-68-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-[1-oxo-3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

10/785,120



RN 82097-71-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-[1-oxo-3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)




IT 82096-44-4

RL: RCT (Reactant); RACT (Reactant or reagent)  
(N-acylation of, by chloropropanoyl chloride)

RN 82096-44-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro- (7CI, 9CI)  
(CA INDEX NAME)








L10 ANSWER 77 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1980:568316 CAPLUS  
 DN 93:168316  
 TI Procataleptogenic 5H-dibenzo[b,e]-1,4-diazepine derivative  
 IN Protiva, Miroslav; Sindelar, Karel; Dlabac, Antonin  
 PA Czech.  
 SO Czech., 3 pp.  
 CODEN: CZXXA9  
 DT Patent  
 LA Czech  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CS 179793	B	19770331	CS 1976-969	19760213
PRAI	CS 1976-969		19760213		
GI					



AB The title compound I did not have cataleptic activity but it potentiated the cataleptic activity of other neuroleptics (perphenazine) (LD and ED given). I was prepared by the following route: a mixture of HCl salt of 5-aminoanthranilic acid, 2,5-Cl<sub>2</sub>C<sub>6</sub>H<sub>3</sub>NO<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, Cu, and HCONMe<sub>2</sub> was refluxed and gave N-(4-chloro-2-nitrophenyl)-5-methoxyanthranilic acid. Reduction with Na<sub>2</sub>S<sub>2</sub>O<sub>4</sub> in a solution of NH<sub>4</sub>OH gave


N-(2-amino-4-chlorophenyl)-5-methoxyanthranilic acid, which was cyclized by refluxing in xylene to 8-chloro-2-methoxydibenzo[b,e]-1,4-diazepin-11[5H,10H]-one. Reaction of this compound with 1-methylpiperazine in a mixture of PhMe and PhOMe in the presence of TiCl<sub>4</sub> gave 8-chloro-2-methoxy-11-(4-methylpiperazino)-5H-dibenzo[b,e]-1,4-diazepine. Demethylation with BBr<sub>3</sub> in CH<sub>2</sub>Cl<sub>2</sub> gave I.

IT **67104-22-7P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and reaction with methylpiperazine)

RN 67104-22-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-2-methoxy-  
 (9CI) (CA INDEX NAME)



L10 ANSWER 78 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1980:447088 CAPLUS

DN 93:47088

TI Synthesis of aryl  $\beta$ -D-glucopyranosides and aryl  $\beta$ -D-glucopyranosiduronic acids

AU Brewster, Keith; Harrison, John M.; Inch, Thomas D.

CS Chem. Def. Establ., Porton Down, SP4 0JQ, UK

SO Tetrahedron Letters (1979), (52), 5051-4

CODEN: TELEAY; ISSN: 0040-4039

DT Journal

LA English

AB Aryl 2,3,4,6-tetra-O-benzyl- $\beta$ -D-glucopyranosides were prepared (30-68%) by stereospecific aryloxylation of 2,3,4,6-tetra-O-benzyl- $\alpha$ -D-glucopyranosyl bromide (I) with phenols (aqueous NaOH or KOH,  $\text{CH}_2\text{Cl}_2$ ,  $\text{PhCH}_2\text{N}+\text{Et}_3 \text{ Cl}^-$  phase transfer catalyst, room temperature, 8-60 h). E.g., 68%

Ph

2,3,4,6-tetra-O-benzyl- $\beta$ -D-glucopyranoside was obtained from I and PhOH. Ph, 4-methoxyphenyl, and 2-tolyl 2,3,4,6-tetra-O-benzyl- $\beta$ -D-glucopyranoside were converted to the corresponding aryl  $\beta$ -D-glucopyranosiduronic acids by sequential catalytic debenzylation (H, Pd-C) catalytic oxidation (Pt, O, 85-90°, pH 8-10), benzylation, and hydrogenolysis (Pd-C, EtOH).


IT 74256-85-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and catalytic debenzylation of)

RN 74256-85-2 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-[[2,3,4,6-tetrakis-O-(phenylmethyl)- $\beta$ -D-glucopyranosyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 74256-87-4P


RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 74256-87-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-( $\beta$ -D-glucopyranosyloxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/785,120




IT **60287-09-4**

RL: RCT (Reactant); RACT (Reactant or reagent)  
(stereospecific aryloxylation by, of tetrabenzylglucopyranoside,  
benzyltriethylammonium chloride-catalyzed)

RN 60287-09-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-hydroxy- (9CI) (CA INDEX NAME)



10/785,120

L10 ANSWER 79 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1978:523990 CAPLUS

DN 89:123990

TI The metabolism of dibenz[b,f]-1,4-oxazepine (CR): In vivo hydroxylation of 10,11-dihydrodibenz[b,f]-1,4-oxazepin-11-(10H)-one and the NIH shift

AU Harrison, J. M.; Clarke, R. J.; Inch, T. D.; Upshall, D. G.

CS Chem. Def. Establ., Porton Down/Salisbury/Wiltshire, UK


SO Experientia (1978), 34(6), 698-9

CODEN: EXPEAM; ISSN: 0014-4754

DT Journal

LA English

GI




AB Studies of the in vivo metabolism by rats of 10,11-dihydrodibenz[b,f]-1,4-oxazepin-11-(10H)-one (I) [3158-85-8] specifically deuterated at C-7 implicate an arene oxide intermediate during the conversion to the 7-hydroxy derivative [60287-11-8] as evidenced by the observation of the NIH shift.

IT **60287-09-4**

RL: BIOL (Biological study)  
(dihydrodibenzoxazepinone metabolite)

RN 60287-09-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-hydroxy- (9CI) (CA INDEX NAME)



L10 ANSWER 80 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1978:443361 CAPLUS

DN 89:43361

TI Neurotropic and psychotropic agents. Part CXVII. Noncataleptic neuroleptics; 8-chloro-2-hydroxy-11-(4-methylpiperazino)-5H-dibenzo[b,e]-1,4-diazepine as a potential metabolite of clozapine

AU Sindelar, Karel; Dlabac, Antonin; Protiva, Miroslav


CS Res. Inst. Pharm. Biochem., Prague, Czech.

SO Collection of Czechoslovak Chemical Communications (1978), 43(1), 309-15  
CODEN: CCCCAK; ISSN: 0366-547X

DT Journal

LA English

GI




AB The title compound I was prepared in 5 steps from 2,5-H<sub>2</sub>N(MeO)C<sub>6</sub>H<sub>3</sub>CO<sub>2</sub>H (II). II was condensed with 2,5-Cl<sub>2</sub>C<sub>6</sub>H<sub>3</sub>NO<sub>2</sub> to give N-(4-chloro-2-nitrophenyl)-5-methoxyanthranilic acid which was reduced to the corresponding amino acid and cyclized to 8-chloro-2-methoxydibenzo[b,e]-1,4-diazepin-11(5H,10H)-one (III). Treatment of III with 1-methylpiperazine and TiCl<sub>4</sub> gave 8-chloro-2-methoxy-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e]-1,4-diazepine which was demethylated with BBr<sub>3</sub> in CH<sub>2</sub>Cl<sub>2</sub> to give I. This potential metabolite of clozapine, per se has no cataleptic activity but it potentiates catalepsy produced by perphenazine in rats.

IT **67104-22-7P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and amination by methylpiperazine)

RN 67104-22-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-2-methoxy-  
(9CI) (CA INDEX NAME)



L10 ANSWER 81 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1977:572879 CAPLUS

DN 87:172879

TI 2-Chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepin-containing solutions for oral or parenteral administration

IN Haeger, Bruce Edwin; Krueger, James Elwood; Lowery, James Alfred; Ritter, Lawrence

PA American Cyanamid Co., USA

SO Ger. Offen., 15 pp.

CODEN: GWXXBX


DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	DE 2633943	A1	19770217	DE 1976-2633943	19760728
	CA 1069823	A1	19800115	CA 1976-256154	19760702
	IL 49996	A1	19810130	IL 1976-49996	19760708
	GB 1546933	A	19790419	GB 1976-28752	19760709
	AU 500641	B2	19790531	AU 1976-15775	19760709
	FI 7602171	A	19770207	FI 1976-2171	19760729
	NL 7608575	A	19770208	NL 1976-8575	19760802
	BE 844903	A1	19770207	BE 1976-169573	19760805
	DK 7603540	A	19770207	DK 1976-3540	19760805
	DK 147727	B	19841126		
	DK 147727	C	19850617		
	SE 7608810	A	19770207	SE 1976-8810	19760805
	SE 431716	B	19840227		
	SE 431716	C	19840607		
	NO 7602713	A	19770208	NO 1976-2713	19760805
	NO 146457	B	19820628		
	NO 146457	C	19821006		
	FR 2320102	A1	19770304	FR 1976-23990	19760805
	JP 52021313	A2	19770217	JP 1976-93257	19760806
PRAI	US 1975-602331	A	19750806		

GI



I

AB Stable aqueous solns. of 2-chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine (I) [1977-10-2] or 1 of its salts suitable for oral or parenteral administration are prepared by mixing I first with propylene glycol [57-55-6], adjusting the pH to 5.0-7.0 with dilute mineral acid, and then adding H<sub>2</sub>O. For example, 63.0 g I was mixed with 2100 mL propylene glycol, and 800 mL H<sub>2</sub>O was added to the mixture. The pH was adjusted to 6.2 by addition of 10% HCl, and the mixture was heated for 30 min at 60°, diluted with H<sub>2</sub>O to 3000 mL, and sterilized by filtration. The final solution contained 2.0% I, and was placed in 2.0 mL ampuls. A concentrate for oral administration comprised 2.5% I in 70% aqueous propylene glycol, and was added to fruit juice in amts. of 3.5 mL/100 g juice before administration. Solns. of 10 mg I/mL in 50%, 60% and 70% aqueous propylene glycol showed good stability, containing only 120, 110, and 100 µg/mL, resp., of the I

10/785,120

hydrolysis product, 2-chloro-dibenz[b,f][1,4]oxazepin-11(10H)-one [3158-91-6], and retaining >98% of the initial I neuroleptic activity after 15 months. Encapsulated suspensions of I succinate [27833-64-3] and parenteral solns. of I as the free base showed comparable neuroleptic activity.


IT 3158-91-6

RL: BIOL (Biological study)

(piperazinyldibenzoxazepine hydrolysis product)

RN 3158-91-6 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)



10/785,120

L10 ANSWER 82 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1976:592783 CAPLUS  
DN 85:192783  
TI Substituted dibenzo[b,f]tetrazolo[1,5-d][1,4]-oxazepines  
IN Crawley, Lantz S.; Safir, Sidney R.  
PA American Cyanamid Co., USA  
SO U.S., 3 pp.  
CODEN: USXXAM  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3966756	A	19760629	US 1975-565907	19750407
PRAI	US 1975-565907	A	19750407		
GI					




AB Dibenzotetrazolooxazepines I (R = Cl, H, F) were prepared by treating the dibenzoxazepinones with PCl<sub>5</sub> and NaN<sub>3</sub>. I (R = Cl) was analgesic in mice in the phenylquinone writhing test at 100 mg/kg orally.

IT **3158-91-6**  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(chlorination and reaction of, with azide)

RN 3158-91-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)




IT **3158-90-5P**  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and chlorination and reaction of, with azide)

RN 3158-90-5 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-fluoro- (7CI, 8CI, 9CI) (CA INDEX NAME)



10/785,120



L10 ANSWER 83 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1976:508617 CAPLUS  
 DN 85:108617  
 TI Oxidation of some dibenz[b,f][1,4]oxazepines by peracetic acid  
 AU Brewster, Keith; Chittenden, Rosemary A.; Harrison, John M.; Inch, Thomas D.; Brown, Charles  
 CS Chem. Def. Establ., Salisbury, UK  
 SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1976), (12), 1291-6  
 CODEN: JCPRB4; ISSN: 0300-922X  
 DT Journal  
 LA English  
 OS CASREACT 85:108617  
 GI




AB Oxidation of substituted dibenz[b,f][1,4]oxazepines with H<sub>2</sub>O<sub>2</sub> in glacial AcOH gave the correspondingly substituted 2-(2-hydroxyphenyl)benzoxazole, 10-formylphenoxazine and dibenz[b,f][1,4]oxazepin-11(10H)-one. E.g., 8-chlorodibenz[b,f][1,4]oxazepine gave 49% benzoxazole I, 12% phenoxazine II, and 16% lactam III. An oxaziridine intermediate is implicated as the common precursor of the products.

IT 60344-90-3P


RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)

RN 60344-90-3 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,4-dimethyl- (9CI) (CA INDEX NAME)



L10 ANSWER 84 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1976:508616 CAPLUS  
 DN 85:108616  
 TI Preparation of the eight monohydroxydibenz[b,f][1,4]oxazepin-11(10H)-ones  
 AU Brewster, Keith; Clarke, Raymond J.; Harrison, John M.; Inch, Thomas D.;  
 Utley, David  
 CS Chem. Def. Establ., Salisbury, UK  
 SO Journal of the Chemical Society, Perkin Transactions 1: Organic and  
 Bio-Organic Chemistry (1972-1999) (1976), (12), 1286-90  
 CODEN: JCPRB4; ISSN: 0300-922X  
 DT Journal  
 LA English  
 OS CASREACT 85:108616  
 GI




AB The 8 possible monohydroxydibenz[b,f][1,4]oxazepin-11(10H)-ones were prepared from substituted diphenyl ethers and their mass spectra determined. E.g., oxidation of 1-methoxy-2-methyl-3-(2-nitrophenoxy)benzene followed by hydrogenation, ring closure, and demethylation gave 1-hydroxydibenz[b,f][1,4]oxazepin-11(10H)-one (I). With the exception of the 7-hydroxy derivative the fragmentation patterns of the isomers were similar, although the relative line intensities allowed distinctions between the isomers to be made. Several irritant monomethoxydibenz[b,f][1,4]oxazepines were also prepared  
 IT **54584-61-1P 60287-33-4P 60287-34-5P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and demethylation of)  
 RN 54584-61-1 CAPLUS  
 CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-methoxy- (9CI) (CA INDEX NAME)




RN 60287-33-4 CAPLUS  
 CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-methoxy- (9CI) (CA INDEX NAME)

10/785,120



RN 60287-34-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-methoxy- (9CI) (CA INDEX NAME)




IT 60287-08-3P 60287-09-4P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
(preparation and mass spectrum of)


RN 60287-08-3 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-hydroxy- (9CI) (CA INDEX NAME)



RN 60287-09-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-hydroxy- (9CI) (CA INDEX NAME)




IT 60287-50-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation, mass spectrum, and reduction of)

RN 60287-50-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-hydroxy- (9CI) (CA INDEX NAME)

10/785,120



L10 ANSWER 85 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1976:432968 CAPLUS

DN 85:32968

TI Condensed heterotricycles: novel transformation of dibenzo[b,e][1,4]diazepinones to benzimidazole derivatives under Vilsmeier-Haack reaction conditions

AU Nagarajan, K.; Shah, R. K.

CS Res. Cent., Ciba-Geigy, Bombay, India

SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1976), 14B(1), 1-3


CODEN: IJSBDB; ISSN: 0376-4699

DT Journal

LA English

OS CASREACT 85:32968

GI




AB Condensation of 2,5-Cl(O<sub>2</sub>N)C<sub>6</sub>H<sub>3</sub>CO<sub>2</sub>Me with o-H<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>NH<sub>2</sub> in Me<sub>2</sub>SO in the presence of Et<sub>2</sub>N gave 2-nitrodibenzo[b,e][1,4]diazepin-11(10H)-one (I, R = NO<sub>2</sub>, R<sup>1</sup> = H) in 37% yield. Reaction of I (R = O<sub>2</sub>N, R<sup>1</sup> = H) with DMF-POCl<sub>3</sub> gave 1-(2-dimethylcarbamoyl-4-nitrophenyl)benzimidazole (II, R<sub>2</sub> = Me<sub>2</sub>N) in high yield. I (R = R<sup>1</sup> = H, R = H, R<sup>1</sup> = Cl) similarly gave analogous products II (R<sub>2</sub> = Me<sub>2</sub>N). II (R = NO<sub>2</sub>, R<sup>1</sup> = H, R<sub>2</sub> = Me<sub>2</sub>N) was hydrolyzed to 1-(2-carboxy-4-nitrophenyl)benzimidazole, identical with a sample synthesized from benzimidazole and 2-chloro-5-nitrobenzoic acid. N-formylmorpholine and I (R = NO<sub>2</sub>, R<sup>1</sup> = H) reacted in the presence of POCl<sub>3</sub> to give the morpholide II (R<sub>2</sub> = morpholino). 2-Nitro-5-acetyldibenzo[b,e][1,4]diazepin-11(10H)-one (III, R = NO<sub>2</sub>, R<sup>1</sup> = H, R<sub>2</sub> = Me) was formed in the reaction of I (R = NO<sub>2</sub>, R<sup>1</sup> = H) with dimethylacetamide-POCl<sub>3</sub>. III (R = NO<sub>2</sub>, R<sup>1</sup> = H, R<sub>2</sub> = Me) was reduced to the amine, which upon diazotization and treatment with hypophosphorus acid yields III (R = R<sup>1</sup> = H, R<sub>2</sub> = Me).

IT 59624-24-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and deamination of)

RN 59624-24-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-acetyl-2-amino-5,10-dihydro- (9CI)  
(CA INDEX NAME)




IT 54255-81-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and ring contraction of)

RN 54255-81-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-amino- (9CI) (CA INDEX NAME)




IT 59624-23-6P

RL: SPN (Synthetic preparation); PREP (Preparation)


(preparation of)

RN 59624-23-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-acetyl-5,10-dihydro-2-nitro- (9CI) (CA INDEX NAME)



L10 ANSWER 86 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1976:150604 CAPLUS  
 DN 84:150604  
 TI Tetracyclic tetrazoles  
 AU Crawley, L. S.; Safir, S. R.  
 CS Lederle Lab., Div., Am. Cyanamid Co., Pearl River, NY, USA  
 SO Journal of Heterocyclic Chemistry (1975), 12(5), 1075-6  
 CODEN: JHTCAD; ISSN: 0022-152X  
 DT Journal  
 LA English  
 OS CASREACT 84:150604  
 GI



I



II


AB The tetracyclic tetrazoles I (X = O, R = H, Cl, F; X = S, R = Cl; X = MeN, R = H) were prepared by treating II with PCl<sub>3</sub> followed by LiN<sub>3</sub>.

IT 3158-90-5 3158-91-6

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (cyclization of, with azide, tetrazolo derivative from)


RN 3158-90-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-fluoro- (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 3158-91-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)





L10 ANSWER 87 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1975:118772 CAPLUS

DN 82:118772

TI Structure-activity relations in the Sintamil series

AU Nagarajan, K.; David, J.; Grewal, R. S.; Govindachari, T. R.

CS CIBA Res. Cent., Bombay, India

SO Indian Journal of Experimental Biology (1974), 12(3), 217-24

CODEN: IJEBA6; ISSN: 0019-5189

DT Journal

LA English

GI For diagram(s), see printed CA Issue.

AB 10-Aminoalkyl-2-nitrodibenz[b,f][1,4]oxazepines exhibited antidepressant activity. Among these, Sintamil (I) [16398-39-3] was the most active. The effects of substituting the dimethylamino group in I by acyclic and cyclic bases as well as shortening the side chain to a C2 chain were discussed. Analogs with other substituents in ring C and position isomers of I, in which the nitro group was moved to other positions, were studied. In connection with the sedative and antinociceptive activities of 2-aminodibenz[b,f][1,4]oxazepin-11(10H)-one [23474-66-0], a number of analogs in this series and in the pyridodibenzoxazepine and pyridobenzoxazine series were evaluated. Potent central nervous depressants were encountered in the class of 11-aminodibenzoxazepines and dibenzthiazepines; moderate depressant activity was exhibited by a group of 11-(aminoalkyloxy)- and 11-(aminoalkylmercapto)dibenzoxazepines and thiazepines, and a 11-(dimethylaminomethyl) derivative Imidazo, pyrimido, triazolo, and tetrazolodibenzoxazepines having common structural features were evaluated.

IT 16398-16-6 23474-55-7 23474-59-1

23474-63-7 23474-66-0 54252-66-3

54252-85-6 54252-86-7 54252-87-8

54252-88-9 54252-90-3 54252-91-4


54252-92-5 54719-75-4

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antidepressant activity of)


RN 16398-16-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-nitro- (8CI, 9CI) (CA INDEX NAME)



RN 23474-55-7 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-chloro- (8CI, 9CI) (CA INDEX NAME)



10/785,120


RN 23474-59-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-methyl- (8CI, 9CI) (CA INDEX NAME)




RN 23474-63-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-amino- (8CI, 9CI) (CA INDEX NAME)




RN 23474-66-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino- (8CI, 9CI) (CA INDEX NAME)



RN 54252-66-3 CAPLUS


CN Acetamide, 2-chloro-N-(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)- (9CI) (CA INDEX NAME)



RN 54252-85-6 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8-acetyl-2-amino- (9CI) (CA INDEX NAME)

10/785,120



RN 54252-86-7 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-methoxy-,  
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 54252-87-8 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,8-diamino- (9CI) (CA INDEX NAME)



RN 54252-88-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-7-methoxy-,  
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 54252-90-3 CAPLUS


CN 4-Morpholineacetamide, N-(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)- (9CI) (CA INDEX NAME)

10/785,120




RN 54252-91-4 CAPLUS

CN Thiourea, N-(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-N'-2-propenyl- (9CI) (CA INDEX NAME)




RN 54252-92-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 54719-75-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,7-diamino-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L10 ANSWER 88 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1975:57661 CAPLUS

DN 82:57661

TI Condensed heterotricycles. 10,11-Ring-annealed dibenz[b,f][1,4]oxazepines

AU Nagarajan, K.; Shah, R. K.

CS Res. Cent., CIBA, Bombay, India

SO Indian Journal of Chemistry (1974), 12(3), 263-9

CODEN: IJOCAP; ISSN: 0019-5103

DT Journal

LA English

OS CASREACT 82:57661

GI For diagram(s), see printed CA Issue.


AB Imino chlorides I (R = H, Cl, NO<sub>2</sub>, R<sub>1</sub> = H, OMe, R<sub>2</sub> = H, Cl) are converted into  $\gamma$ -hydroxypropylamines and then by treatment with POCl<sub>3</sub> and alkali into II. Mercaptotriazolodibenzoxazepines, triazolodibenzoxazepines, and tetrazolodibenzoxazepines were similarly prepared, but the pyrrolidone III could not be cyclized to the pyrrolodibenzoxazepine. During the formation of I (R = NO<sub>2</sub>, R<sub>1</sub> = R<sub>2</sub> = H), benzoxazole (IV) is obtained. In the reactions of I (R = NO<sub>2</sub>, R<sub>1</sub> = R<sub>2</sub> = H) with amines, similar benzoxazoles are obtained as byproducts.

IT 54584-61-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and reaction of, with dimethylaniline and phosphorus oxychloride)

RN 54584-61-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-methoxy- (9CI) (CA INDEX NAME)




IT 3158-91-6 16398-16-6 16398-18-8

RL: RCT (Reactant); RACT (Reactant or reagent)  
(reaction of, with dimethylaniline and phosphorus oxychloride)

RN 3158-91-6 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 16398-16-6 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-nitro- (8CI, 9CI) (CA INDEX NAME)

10/785,120



RN 16398-18-8 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8-chloro-2-nitro- (8CI, 9CI) (CA  
INDEX NAME)



L10 ANSWER 89 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1975:57660 CAPLUS

DN 82:57660

TI Condensed heterotricycles. Dibenz[b,f][1,4]oxazepin-11(10H)-thiones, 11-substituted dibenz[b,f][1,4]oxazepines, and dibenz[b,f][1,4]thiazepine analogs

AU Nagarajan, K.; Kulkarni, C. L.; Venkateswarlu, A.; Shah, R. K.

CS Res. Cent., CIBA, Bombay, India

SO Indian Journal of Chemistry (1974), 12(3), 258-62

CODEN: IJOCAP; ISSN: 0019-5103

DT Journal

LA English

GI For diagram(s), see printed CA Issue.


AB Reaction of the imino chloride I obtained from 2-nitrodibenzoxazepinone, POCl<sub>3</sub>, and PhNMe<sub>2</sub>, with cyclic secondary bases, gave 11-amino derivs. and with γ-dimethyl-aminopropanol, the aminoalkoxy derivative, isomeric with Sintamil. AlCl<sub>3</sub>-catalyzed cyclizations of o-isothiocyanatodiphenyl ethers and diphenyl sulfides gave dibenzoxazepine and thiazepinethiones which were converted to 11-amino derivs. by reaction with amines and to 11-aminoalkylmercapto derivatives by reaction with aminoalkyl chlorides. Amidoximes and azines were obtained from thiones. 11-Dimethylaminomethyldibenzoxazepine was obtained along with the ring-cleaved product by cyclization of 2,5-PhO(Cl)C<sub>6</sub>H<sub>3</sub>NHCOCH<sub>2</sub>NMe<sub>2</sub> with polyphosphoric acid and POCl<sub>3</sub> or by cyclization of the chloroacetamide, followed by reaction with Me<sub>2</sub>NH. Phenanthridinethione is readily obtained by the cyclization of 2-PhC<sub>6</sub>H<sub>4</sub>NCS.

IT 16398-16-6

RL: RCT (Reactant); RACT (Reactant or reagent)  
(chlorination of)

RN 16398-16-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-nitro- (8CI, 9CI) (CA INDEX NAME)



L10 ANSWER 90 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1975:4329 CAPLUS

DN 82:4329

TI 11-(1-Piperazinyl)-5H-dibenzo[b,e][1,4]diazepines

IN Hunziker, Fritz

PA Dr. A. Wander, A.-G.

SO Ger. Offen., 28 pp.


CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2413610	A1	19741010	DE 1974-2413610	19740321
	NL 7403657	A	19740925	NL 1974-3657	19740319
	DD 110498	C	19741220	DD 1974-177349	19740321
	BE 812742	A1	19740923	BE 1974-142382	19740322
	JP 49126691	A2	19741204	JP 1974-31612	19740322
	AU 7467043	A1	19750925	AU 1974-67043	19740322
	ZA 7401884	A	19751126	ZA 1974-1884	19740322
	FR 2222102	A1	19741018	FR 1974-10147	19740325
PRAI	CH 1973-4259	A	19730323		
	CH 1973-5147	A	19730410		
	CH 1973-6644	A	19730510		
GI	For diagram(s), see printed CA Issue.				
AB	Twenty-three dibenzodiazepines I [Rn = 2,4-, 2,7-, 2,8-, 3,7-, 3,8-, or 7,8-Cl <sub>2</sub> , 2,8-MeCl, -ClBr, -ClMe, -Cl(MeO), or -Cl(MeS), 8,2-Cl(Me <sub>2</sub> NSO <sub>2</sub> ), or 7,8-(MeO) <sub>2</sub> , -OCH <sub>2</sub> O, or -OCH <sub>2</sub> CH <sub>2</sub> O; R <sub>1</sub> = H or Me; R <sub>2</sub> = H, Me, or CH <sub>2</sub> CH <sub>2</sub> OH] or their salts were prepared and useful as neuroleptics and (or) antidepressants. Thus, N-methylpiperazine (II) reacted with 2,8-dichloro-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-11-one (III) in PhOMe containing TiCl <sub>4</sub> to give I (Rn = 2,8-Cl <sub>2</sub> , R <sub>1</sub> = H, R <sub>2</sub> = Me), which was also prepared from II and the thioxo analog of III or by methylation of I (Rn = 2,8-Cl <sub>2</sub> , R <sub>1</sub> = R <sub>2</sub> = H).				
IT	<b>55051-41-7P</b>				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(preparation and reaction with piperazines)				
RN	55051-41-7 CAPLUS				
CN	11H-Dibenzo[b,e][1,4]diazepin-11-one, 2,8-dichloro-5,10-dihydro- (9CI) (CA INDEX NAME)				





L10 ANSWER 91 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1975:4223 CAPLUS

DN 82:4223

TI Condensed heterotricycles. Amino and aminoalkyldibenz[b,f][1,4]oxazepin-11(10H)-ones

AU Nagarajan, K.; Venkateswarlu, A.; Kulkarni, C. L.; Goud, A. Nagana; Shah, R. K.

CS Res. Cent., CIBA, Bombay, India

SO Indian Journal of Chemistry (1974), 12(3), 236-46

CODEN: IJOCAP; ISSN: 0019-5103

DT Journal

LA English

OS CASREACT 82:4223

GI For diagram(s), see printed CA Issue.


AB Treatment of 2-nitrodibenz[b,f][1,4]-oxazepin-11(10H)-one (I, R = NO<sub>2</sub>, R<sub>1</sub> - R<sub>5</sub> = H) (II) with dimethylaminopropyl chloride in aqueous acetone-alkali gave I [R = NO<sub>2</sub>, R<sub>1</sub>-R<sub>4</sub> = H, R<sub>5</sub> (CH<sub>2</sub>)<sub>3</sub>NMe<sub>2</sub>] characterized as the hydrochloride, Sintamil. Other analogs e.g., I (R = H, NO<sub>2</sub>; R<sub>1</sub> = H, NO<sub>2</sub>; R<sub>2</sub> = H, NO<sub>2</sub>, MeO; R<sub>3</sub> = H, MeO, Me, Ac; R<sub>4</sub> = H, NO<sub>2</sub>; R<sub>5</sub> = aminoalkyl), were also prepared. III undergoes ring cleavage with NaOMe to 2,5-MeO(O<sub>2</sub>N)C<sub>6</sub>H<sub>3</sub>CON-[(CH<sub>2</sub>)<sub>3</sub>NMe<sub>2</sub>]C<sub>6</sub>H<sub>4</sub>OH-2 which is converted into its Me ether. II undergoes similar ring cleavage with NaOMe, dimethylamine, and NaOH to form IV (R = MeO, NMe<sub>2</sub>, and OH). The last reagent brings about, in addition a Smiles-type rearrangement leading to the formation of 2,4-HO<sub>2</sub>C(O<sub>2</sub>N)C<sub>6</sub>H<sub>3</sub>NHC<sub>6</sub>H<sub>4</sub>OH-2. Treatment of the 8-nitrodibenzoxazepinone with dimethylaminopropyl chloride in DMF and sodamide yields in addition to the expected N-(CH<sub>2</sub>)<sub>3</sub>NMe<sub>2</sub> derivative, the ring cleavage product 2-HO-C<sub>6</sub>H<sub>4</sub>CON[(CH<sub>2</sub>)<sub>3</sub>NMe<sub>2</sub>]C<sub>6</sub>H<sub>3</sub>(NMe)<sub>2</sub>NO<sub>2</sub>-2.5. Nitration expts. on dibenzoxazepinones without a substituent on the lactam N or with a dimethylaminopropyl group are described. Many nitro derivs. are reduced to amines.

IT 54252-66-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and reaction with morpholine)

RN 54252-66-3 CAPLUS

CN Acetamide, 2-chloro-N-(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-(9CI) (CA INDEX NAME)




IT 23474-66-0P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and reaction with chloroacetyl chloride)

RN 23474-66-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino- (8CI, 9CI) (CA INDEX NAME)

10/785,120




IT 16398-26-8P 23474-55-7P 23474-59-1P  
23474-63-7P 54252-64-1P 54252-85-6P  
54252-86-7P 54252-87-8P 54252-88-9P  
54252-89-0P 54252-90-3P 54252-91-4P  
54252-92-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 16398-26-8 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,7,9-trinitro- (8CI, 9CI) (CA  
INDEX NAME)




RN 23474-55-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-chloro- (8CI, 9CI) (CA  
INDEX NAME)



RN 23474-59-1 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-methyl- (8CI, 9CI) (CA  
INDEX NAME)




RN 23474-63-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-amino- (8CI, 9CI) (CA INDEX NAME)


10/785,120




RN 54252-64-1 CAPLUS  
CN Dibenzo[b,f][1,4]oxazepin-11(10H)-one, 2,7,9-triamino- (9CI) (CA INDEX NAME)



RN 54252-85-6 CAPLUS  
CN Dibenzo[b,f][1,4]oxazepin-11(10H)-one, 8-acetyl-2-amino- (9CI) (CA INDEX NAME)




RN 54252-86-7 CAPLUS  
CN Dibenzo[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 54252-87-8 CAPLUS  
CN Dibenzo[b,f][1,4]oxazepin-11(10H)-one, 2,8-diamino- (9CI) (CA INDEX NAME)

10/785,120



RN 54252-88-9 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-7-methoxy-,  
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 54252-89-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,7-diamino- (9CI) (CA INDEX NAME)



RN 54252-90-3 CAPLUS


CN 4-Morpholineacetamide, N-(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)- (9CI) (CA INDEX NAME)



RN 54252-91-4 CAPLUS


CN Thiourea, N-(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-N'-2-propenyl- (9CI) (CA INDEX NAME)

10/785,120



RN 54252-92-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-(dimethylamino)- (9CI) (CA INDEX NAME)



L10 ANSWER 92 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1974:552201 CAPLUS

DN 81:152201

TI Condensed heterotricycles. Beckmann rearrangement of xanthone and thioxanthone oximes as a route to dibenz[b,f][1,4]-oxazepines and thiazepines

AU Nagarajan, K.; Kulkarni, C. L.; Venkateswarlu, A.

CS Res. Cent., CIBA, Bombay, India

SO Indian Journal of Chemistry (1974), 12(3), 247-51

CODEN: IJOCAP; ISSN: 0019-5103

DT Journal

LA English

GI For diagram(s), see printed CA Issue.


AB Beckmann rearrangement of xanthone and thioxanthone oximes yields dibenzoxazepinone (I, X = O) and thiazepinone (I, X = S) resp. A mixture of the two possible rearrangement products is obtained from the rearrangement of 2-nitroxanthone oxime and from 2-chlorothioxanthone oxime. The 1,5-benzoxazepine II was formed in the  $\text{LiAlH}_4$  reduction of chromanone oxime III.  $\text{LiAlH}_4$  reduction of xanthone oxime yields 9,9'-bis(xanthhydryl) ether. A few xanthone and thioxanthone anils were prepared

IT **16398-16-6P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 16398-16-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-nitro- (8CI, 9CI) (CA INDEX NAME)



L10 ANSWER 93 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1974:552199 CAPLUS

DN 81:152199

TI Condensed heterotricycles. Synthesis of dibenz[b,f][1,4]oxazepines, dibenz[b,f][1,4]thiazepines, and dibenz[b,e][1,4]diazepines by cyclization of 2-halo-2'-hydroxy(mercapto or amino)benzanilides

AU Nagarajan, K.; Venkateswarlu, A.; Kulkarni, C. L.; Shah, R. K.

CS Res. Cent., CIBA, Bombay, India

SO Indian Journal of Chemistry (1974), 12(3), 227-35

CODEN: IJOCAP; ISSN: 0019-5103

DT Journal

LA English

GI For diagram(s), see printed CA Issue.


AB The action of hot aqueous alkali on 2-chloro-5-nitrobenzamides on o-aminophenols I (R, R2, R3 = H, R1 = H, Me, Cl, MeO) affords high yields of 2-nitrodibenz[b,f][1,4]oxazepin-11(10H)-ones II. Pyrolysis of the sodium salts of amides III (R, R1, R2, R3, R4, R5, R6 = H, Ac, NO2, Cl) gives the analogous tricyclic lactams IV. The synthesis has been extended to aminoalkyldibenzoxazepinones, such as the antidepressant Sintamil N-(CH2)3NMe2 derivative of IV (R-R3, R5 = H, R4 = NO2).HCl and the R4 = Cl analog. 2-Nitrodibenzoxazepine is obtained from the Schiff base and converted to a quaternary salt and the dihydro derivs. N-(2-Chloro-5-nitrobenzoyl)-o-aminothiophenol fails to undergo cyclization to a dibenzothiazepinone, since it readily passes over to a benzothiazole. However, 2-chloro and 2,5-dichlorobenzoyl derivs. of o-aminothiophenol can be converted to the expected tricycles VII. Among the o-phenylenediamine derivs. tried, the N-(2-chloro-5-nitrobenzoyl)-N'-(p-tolylsulfonyl) compound gives the dibenzodiazepine VIII, while pyrolysis of 2-amino-2'-carbomethoxy-4'-nitrodiphenylamine leads to IX.

IT **23474-66-0P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and deamination of)

RN 23474-66-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino- (8CI, 9CI) (CA INDEX NAME)



IT **3158-88-1P 3158-91-6P 16398-16-6P**

**16398-17-7P 16398-18-8P 16398-19-9P**

**16398-20-2P 16398-21-3P 16398-22-4P**

**16398-23-5P 16398-24-6P 20169-49-7P**


**54255-57-1P 54255-81-1P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 3158-88-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)


10/785,120




RN 3158-91-6 CAPLUS  
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 16398-16-6 CAPLUS  
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-nitro- (8CI, 9CI) (CA INDEX NAME)



RN 16398-17-7 CAPLUS  
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,8-dinitro- (8CI, 9CI) (CA INDEX NAME)



RN 16398-18-8 CAPLUS  
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8-chloro-2-nitro- (8CI, 9CI) (CA INDEX NAME)




RN 16398-19-9 CAPLUS




10/785,120

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8-methyl-2-nitro- (8CI, 9CI) (CA INDEX NAME)




RN 16398-20-2 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,7-dinitro- (8CI, 9CI) (CA INDEX NAME)




RN 16398-21-3 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8-acetyl-2-nitro- (8CI, 9CI) (CA INDEX NAME)



RN 16398-22-4 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 6,8,9-trichloro-2-nitro- (8CI, 9CI) (CA INDEX NAME)




RN 16398-23-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-nitro- (8CI, 9CI) (CA INDEX NAME)


10/785,120




RN 16398-24-6 CAPLUS  
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 7-methoxy-2-nitro- (8CI, 9CI) (CA INDEX NAME)



RN 20169-49-7 CAPLUS  
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(4-methylphenyl)sulfonyl]-2-nitro- (9CI) (CA INDEX NAME)




RN 54255-57-1 CAPLUS  
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8-methoxy-2-nitro- (9CI) (CA INDEX NAME)



RN 54255-81-1 CAPLUS  
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-nitro- (9CI) (CA INDEX NAME)

10/785,120



L10 ANSWER 94 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1974:536120 CAPLUS

DN 81:136120

TI Condensed heterotricycles. Potential metabolites of dibenz[b,f][1,4]oxazepine antidepressant, Sintamil

AU Nagarajan, K.; Maller, R. K.; Anjaneyulu, B.; Goud, A. Nagana; Venkateswarlu, A.

CS Res. Cent. , CIBA, Bombay, India

SO Indian Journal of Chemistry (1974), 12(3), 270-4

CODEN: IJOCAP; ISSN: 0019-5103

DT Journal

LA English

GI For diagram(s), see printed CA Issue.


AB The demethyl derivative [I, R = (CH<sub>2</sub>)<sub>3</sub>NHMe, R<sub>1</sub> = H] (II) of Sintamil [I, R = (CH<sub>2</sub>)<sub>3</sub>NMe<sub>2</sub>, R<sub>1</sub> = H] (III) was prepared by alkylation of I (R, R<sub>1</sub> = H) (IV) with Cl(CH<sub>2</sub>)<sub>3</sub>NMeCHO followed by acid hydrolysis, by treating III with BrCN followed by hot HCl hydrolysis, or by refluxing III with ClCO<sub>2</sub>Et in toluene to give a urethane which was treated with HBr in HOAc. IV was added to CH<sub>2</sub>:CHCN and converted to the ester I (R = CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>Me, R<sub>1</sub> = H), which was also obtained by base catalyzed addition of IV to CH<sub>2</sub>:CHCO<sub>2</sub>Me. Treatment of 2,5-Cl(O<sub>2</sub>N)C<sub>6</sub>H<sub>3</sub>COCl with 3,4-HO(H<sub>2</sub>N)C<sub>6</sub>H<sub>3</sub>OCH<sub>2</sub>Ph gave an amide, which was cyclized in aqueous alkali to give I (R = H, R<sub>1</sub> = OCH<sub>2</sub>Ph), alkylated with Cl(CH<sub>2</sub>)<sub>3</sub>NMe<sub>2</sub>, and debenzylated in hot HCl to yield I [R = (CH<sub>2</sub>)<sub>3</sub>NMe<sub>2</sub>, R<sub>1</sub> = OH].

IT 16398-16-6

RL: RCT (Reactant); RACT (Reactant or reagent)  
(alkylation of)

RN 16398-16-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-nitro- (8CI, 9CI) (CA INDEX NAME)




IT 54026-42-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 54026-42-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-nitro-7-(phenylmethoxy)- (9CI)  
(CA INDEX NAME)



L10 ANSWER 95 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1974:520710 CAPLUS

DN 81:120710

TI Antiulcerous 2-chloro-5,10-dihydro-5-(1-pyrrolidinylacetyl)-11H-dibenzo[b,e][1,4]diazepin-11-one

IN Schmidt, Guenther; Machleidt, Hans; Leitold, Matyas; Engelhorn, Robert

PA Thomae, Dr. Karl, G.m.b.H.

SO Ger. Offen., 9 pp. Division of Ger. Offen. 2,022,790 (CA 74; 100123p).

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2065570	A1	19740704	DE 1970-2065570	19700509
	DE 2065570	B2	19760520		
	DE 2065570	C3	19770127		
PRAI	DE 1970-2065570	A	19700509		

GI For diagram(s), see printed CA Issue.


AB The dibenzodiazepinone I (R = 1-pyrrolidinyl) (II) was prepared in 50% yield by refluxing I (R = Cl) and pyrrolidine in dioxane. II had antiulcerous activity when tested orally in the rat, stomach secretion-inhibiting activity when tested intraduodenally or i.p. in the rat, and spasmolytic activity when tested in the isolated guinea pig colon.

IT **29174-20-7P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 29174-20-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-(1-pyrrolidinylacetyl)- (8CI, 9CI) (CA INDEX NAME)


IT **29174-19-4**

RL: RCT (Reactant); RACT (Reactant or reagent)  
(reaction with pyrrolidine)

RN 29174-19-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5-(chloroacetyl)-5,10-dihydro- (8CI, 9CI) (CA INDEX NAME)

10/785,120



L10 ANSWER 96 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1974:403984 CAPLUS

DN 81:3984

TI Neuroleptic and antiemetic dibenzo[b,f][1,4]oxazepine derivatives

IN Schmutz, Jean; Hunziker, Fritz; Kuenzle, Franz M.

PA Dr. A. Wander, A.-G.

SO Fr. Demande, 20 pp. Addn. to Fr. 2,102,073 (See Ger. Offen. 2,139,016 CA 76;140923x).

CODEN: FRXXBL

DT Patent

LA French

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2187338	A2	19740118	FR 1973-20407	19730605
	FR 2187338	B2	19760409		
	AU 7356683	A1	19741212	AU 1973-56683	19730607
	ZA 7303873	A	19750129	ZA 1973-3873	19730607
PRAI	CH 1972-8441	A	19720607		

GI For diagram(s), see printed CA Issue.


AB Dibenzoxazepine derivs. I (R = COCHMe2, COBu, COCH2CHMe2, COCHMeEt, COCMe3, COCH2CH2CHMe2) were prepared by esterifying I (R = H), prepared from 2-O2NC6H4OC6H4SMe-4 in 7 steps. I had a neuroleptic and antiemetic ED50 in the apomorphine antagonism test in rats of 2.4-3.6 mg/kg i.v.

IT **31293-95-5P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and chlorination of)

RN 31293-95-5 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-[(trifluoromethyl)sulfonyl]- (8CI, 9CI) (CA INDEX NAME)

IT **31293-91-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and oxidation of)

RN 31293-91-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-[(trifluoromethyl)thio]- (8CI, 9CI) (CA INDEX NAME)



10/785,120

L10 ANSWER 97 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1974:83088 CAPLUS

DN 80:83088

TI Dibenzoxazepines

IN Schmutz, Jean; Hunziker, Fritz; Kuenzle, Franz M.

PA Dr. A. Wander, A.-G.

SO Patentschrift (Switz.), 5 pp.

CODEN: SWXXAS

DT Patent

LA German

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CH 544767	A	19740115	CH 1972-15415	19700806
	US 3891647	A	19750624	US 1973-326121	19730123
PRAI	CH 1970-11922	A	19700806		
	CH 1971-7915	A	19710601		
	US 1971-166997	A2	19710728		
	CH 1972-8441	A	19720606		
	CH 1972-15415	A	19721020		
	CH 1972-15416	A	19721020		

GI For diagram(s), see printed CA Issue.


AB Dibenz[bf][1,4]oxazepines I (R1 = C3-13 alkyl; O2CR1 = oleoyloxy) (12 compds.) and their salts were prepared by N-alkylation of piperazinodibenzoxazepine II with halo esters R1-CO2CH2CH2Cl. II was prepared by chlorination of 2-nitrophenyl 4-(trifluoromethylthio)phenyl ether and then successively treated with SbF3, hydrogenated, treated with COCl2, cyclized, oxidized with H2O2, and then treated with POCl3-P2O5. The resulting imino chloride III was N-alkylated piperazine to give II.

IT **31293-91-1P 31293-95-5P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 31293-91-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-[(trifluoromethyl)thio]- (8CI, 9CI) (CA INDEX NAME)



RN 31293-95-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-[(trifluoromethyl)sulfonyl]- (8CI, 9CI) (CA INDEX NAME)





L10 ANSWER 98 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1974:83086 CAPLUS

DN 80:83086

TI Dibenzoxazepines

IN Schmutz, Jean; Hunziker, Fritz; Kuenzle, Franz M.

PA Dr. A. Wander, A.-G.

SO Patentschrift (Switz.), 4 pp.

CODEN: SWXXAS

DT Patent

LA German

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CH 544768	A	19740115	CH 1972-15416	19700806
	US 3891647	A	19750624	US 1973-326121	19730123
PRAI	CH 1970-11922	A	19700806		
	CH 1971-7915	A	19710601		
	US 1971-166997	A2	19710728		
	CH 1972-8441	A	19720606		
	CH 1972-15415	A	19721020		
	CH 1972-15416	A	19721020		

GI For diagram(s), see printed CA Issue.


AB Dibenz[bf][1,4]oxazepines I (R1 = C3-13 alkyl; R1CO2 = oleoyloxy) (12 compds.) and their salts were prepared by treating dibenzoxazepine II with POCl3 and the resulting imino chloride III was treated with piperazine IV. III was prepared by successive chlorination of 2-nitrophenyl 4-(methylthio)phenyl ether, SbF3 treatment, hydrogenation, and COCl2 treatment, POCl3-P2O5 cyclization, and H2O2 oxidation

IT **31293-91-1P 31293-95-5P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 31293-91-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-[(trifluoromethyl)thio]- (8CI, 9CI) (CA INDEX NAME)



RN 31293-95-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-[(trifluoromethyl)sulfonyl]- (8CI, 9CI) (CA INDEX NAME)



10/785,120

L10 ANSWER 99 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1974:48047 CAPLUS

DN 80:48047

TI 7-Amino-2-chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine and its salts

IN Howell, Charles F.

PA American Cyanamid Co.

SO U.S., 4 pp. Continuation-in-part of U. S. 3,705,245 (CA 78;58481j).

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3773768	A	19731120	US 1972-280033	19720811
	US 3660406	A	19720502	US 1970-84221	19701026
	US 3705245	A	19721205	US 1972-220371	19720124
PRAI	US 1970-84221	A2	19701026		
	US 1972-220371	A2	19720124		

GI For diagram(s), see printed CA Issue.


AB The dibenzoxazepine I (R = NO<sub>2</sub>) was prepared by treating 2-chlorodibenz[b,f][1,4]oxazepin-11(10H)-one (II) with N-methylpiperazine, followed by nitration. Zn-HCl reduction of I (R = NO<sub>2</sub>) gave I (R = NH<sub>2</sub>), which was diazotized in the presence of HOAc and hydrolyzed to I (R = OH). Alternatively, the nitration and subsequent steps were carried out on II before treatment with N-methylpiperazine. I are tranquilizers with ED<sub>50</sub> for the depression of motor activity in rats of 0.24-28 mg/kg i.p.

IT 3158-91-6

RL: RCT (Reactant); RACT (Reactant or reagent)  
(nitration of)

RN 3158-91-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)




IT 37081-73-5P 37081-74-6P 37116-83-9P

51370-03-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 37081-73-5 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 7-amino-2-chloro- (9CI) (CA INDEX NAME)



RN 37081-74-6 CAPLUS


10/785,120

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro-7-hydroxy- (9CI) (CA INDEX NAME)




RN 37116-83-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro-7-nitro- (9CI) (CA INDEX NAME)



RN 51370-03-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 7-(acetyloxy)-2-chloro- (9CI) (CA INDEX NAME)



L10 ANSWER 100 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1973:97273 CAPLUS

DN 78:97273

TI Synthesis of some substituted salicylanilides of expected biological activity

AU Islam, A. M.; Hannout, I. B.; Hassan, E. A.; Ihsan, A. E.

CS Fac. Sci., Al-Azhar Univ., Cairo, Egypt

SO Journal fuer Praktische Chemie (Leipzig) (1972), 314(5-6), 727-34

CODEN: JPCEAO; ISSN: 0021-8383

DT Journal

LA English

OS CASREACT 78:97273

GI For diagram(s), see printed CA Issue.


AB 5,2-R(HO)C<sub>6</sub>H<sub>3</sub>CONHC<sub>6</sub>H<sub>4</sub>R<sub>1</sub> (I; R = H, Cl; R<sub>1</sub> = H, Cl, Me, NO<sub>2</sub>) were prepared in 50-94% yield by reaction of 5,2-R(HO)C<sub>6</sub>H<sub>3</sub>CO<sub>2</sub>Ph (II) with R<sub>1</sub>C<sub>6</sub>H<sub>4</sub>NH<sub>2</sub> at 180°. Reaction of II with o-HOC<sub>6</sub>H<sub>4</sub>NH<sub>2</sub> gave 52-6% dibenzoxazepinones III. Condensation of II (R = H) with XYC<sub>6</sub>H<sub>3</sub>NH<sub>2</sub> (X = 2-Cl, 2-Br; Y = 4-, 5-O<sub>2</sub>N) yielded 81-95% o-HOC<sub>6</sub>H<sub>4</sub>CONHC<sub>6</sub>H<sub>3</sub>XY. Coupling some I (R = H) with diazotized p-R<sub>2</sub>C<sub>6</sub>H<sub>4</sub>NH<sub>2</sub> (R<sub>2</sub> = O<sub>2</sub>N, NaO<sub>3</sub>S) gave 55-82% p-R<sub>2</sub>C<sub>6</sub>H<sub>4</sub>N:NC<sub>6</sub>H<sub>3</sub>(CONHC<sub>6</sub>H<sub>4</sub>R<sub>1</sub>)OH-3,4 (IV). IV (R<sub>2</sub> = NaO<sub>3</sub>S) were reduced with NaHSO<sub>3</sub> to give 61-70% 2,5-HO(H<sub>2</sub>N)C<sub>6</sub>H<sub>3</sub>CONHC<sub>6</sub>H<sub>4</sub>R<sub>1</sub>.

IT **3158-91-6P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 3158-91-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)



10/785,120

L10 ANSWER 101 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1973:58481 CAPLUS

DN 78:58481

TI 7-Amino-2-chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepines acting on the central nervous system

IN Howell, Charles Frederick; Greenblatt, Eugene Newton

PA American Cyanamid Co.

SO U.S., 4 pp. Continuation-in-part of U.S. 3,660,406 (CA 77;62038s).

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3705245	A	19721205	US 1972-220371	19720124
	US 3773768	A	19731120	US 1972-280033	19720811
PRAI	US 1970-84221	A2	19701026		
	US 1972-220371	A2	19720124		

GI For diagram(s), see printed CA Issue.


AB Continuation-in-part of U.S. 3,660,406 (CA 77: 62038s). Three dibenzoxazepines [I, R = NH<sub>2</sub> (II), NO<sub>2</sub>, OH] useful as antidepressants and tranquilizers were prepared. Thus, 2-chlorodibenz[b,f][1,4]oxazepin-11-(10H)-one was nitrated by AcONO<sub>2</sub> in HOAc to give the 6-NO<sub>2</sub> derivative, which was treated with PCl<sub>5</sub> and 2-methylpiperazine to give I (R = NO<sub>2</sub>) (III). Reduction of III in EtOH with Zn gave the title compound (II). Diazotization of II followed by hydrolysis gave the OH compound (I, R = OH).

IT 3158-91-6

RL: RCT (Reactant); RACT (Reactant or reagent)  
(nitration of)

RN 3158-91-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)




IT 37081-73-5P 37116-83-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and reactions of)

RN 37081-73-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 7-amino-2-chloro- (9CI) (CA INDEX NAME)




RN 37116-83-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro-7-nitro- (9CI) (CA INDEX

10/785,120

NAME)




IT **37081-74-6P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 37081-74-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro-7-hydroxy- (9CI) (CA INDEX  
NAME)



L10 ANSWER 102 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1972:462038 CAPLUS

DN 77:62038

TI 2-Chloro-7-hydroxy-11-(1-piperazinyl)dibenz[b,f][1,4]oxazepines as tranquilizers and antidepressants

IN Howell, Charles F.; Greenblatt, Eugene N.

PA American Cyanamid Co.

SO U.S., 4 pp.

CODEN: USXXAM


DT Patent

LA English

FAN.CNT 3


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3660406	A	19720502	US 1970-84221	19701026
	AU 7134001	A1	19730405	AU 1971-34001	19710929
	GB 1340898	A	19731219	GB 1971-45427	19710929
	IL 37953	A1	19750728	IL 1971-37953	19711017
	CA 971169	A1	19750715	CA 1971-125540	19711019
	BE 774398	A1	19720425	BE 1971-109689	19711025
	AT 311979	B	19731210	AT 1971-9218	19711025
	AT 311983	B	19731210	AT 1972-10567	19711025
	SU 437301	D	19740725	SU 1971-1708711	19711025
	PL 81422	P	19750830	PL 1971-151205	19711025
	SE 380528	B	19751110	SE 1971-13522	19711025
	DK 134066	B	19760906	DK 1971-5177	19711025
	DE 2153349	A	19720427	DE 1971-2153349	19711026
	NL 7114713	A	19720428	NL 1971-14713	19711026
	FR 2111840	A5	19720609	FR 1971-38476	19711026
	FR 2111840	B1	19750801		
	DD 97210	C	19730423	DD 1971-158567	19711026
	ES 396390	A1	19750101	ES 1971-396390	19711026
	CH 576470	A	19760615	CH 1971-15573	19711026
	CS 172359	P	19761229	CS 1971-7545	19711026
	ES 399188	A1	19750601	ES 1972-399188	19720125
	US 3773768	A	19731120	US 1972-280033	19720811
	CA 969937	A2	19750624	CA 1973-176267	19730712
PRAI	US 1970-84221	A	19701026		
	CA 1971-125540	A3	19711019		
	US 1972-220371	A2	19720124		
GI	For diagram(s), see printed CA Issue.				
AB	Chlorodibenz[b,f][1,4]oxazepin-11(10H)-one (I) was transformed by nitration, reduction, and hydrolysis into II (R = NO <sub>2</sub> , NH <sub>2</sub> , OH, resp.); the corresponding III, useful as tranquilizers and antidepressants, were prepared from II. Thus, I with AcONO <sub>2</sub> gave II (R = NO <sub>2</sub> ), which was treated with PCl <sub>5</sub> and with N-methylpiperazine to give III (R = NO <sub>2</sub> ). The N <sub>4</sub> -oxides of III were also prepared				
IT	<b>37081-73-5P 37081-74-6P 37081-78-0P</b> <b>37116-83-9P</b> RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN	37081-73-5 CAPLUS				
CN	Dibenz[b,f][1,4]oxazepin-11(10H)-one, 7-amino-2-chloro- (9CI) (CA INDEX NAME)				

10/785,120




RN 37081-74-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro-7-amino- (9CI) (CA INDEX NAME)




RN 37081-78-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro-9-hydroxy- (9CI) (CA INDEX NAME)



RN 37116-83-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro-7-nitro- (9CI) (CA INDEX NAME)





L10 ANSWER 103 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1972:140923 CAPLUS

DN 76:140923

TI Neuroleptic and antiemetic 2-(trifluoromethylsulfonyl)dibenz[b,f]-1,4-oxazepine derivatives

IN Schmutz, Jean; Hunziker, Fritz; Kuenzle, Martin F.

PA Dr. A. Wander, A.-G.

SO Ger. Offen., 26 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2139016	A	19720210	DE 1971-2139016	19710804
	CH 549593	A	19740531	CH 1970-11922	19700806
	NL 7110453	A	19720208	NL 1971-10453	19710729
	GB 1355866	A	19740605	GB 1971-36235	19710802
	FR 2102073	A1	19720407	FR 1971-28447	19710803
	FR 2102073	A5	19720407		
	BE 770956	A1	19720204	BE 1971-106758	19710804
	DK 128355	B	19740416	DK 1971-3817	19710804
	IL 37437	A1	19740516	IL 1971-37437	19710804
	ES 393891	A1	19740701	ES 1971-393891	19710804
	SU 450411	D	19741115	SU 1971-1850487	19710804
	SU 451246	D	19741125	SU 1971-1850485	19710804
	SU 461501	D	19750225	SU 1971-1690481	19710804
	NO 132097	B	19750609	NO 1971-2929	19710804
	PL 82244	P	19751031	PL 1971-149831	19710804
	AU 7132060	A1	19730308	AU 1971-32060	19710805
	CA 956942	A1	19741029	CA 1971-119861	19710805
	AT 7106870	A	19750115	AT 1971-6870	19710805
	AT 325619	B	19751027		
	AT 928373	A	19750115	AT 1973-9283	19710805
	SE 379046	B	19750922	SE 1971-10035	19710805
	AT 325624	B	19751027	AT 1971-325624	19710805
	ZA 7105245	A	19730328	ZA 1971-5245	19710806
PRAI	CH 1970-11922	A	19700806		
	CH 1971-7905	A	19710601		
	CH 1971-7915	A	19710601		

GI For diagram(s), see printed CA Issue.

AB Four title compds. [I; Q = 1,4-piperazinediyl; R = Me(CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>; n = 3, 5, 8, or 12], useful i.m. in 20-60 mg doses as 1-3% oily solns., were prepared by reaction of I (QR = H) with HQR, of I (QR = 1-piperazinyl) with Me(CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>Cl, or of I (Q = 1,4-piperazinediyl, R = CH<sub>2</sub>CH<sub>2</sub>OH) (II) with Me(CH<sub>2</sub>)<sub>n</sub>COCl. Thus, Cl was passed into o-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>OC<sub>6</sub>H<sub>4</sub>SMe-p in CHCl<sub>3</sub> at 20° with exposure to light to give o-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>OC<sub>6</sub>H<sub>4</sub>SCCl<sub>3</sub>-p (III). III (61.3 g) and 41 g SbF<sub>3</sub> in sulfolane was heated <30 min to 150°, the mixture kept 1.5 hr at this temperature, and HCl added to give o-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>OC<sub>6</sub>H<sub>4</sub>SCF<sub>3</sub> (IV). IV was hydrogenated over Raney Ni to give o-H<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>OC<sub>6</sub>H<sub>4</sub>SCF<sub>3</sub> (V). COCl<sub>2</sub> was passed into refluxing V in 20% COCl<sub>2</sub>-PhMe to give o-OCNC<sub>6</sub>H<sub>4</sub>OC<sub>6</sub>H<sub>4</sub>-SCF<sub>3</sub> (VI). VI and P<sub>2</sub>O<sub>5</sub> was refluxed 24 hr in POCl<sub>3</sub>, the mixture evaporated, ice added to the residue, and the mixture neutralized with NaOH and kept 24 hr to give 2-(trifluoromethylthio)-10,11-dihydro-11-oxodibenz[b,f]-1,4-oxazepine (VII). H<sub>2</sub>O<sub>2</sub> (30%) was added to VII in HOAc and the mixture heated 1 hr at 70° and 1.5 hr at 100-10° to give 2-(trifluoromethylsulfonyl)-10,11-dihydro-11-oxodibenz[b,f]-1,4-oxazepine (VIII). VIII and PhNMe<sub>2</sub> was refluxed 4.5 hr in POCl<sub>3</sub>, 1-(β-hydroxyethyl)piperazine added, and the mixture refluxed 5 hr to give II. II and C<sub>6</sub>H<sub>13</sub>COCl in pyridine was kept overnight and the mixture alkalized to give I [Q = 1,4-piperazinediyl, R =

10/785,120


Me(CH<sub>2</sub>)<sub>5</sub>CO<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>].

IT **31293-91-1P 31293-95-5P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 31293-91-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-[(trifluoromethyl)thio]- (8CI,  
9CI) (CA INDEX NAME)



RN 31293-95-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-[(trifluoromethyl)sulfonyl]- (8CI,  
9CI) (CA INDEX NAME)



L10 ANSWER 104 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1971:141907 CAPLUS

DN 74:141907

TI Amino-substituted dibenz[b,f][1,4]oxazepin-11(10H)-ones, useful as analgesics, antipyretics, and sedatives in warmblooded animals

IN Schmidt, Guenther

PA Boehringer Ingelheim G.m.b.H.

SO U.S., 6 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3546214	A	19701208	US 1968-743601	19680710
	FR 1574968	A	19690718	FR 1968-1574968	19680711
	GB 1164579	A	19690917	GB 1968-1164579	19680711
PRAI	DE 1966-1695900	A	19670711		

GI For diagram(s), see printed CA Issue.

AB The title compds. (I, R = NH<sub>2</sub>) and analogs are prepared by reduction of the corresponding nitro derivs. Thus, I (R = 2-NO<sub>2</sub>) in dioxane hydrogenated 2 hr over 2 g Raney Ni at 50°/31 atm gave I (R = NH<sub>2</sub>), m. 200-2°; HCl salt m. 320° (decomposition). I (R = NH<sub>2</sub>) was similarly obtained by catalytic hydrogenation over PtO<sub>2</sub> in MeOH and Pd-C in MeOH; and by reduction with Sn/HCl in alc., by 80% N<sub>2</sub>H<sub>4</sub>.H<sub>2</sub>O in boiling alc., by Na<sub>2</sub>S<sub>2</sub>O<sub>6</sub> in refluxing alc., with SnCl<sub>2</sub> and 5N HCl, and with Fe/HCl. Various I were similarly produced and converted to their acid addition salts.

IT 23474-55-7P 23474-56-8P 23474-59-1P


23474-60-4P 23474-63-7P 23474-65-9P

23474-66-0P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 23474-55-7 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-chloro- (8CI, 9CI) (CA INDEX NAME)



RN 23474-56-8 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-chloro-, monohydrochloride  
(8CI) (CA INDEX NAME)


10/785,120



● HCl


RN 23474-59-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-methyl- (8CI, 9CI) (CA INDEX NAME)



RN 23474-60-4 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-methyl-, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 23474-63-7 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-amino- (8CI, 9CI) (CA INDEX NAME)



RN 23474-65-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-, monohydrochloride (8CI) (CA INDEX NAME)


10/785,120



● HCl

RN 23474-66-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino- (8CI, 9CI) (CA INDEX NAME)



L10 ANSWER 105 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1971:100126 CAPLUS  
 DN 74:100126  
 TI Psychotropic 11-(1-piperazinyl)dibenz[b,f][1,4]oxazepines  
 IN Hunziker, Fritz; Schmutz, Jean; Kuenzle, Franz M.  
 PA Dr. A. Wander, A.-G.  
 SO Ger. Offen., 44 pp.  
 CODEN: GWXXBX

DT Patent


LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2037733	A	19710218	DE 1970-2037733	19700730
	CH 518304	A	19720131	CH 1969-518304	19690806
	CH 531534	A	19730131	CH 1970-8679	19700611
	GB 1318401	A	19730531	GB 1970-35011	19700720
	GB 1318402	A	19730531	GB 1973-1718	19700720
	NL 7011063	A	19710209	NL 1970-11063	19700727
	US 3717637	A	19730220	US 1970-58984	19700728
	FR 2068464	A1	19710827	FR 1970-28684	19700804
	FR 2068464	A5	19710827		
	ES 382423	A1	19730416	ES 1970-382423	19700804
	SU 438184	D	19740730	SU 1970-1732950	19700804
	SU 439092	D	19740805	SU 1970-1713244	19700804
	JP 49040236	B4	19741031	JP 1970-67810	19700804
	SU 451247	D	19741125	SU 1970-1732949	19700804
	SE 373851	B	19750217	SE 1970-10667	19700804
	CA 965785	A1	19750408	CA 1970-89826	19700804
	PL 80952	B	19750830	PL 1970-142517	19700804
	SU 484690	D	19750915	SU 1970-1473416	19700804
	SU 508202	D	19760325	SU 1970-1713243	19700804
	CS 168536	P	19760629	CS 1970-5438	19700804
	ZA 7005412	A	19720329	ZA 1970-5412	19700805
	AT 314539	B	19740410	AT 1970-7140	19700805
	AT 314546	B	19740410	AT 1972-5152	19700805
	AT 314547	B	19740410	AT 1972-5153	19700805
	AT 314548	B	19740410	AT 1972-5154	19700805
	AT 314549	B	19740410	AT 1972-5155	19700805
	NO 130589	B	19740930	NO 1970-3019	19700805
	ES 393047	A1	19740516	ES 1971-393047	19710708
	ES 393048	A1	19740516	ES 1971-393048	19710708
	ES 393049	A1	19740516	ES 1971-393049	19710708
	ES 393050	A1	19740516	ES 1971-393050	19710708
	ES 393046	A1	19740601	ES 1971-393046	19710708
PRAI	CH 1969-11925	A	19690806		
	CH 1969-12595	A	19690820		
	CH 1969-15039	A	19691007		
	CH 1970-8679	A	19700611		
	CH 1970-8699	A	19700611		
GI	For diagram(s), see printed CA Issue.				
AB	The psychotropic title compds. (I, X = S, SO <sub>2</sub> ) were prepared by reaction of the dibenz[b,f][1,4]oxazepines with piperazines, by cyclization of the o-aminodiphenyl ethers, by reaction of 11-aminodibenz[b,f][1,4]oxazepines with iminodiethanol esters or piperazines, or by alkylation of I (R = H). Among approx. 10 compds. prepared were I (R and X given): Me, S; Et, SO <sub>2</sub> ; HO(CH <sub>2</sub> ) <sub>3</sub> , SO <sub>2</sub> .				
IT	<b>31293-91-1P 31293-95-5P</b>				
	RL: SPN (Synthetic preparation); PREP (Preparation)				
	(preparation of)				
RN	31293-91-1 CAPLUS				


10/785,120

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-[(trifluoromethyl)thio]- (8CI,  
9CI) (CA INDEX NAME)



RN 31293-95-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-[(trifluoromethyl)sulfonyl]- (8CI,  
9CI) (CA INDEX NAME)



L10 ANSWER 106 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1971:100124 CAPLUS

DN 74:100124

TI 5-(Piperidinoacetyl)-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-11-ones

IN Schmidt, Guenther; Machleidt, Hans; Engelhorn, Robert; Leitold, Matyas

PA Thomae, Dr. Karl, G.m.b.H.

SO Ger. Offen., 20 pp. Addn. to Ger. Offen. 1,795,176

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 1931487	A	19710107	DE 1969-1931487	19690620
	DE 1931487	B2	19750417		
	DE 1931487	C3	19751218		
	DE 1795176	A	19720203	DE 1967-1795176	19680820
	FI 49509	B	19750401	FI 1969-2162	19690722
	RO 56187	P	19750615	RO 1969-60620	19690724
	US 3634408	A	19720111	US 1969-848356	19690807
	ES 370395	A1	19710416	ES 1969-370395	19690811
	SU 512704	D	19760430	SU 1969-1357008	19690812
	CH 510685	A	19710731	CH 1969-510685	19690813
	AT 292709	B	19710910	AT 1969-7959	19690819
	NO 125386	B	19720904	NO 1969-3363	19690819
	PL 69663	P	19730831	PL 1969-135429	19690819
	DK 135043	B	19770228	DK 1969-4431	19690819
	DK 135043	C	19770822		
	BE 737747	A	19700220	BE 1969-737747	19690820
	NL 6912653	A	19700224	NL 1969-12653	19690820
	FR 2016008	A5	19700430	FR 1969-28589	19690820
	FR 2016008	B1	19731221		
	GB 1236112	A	19710623	GB 1969-1236112	19690820
	BR 6911744	A0	19730118	BR 1969-211744	19690820
	SE 367199	B	19740520	SE 1969-11570	19690820
	CS 163730	P	19751107	CS 1969-5774	19690820
PRAI	DE 1967-1795176	A	19680820		
	DE 1969-1931487	A	19690620		

GI For diagram(s), see printed CA Issue.

AB The antiulcerous title compds. (I), which inhibit the secretion of gastric juice, were prepared Thus, refluxing 5-chloroacetyl-10,11-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one and 2-methylpiperidine in C<sub>6</sub>H<sub>6</sub> 18 hr gave 45% I (R = Me, R<sub>1</sub> = R<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = R<sub>5</sub> = R<sub>6</sub> = H). Similarly prepared were I (R-R<sub>6</sub> given): H, Me, H, H, H, H, H; H, H, Me, H, H, H, H; Et, H, H, H, H, H, H; Et, H, H, H, H, Me, H; H, H, MeO, H, H, H, H; Me, H, H, H, Cl, H, H; Et, H, H, H, Cl, H, H; Me, H, H, H, Cl, Et, H; Et, H, H, H, H, Et, H; H, H, Pr, H, H, H, H; Me, H, H, H, H, Et, H; Me, H, H, H, H, H, Cl; Me, H, H, Me, H, H, H.

IT 29174-44-5P 29174-45-6P


RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 29174-44-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-[(2-methylpiperidino)acetyl]- (8CI) (CA INDEX NAME)




10/785,120



RN 29174-45-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5-[(2-ethylpiperidino)acetyl]-5,10-dihydro- (8CI) (CA INDEX NAME)



10/785,120

L10 ANSWER 107 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1971:100123 CAPLUS

DN 74:100123

TI Ulcer- and secretion-inhibiting 5-(aminoacetyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-ones

IN Schmidt, Guenther; Machleidt, Hans; Leitold, Matays; Engelhorn, Robert

PA Thomae, Dr. Karl, G.m.b.H.

SO Ger. Offen., 10 pp. Addn. to Ger. Offen. 1,795,176

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2022790	A	19710211	DE 1970-2022790	19700509
	DE 2022790	B2	19760708		
	DE 2022790	C3	19770707		
	FI 49509	B	19750401	FI 1969-2162	19690722
	FR 2016008	A5	19700430	FR 1969-28589	19690820
	FR 2016008	B1	19731221		
PRAI	FI 1969-2162	A	19690722		
	DE 1967-1795176	A	19680820		
	DE 1969-1931487	A	19690620		

GI For diagram(s), see printed CA Issue.


AB The title compds. (I) and their physiol. compatible salts, the activities of which were tested in rats and guinea-pigs, were prepared by refluxing the 5-chloroacetyl derivative and the cyclic amine in a solvent. Prepared were I bis(hydrogenfumarate) (R = Me, X = H, n = 1) and I (R = H, X = Cl, n = 0) of LD50 3400 and >1500 mg/kg, resp., in mice on oral administration. Formulations containing I are reported.

IT **29174-19-4P 29174-20-7P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 29174-19-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5-(chloroacetyl)-5,10-dihydro- (8CI, 9CI) (CA INDEX NAME)



RN 29174-20-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-(1-pyrrolidinylacetyl)- (8CI, 9CI) (CA INDEX NAME)

10/785,120



10/785,120

L10 ANSWER 108 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1971:100121 CAPLUS  
DN 74:100121  
TI Antiulcerous N-(diallylaminoalkanoyl)-1,4-benzodiazepinones  
IN Schmidt, Guenther; Engelhorn, Robert; Leitold, Matyas  
PA Thomae, Dr. Karl, G.m.b.H.  
SO Ger. Offen., 28 pp. Addn. to Ger. Offen. 1,795,183  
CODEN: GWXXBX  
DT Patent  
LA German  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 1936670	A	19710204	DE 1969-1936670	19690718
	DE 1936670	B2	19760318		
	DE 1936670	C3	19761104		
	FI 50242	B	19750930	FI 1970-1744	19700622
	SE 380800	B	19751117	SE 1970-8854	19700625
	CS 164864	P	19751128	CS 1970-4848	19700709
	US 3691159	A	19720912	US 1970-54624	19700713
	ZA 7004861	A	19720329	ZA 1970-4861	19700715
	CH 530988	A	19730115	CH 1970-530988	19700715
	RO 55559	P	19731120	RO 1970-63923	19700715
	ES 381898	A1	19730401	ES 1970-381898	19700716
	BE 753664	A	19710118	BE 1970-753664	19700717
	NL 7010618	A	19710120	NL 1970-10618	19700717
	NL 165933	B	19810115		
	NL 165933	C	19810615		
	FR 2059530	A5	19710604	FR 1970-26501	19700717
	FR 2059530	B1	19740830		
	GB 1265467	A	19720301	GB 1970-1265467	19700717
	AT 298495	B	19720510	AT 1970-6542	19700717
	NO 127447	B	19730625	NO 1970-2815	19700717
	IL 34947	A1	19731128	IL 1970-34947	19700717
	DK 135285	B	19770328	DK 1970-3725	19700717
	PL 79758	P	19750630	PL 1970-142155	19700718
	US 3749785	A	19730731	US 1972-277096	19720801
	NL 8100572	A	19810601	NL 1981-572	19810206
	NL 170856	B	19820802		
	NL 170856	C	19830103		
PRAI	DE 1969-1936670	A	19690718		
	US 1970-54624	A3	19700713		
	NL 1970-10618		19700717		

GI For diagram(s), see printed CA Issue.

AB The title compds. (I) were prepared from II and (CH<sub>2</sub>:CHCH<sub>2</sub>)<sub>2</sub>NH (III). I of LD<sub>50</sub> >1500 mg/kg (orally in mice) had antiulcerous effects in rats and inhibited gastric secretion. Thus, refluxing II (Q = N, R = R<sub>1</sub> = H, n = 1) and III 18 hr in C<sub>6</sub>H<sub>6</sub> gave the corresponding I. Among about 15 I prepared were (Q, R, R<sub>1</sub>, and n given): N, Et, H, 1; N, H, H, 2; CH, Me, H, 1; CH, Me, Cl, 2; CH, H, Cl, 2.

IT 31262-24-5P 31265-74-4P 31265-76-6P

31265-79-9P 31265-85-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 31262-24-5 CAPLUS


CN 11H-Dibenzo[b,e]-[1,4]diazepin-11-one, 2-chloro-5-(N,N-diallyl-glycyl)-5,10-dihydro-, fumarate (2:1) (8CI) (CA INDEX NAME)

CM 1

CRN 31265-74-4

10/785,120

CMF C21 H20 Cl N3 O2




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.



RN 31265-74-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5-(N,N-diallylglycyl)-5,10-dihydro- (8CI) (CA INDEX NAME)



RN 31265-76-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5-(N,N-diallyl-beta-alanyl)-5,10-dihydro-, monohydrochloride (8CI) (CA INDEX NAME)


10/785,120



● HCl


RN 31265-79-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5-(N,N-diallylalanyl)-5,10-dihydro- (8CI) (CA INDEX NAME)



RN 31265-85-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5-(3-chloro-1-oxopropyl)-5,10-dihydro- (9CI) (CA INDEX NAME)



L10 ANSWER 109 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1971:74869 CAPLUS

DN 74:74869

TI Effects of a group of dibenzodiazepines on fatal systemic anaphylaxis in mice, rats, and guinea pigs

AU Greig, Margaret E.; Gibbons, Anna J.; Young, Gerald Alan

CS Res. Lab., Upjohn Co., Kalamazoo, MI, USA

SO Journal of Medicinal Chemistry (1971), 14(2), 153-6

CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

GI For diagram(s), see printed CA Issue.


AB The varying degrees of protection against fatal systemic anaphylaxis in 3 species of animals by 34 dibenzodiazepines (I) were correlated with their inhibition of chymotrypsin activity. The most active compds. being I[R1 = (CH<sub>2</sub>)<sub>3</sub>NMe<sub>2</sub>, R = R<sub>2</sub> = H] and I[R1 = (CH<sub>2</sub>)<sub>3</sub>NMe<sub>2</sub>, RR = O, R<sub>2</sub> = H] were superior to tripeleennamine in protecting mice against the fatal anaphylaxis. I was comparable to cyproheptadine in mice and rats, but was superior in guinea pigs.

IT 32038-67-8

RL: BIOL (Biological study)  
(anaphylaxis prevention by)

RN 32038-67-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5-[3-(dimethylamino)propyl]-5,10-dihydro-, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

10/785,120

L10 ANSWER 110 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1970:520695 CAPLUS

DN 73:120695

TI 5,10-Dihydro-11H-dibenzo[b,e] [1,4]diazepine-11-ones substituted in 5-position, and their ulcer-inhibiting activity

IN Schmidt, Guenther; Engelhorn, Robert; Leitold, Matyas; Machleidt, Hans

PA Thomae, Dr. Karl, G.m.b.H.

SO S. African, 49 pp.


CODEN: SFXAB

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	ZA 6905930		19700312		
	DE 1795176			DE	
	FR 2016008			FR	
	GB 1236112			GB	
	US 3634408		19720000	US	
PRAI	DE		19680820		
	DE		19690620		
AB	I (R = H, 2-Cl, 8-Cl; R1 = H, Me; X = pyrrolidino, piperidino, morpholino, 4-substituted 1-piperazinyl, etc.) ulcer- and secretion-inhibiting compds., are prepared from II. Thus, 10 g 5-(chloroacetyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]-diazepin-11-one and 10 ml N-methylpiperazine gave I (R = R1 = H; X = 4-methyl-1-piperazinyl). Forty-seven prepns. are given.				
IT	29174-19-4P 29174-20-7P 29174-23-0P 29174-26-3P 29174-44-5P 29174-45-6P 29183-81-1P 29183-82-2P RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN	29174-19-4 CAPLUS				
CN	11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5-(chloroacetyl)-5,10-dihydro- (8CI, 9CI) (CA INDEX NAME)				




RN 29174-20-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-(1-pyrrolidinylacetyl)- (8CI, 9CI) (CA INDEX NAME)



10/785,120




RN 29174-23-0 CAPLUS  
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-(piperidinoacetyl)- (8CI) (CA INDEX NAME)




RN 29174-26-3 CAPLUS  
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-(morpholinoacetyl)- (8CI) (CA INDEX NAME)

10/785,120



RN 29174-44-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-[(2-methylpiperidino)acetyl]- (8CI) (CA INDEX NAME)



RN 29174-45-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5-[(2-ethylpiperidino)acetyl]-5,10-dihydro- (8CI) (CA INDEX NAME)

10/785,120



RN 29183-81-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-[(4-methyl-1-piperazinyl)acetyl]-, dihydrochloride (8CI) (CA INDEX NAME)




● 2 HCl

RN 29183-82-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-5-[(4-methyl-1-piperazinyl)acetyl]-, dihydrochloride (8CI) (CA INDEX NAME)

10/785,120



L10 ANSWER 111 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1970:111530 CAPLUS

DN 72:111530

TI Antidepressant 10-(aminoalkyl)-11-oxo-10,11-dihydrodibenz[b,f][1,4]oxazepines

IN Nagarajan, Kuppuswamy

PA CIBA Ltd.

SO Patentschrift (Switz.), 9 pp.

CODEN: SWXXAS

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CH 481936	A	19691130	CH 1966-481936	19661205
PRAI	CH 1966-17305	A	19661205		

GI For diagram(s), see printed CA Issue.


AB A solution of 6.6 g 2,5-Cl(O2N)C6H3COCl in 50 ml dry Et2O was added over 1 hr to a stirred mixture of 5.2 g Na-HCO3 in 50 ml H2O and 3.3 g o-HOC6H4NH2 in 50 ml Et2O at 0° to give 2,5-Cl(O2N)C6H3CO NHC6H4OH-o, m. 189-92° (aqueous MeOH), which (4.5 g) was heated with 0.8 g NaOH in 150 ml H2O on a steam bath 16 hr to give 2-nitro-11-oxo-10,11-dihydrodibenz[b,f][1,4]oxazepine (I), m. 258-60° (Me2CO-MeOH). I (3 g), 4.7 g Me2N(CH2)3Cl.HCl (II), 18 ml H2O, 1.8 g NaOH, and 30 ml Me2CO was refluxed 5 hr, Me2CO distilled, and the residue diluted with H2O to give III (n = 3, R = Me2N, R1 = R2 = R3 = R4 = R6 = H, R5 = NO2) (IV), oil; HCl salt m. 223-6° (absolute EtOH); oxalate m. 212-14° (decomposition) (aqueous MeOH); maleate m. 166-8° (MeOH-Et2O). Fuming HNO3 (2 ml) was added to 1 g IV in 5 ml concentrated H2SO4 at 0° and ice and NH4OH added after 1.5 hr to give III (n = 3, R = Me2N, R1 = R2 = R4 = R6 = H, R3 = R5 = NO2) (V); HCl salt hemihydrate m. 205° (decomposition) (EtOH); picrate m. 158-60° (decomposition) (Me2COMeOH). 11-Oxo-10, 11-dihydrodibenz[b,f][1,4]oxazepine was treated with NaH in HCONMe2, followed by II to give III (n = 3, R = Me2N, R1 = R2 = R3 = R4 = R5 = R6 = H) (VI); maleate m. 124-6°. VI treated with H2SO4-HNO3 as above gave V. IV.HCl (11.3 g) in 250 ml MeOH was hydrogenated 1.5 hr at 29° and 4.3 atm in the presence of 0.3 g Pt oxide to give III.HCl (n = 3, R = Me2N, R1 = R2 = R3 = R4 = R6 = H, R5 = NH2), m. 222-4° (EtOH), which was converted into the base and treated with Ac2O and Et3N 2 days at room temperature to give III (n = 3, R = Me2N, R1 = R2 = R3 = R4 = R6 = H, R5 = NHAc) (VII), oil. VII and concentrated HNO3 kept 1 hr at 0° gave III (n = 3, R = Me2N, R1 = R2 = R3 = R4 = H, R5 = NHAc, R6 = NO2); HI salt m. 156-9° (MeOH-EtOH-Et2O). By similar methods were prepared VIII, HCl salt m. 239-41°, and 15 other III. CNBr (2.6 g) in 15 ml dry Et2O was added over 15 min to 5.6 g IV in 25 ml dry Et2O and the mixture stirred 4 hr at room temperature to give III [n = 3, R = Me(CN)N, R1 = R2 = R3 = R4 = R6 = H, R5 = NO2], m. 135-6° (CHCl3-hexane). This refluxed 4 hr with 4N HCl or heated 3 hr at 140-60° with polyphosphoric acid gave III (R1 = R2 = R3 = R4 = R6 = H, R = Me2NH, R5 = NO2). (IX) ClCO2Et (4.3 g) in 5 ml dry xylene was added over 10 min to 3.4 g IV in 20 ml dry xylene and the mixture refluxed 6 hr to give III [n = 3, R = EtO2CNMe, R1 = R2 = R3 = R4 = R6 = H, R5 = NO2], which (1.4 g) in 12 ml 48% HBr in AcOH was kept 3 days to give IX. The title compds. are local anesthetics and antidepressants, also showing antiinflammatory, antihistaminic, antiserotonin and anti-acetylcholine activity.

IT ~~16398-16-6P~~RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 16398-16-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-nitro- (8CI, 9CI) (CA INDEX NAME)

10/785,120



L10 ANSWER 112 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1969:491552 CAPLUS

DN 71:91552

TI 11-(1-Piperazinyl)dibenz[b,f][1,4]oxazepines and -thiazepines

IN McEvoy, Francis J.; Allen, George R., Jr.

PA American Cyanamid Co.

SO Ger. Offen., 28 pp. Addn. to Ger., Offen. 1670032

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 1802728		19690626	DE	
	FR 326			FR	
	US 3560622		19710000	US	
PRAI	US		19671013		

OS MARPAT 71:91552

GI For diagram(s), see printed CA Issue.

AB The title compds. (Ia and Ib) were prepared for use as tranquilizers and antidepressants. Thus, 29.8 g. (p-F3COC6H4NH2)2.H2SO4 in 300 ml. H2O and 33 ml. 98% H2SO4 treated dropwise within 15 min. at 0° with 7.6 g. NaNO2 in 75 ml. H2O, the solution stirred 40 min. gave F3COC6H4OH (I), an oil. I (11.6 g.) in 200 ml. Et2O treated 15 min. with 1 equivalent NaH in mineral oil, on ceasation of gas evolution the mixture refluxed 10 min., evaporated, and the residue dissolved in HCONMe2, added to 10.3 g. o-ClC6H4NO2 in 100 ml. HCONMe2, the solution refluxed 90 min. and worked up gave 2-RC6H4OC6H4OCF3-4 (II, R = NO2) (IIa), an oil. IIa in 200 ml. EtOH treated with H in the presence of 16 g. Raney Ni gave II (R = NH2) (III). III in 150 ml. C5H5N treated dropwise with 8.0 ml. ClCO2Ph, the mixture kept 18 hrs. at room temperature and worked up, the product in 150 ml. C6H6 treated 70 min. with 23 ml. 1-methylpiperazine gave 4-methyl-2'-(p-trifluoromethoxy)-1-piperazinecarboxanilide (IV), m. 98-100°, HCl salt m. 214-16°, IV.HCl (2.5 g.) refluxed 24 hrs. with 2.5 g. P2O5 in 5 ml. POCl3 treated with 6N HCl gave Ia (R = Me), m. 200-10°. Also prepared was 4-methyl-2'-(p-trifluoromethoxyphenylthio)-1-piperazinecarboxanilide-HCl, which on treatment with P2O5 in POCl3 gave Ib (R = Me). 2-(p-Trifluoromethoxyphenoxy)phenyl isocyanate, prepared by treatment of 2-(p-trifluoromethoxyphenoxy)aniline with COCl2 in o-Cl2C6H4, treated with AlCl3 gave 2-trifluormethoxy-10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepine (V), m. 172-5°. V treated with POCl3 gave 11-chloro-2-trifluoromethoxydibenz-[b,f][1,4]oxazepine, which on treatment with 1-methylpiperazine gave 11-(4-methyl-1-piperazinyl)-2-trifluoromethoxydibenz-[b,f][1,4]oxazepine, diHCl.2H2O m. 201-10°. Similarly were prepared Ib (R = H), Ia (R = HOCH2CH2), Ia (R = H). 2-p-Trifluoromethoxyphenoxy)carbanilate treated with 1-(2-hydroxyethyl)piperazine gave 4-(2-hydroxyethyl)-2'-(p-trifluoromethoxy)-1-piperazinecarboxanilide (VI), m. 76-8°, HCl salt m. 212-14°. VI.HCl treated with P2O5 in POCl3 gave Ia (R = HOCH2CH2), m. 245° (decomposition). Pharmaceutical formulations were given.


IT 23891-39-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 23891-39-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-(trifluoromethoxy)- (8CI) (CA  
INDEX NAME)

10/785,120





L10 ANSWER 113 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1969:481451 CAPLUS

DN 71:81451

TI 11-[Piperazinyl]dibenz[b,f][1,4]oxazepines and analogous thiazepine tranquilizers

IN Howell, Charles F.; Hardy, Robert A., Jr.; Quinones, Nicanor Q.

PA American Cyanamid Co.

SO U.S., 6 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3458516	A	19690729	US 1968-705900	19680216
PRAI	US 1968-705900	A	19680216		

GI For diagram(s), see printed CA Issue.

AB I, which are physiol. active on the central nervous system, were prepared for use as tranquilizers and hypnotics. Thus, 27.8 g. p-RC6H4OR1 (II, R = COMe, R1 = H), 31.5 g. o-ClC6H4NO2, 27.6 g. K2CO3 and 0.2 g. Zn precipitated Cu were refluxed in 200 ml. C6H6 4 hrs. to give II (R = COMe, R1 = o-C6H4NO2), m. 95-6°, which was reduced in EtOH in the presence of H and Pd to give II (R = COMe, R1 = o-C6H4NH2) (III)m. 70-1°. III (10 g.) in 100 ml. CHCl3 was mixed with 15 ml. ClCO2Et in 150 ml. Et2O at 0-15° and 15 ml. pyridine was added. The mixture was refluxed 2 hrs. to give II (R = COMe, R1 = o-C6H4NHCOEt), m. 56-8°, 26 g. of which was heated at 100° 3 days with 30 ml. N-methylpiperazine and a trace of NaOMe, refluxed 4 hrs. and concentrated to give

2'-(p-acetylphenoxy)-4-

methyl-1-piperazinylcarboxanilide, m. 131-4°. The hydrochloride of this product (10 g.) was refluxed 20 hrs. with 40 ml. POCl3 and 10 g. P2O5 and concentrated to give a 6 g. mixture of bases, separated by partition

chromatog. to

give I (R = Ac, R1 = Me, X = O), m. 116-18°. p-HOC6H4SO2Na.2H2O (56 g.) was refluxed 4 hrs. with 110 ml. Ac2O to give a solid which was treated with 200 ml. PhMe and 60 g. PCl5 and refluxed 1 hr. The mixture obtained was treated with 200 ml. CHCl3 and saturated at 0-10° with Me2NH for 4 hrs. Concentration of the filtered solution gave II (R = SO2NMe2,

R1 =

H) as an oil which was stirred with 40 g. K2CO3 in 200 ml. HCONMe2 at 10° for 2 hrs. and refluxed for 4 hrs. with 40 g. o-ClC6H4NO2 in the presence of Zn precipitated Cu to give II (R = SO2NMe2, R1 = o-C6H4NO2) (IIa), m. 111-12°. IIa (20 g.) was treated with 60 g. SnCl2 in 600 ml. Et2O and 20 ml. concentrated HCl was added at reflux to give II (R = SO2NMe2, R1 = o-C6H4NH2) (IIb), m. 152-5°. IIb was treated in the same way as III to give II (R = SO2NMe2, R1 = o-C6H4NHCOEt), m. 134-5°, 2'-(p-dimethylsulfamoylphenoxy)-4-methyl-1-piperazino-carboxanilide-HCl, m. 241-3°, and I (R = SO2NMe2, R1 = Me, X = O) with a maleate salt m. 142-5°. The following I were also prepared (R, R1, X, and m.p., given): ClC2H2, Me, O, 64-8°; SO2NMe2, H, S, 176-8°; SO2NMe2, H, O, 187-9°; SO2NMe2, Me, S, 162-5°; CO2Et, Me, O, 109-11°; NO2, Me, O, 189-91°; NH2, Me, O, 112-13°. Other intermediates prepared were (compound and m.p., given). 4-(N,N-dimethylsulfamoyl)diphenyl disulfide, 132-6°; 4-mercapto-N,N-dimethylbenzenesulfon-amide, 100-2°; o-(p-dimethylsulfamoylphenylthio)aniline, 120-2°; p-(o-aminophenylthio)acetophenone, 78-80°; 2'-(p-dimethylsulfamoylphenylthio)-4-methyl-1-piperazinocarboxanilide, 151-2°.


IT 16398-16-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

10/785,120

RN 16398-16-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-nitro- (8CI, 9CI) (CA INDEX NAME)



L10 ANSWER 114 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1969:450016 CAPLUS

DN 71:50016

TI Aminodibenz[b,f][1,4]oxazepin-11(10H)-ones

IN Schmidt, Guenther

PA Thomae, Dr. Karl, G.m.b.H.

SO S. African, 28 pp.

CODEN: SFXXAB

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	ZA 6804436		19681122		
	FR 1574968			FR	
	FR 7681			FR	
	GB 1164579			GB	
PRAI	DE		19670711		

OS MARPAT 71:50016

GI For diagram(s), see printed CA Issue.


AB The title compds. (I, R = NH<sub>2</sub>) useful as analgesics and sedatives, are prepared by reduction of the corresponding nitro compds. by a variety of methods. Thus, 2.8 g. 2-nitrodibenz[b,f][1,4]oxazepin-11(10H)-one (II) was suspended in 200 cc. of dioxane, mixed with 2 g. Raney Ni and hydrogenated at 50° and 31 atmospheric 2 hrs. to give I (R<sub>1</sub> = R<sub>2</sub> = H, R = 2-NH<sub>2</sub>), m. 200-2° (EtOH or 50% aqueous HCONMe<sub>2</sub>); HCl salt m. 320° (decomposition) (dilute HCl). Na<sub>2</sub>S<sub>2</sub>O<sub>6</sub>, Fe/HCl, N<sub>2</sub>H<sub>4</sub>.H<sub>2</sub>O/Raney Ni, Sn/HCl, PtO<sub>2</sub> and Pd/C were also used as catalysts. Hydrogenations of the nitro compds. were carried out to give the following I (R, R<sub>1</sub>, R<sub>2</sub>, and m.p. given): 3-NH<sub>2</sub>, H, H, 287-9°; H, H, 7-NH<sub>2</sub>, 268-71°; 2-NH<sub>2</sub>, Me, H, 133-6°; 2-NH<sub>2</sub>, Et, H, 165-6°; 2-NH<sub>2</sub>, H, 8-Me, 169-70° (HCl salt m. >300°); 2-NH<sub>2</sub>, Et, Me, 114-15° [HCl salt m. 248-50° (decomposition)]; 2-NH<sub>2</sub>, H, 8-Cl, 266-7°; 2-NH<sub>2</sub>, Et, 8-Cl, 166-7°; [HCl salt m. 255° (decomposition)]; 3-NH<sub>2</sub>, Me, H, 187-9°; H, Me, 7-NH<sub>2</sub>, 194-6°.

IT 23474-55-7P 23474-56-8P 23474-59-1P  
 23474-60-4P 23474-63-7P 23474-65-9P  
 23474-66-0P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)

RN 23474-55-7 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-chloro- (8CI, 9CI) (CA INDEX NAME)



RN 23474-56-8 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-chloro-, monohydrochloride (8CI) (CA INDEX NAME)

10/785,120




● HCl

RN 23474-59-1 CAPLUS  
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-methyl- (8CI, 9CI) (CA INDEX NAME)




RN 23474-60-4 CAPLUS  
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-methyl-, monohydrochloride (8CI) (CA INDEX NAME)




● HCl

RN 23474-63-7 CAPLUS  
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-amino- (8CI, 9CI) (CA INDEX NAME)



RN 23474-65-9 CAPLUS  
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-, monohydrochloride (8CI) (CA INDEX NAME)


10/785,120



● HCl

RN 23474-66-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino- (8CI, 9CI) (CA INDEX NAME)



L10 ANSWER 115 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1969:106484 CAPLUS

DN 70:106484

TI Seven-membered heterocycles. XII. Dibenzo[b,f]-1,4-oxazepin-11(10H)-ones and dibenzo[b,e]-1,4-oxazepin-11(5H)-ones

AU Kuenzle, F.; Schmutz, J.

CS Forschungsinst., Dr. A. Wander A.-G., Bern, Switz.

SO Helvetica Chimica Acta (1969), 52(3), 622-8

CODEN: HCACAV; ISSN: 0018-019X

DT Journal

LA German

OS CASREACT 70:106484

AB 2-(R-Substituted)-dibenz[b,f]-1,4-oxazepin-11-(10H)-ones (I) (where R = NO<sub>2</sub>, CN, SO<sub>2</sub>R<sub>1</sub>, or SO<sub>2</sub>NR<sub>21</sub>; and R<sub>1</sub> = Me or Et, or NR<sub>21</sub> = pyrrolidinyl) were prepared by cyclization of 3,6-RXC<sub>6</sub>H<sub>3</sub>CONHC<sub>6</sub>H<sub>4</sub>OH-o (II) (where X = Cl or Br). Cyclization of II (R = SO<sub>2</sub>NMe<sub>2</sub>) in N-methylpyrrolidinone also gave Smiles rearrangement to 2-(dimethylaminosulfonyl)dibenz-[b,e]-1,4-oxazepin-11(5H)-one, also obtained from 2,4-HO<sub>2</sub>C-RC<sub>6</sub>H<sub>3</sub>NHC<sub>6</sub>H<sub>4</sub>OH-o (III) (where R = SO<sub>2</sub>NMe<sub>2</sub>). Hydrolysis of II (where R = SO<sub>2</sub>Me) gave III (R = SO<sub>2</sub>Me<sub>2</sub>). Treatment of I (R = NO<sub>2</sub>) with dilute NaOH gave III (R = NO<sub>2</sub>).

IT 16398-16-6P 22361-74-6P 22361-75-7P


22361-76-8P 22361-77-9P 22361-78-0P

22361-79-1P 22362-39-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 16398-16-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-nitro- (8CI, 9CI) (CA INDEX NAME)




RN 22361-74-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-2-carbonitrile, 10,11-dihydro-11-oxo- (8CI) (CA INDEX NAME)




RN 22361-75-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-(methylsulfonyl)- (8CI) (CA INDEX NAME)




RN 22361-76-8 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-(ethylsulfonyl)- (8CI) (CA INDEX NAME)




RN 22361-77-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-2-sulfonamide, 10,11-dihydro-N,N-dimethyl-11-oxo- (8CI, 9CI) (CA INDEX NAME)




RN 22361-78-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-2-sulfonamide, N,N-diethyl-10,11-dihydro-11-oxo- (8CI) (CA INDEX NAME)



RN 22361-79-1 CAPLUS


CN Pyrrolidine, 1-[(10,11-dihydro-11-oxo-dibenz[b,f][1,4]oxazepin-2-yl)sulfonyl]- (8CI) (CA INDEX NAME)



10/785,120


RN 22362-39-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-(methylthio)- (8CI) (CA INDEX NAME)





L10 ANSWER 116 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1969:87772 CAPLUS  
DN 70:87772  
TI Cyclization reactions of methyl 2-chloro-3,5-dinitrobenzoate  
AU Gupta, Chhitar M.; Bhaduri, Amiya P.; Khanna, Nandoo M.  
CS Cent. Drug Res. Inst., Lucknow, India  
SO Indian Journal of Chemistry (1968), 6(12), 758-9  
CODEN: IJOCAP; ISSN: 0019-5103  
DT Journal  
LA English  
AB Reaction of Me 2-chloro-3,5-dinitrobenzoate with guanidine,  
2-aminopyridine, o-phenylenediamine and phenylhydrazine gives  
2-amino-6,8-dinitro-4(H)-quinazolinone, 1,3-dinitro-6a-pyrido[1,2-  
a]quinazolin-5-one, 2,4-dinitro-11-oxo-5H,10H-dibenzo[be]-1,4-diazepine  
and 5,7-dinitro-2-phenylindazolone, resp.  
IT **22177-14-6P**  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 22177-14-6 CAPLUS  
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2,4-dinitro- (8CI, 9CI)  
(CA INDEX NAME)



L10 ANSWER 117 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1969:57923 CAPLUS

DN 70:57923

TI 11-Tertiary-aminodibenz[b,f][1,4]oxazepines and thiazepines

IN Howell, Charles F.; Hardy, Robert A., Jr.; Quinones, Nicanor Q.

PA American Cyanamid Co.

SO Fr., 20 pp.

CODEN: FRXXAK

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 1508536		19680105	FR	
	DE 1645954			DE	
	FR 6274			FR	
	GB 1177956			GB	
	GB 1177957			GB	

PRAI US 19660117

OS MARPAT 70:57923

GI For diagram(s), see printed CA Issue.

AB Title products (I) (optional 10 → 11 unsatn.) with central nervous system activity are prepared. Thus, a solution of 7.9 g. carbonyldiimidazole in 80 cc. tetrahydrofuran is added to a mixture of 9 g. 2-chloro-5-(trifluoromethyl)benzoic acid and 10 cc. tetrahydrofuran, and the mixture is refluxed 30 min., treated with 4.36 g. o-aminophenol, refluxed 15 min., and evaporated to dryness to give 2-chloro-2'-hydroxy-5-(trifluoromethyl)benzanilide (II), m. 112-13°. A mixt of 6.4 g. PC15, 20 cc. benzene, and 6.5 g. II is refluxed 5 min., then a solution of 4 g. N-methylpiperazine in 40 cc. toluene is added, and the mixture is refluxed 1 hr. and treated to give 1-[1-(6-chloro- $\alpha,\alpha,\alpha$ -trifluoro-m-tolyl)-N-(o-hydroxyphenyl)-formimidoyl]-4-methylpiperazine, which (3.3 g.) is mixed with 1.1 g. K<sub>2</sub>CO<sub>3</sub>, 0.3 g. powdered Cu, and 8 cc. AcNMe<sub>2</sub>, and heated at 180° for 1 hr., cooled, mixed with 80 cc. water and 20 cc. ether, and filtered. The organic layer is evaporated to give 2-(trifluoromethyl)-11-(4-methyl-1-piperazinyl)dibenz[b, f][1, 4]oxazepine, m. 215-16°. A mixture of 2-chloro-2'-hydroxy-5-nitrobenzanilide, PC15, and anhydrous benzene is refluxed until a clear solution

is obtained, then N-methylpiperazine is added and the mixture refluxed to give 1-[1-(2-chloro-5-nitrophenyl)-N-(o-hydroxyphenyl)formimidoyl]-4-methylpiperazine, which is heated with anhydrous K<sub>2</sub>CO<sub>3</sub> and powdered Cu in AcNMe<sub>2</sub> to give 2-nitro-11-(4-methyl-1-piperazinyl)dibenzo[b, f][1, 4]oxazepine (III), m. 189-91°. A solution of 0.35 g. III in 10 cc. 0.3N HCl is hydrogenated over 3 mg. PtO<sub>2</sub> to give 2-amino-11-(4-methyl-1-piperazinyl)dibenz[b, f][1, 4]oxazepine, which in turn is diazotized with 52 mg. NaNO<sub>2</sub> and treated with 90 mg. Cu<sub>2</sub>Cl<sub>2</sub> to give 2-chloro-11-(4-methyl-1-piperazinyl)dibenz[b, f][1, 4]oxazepine, m. 108-11°. Similarly the following were prepared: 11-(4-methyl-1-piperazinyl)dibenz[b, f][1, 4]oxazepine, m. 97-8°; 2-fluoro-11-(4-methyl-1-piperazinyl)-dibenz[b, f][1, 4]oxazepine (fumarate m. 204-5°); 2-chloro-11-(4-methyl-1-piperazinyl)dibenzo[b, f][1, 4]thiazepine, m. 93°; 11-[N-methyl-2-(methylamino)ethylamino]dibenz[b, f][1, 4]oxazepine-2 HCl, m. 220-5°; 2-chlorodibenz[b, f][1, 4]oxazepin-11(10H)-one, m. 245-6°; 2-(trifluoromethyl)dibenz[b, f][1, 4]oxazepin-11(10H)-one, m. 213-14°; 2-nitrodibenz[b, f][1, 4]oxazepin-11(10H)-one, m. 260-2°; 11-aminodibenz[b, f][1, 4]oxazepine, m. 198-200° (HCl salt m. 239-41°); 11-(dimethylamino)dibenz[b, f][1, 4]oxazepine, m. 111-13°; 2-chloro-11-(dimethylamino)dibenz[b, f][1, 4]oxazepine, m. 234-6° (decomposition); 2-chloro-11-(1-

10/785,120


piperazinyl)dibenzo[b, f][1, 4]thiazepine, m. 127-33° (HCl salt m. 218°); 11-(1-piperazinyl)dibenz[b, f][1, 4]oxazepine, m. 116-17°; 2-chloro-11-(1-piperazinyl)dibenz[b, f][1, 4]oxazepine, m. 175-6°; 2-chloro-11 - [4 - (2 - hydroxyethyl) - 1 - piperazinyl]dibenz[b, f]-[1, 4]oxazepine(fumarate m. 201-4°).

IT **3158-91-6P 16398-16-6P 21636-22-6P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 3158-91-6 CAPLUS

CN Dibenz[b, f][1, 4]oxazepin-11(10H)-one, 2-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 16398-16-6 CAPLUS

CN Dibenz[b, f][1, 4]oxazepin-11(10H)-one, 2-nitro- (8CI, 9CI) (CA INDEX NAME)



RN 21636-22-6 CAPLUS

CN Dibenz[b, f][1, 4]oxazepin-11(10H)-one, 2-(trifluoromethyl)- (8CI) (CA INDEX NAME)



L10 ANSWER 118 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1968:506685 CAPLUS

DN 69:106685

TI New synthesis of dibenz[b,f][1,4]oxazepine, dibenzo[b,f][1,4]thiazepine, and dibenzo[b,e][1,4]diazepine derivatives

AU Nagarajan, K.; Kulkarni, C. L.; Venkateswarlu, A.

CS CIBA Res. Centre, Goregaon, India

SO Indian Journal of Chemistry (1968), 6(4), 225-6

CODEN: IJOCAP; ISSN: 0019-5103

DT Journal

LA English


AB Beckmann rearrangement of xanthone oxime (Graebe and Roder, 1899) in ether using  $\text{PCl}_5$  catalyst afforded 50% 10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepine (I), m.  $210-12^\circ$ , identical with a sample obtained by thermal lactamization of 2-amino-2'-carbethoxydiphenyl ether (CA 61:8326d). Similarly, thioxanthone oxime, m.  $192-3^\circ$ , gave on rearrangement 52% 10,11-dihydro-11-oxodibenzo[b,f][1,4]thiazepine, m.  $261-2^\circ$ , identical with a sample prepared by the alternative procedure. I was also prepared by refluxing N-(2-chlorobenzoyl)-2-hydroxyaniline (II), m.  $188-90^\circ$ , as its dry Na salt in  $\text{HCONMe}_2$  72 hrs. Ano. of analogs with other substituents in the nuclei were similarly synthesized. As expected, activation of the Cl atom by electron-withdrawing groups suitably situated in the aroyl part of II facilitated ring closure. An extension to N-( $\gamma$ -dimethylaminopropyl)-N-(2,5-dichlorobenzoyl)-2-hydroxyaniline, m.  $176-9^\circ$ , offered an efficient alternative synthesis of 80% 2-chloro-10,11-dihydro-10-( $\gamma$ -dimethylaminopropyl)-11-oxodibenz[b,f][1,4]oxazepine (III) of psychotropic interest (CA 62: 16283a). III was characterized as the HCl salt, m.  $191-3^\circ$ , identical with an authentic sample (CA 62: 16283a). N-(2-Chlorobenzoyl)-o-phenylenediamine as its N-p-tolylsulfonyl derivative could not be cyclized. However, N-(2-chloro-5-nitrobenzoyl)-N'-(p-tolylsulfonyl)-o-phenylenediamine, m.  $161-3^\circ$ , could be similarly treated to afford 60% 10,11-dihydro-2-nitro-11-oxo-5-(p-tolylsulfonyl)dibenzo[b,e][1,4]diazepine, m.  $252-5^\circ$ .

IT 20169-49-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 20169-49-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(4-methylphenyl)sulfonyl]-2-nitro- (9CI) (CA INDEX NAME)



L10 ANSWER 119 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1968:427464 CAPLUS

DN 69:27464

TI Preparation of dibenzo[b,f][1,4]thiazepines and dibenz[b,f][1,4]oxazepines

IN Schmutz, Jean; Hunziker, Fritz; Schindler, Othmar; Kuenzle, Franz M.

PA Dr. A. Wander, A.-G.

SO U.S., 4 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3367930	A	19680206	US 1964-399096	19640924
PRAI	US 1964-399096	A	19640924		

GI For diagram(s), see printed CA Issue.

AB I, in which X is O, S, CH<sub>2</sub>, or C<sub>2</sub>H<sub>4</sub>, were prepared by cyclization of the corresponding isocyanate. Thus, 98 g. AlCl<sub>3</sub> in 900 ml. o-Cl<sub>2</sub>C<sub>6</sub>H<sub>4</sub> at 90-100° was mixed with 183.2 g. 2-isocyanato-4'-chlorodiphenyl sulfide, prepared by the reaction of 2-amino-4'-chlorodiphenyl sulfide with COCl<sub>2</sub>, in 600 ml. o-Cl<sub>2</sub>C<sub>6</sub>H<sub>4</sub> added dropwise and the mixture was heated to 150° in 1 hr., poured over ice, and steamed-distilled. The residue after filtration was boiled with 700 ml. Me<sub>2</sub>CO to give I (R = 4-Cl, R<sub>1</sub> = R<sub>2</sub> = H, X = S), m. 260-2°. Other I were prepared similarly (R, R<sub>1</sub>, R<sub>2</sub>, X, and m.p. given): H, H, H, O, 215-17°; 1-Cl, H, H, O, 251-5°; H, H, H, S, 259-60°; 2-F, H, H, S, 257-8°; 2-Br, H, H, S, 270-1°; 2-Me, H, H, S, 239-40°; 2-tert-Bu, H, H, S, 239-42°; 4-Me, H, H, S, 253-4°; H, H, 8-Cl, S, 302-3°; 1-Me, H, H, O, 229-31°; 3-Me, H, H, O, 218-19°; 2-Cl, H, H, O, 244-5°; 2-Me, H, H, O, 193-6°; 4-Cl, H, H, O, 256-9°; 4-Me, H, H, O, 192-4°; H, H, 7-Cl, O, 295°; H, H, 8-Cl, O, 258-61°; H, 2-Cl, 8-Cl, O, 293-4°; H, H, 6-Cl, O, 284-5°; 2-F, H, H, O, 245-6°; 2-Br, H, H, O, 240-1°; 1-Me, 4-Me, H, O, 251-3°; 3-Me, 4-Me, H, O, 213-14°; H, H, H, CH<sub>2</sub>, 201-3°; H, H, H, CHMe, 203-6°; 2-OMe, H, H, S, 128-9°; 4-Cl, H, H, S, 271-3°; H, H, 8-OMe, S, 221-3°; H, H, 8-OH, S, 298-300°; 4-Cl, H, 8-Cl, S, 287-8°; 1-Cl, 4-Me, H, S, 319-21°; H, 4-Me, 7-Cl, S, 318-21°; H, 4-Me, 8-Cl, S, 298-300°; 3-Cl, H, H, O, 266-7°; 4-Et, H, H, O, 153-4°; 1-Cl, 4-Cl, H, O, 221-2°; 2-Cl, 4-Cl, H, O, 260-4°; H, 4-Cl, 8-Cl, O, 296-7°; 1-Cl, 4-Me, H, O, 258-9°; H, 4-Me, 7-Cl, O, 310-11°; H, 4-Me, 8-Cl, O, 259°; 2-Cl, H, H, CH<sub>2</sub>, 261-2°; H, H, 8-Cl, CH<sub>2</sub>, 239-40°. Also prepared similarly were 3-chloro-5,6-dihydro-6-oxo-11H-dibenz[b,e]azepine, m. 273-5°, and 5,6,11,12-tetrahydro-6-oxodibenz[b,f]azocine, m. 240-3°.

IT 3158-86-9P 3158-88-1P 3158-90-5P

3158-91-6P 3158-92-7P 3158-93-8P

3158-94-9P 3158-95-0P 3158-96-1P

3950-69-4P 3950-70-7P 3950-71-8P

3950-72-9P 3950-73-0P 3950-74-1P

3950-75-2P 3950-76-3P 3950-77-4P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

RN 3158-86-9 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-methyl- (7CI, 8CI) (CA INDEX NAME)

10/785,120




RN 3158-88-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 3158-90-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-fluoro- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 3158-91-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 3158-92-7 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-bromo- (7CI, 8CI) (CA INDEX NAME)



RN 3158-93-8 CAPLUS


10/785,120

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-methyl- (7CI, 8CI) (CA INDEX NAME)




RN 3158-94-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 3158-95-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-methyl- (7CI, 8CI) (CA INDEX NAME)



RN 3158-96-1 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-ethyl- (7CI, 8CI) (CA INDEX NAME)




RN 3950-69-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,4-dichloro- (7CI, 8CI) (CA INDEX NAME)


10/785,120




RN 3950-70-7 CAPLUS  
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,4-dichloro- (7CI, 8CI) (CA INDEX NAME)



RN 3950-71-8 CAPLUS  
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,8-dichloro- (7CI, 8CI) (CA INDEX NAME)




RN 3950-72-9 CAPLUS  
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4,8-dichloro- (7CI, 8CI) (CA INDEX NAME)



RN 3950-73-0 CAPLUS  
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,4-dimethyl- (7CI, 8CI) (CA INDEX NAME)




10/785,120




RN 3950-74-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3,4-dimethyl- (7CI, 8CI) (CA INDEX NAME)




RN 3950-75-2 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1-chloro-4-methyl- (7CI, 8CI) (CA INDEX NAME)



RN 3950-76-3 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 7-chloro-4-methyl- (7CI, 8CI) (CA INDEX NAME)



RN 3950-77-4 CAPLUS

10/785,120

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8-chloro-4-methyl- (7CI, 8CI) (CA  
INDEX NAME)



L10 ANSWER 120 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1968:95871 CAPLUS

DN 68:95871

TI 10-( $\omega$ -Diethylaminoalkyl)-2,4-dichlorodibenz[b,f][1,4]oxazepin-11(10H)-ones

PA Societe d'Etudes Scientifiques et Industrielles de l'Ile-de-France

SO Fr. M., 6 pp.

CODEN: FMXXAJ

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR M4500		19661114	FR	19650715

OS MARPAT 68:95871

GI For diagram(s), see printed CA Issue.


AB Compds. of the general formula I are prepared and tests on rats and mice show that they have anticonvulsive properties. Thus, a mixture of 23 g. Na in 400 ml. alc., 177 g. 2,4,6-MeCl<sub>2</sub>C<sub>6</sub>H<sub>2</sub>OH, 500 ml. HCONMe<sub>2</sub>, and 158 g. o-ClC<sub>6</sub>H<sub>4</sub>NO<sub>2</sub> is refluxed 12-13 hrs. to give 78% 2-(o-nitrophenoxy)-3,5-dichlorotoluene (II), m. 100°. A solution is prepared from 52 g. II, 160 ml. HOAc, and 17 ml. water, treated with a mixture of 68 g. CrO<sub>3</sub>, 136 ml. water, 290 ml. HOAc, and 107 g. 93% H<sub>2</sub>SO<sub>4</sub>, and refluxed 5.5 hrs. to give 2-(o-nitrophenoxy)-3,5-dichlorobenzoic acid (III), m. 175-6°. A mixture of 94 g. III, 290 ml. water, 30 ml. 30% MeOH, and 156 g. Na<sub>2</sub>S<sub>2</sub>O<sub>4</sub> is refluxed 2 hrs. to give 2-(o-aminophenoxy)-3,5-dichlorobenzoic acid (IV), m. 190-1°. A mixture of 31 g. IV and 460 ml. xylene is refluxed 7 hrs. to give 93% 2,4-dichlorodibenz[b,f][1,4]oxazepin-11(10H)-one (V), m. 261-2°. V (39 g.) is added to a solution of 3.5 g. Na in 70 ml. alc., the mixture refluxed 10 min., the alc. distilled, the mixture collected, the precipitate dissolved in 350 ml. PhMe, and the solution cooled, treated with 22 g. Et<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>Cl, refluxed 8 hrs., cooled, and treated with concentrated HCl to give 94% 10-(3-diethylaminoethyl)-2,4-dichlorodibenzo[b,f][1,4]oxazepin-11(10H)-one-HCl, m. 146-7°. Similarly prepared is I (n = 3).HCl, m. 170°.

IT 3950-70-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 3950-70-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,4-dichloro- (7CI, 8CI) (CA INDEX NAME)



10/785,120

L10 ANSWER 121 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1967:502756 CAPLUS

DN 67:102756

TI Aminoalkyldibenzodiazepines

IN Hanze, Arthur R.

PA Upjohn Co.

SO Fr. M., 3 pp.

CODEN: FMXXAJ

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR M3747		19660117	FR	
PRAI	US		19620828		

OS MARPAT 67:102756

GI For diagram(s), see printed CA Issue.


AB Oral and parenteral combinations with the usual vehicles are described containing title compds. (I) where R1 and R2 are H or lower alkyl or together with -N = form a saturated heterocyclic amino group containing 5-7 atoms in the ring, e.g. pyrrolidino, morpholino or thiomorpholino. Y is H or Cl or F or lower alkyl or alkoxy or CF3. Examples of I are 5-(2-diethylaminoethyl)-[5H]-dibenzo[b,e][1,4]diazepin-11(10H)-one, m. 132.5-3.5°; and its analogs: 3-dimethylaminopropyl, m. 147.5-49°, 3-diethylaminopropyl, m. 115.5-17°, 3-methylaminopropyl, m. 146.5-47.5°, 3-dimethylaminopropyl-3-chloro, m. 145.5-6.5°. These and their acid addition salts are useful as tranquilizing, hypotensive, and antihistaminic agents and inhibitors of pseudocholinesterase.

IT 18277-21-9

RL: BIOL (Biological study)  
(pharmaceutical preps. containing)

RN 18277-21-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5-[3-(dimethylamino)propyl]-5,10-dihydro- (8CI) (CA INDEX NAME)



L10 ANSWER 122 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1967:490856 CAPLUS  
 DN 67:90856  
 TI 10-Aminoalkyl 10,11-dihydrodibenzo[b,f][1,4]oxazepines  
 PA CIBA Ltd.  
 SO Neth. Appl., 43 pp.  
 CODEN: NAXXAN  
 DT Patent  
 LA Dutch  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	NL 6608671		19661227	NL	
PRAI	CH		19650623		
	CH		19660404		

GI For diagram(s), see printed CA Issue.

AB The title compds. (I), wherein at least one of the benzo-moieties is substituted by a NO<sub>2</sub> group, especially I (R<sub>1</sub> = 2-NO<sub>2</sub>, R<sub>2</sub> = H, A = (CH<sub>2</sub>)<sub>3</sub>, Am = NMe<sub>2</sub>, X = O) (Ia), are prepared and have antidepressive properties. They reverse the reserpine-induced hyperthermia and ptosis and (or) potentiate the activity of 3,4-dihydroxyphenylalanine in mice, which are treated with a monoamine oxidase inhibitor. II are prepared via III. Thus, a solution of 6.6 g. 2-chloro-5-nitrobenzoyl chloride in 50 ml. Et<sub>2</sub>O is added over 1 hr. at 0° to a stirred mixture of 5.2 g. o-aminophenol in 50 ml. Et<sub>2</sub>O. After stirring the mixture a few hrs. a 1st crop of III (R<sub>1</sub> = 3-NO<sub>2</sub>, R<sub>2</sub> = H) (IIIa), m. 189-91° (H<sub>2</sub>O-MeOH) is obtained. Work up of the ethereal layer of the filtrate by washing with dilute HCl and H<sub>2</sub>O, followed by evaporation, yields a 2nd crop IIIa. Similarly, the following III are prepared (R<sub>1</sub>, R<sub>2</sub>, and m.p. given) 5-NO<sub>2</sub>, 5-Cl, 221-2°; 5-NO<sub>2</sub>, 5-Me, 200°; 5-NO<sub>2</sub>, 5-NO<sub>2</sub>, 239-44° (IIIb); 5-NO<sub>2</sub>, 4-NO<sub>2</sub>, 201-4°; 5-NO<sub>2</sub>, 5-Ac, 230-1°; 5-NO<sub>2</sub>, 3,5,6-Cl<sub>3</sub>, 199-202°; 4-NO<sub>2</sub>, H, 199°; 5-NO<sub>2</sub>, 4-MeO, 195-7°. A solution of 4.5 g. IIIa and 0.8 g. NaOH in 150 ml. H<sub>2</sub>O is heated 16 hrs. at 100° to yield II (X = O, R<sub>1</sub> = 2-NO<sub>2</sub>, R<sub>2</sub> = H) (IIa), m. 258-60° (Me<sub>2</sub>CO-MeOH). In an alternative method, a solution of 20 g. IIIb in 60 ml. N aqueous NaOH is evaporated to dryness by azeotropic distillation with

C<sub>6</sub>H<sub>6</sub>. The residue is dissolved in 150 ml. HCONMe<sub>2</sub> (DMF), refluxed 2 hrs., and diluted with H<sub>2</sub>O to give II (X = O, R<sub>1</sub> = 2-NO<sub>2</sub>, R<sub>2</sub> = 8-NO<sub>2</sub>), m. > 330° (H<sub>2</sub>O-EtOH). The following II (X = O) are prepared by similar methods (R<sub>1</sub>, R<sub>2</sub>, m.p., and reaction medium given): 2-NO<sub>2</sub>, 8-Cl, >320°, H<sub>2</sub>O; 2-NO<sub>2</sub>, 8-Me, 326-7°, H<sub>2</sub>O; 2-NO<sub>2</sub>, 7-NO<sub>2</sub>, 285-90°, DMF; 2-NO<sub>2</sub>, 8-Ac >330°, DMF; 2-NO<sub>2</sub>, 3,5,6-Cl<sub>3</sub>, 320-2°, DMF; 3-NO<sub>2</sub>, H, 295-7°, DMF; 2-NO<sub>2</sub>, 7-MeO, 292-4°, DMF. The preparation of IIa by 2 other methods is also given. Thus, a mixture of 8.5 g. 2-nitroxanthone and 13.8 g. NH<sub>2</sub>OH.HCl in 150 ml. C<sub>5</sub>H<sub>5</sub>N is refluxed 75 hrs. The solvent is distilled and the residue is washed repeatedly with cold H<sub>2</sub>O, dilute HCl, H<sub>2</sub>O and a small amount of CHCl<sub>3</sub> to yield 9-hydroximino-2-nitroxanthone, m. 210-11° (CHCl<sub>3</sub>), 1 g. of which with 5 g. PCl<sub>5</sub> in 150 ml. anhydrous Et<sub>2</sub>O is stirred several days. After adding H<sub>2</sub>O, the organic layer is evaporated and the residue is washed with dilute

NaOH and with H<sub>2</sub>O to yield IIa, m. 245-50° (Me<sub>2</sub>CO-MeOH). Further, a solution of 1.25 g. 2-isocyanato-4'-nitrodiphenyl ether in 5 ml. o-dichlorobenzene (DCB) is added over 10 min. at 100° to a suspension of 0.7 g. anhydrous AlCl<sub>3</sub> in 10 ml. DCB. The mixture is heated slowly to 150° and kept at this temperature for 1 hr. After cooling the mixture is decomposed by addition of ice-cold dilute HCl and extracted with CHCl<sub>3</sub> to

yield IIa, m. 260-1.5° (Me<sub>2</sub>CO-MeOH). On treating 5 g. IIa with an ice-cold solution of 50 ml. concentrated HNO<sub>3</sub> in 50 ml. H<sub>2</sub>SO<sub>4</sub> and heating the mixture

at 60-70°, a dark yellow clear solution is obtained which is poured into excess H<sub>2</sub>O to yield II [X = O, R<sub>1</sub> = R<sub>2</sub> = (presumably) 2,7,9-(NO<sub>2</sub>)<sub>3</sub>], m. 232-5° (Me<sub>2</sub>CO-MeOH). Portionwise addition of 1 g. II (X = O, R<sub>1</sub> = R<sub>2</sub> = H) over 10 min. at 60° to 10 ml. concentrated HNO<sub>3</sub> gives a clear solution which after 5 min. becomes cloudy. After stirring the mixture 1 hr. at 60° and 30 min. at room temperature, it is diluted with 25 ml. ice-water to yield II (X = O, R<sub>1</sub> = H, R<sub>2</sub> = H, R<sub>2</sub> = 7-NO<sub>2</sub>), m. 315-18° (DMF-EtOH). A mixture of 9.3 g. 2-chloro-5-nitrobenzaldehyde, 5.2 g. o-aminophenol, and 75 ml. anhydrous EtOH is refluxed 6 hrs. and worked up to yield N-(2-chloro-5-nitrobenzylidene)-2-hydroxyaniline, m. 161-3° (EtOH). To a suspension of this product in 5 ml. 2-3N aqueous NaOH is added 10 ml. EtOH and the mixture is heated until a clear solution is obtained. After evaporating the mixture to dryness, the residue in 100 ml. DMF is refluxed 5 min. and extracted with 150 ml. Et<sub>2</sub>O. The extract is washed successively with H<sub>2</sub>O, 15 ml. 10% aqueous NaOH, and H<sub>2</sub>O, to yield 2-nitrodibenzo[b,f][1,4]oxazepine (IIb), m. 155° (Et<sub>2</sub>O-hexane). IIb (2.2 g.) in 10 ml. dioxane and 15 ml. MeOH is reduced by portionwise addition of 0.5 g. NaBH<sub>4</sub> to yield II (X = H<sub>2</sub>, R<sub>1</sub> = 2-NO<sub>2</sub>, R<sub>2</sub> = H) m. 140-1° (Et<sub>2</sub>O-hexane). A mixture of 3 g. IIa, 4.7 g. Cl(CH<sub>2</sub>)<sub>3</sub>NMe<sub>2</sub>.HCl and 1.8 g. NaOH in 18 ml. H<sub>2</sub>O and 30 ml. Me<sub>2</sub>CO is refluxed 5 hrs. After distilling the organic solvent in vacuo, the residue is diluted with H<sub>2</sub>O to yield the free base of Ia, which is extracted with Et<sub>2</sub>O. [TABLE OMITTED] The extract is washed with H<sub>2</sub>O and treated with concentrated HCl, to yield the hydrochloride of Ia, m. 223-6° (anhydrous EtOH). Other I (X = O) prepared by similar methods are given in the table (\* = piperidinoethyl). In another method, 14 g. 3-bromopropanol, 10.3 g. IIa, and 21 g. anhydrous K<sub>2</sub>CO<sub>3</sub> in 350 ml. hot Me<sub>2</sub>CO is refluxed 4 hrs., the inorg. salts are filtered off, and the filtrate is evaporated. The residue is taken up in 50 ml. cold Et<sub>2</sub>O and filtered. The solvent and unreacted 3-bromopropanol is distilled at 50-60°/3 mm. to yield crude IV (Z = OH) as an oily residue. This is dissolved in 100 ml. C<sub>6</sub>H<sub>6</sub>, 20 ml. SOCl<sub>2</sub> is added while cooling, and the solution is refluxed 3 hrs. to yield IV (Z = Cl) (IVa), m. 105-7°. Reaction of IVa with HNMe<sub>2</sub> in a closed vessel, followed by the usual work up yields the HCl salt of Ia, m. 215-17°. A solution of 2.6 g. BrCN in 15 ml. anhydrous Et<sub>2</sub>O is added dropwise over 15 min. to a solution of 5.6 g. Ia in 25 ml. Et<sub>2</sub>O. After stirring the mixture 4 hrs. at room temperature, 25 ml. H<sub>2</sub>O is added to yield IV (Z = NMeCN) (IVb), m. 135-6° (CHCl<sub>3</sub>-hexane). Work up of the organic layer of the filtrate gives a 2nd crop of IVb. A suspension of 3 g. IVb in 75 ml. 4N HCl is refluxed 4 hrs. After cooling, the mixture is extracted with Et<sub>2</sub>O, and the aqueous layer is alkalinized by addition of liquid NH<sub>3</sub> (sic) and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The extract is concentrated and saturated with gaseous HCl to give the HCl salt of I (X = O, R<sub>1</sub> = 2-NO<sub>2</sub>, R<sub>2</sub> = H, A = (CH<sub>2</sub>)<sub>3</sub>, Am = NHMe) (Ib), m. 215-17° (EtOH/Et<sub>2</sub>O). Ib is obtained by heating a mixture of 2 g. IVb and 25 g. polyphosphoric acid, first for 30 min. at 140° and then 3 hrs. at 160° and working up the mixture by usual methods. A solution of 4.3 g. ClCO<sub>2</sub>Et in 4 ml. anhydrous xylene is added over 10 min. to a solution of 3.4 g. Ia in 20 ml. anhydrous xylene and the mixture is refluxed 6 hrs. After cooling the mixture is divided between 50 ml. Et<sub>2</sub>O and 50 ml. dilute HCl and the organic solution is worked up to yield crude IV (Z = NMeCO<sub>2</sub>Et) (IVc). A mixture of 1.4 g. IVc and 12 ml. 48% HBr in AcOH is kept 3 days at room temperature, 100 ml. Et<sub>2</sub>O is added. After cooling, the supernatant is decanted and the residue is treated with 100 ml. H<sub>2</sub>O and


filtered. Work up of the filtrate yields Ib. Finally a hot solution of 5.1 g. IIa in 125 ml. anhydrous dioxane is added to a suspension of 1 g. NaNH<sub>2</sub> in the same solvent, after 30 min. followed by 3.4 g. N-formyl-N-methylaminopropyl chloride. The mixture is refluxed 6 hrs. to yield crude IV (Z = NMeCHO), a dark oil, which on hydrolysis with 30 ml. 6N HCl in 70 ml. EtOH yields Ib.

IT 16398-16-6P 16398-17-7P 16398-18-8P  
16398-19-9P 16398-20-2P 16398-21-3P  
16398-22-4P 16398-23-5P 16398-24-6P  
16398-26-8P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 16398-16-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-nitro- (8CI, 9CI) (CA INDEX NAME)




RN 16398-17-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,8-dinitro- (8CI, 9CI) (CA INDEX NAME)



RN 16398-18-8 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8-chloro-2-nitro- (8CI, 9CI) (CA INDEX NAME)




RN 16398-19-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8-methyl-2-nitro- (8CI, 9CI) (CA INDEX NAME)


10/785,120




RN 16398-20-2 CAPLUS  
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,7-dinitro- (8CI, 9CI) (CA INDEX NAME)




RN 16398-21-3 CAPLUS  
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8-acetyl-2-nitro- (8CI, 9CI) (CA INDEX NAME)



RN 16398-22-4 CAPLUS  
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 6,8,9-trichloro-2-nitro- (8CI, 9CI) (CA INDEX NAME)



RN 16398-23-5 CAPLUS  
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-nitro- (8CI, 9CI) (CA INDEX NAME)






10/785,120


RN 16398-24-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 7-methoxy-2-nitro- (8CI, 9CI) (CA INDEX NAME)



RN 16398-26-8 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,7,9-trinitro- (8CI, 9CI) (CA INDEX NAME)



L10 ANSWER 123 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1967:402582 CAPLUS

DN 67:2582

TI Oximes of 2- and 4-phenylxanthenes and their Beckmann rearrangement

AU Troshchenko, A. T.; Lobanova, T. P.

CS Novosibirsk. Inst. Org. Khim., Novosibirsk, USSR

SO Zhurnal Organicheskoi Khimii (1967), 3(3), 501-3

CODEN: ZORKAE; ISSN: 0514-7492

DT Journal

LA Russian


GI For diagram(s), see printed CA Issue.

AB A mixture of 5 g. 4-phenylxanthone (I), 18 g.  $\text{NH}_2\text{OH}\cdot\text{HCl}$ , and 50 ml. anhydrous pyridine was boiled 25 hrs. Pyridine was partially evaporated and the product crystallized from MeOH and  $\text{C}_6\text{H}_6$  to yield 85% 4-phenylxanthone oxime (II), m.  $159-60^\circ$ , which heated with dilute HCl gave I, m.  $143-5^\circ$ . In the same way 2-phenylxanthone oxime (III), m.  $131-2^\circ$  (benzene), was prepared in 86% yield. Heating 0.1 g. II in 5 g. polyphosphoric acid 1 hr. at  $150-60^\circ$ , followed by precipitation with water and recrystn. gave 60% yield of 2-(2-aminophenoxy)biphenyl-3-carboxylic acid lactam, m.  $174-6^\circ$  (alc.), which on ammonolysis with alc.  $\text{NH}_4\text{OH}$  solution in a sealed tube at  $210-30^\circ$  14 hrs. gave 80% yield of o-aminophenol, m.  $173-4^\circ$ , and 81% yield of 2-amino-3-phenylbenzoic acid (IV), m.  $209-12^\circ$  (alc.). Last reaction proved anti-configuration of II. Diazotization of IV followed by heating with 60%  $\text{H}_2\text{SO}_4$  gave 2-hydroxy-3-phenylbenzoic acid, m.  $178-9^\circ$ . Heating II in polyphosphoric acid gave only II and no Beckmann rearrangement product.

IT **16190-72-0P**RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 16190-72-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-phenyl- (8CI) (CA INDEX NAME)



L10 ANSWER 124 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1967:94957 CAPLUS

DN 66:94957

TI Heterocycles with 7-membered rings. IX. 11- Amino substituted dibenzo[b,f]-1,4-thiazepines and -oxazepines

AU Schmutz, Jean; Kuenzle, G.; Hunziker, Fritz; Gauch, R.

CS Forschungsinst. Dr. A. Wander A.-G., Bern, Switz.

SO Helvetica Chimica Acta (1967), 50(1), 245-54

CODEN: HCACAV; ISSN: 0018-019X

DT Journal

LA German

OS CASREACT 66:94957

GI For diagram(s), see printed CA Issue.

AB cf. CA 65, 13654g; 64, 8182g. (o-NH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>)<sub>2</sub>S (40 g.) in 150 ml. PhMe was added to 170 ml. 20% COCl<sub>2</sub> in PhMe and heated to give clear solution. The excess COCl<sub>2</sub> was removed by passing N and PhMe was evaporated to give 42.2 g. (o-OCNC<sub>6</sub>H<sub>4</sub>)<sub>2</sub>S, b<sub>0.07</sub> 125-30°. 2-Isocyanato-4'-methoxydiphenyl sulfide, b<sub>0.07</sub> 155-60°, and 2-isocyanato-4'-methoxydiphenyl ether, m. 43-5°, were similarly prepared. o-OCNC<sub>6</sub>H<sub>4</sub>SC<sub>6</sub>H<sub>4</sub>OMe-p (28 g.) in 100 ml. benzene was added to 28 g. N-methylpiperazine in 100 ml. benzene dropwise and refluxed for 2 hrs. to give 4-methyl-1-piperazinocarboxy[2-(4-methoxyphenylthio)anilide], m. 83-4°. 1-Piperidinocarboxy(2-phenylthioanilide) (I), m. 84-5°, 1-piperidinocarboxy(2-phenoxyanilide), m. 49-50°, 4-methyl-1-piperazinocarboxy(2-phenoxyanilide), m. 65-8°, and 4-methyl-1-piperazinocarboxy[2-(4-methoxyphenoxy)anilide], m. 78-9°, were similarly prepared. I (7 g.) and 40 ml. POCl<sub>3</sub> were refluxed for 14 hrs., treated with ice-water and concentrated NH<sub>4</sub>OH after removal of excess POCl<sub>3</sub> and extracted with ether. The ether phase was extracted with dilute HCl and basified with concentrated NH<sub>4</sub>OH. The

base was taken up with ether to give 11-(1-piperidinyl)dibenzo[b,f]-1,4-thiazepine (II), m. 133-4°. 11-(1-Piperidinyl)dibenzo[b,f]-1,4-oxazepine, m. 90-2°, was similarly prepared. Similarly prepared were dibenzo[b,f]-1,4-thiazepines (III, X = S); 11-amino, m. 176-7°; 11-(β-dimethylaminoethyl)amino, m. 96-7°; 11-(β-dimethylaminoethyl)methylamino, m. 89-90°; 11-(γ-dimethylaminopropyl)amino, m. 124-6°; 11-(γ-dimethylaminopropyl)methylamino, m. 69-70°; 11-(N-methylpiperazino), m. 102-3°; 11-(N-methylpiperazino), 2-fluoro, m. 80-4°; 11-piperazino, 2-chloro, m. 132-4°; 11-(N-methylpiperazino), 2-chloro, m. 121-3°; 11-[N-(β-hydroxyethyl)piperazino], 2-chloro, m. 194-200° (decomposition) (2HCl); 11-[N-(β-methoxyethyl)piperazino], 2-chloro, m. 215-25° (decomposition) (2HCl); 11-(N-methylpiperazino), 2-bromo, m. 137-8°; 11-(N-methylpiperazino), 2-methyl, m. 99-107°; 11-(N-methylpiperazino), 2-methoxy, m. 213-49° (decomposition) (2HCl); 11-(N-methylpiperazino), 3-chloro, m. 205° (decomposition) (HCl); 11-(N-methylpiperazino), 4-chloro, m. 130-1°; 11-(N-methylpiperazino), 6-chloro, m. 83-8°; 11-(N-methylpiperazino), 7-chloro, m. 137-9°; 11-(N-methylpiperazino), 8-chloro, m. 166-7°. Similarly prepared were dibenzo[b,f]-1,4-oxazepines (III, X = O): 11-(β-dimethylaminoethyl)amino, m. 88-9°; 11-(γ-dimethylaminoethyl)amino, m. 108-9°; 11-piperazino, 2-chloro, m. 178-80°, 11-[N-(β-hydroxyethyl)piperazino], 2-chloro, m. 197-237° (decomposition) (2HCl); 11-(N-methylpiperazino), m. 96-8°; 11-(N-methylpiperazino), 2-fluoro, m. 81-6°; 11-(N-methylpiperazino), 2-chloro, m. 108-10°; 11-(N-methylpiperazino), 2-bromo, m. 95-9°; 11-(N-methylpiperazino), 2-methyl, m. 130-1°; 11-(N-methylpiperazino), 2-methoxy, m. 107-8°; 11-(N-methylpiperazino), 3-chloro, m. 122-4°; 11-(N-methylpiperazino), 4-chloro, m. 173-4°; 11-(N-


methylnpiperazino), 6-chloro, m. 84-7°; 11-(N-methylnpiperazino), 7-chloro, m. 147-8°; 11-(N-methylnpiperazino), 8-chloro, m. 105-6°. 2-Chloro-10,11-dihydro-11-oxodibenzo[b,f]-1,4-thiazepine (22 g.) in 400 ml. AcOH at 80° was treated with 33.6 ml. 30% H<sub>2</sub>O<sub>2</sub> for 2 hrs., and refluxed for 1.5 hrs. to give 2-chloro-10,11-dihydro-11-oxodibenzo[b,f]-1,4-thiazepine 5,5-dioxide (IV), m. 270-1°. 10,11-Dihydro-11-oxodibenzo[b,f]-1,4-thiazepine (50 g.) with 400 ml. POCl<sub>3</sub> and 15 ml. PhNMe<sub>2</sub> was refluxed for 5 hrs., and ether extraction gave 49 g. 11-chlorodibenzo[b,f]-1,4-thiazepine (V), m. 110-11°. Similarly prepared were V derivs.: 2-fluoro, m. 71-2°, 2-chloro, m. 132-4°; 2-bromo, m. 141-2°; 2-methyl, m. 124-6°; 4-chloro, m. 117-21°; 6-chloro, m. 144-7°; 8-chloro, m. 118-19°. Similarly prepared were 11-chlorodibenzo[b,f]-1,4-oxazepines: 2-fluoro, m. 94-6°; 2-chloro, m. 131-4°; 2-bromo, m. 143-6°; 2-methyl, m. 57-9°; 3-chloro, m. 111-13°; 4-chloro, m. 95-6°; 6-chloro, m. 115-16°; 7-chloro, m. 147-9°. V (4.9 g.) in 50 ml. xylene was refluxed with 3.4 g. piperidine for 5 hrs. and extracted with dilute HCl after removal of piperidine-HCl. Basification with NH<sub>4</sub>OH and ether extraction gave 4.8 g. II. IV (11.3 g.) with 39 ml. PhNMe<sub>2</sub> and 90 ml. POCl<sub>3</sub> was refluxed for 4 hrs., evaporated in vacuo, dissolved in xylene and treated with ice-water. Organic phase was concentrated to 200 ml. solution in vacuo and refluxed with 15 ml. N-methylnpiperazine for 5 hrs., washed with NaOH, water and dilute HCl, and basified with NH<sub>4</sub>OH to give 7.5 g. 2-chloro-11-(4-methyl-1-piperazinyl)dibenzo[b,f]-1,4-thiazepine 5,5-dioxide (VI), m. 155-6°. Similarly prepared was 2-chloro-11-(1-piperazinyl)dibenzo[b,f]-1,4-thiazepine 5,5-dioxide, m. 189-91° (decomposition). Hydrolysis of 2 g. 2-chloro-11-(4-methyl-1-piperazinyl)dibenzo[b,f]-1,4-oxazepine by heating with 100 ml. 2N HCl for 16 hrs. gave 1.4 g. 2-chloro-10,11-dihydro-11-oxodibenzo[b,f]-1,4-oxazepine, m. 242-4°. Oxidation of 8.6 g. VI in 50 ml. AcOH with 7.6 ml. 30% H<sub>2</sub>O<sub>2</sub> at 20° for 8 days gave 2.25 g. IV, 2.05 g. starting material, and 2.2 g. 2-chloro-11-(4-methyl-1-piperazinyl)dibenzo[b,f]-1,4-thiazepine 5-oxide (VII), m. 134-7°. 2-Chloro-11-(4-methyl-1-piperazinyl)dibenzo[b,f]-1,4-thiazepine (6.9 g.) in 10 ml. AcOH and 60 ml. water at 0° was treated with 4.5 g. NaIO<sub>4</sub>, and the precipitate formed was dissolved at 20° by prolonged stirring, kept overnight, diluted with water, basified with NH<sub>4</sub>OH and extracted with HCl. CHCl<sub>3</sub> washing, NH<sub>4</sub>OH basification and ether extraction gave 5.8 g. VII. 2-Chloro-11-(1-piperazinyl)dibenzo[b,f]-1,4-thiazepine 5-oxide, m. 197-200° was similarly prepared. Thin-layer chromatog. data for the sulfoxides are given.

IT 3158-91-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 3158-91-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)



L10 ANSWER 125 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1966:43922 CAPLUS

Correction of: 1965:472112

DN 64:43922

Correction of: 63:72112

OREF 64:8223b-h

TI Dibenzazepine, dibenzothiazepine, and morphanthridine derivatives

PA Dr. A. Wander A.-G.

SO 11 pp.

DT Patent

LA Unavailable

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	NL 6411504		19650412	NL	
PRAI	CH		19631009		

GI For diagram(s), see printed CA Issue.

AB A series of compds. (I and II) was prepared o-H<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>SC<sub>6</sub>H<sub>4</sub>Cl-p (83 g.) in 650 cc. dry MePh treated dropwise at -5 to 0° with stirring with 330 cc. 20% COCl<sub>2</sub>-MePh, refluxed 15 min. while being treated with gaseous COCl<sub>2</sub>, and purged with N yielded 91.5 g. p-ClC<sub>6</sub>H<sub>4</sub>-SC<sub>6</sub>H<sub>4</sub>NCO-o (III), b<sub>0.07</sub> 140-5°, m. 37-40°. III (183.2 g.) in 600 cc. o-C<sub>6</sub>H<sub>4</sub>Cl<sub>2</sub> added dropwise at 90-100° to 98 g. AlCl<sub>3</sub> in 900 cc. o-C<sub>6</sub>H<sub>4</sub>Cl<sub>2</sub>, heated 1 hr. at 150° poured onto ice, and steam distilled, and the residue boiled with 700 cc. Me<sub>2</sub>CO yielded 181 g. I (R = 2-Cl, R<sub>1</sub> = H, X = S), m. 260-2°. o-OCN-C<sub>6</sub>H<sub>4</sub>OPh (166.9 g.), 111 g. AlCl<sub>3</sub>, and 1000 cc. o-C<sub>6</sub>H<sub>4</sub>Cl<sub>2</sub> yielded similarly 163.5 g. I (R = R<sub>1</sub> = H, X = O), m. 215-17°. o-OCN-C<sub>6</sub>H<sub>4</sub>OC<sub>6</sub>H<sub>4</sub>Cl-m (143.2 g.), b<sub>0.07</sub> 125-30°, cyclized with 81.5 g. AlCl<sub>3</sub> in 1000 cc. o-C<sub>6</sub>H<sub>4</sub>Cl<sub>2</sub> yielded 110.5 g. I (R = 3-Cl, R<sub>1</sub> = H, X = O), m. 266-7° (C<sub>5</sub>H<sub>5</sub>N), and 18 g. I (R = 1-Cl, R<sub>1</sub> = H, X = O), m. 251-5° (C<sub>5</sub>H<sub>5</sub>N). 2,5-BzClC<sub>6</sub>H<sub>3</sub>NH<sub>2</sub> reduced with N<sub>2</sub>H<sub>4</sub>.H<sub>2</sub>O in basic medium, and the resulting 5,2-Cl-(PhCH<sub>2</sub>)-C<sub>6</sub>H<sub>3</sub>NH<sub>2</sub> treated with 20% COCl<sub>2</sub>-MePh gave 4,2-Cl(OCN)-C<sub>6</sub>H<sub>3</sub>CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub> (IV), b<sub>0.1</sub> 118-21°. IV (20.2 g.) cyclized at 120° with 13 g. AlCl<sub>3</sub> in 110 cc. o-C<sub>6</sub>H<sub>4</sub>Cl<sub>2</sub> yielded 19.5 g. II (R<sub>1</sub> = 7-Cl, R = H, R<sub>2</sub> = H), m. 273-5° (AcOH). o-H<sub>2</sub>N-C<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>CH<sub>2</sub>Ph (9 g.) in 10 cc. dry MePh treated dropwise with COCl<sub>2</sub>-MePh and then refluxed during 0.5 hr. with gaseous COCl<sub>2</sub>, purged with N, and evaporated, and the residue (11 g.) cyclized at 130° with 5.5 g. AlCl<sub>3</sub> in 60 cc. o-C<sub>6</sub>H<sub>4</sub>Cl<sub>2</sub> yielded 4 g. 5,6,11,12-tetrahydrobenz[b,f]azocine, m. 240-3° (CHCl<sub>3</sub>-Et<sub>2</sub>O). Similarly were prepared the I listed in the table. Similarly were prepared the following II (R, R<sub>1</sub>, R<sub>2</sub>, m.p., and yield given): H, H, H, 201-3°, 96; H, H, Me, 203-6° 87; 2-Cl, H, H, 261-2° 93; H, 8-Cl, H, 239-40°, 89°.


IT 3158-86-9, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-methyl-  
 3158-88-1, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-chloro-  
 3158-90-5, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-fluoro-  
 3158-91-6, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro-  
 3158-92-7, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-bromo-  
 3158-93-8, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-methyl-  
 3158-94-9, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-chloro-  
 3158-95-0, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-methyl-  
 3158-96-1, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-ethyl-  
 3950-69-4, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,4-dichloro-  
 3950-70-7, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,4-dichloro-  
 3950-71-8, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,8-dichloro-  
 3950-72-9, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4,8-dichloro-  
 3950-73-0, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,4-dimethyl-  
 3950-74-1, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3,4-dimethyl-  
 3950-75-2, Dibenz[b,f][1,4]oxazepin-11(10H)-one,  
 1-chloro-4-methyl- 3950-76-3, Dibenz[b,f][1,4]oxazepin-11(10H)-

10/785,120

one, 7-chloro-4-methyl- **3950-77-4**, Dibenz[b,f][1,4]oxazepin-  
11(10H)-one, 8-chloro-4-methyl-  
(preparation of)


RN 3158-86-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-methyl- (7CI, 8CI) (CA INDEX  
NAME)




RN 3158-88-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-chloro- (7CI, 8CI, 9CI) (CA INDEX  
NAME)




RN 3158-90-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-fluoro- (7CI, 8CI, 9CI) (CA INDEX  
NAME)



RN 3158-91-6 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro- (7CI, 8CI, 9CI) (CA INDEX  
NAME)




RN 3158-92-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-bromo- (7CI, 8CI) (CA INDEX NAME)


10/785,120




RN 3158-93-8 CAPLUS  
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-methyl- (7CI, 8CI) (CA INDEX NAME)



RN 3158-94-9 CAPLUS  
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 3158-95-0 CAPLUS  
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-methyl- (7CI, 8CI) (CA INDEX NAME)




RN 3158-96-1 CAPLUS  
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-ethyl- (7CI, 8CI) (CA INDEX NAME)

10/785,120




RN 3950-69-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,4-dichloro- (7CI, 8CI) (CA INDEX NAME)




RN 3950-70-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,4-dichloro- (7CI, 8CI) (CA INDEX NAME)



RN 3950-71-8 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,8-dichloro- (7CI, 8CI) (CA INDEX NAME)




RN 3950-72-9 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4,8-dichloro- (7CI, 8CI) (CA INDEX NAME)




10/785,120




RN 3950-73-0 CAPLUS  
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,4-dimethyl- (7CI, 8CI) (CA INDEX NAME)



RN 3950-74-1 CAPLUS  
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3,4-dimethyl- (7CI, 8CI) (CA INDEX NAME)




RN 3950-75-2 CAPLUS  
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1-chloro-4-methyl- (7CI, 8CI) (CA INDEX NAME)



RN 3950-76-3 CAPLUS  
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 7-chloro-4-methyl- (7CI, 8CI) (CA

10/785,120

INDEX NAME)




RN 3950-77-4 CAPLUS

```

CN      Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8-chloro-4-methyl- (7CI, 8CI) (CA
INDEX NAME)

```



L10 ANSWER 126 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1965:82580 CAPLUS

DN 62:82580

OREF 62:14681g-h,14682a-h,14683a-c

TI Seven-membered heterocycles. IV. New synthesis of dibenzo[b,f]-1,4-thiazepine, -oxazepine, and dibenzo[b,e]azepine lactams

AU Schmutz, J.; Kuenzle, F.; Hunziker, F.; Buerki, A.

CS A. Wander A.-G., Bern, Switz.

SO Helvetica Chimica Acta (1965), 48(2), 336-47

CODEN: HCACAV; ISSN: 0018-019X

DT Journal

LA German

OS CASREACT 62:82580

GI For diagram(s), see printed CA Issue.

AB cf. CA 61, 8313c. I, II, and III were prepared in good yields by the intramol. application of the Leuckart amide synthesis by using isocyanatodiphenyl sulfides, oxides, and methanes. The appropriate o-chloronitrobenzene (1.1 moles) and 1 mole suitable thiophenol treated with 1.1 moles NaOH in EtOH, or the chloronitrobenzene and excess phenol treated with KOH, or the Na phenolate treated in Me<sub>2</sub>SO with excess chloronitrobenzene gave the corresponding IV (R = NO<sub>2</sub>, X = S, O). o-ClC<sub>6</sub>H<sub>4</sub>NO<sub>2</sub> (115.8 g.) and p-MeOC<sub>6</sub>H<sub>4</sub>SH in 450 cc. boiling EtOH treated dropwise with 30.7 g. NaOH in 70 cc. H<sub>2</sub>O and refluxed 1 hr. yielded 164.5 g. p-MeOC<sub>6</sub>H<sub>4</sub>SC<sub>6</sub>H<sub>4</sub>NO<sub>2</sub>-o, m. 97-8° (Me<sub>2</sub>CO-Et<sub>2</sub>O).. 2,3-Me<sub>2</sub>C<sub>6</sub>H<sub>3</sub>OH (30 g.) in 150 cc. dry Et<sub>2</sub>O added dropwise with stirring to 8.7 g. NaNH<sub>2</sub> in 100 cc. dry Et<sub>2</sub>O and refluxed 15 min., the Et<sub>2</sub>O replaced by 150 cc. Me<sub>2</sub>SO, and the mixture treated at 140° with 35.2 g. o-ClC<sub>6</sub>H<sub>4</sub>NO<sub>2</sub> in 60 cc. Me<sub>2</sub>SO and heated 1 hr. at 140° yielded 51.1 g. 2,3-Me<sub>2</sub>C<sub>6</sub>H<sub>3</sub>OC<sub>6</sub>H<sub>4</sub>N<sub>2</sub>-o, m. 76-8°, b0.07 130-5°. The various IV (R = NO<sub>2</sub>, X = S, O) were reduced with Raney Ni in EtOH or in AcOEt to the corresponding IV (R = NH<sub>2</sub>). By these methods were prepared the IV listed in the 1st table. The appropriate o-amino-benzophenone reduced with Na in EtOH or in the presence of a Cl-substituent with N<sub>2</sub>H<sub>4</sub> in (HOCH<sub>2</sub>CH<sub>2</sub>)<sub>2</sub>O or treated with MeMgI (or EtMgI), dehydrated with dilute H<sub>2</sub>SO<sub>4</sub>, and hydrogenated in AcOEt over Pd-C yielded the corresponding o-aminodiphenylmethanes. o-MeC<sub>6</sub>H<sub>4</sub>COC<sub>6</sub>H<sub>4</sub>NH<sub>2</sub>-o (30 g.) in 180 cc. absolute EtOH added rapidly with stirring to 18 g. Na and refluxed 0.5 hr. yielded 26 g. o-MeC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>NH<sub>2</sub>-o, m. 67-9° (Et<sub>2</sub>O-petr. ether). 5,2-Cl(H<sub>2</sub>N)C<sub>6</sub>H<sub>3</sub>Bz (50 g.) in 600 cc. dry Et<sub>2</sub>O added dropwise with stirring to MeMgI from 27.5 g. Mg and 150 g. MeI in 600 cc. dry Et<sub>2</sub>O and refluxed 3 hrs. yielded 43.8 g. 5,2-Cl(H<sub>2</sub>N)C<sub>6</sub>H<sub>3</sub>CMePhOH (V), m. 93-4° (Et<sub>2</sub>O-petr. ether). V (46.5 g.) and 320 cc. 35% H<sub>2</sub>SO<sub>4</sub> refluxed 1 hr. gave 41.7 g. 5,2-Cl(H<sub>2</sub>N)C<sub>6</sub>H<sub>3</sub>CPh:CH<sub>2</sub> (VI), b0.1 142-5°. VI treated 15 min. at 70° and 12 hrs. at 20° with Ac<sub>2</sub>O-C<sub>5</sub>H<sub>5</sub>N gave the N-Ac derivative, m. 134-5° (Me<sub>2</sub>CO-Et<sub>2</sub>O). VI (22.9 g.) in 150 cc. AcOEt hydrogenated at 20° over 2.5 g. 5% Pd-C yielded 22 g. 5,2-Cl(H<sub>2</sub>N)C<sub>6</sub>H<sub>3</sub>CHPhMe, b0.07 127-30° N-Ac derivative m. 98-9° (Et<sub>2</sub>O-petr. ether). Similarly were prepared the IV listed in the 2nd table. o-H<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>SC<sub>6</sub>H<sub>4</sub>Cl-p (83 g.) in 650 cc. dry MePh added dropwise at -5 to 0° with stirring to 330 cc. 20% COCl<sub>2</sub> in MePh, and the mixture refluxed 15 min. while being treated with gaseous COCl<sub>2</sub> and then purged with N gave 91.5 g. o-OCNC<sub>6</sub>H<sub>4</sub>SC<sub>6</sub>H<sub>4</sub>Cl-p (VII), b0.07 140-5°, m. 37-40°. VII (183.2 g.) in 600 cc. o-C<sub>6</sub>H<sub>4</sub>Cl<sub>2</sub> added dropwise during 15 min. with stirring to 98 g. AlCl<sub>3</sub> in 900 cc. o-C<sub>6</sub>H<sub>4</sub>Cl<sub>2</sub> at 90-100° and heated 1 hr. at 150° yielded 181 g. I (R = 2-Cl, R' = H), m. 260-2° (CHCl<sub>3</sub>). 2,4-OCN(MeO)C<sub>6</sub>H<sub>3</sub>SPh (38.7 g.) and 20.9 g. AlCl<sub>3</sub> in 350 cc. o-C<sub>6</sub>H<sub>4</sub>Cl<sub>2</sub> gave similarly 8.5 g. I (R = H, R' = 8-MeO) (VIII), m. 221-3°, and 8.8 g. I (R = H, R' = 8-OH) (IX), m. 298-300° (dioxane-Et<sub>2</sub>O). Similarly were prepared the following I (R, R', and m.p. given): H, H, 259-60°; 2-F, H, 257-8° (AcOH); 2-Br, H, 270-1°; 2-Me, H, 239-40° (CHCl<sub>3</sub>); 2-tert-Bu, H,


239-42° (AcOH); 2-MeO, H, 128-9° (Me<sub>2</sub>CO-Et<sub>2</sub>O); 4-Cl, H, 271-3° (dioxane); 4-Me, H, 253-4°; H, 8-Cl, 302-3°; 4-Cl, 8-Cl, 287-8° (AcOH); 1-Cl, 4-Me, 319-21° (HCONMe<sub>2</sub>); 4-Me, 7-Cl, 318-21° (AcOH); 4-Me, 8-Cl, 298-300° (AcOH). IX (150 mg.) in 40 cc. MeOH treated 10 hrs. at 20° with CH<sub>2</sub>N<sub>2</sub>-Et<sub>2</sub>O gave 130 mg. VIII, m. 221-3° (Me<sub>2</sub>CO-petr. ether). o-ONCC<sub>6</sub>H<sub>4</sub>OPh (166.9 g.) with 111 g. AlCl<sub>3</sub> in 1 l. o-C<sub>6</sub>H<sub>4</sub>Cl<sub>2</sub> yielded similarly 163.5 g. II (R = R' = H), m. 215-17° (AcOH). o-OCNC<sub>6</sub>H<sub>4</sub>OC<sub>6</sub>H<sub>4</sub>Me-m (87.9 g.), b0.07 100-3°, cyclized with 54.8 g. AlCl<sub>3</sub> in 800 cc. o-C<sub>6</sub>H<sub>4</sub>Cl<sub>2</sub> yielded 49 g. II (R = 3-Me, R' = H), m. 218-19° (AcOH), and 4.5 g. II (R = 1-Me, R' = H), prisms, m. 229-31° changing at about 200° to plates. o-OCNC<sub>6</sub>H<sub>4</sub>OC<sub>6</sub>H<sub>4</sub>Cl-m (143.2 g.), b0.07 125-30°, 81.5 g. AlCl<sub>3</sub>, and 1 l. o-C<sub>6</sub>H<sub>4</sub>Cl<sub>2</sub> yielded 145 g. mixture, m. 215-50°, which fractionally recrystd. from 2.5 l. C<sub>5</sub>H<sub>5</sub>N gave II (R = 3-Cl, R' = H), m. 266-7°, and 18 g. II (R = 1-Cl, R' = H), m. 251-5° (AcOH). Similarly were prepared the following II (R, R' and m.p. given): 1-Cl, H, 251-5° (AcOH); 2-F, 245-6° (Me<sub>2</sub>CO); 2-Cl, H, 244-5° (AcOH); 2-Br, H, 240-1° (AcOH); 2-Me, H, 193-6° (Me<sub>2</sub>CO); 3-Cl, H, 266-7° (C<sub>5</sub>H<sub>5</sub>N); 4-Cl, H, 256-9° (AcOH); 4-Me, H, 192-4° (Me<sub>2</sub>CO); 4-Et, H, 147-9° and 153-4° (Me<sub>2</sub>CO); H, 6-Cl, 284-5° (AcOH); H, 7-Cl, .apprx.295° (AcOH); H, 8-Cl, 258-61° (Me<sub>2</sub>CO); 1-Cl, 4-Cl, 221-2° (AcOH); 2-Cl, 4-Cl, 260-4° (AcOH); 2-Cl, 8-Cl, 293-4° (AcOH); 4-Cl, 8-Cl, 296-7° (AcOH); 1-Me, 4-Me, 251-3° (dioxane); 3-Me, 4-Me, 213-14° (CHCl<sub>3</sub>-Et<sub>2</sub>O); 1-Cl, 4-Me, 258-9° (AcOH); 4-Me, 7-Cl, 310-11° (dioxane); 4-Me, 8-Cl, 259° (dioxane). Similarly were prepared the following III (R, R', R'', and m.p. given): H, H, H, 201-3° (Me<sub>2</sub>CO-H<sub>2</sub>O); H, H, Me, 203-6° (Me<sub>2</sub>CO); H, H, Et, 198-200° (CHCl<sub>3</sub>Me<sub>2</sub>CO); 2-Cl, H, H, 261-2° (Me<sub>2</sub>CO); 2-Cl, H, Me, 235-6° (AcOH); 3-Cl, H, H, 273-5° (sublimed); 3-Cl, H, Me, 196-8° (Me<sub>2</sub>CO-Et<sub>2</sub>O); H, 8-Cl, H, 239-40° (CHCl<sub>3</sub>-petr. ether); H, 8-Cl, Me, 258-60° (CHCl<sub>3</sub>-petr. ether); H, 8-Me, H, 207-9° (Me<sub>2</sub>CO); H, 8-Me, Me, 236-40° (Me<sub>2</sub>CO); H, 10-Me, H, 231-2° (CHCl<sub>3</sub>-Et<sub>2</sub>O).

IT 3158-86-9, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-methyl-  
 3158-88-1, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-chloro-  
 3158-90-5, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-fluoro-  
 3158-91-6, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro-  
 3158-92-7, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-bromo-  
 3158-93-8, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-methyl-  
 3158-94-9, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-chloro-  
 3158-95-0, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-methyl-  
 3158-96-1, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-ethyl-  
 3950-69-4, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,4-dichloro-  
 3950-70-7, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,4-dichloro-  
 3950-71-8, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,8-dichloro-  
 3950-72-9, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4,8-dichloro-  
 3950-73-0, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,4-dimethyl-  
 3950-74-1, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3,4-dimethyl-  
 3950-75-2, Dibenz[b,f][1,4]oxazepin-11(10H)-one,  
 1-chloro-4-methyl- 3950-76-3, Dibenz[b,f][1,4]oxazepin-11(10H)-  
 one, 7-chloro-4-methyl- 3950-77-4, Dibenz[b,f][1,4]oxazepin-  
 11(10H)-one, 8-chloro-4-methyl-  
 (preparation of)

RN 3158-86-9 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-methyl- (7CI, 8CI) (CA INDEX NAME)

10/785,120




RN 3158-88-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 3158-90-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-fluoro- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 3158-91-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 3158-92-7 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-bromo- (7CI, 8CI) (CA INDEX NAME)



RN 3158-93-8 CAPLUS


10/785,120

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-methyl- (7CI, 8CI) (CA INDEX NAME)




RN 3158-94-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 3158-95-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-methyl- (7CI, 8CI) (CA INDEX NAME)



RN 3158-96-1 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-ethyl- (7CI, 8CI) (CA INDEX NAME)



RN 3950-69-4 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,4-dichloro- (7CI, 8CI) (CA INDEX NAME)

10/785,120




RN 3950-70-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,4-dichloro- (7CI, 8CI) (CA INDEX NAME)




RN 3950-71-8 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,8-dichloro- (7CI, 8CI) (CA INDEX NAME)



RN 3950-72-9 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4,8-dichloro- (7CI, 8CI) (CA INDEX NAME)



RN 3950-73-0 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,4-dimethyl- (7CI, 8CI) (CA INDEX NAME)

10/785,120




RN 3950-74-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3,4-dimethyl- (7CI, 8CI) (CA INDEX NAME)




RN 3950-75-2 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1-chloro-4-methyl- (7CI, 8CI) (CA INDEX NAME)



RN 3950-76-3 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 7-chloro-4-methyl- (7CI, 8CI) (CA INDEX NAME)




RN 3950-77-4 CAPLUS



10/785,120

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8-chloro-4-methyl- (7CI, 8CI) (CA  
INDEX NAME)



L10 ANSWER 127 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1964:425478 CAPLUS

DN 61:25478

OREF 61:4380e-h

TI 5-(Basic substituted)-10,11-dihydro-11-oxo-5H-dibenzo-[b,e][1,4]-diazepine derivatives (I)

PA Dr. A. Wander A.-G.

SO 6 pp.

DT Patent

LA Unavailable

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 959995		19640603	GB	
	CH 380144			CH	
	US 3150125		1964	US	
PRAI	CH		19590922		

AB The title compds. are prepared by cyclization of the appropriate o-amino-o'-carboxydiphenylamines. Hence, 23.3 g. N- [β-(dimethylamino)ethyl]-2-nitrodiphenylamine-2'-ethyl carboxylate was catalytically hydrogenated and the resulting 2-amino compound dissolved in 500 cc. xylene. After 4 hrs. the xylene was distilled and the residue dried, boiled with 200 cc. N AcOH, and made alkaline with NH<sub>3</sub> to give 9.7 g. 5-[β-(dimethylamino)ethyl]-10,11-dihydro-11-oxo-5H-dibenzo [b,e][1,4]diazepine (I), m. 195-6°. Similarly prepared are the following derivs. of I (% yield and m.p. given): 7-chloro, 54, 197-8°; 8-chloro, 44, 180-4°; 8-methyl, 40, 165-7°; 8-methoxy, 56, 157-9°; 3-chloro, 38, 194°; 8-chloro-10-methyl, 57, - (b0.01 179°); 8-methoxy-10-methyl, 62, 115-18°; 8,10-dimethyl, 56, 71-4°; 7-methoxy, 68, 203-5°; 7-methylthio, 63, 185-7°; 7-chloro-10-methyl, 59, - (hydrochloride m. 216-19°). Further derivs. of I were prepared (substituents): 5-[γ-(dimethylamino)propyl], 59, 141-4°; 5-[γ-(dimethylamino)propyl]-7-chloro, 56, - [hydrochloride m. 244-5° (decomposition)]; 5-[γ-(dimethylamino)propyl]-8-chloro, 42, 184-7°; 5-[γ-(dimethylamino)propyl]-10-benzyl, 47, b0.03 230°; 5-(β-piperidinoethyl), 75, 184-6°; 5-(γ-piperidinopropyl), 58, 141-3°; 5-(β-morpholinoethyl), 66, 218-19°; 5-[β-(N'-methylpiperazino)ethyl], 60, 159-61°; 5-(pyrrolidinoethyl)-7-chloro-10-methyl, 67, - (hydrochloride m. 221-6°). These compds. are useful as parasympatholytics, antihistaminics, spasmolytics, tranquilizers, and psychic energizers.

IT **93407-98-8**, 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5-[2-(dimethylamino)ethyl]-5,10-dihydro- (preparation of)

RN 93407-98-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5-[2-(dimethylamino)ethyl]-5,10-dihydro- (7CI) (CA INDEX NAME)



L10 ANSWER 128 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1964:30958 CAPLUS

DN 60:30958

OREF 60:5505a-h,5506a-c

TI Seven-membered heterocycles. II. 5H-Dibenzo[b,e]-1,4-diazepines with basic substituents at position 5

AU Hunziker, F.; Kuenzle, F.; Schmutz, J.

CS Forschungsinst. Dr. A. Wander A.-G., Bern, Switz.

SO Helvetica Chimica Acta (1963), 46(6), 2337-46

CODEN: HCACAV; ISSN: 0018-019X

DT Journal

LA German

OS CASREACT 60:30958

GI For diagram(s), see printed CA Issue.

AB cf. CA 59, 8753f. Pepn. of compds. of types I, II, and III is described. The various I were prepared in 4 steps from the appropriate o-PhNHC<sub>6</sub>H<sub>4</sub>NO<sub>2</sub>. Thus, e.g., 12.2 g. 2,5-O<sub>2</sub>N(MeO)C<sub>6</sub>H<sub>3</sub>NHPh was refluxed 1 hr. with 23.5 g. NaNH<sub>2</sub> in absolute dioxane, 8.7 g. Me<sub>2</sub>N(CH<sub>2</sub>)<sub>3</sub>Cl in 40 ml. C<sub>6</sub>H<sub>6</sub> added, and the mixture refluxed 20 hrs. and worked up to give 76% N-(γ-dimethylaminopropyl)-2-nitro-5-methoxydiphenylamine, m. 85-7° (Et<sub>2</sub>O-petr. ether). The NO<sub>2</sub> group in N-(β-dimethylaminoethyl)-2-nitro-5-chlorodiphenylamine was reduced with Raney Ni and H at 20° and 1 atmospheric in AcOEt to give 96% N-(β-dimethylaminoethyl)-2-amino-5-chlorodiphenylamine, m. 101-2° (Et<sub>2</sub>O-petr. ether). Reduction of similar nitro compds, without Cl or MeS substituents was performed in alc., while Na<sub>2</sub>S<sub>2</sub>O<sub>4</sub> in aqueous-alc. KOH was used to reduce the nitro precursor of N-(β-dimethylaminoethyl)-2-amino-2'-methylthiodiphenylamine. A mixture of 35 ml. anhydrous HCO<sub>2</sub>H and 4.1 g. Ac<sub>2</sub>O was refluxed 2 hrs., 7 g. o-H<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>NPh-(CH<sub>2</sub>)<sub>2</sub>NMe<sub>2</sub> added, the mixture refluxed 1.5 hrs., evaporated to dryness in vacuo, and the residue worked up to give 88% N-(β-dimethylaminoethyl)-2-formamidodiphenylamine (IV, R = R<sub>1</sub> = H, n = 2), m. 85-6° (Et<sub>2</sub>O-petr. ether). The following R<sub>1</sub> substituted derivs. of IV were similarly prepared (R, R<sub>1</sub>, n, and b.p. or m.p. given): Me, H, 2, 72°; iso-Pr, H, 2, b0.01 170°; Me, 4'-OMe, 2, -(HCl salt m. 192-4°); Me, 3'-OMe, 2 (IVa), 79-80°; Me, 2'-OMe, 2, 94-5°; Me, 2'-SMe, 2, 130-2°; H, 5-Cl, 2, 123-5°; Me, 5-Cl, 2 (IVb), b0.04 175-80°; Me, 5-OMe, 2, b0.05 200°; Me, 4-Me, 2, 89-92°; H, H, 3, 60-1°; Me, H, 3, b0.01 154-5°; Me, 4'-OMe, 3, b0.07 182-6°; Me, 3'-OMe, 3, b0.07 190-5°; Me, 2'-OMe, 3, b0.07 185-90°; H, 5-Cl, 3, 99-101°; Me, 5Cl, 3, b0.03 182°; and Me, 5-OMe, 3, b0.05 200°. I were prepared by treatment of IV with polyphosphoric acid (PPA) (R, R<sub>1</sub>, n, and b.p. or m.p. given): Me, Cl, 2, m. 97-8°; H, H, 2, m. 98°; Me, H, 2 (Ia), m. 113-15°; iso-Pr, H, 2, m. 72-4°; Me, 1-OMe, 2 (Ib), m. 104-5°; Me, 2-OMe, 2, m. 103-4°; Me, 3-OMe, 2 (Ic), m. 100-1°; Me, 4-OMe, 2, m. 94-7°; Me, 4-SMe, 2, m. 78-81°; H, 7-Cl, 2, m. 91-3°; Me, 7-OMe, 2, m. 101-3°; Me, 8-Me, 2, -(maleate m. 151-4°); H, H, 3, b0.01 162°; Me, H, 3, b0.01 164°; Me, 2-OMe, 3, -(maleate m. 138-9°); Me, 3-OMe, 3, -(maleate m. 160-4°); Me, 4-OMe, 3, m. 90-1°; H, 7-Cl, 3, -(maleate m. 155-6°); Me, 7-Cl, 3, -(maleate m. 182-6°); Me, 7-OMe, 3, -(maleate m. 152-5°). Ib and Ic were separated from a single reaction mixture. In a typical preparation of II, 2-(o-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>NH)C<sub>6</sub>H<sub>4</sub>CO<sub>2</sub>Et was alkylated with NaNH<sub>2</sub> and Me<sub>2</sub>N(CH<sub>2</sub>)<sub>3</sub>Cl to give Et N-(γ-dimethylaminopropyl)-2-nitrodiphenylamine-2'-carboxylate, which was hydrogenated over 5% Pd-C at 20°/1 atmospheric, and the product worked up to give II (R = R<sub>1</sub> = H, n = 3), m. 151-2° (Et<sub>2</sub>O-petr. ether). The following II were similarly prepared (R, R<sub>1</sub>, n, and m.p. given): H, H, 2, 194-6°; H, 3-Cl, 2, 194-7°; H, 7-Cl, 2, 202-4°; H, 7-OMe, 2, 203-5°; H, 7-SMe, 2, 185-7°; H, 8-Me, 2, 165-7°; Me, 8-Me, 2,

71-5°; H, 8-Cl, 2 (IIa), 186-7°; H, 8-CF<sub>3</sub>, 2, 122-38°; H, 8-OMe, 2, 157-9°; Me, 8-OMe, 2, 115-18°; H, 7-Cl, 3, -(HCl salt m. 244-5°); H, 8-Cl, 3, 183-5°. III derivs, were prepared by 2 routes. The appropriate I or preferably II was reduced with a large excess of LiAlH<sub>4</sub> in tetrahydrofuran. The second method involved catalytic reduction. Thus, a mixture of 20 g. Ia, 3 g. Raney

Ni,

I g. 5% Pd-C, and 120 ml. EtOH was hydrogenated at 20° and I atmospheric, filtered, evaporated to dryness, and the residue in Et<sub>2</sub>O passed through Al<sub>2</sub>O<sub>3</sub> and evaporated to give 89% III (R = R<sub>2</sub> = H, R<sub>1</sub> = Me, n = 2), m. 75-6° (Et<sub>2</sub>O-petr. ether). The following III were prepared similarly (R, R<sub>1</sub>, R<sub>2</sub>, n, and m.p. given): H, H, H, 2 (IIIa) - (b0.03 162-4°); Ac, H, H, 2, 114°; Ac, Me, H, 2, 126-8°; Bz, Me, H, 2, 97-8°; H, Me, 2-OMe, 2, 73-6°; H, Me, 4-OMe, 2, 101-3°; H, H, 7-Cl, 2, 114-16°; H, Me, 7-Cl, 2 (IIIb), 107-9°; H, H, 8-Me, 2, 75-8°; H, H, 8-Cl, 2, 107-9°; H, H, H, 3, 102-4° H, Me, H, 3, 86-8°; Ac, Me, H, 3, 81-2°; H, H, 7-Cl, 3, 114-16°; H, Me, 7-Cl, 3, 74-8°. Conversion of III to I was also achieved. Thus, a mixture of 1.32 g. IIIa 3.5 g. Hg(OAc)<sub>2</sub>, 25 ml. AcOH, and 75 ml. H<sub>2</sub>O was heated 2.5 hrs. at 110°, cooled, filtered, and worked up to give 0.30 g. Ia. Alkylation of V (R = H) (VI) was also examined. Thus, a mixture of 12.0 g. VI, 70 ml. absolute dioxane, tert-BuOK


(from

2.1 g. K), and 40 ml. tert-BuOH was refluxed 1 hr., treated with 20 g. MeI, refluxed 4 hrs., and evaporated to dryness in vacuo. The residue was distributed between aqueous KHCO<sub>3</sub>-CHCl<sub>3</sub> and the organic layer worked up to give 72% V (R = Me), m. 165-6° (CHCl<sub>3</sub>-petr. ether). The 8-Me derivative of V (R = Me), m. 166-8° (Me<sub>2</sub>CO-petr. ether), was similarly prepared. The compds. were tested pharmacol. by comparing their antibenzoquinolizine effect against tetrabenazine (Nitomane). Several III were effective; IIIb was comparable to Imipramine. The same effect was generally much weaker in I. II (especially those with a substituent at C-8) showed antihistamine and antianaphylactic effects. IIa showed less acute per os toxicity and was 2 and 4 times, resp., as effective against histamine-induced asthma and anaphylactic shock in the guinea pig as (±)-Chlorpheniramine. A discussion of infrared and ultraviolet spectra (maximum are recorded) is presented for some of the compds. prepared

IT **93407-98-8**, 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5-[2-(dimethylamino)ethyl]-5,10-dihydro-  
(preparation of)

RN 93407-98-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5-[2-(dimethylamino)ethyl]-5,10-dihydro- (7CI) (CA INDEX NAME)



L10 ANSWER 129 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1963:448394 CAPLUS

DN 59:48394

OREF 59:8753f-h,8754a-h,8755a-c

TI Chemistry and pharmacology of dibenzo[b,e][1,4]diazepine derivatives with basic substituents in position 10

AU Hunziker, F.; Lauener, H.; Schmutz, J.

CS Forschungsinst. Dr. A. Wander A.-G., Bern, Switz.

SO Arzneimittel-Forschung (1963), 13, 324-8

CODEN: ARZNAD; ISSN: 0004-4172

DT Journal

LA Unavailable

GI For diagram(s), see printed CA Issue.

AB A series of I derivs. was prepared according to Clemono, et al. (CA 19, 293) and Burton and Gibson (CA 19, 987) by an Ullmann-synthesis from o-bromonitrobenzenes and free anthranilic acid derivs. in presence of K<sub>2</sub>CO<sub>3</sub> and catalytic amts. of Cu in a higher alcohol as solvent. The N-methylated anthranilic acids gave lower yields (50-60%) than the corresponding primary amines. The esters of I were best obtained via the acid chlorides. Thus, the following I derivs. were prepared (R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, and m.p. given): H, 4-Me, H, 213-15°; H, 4-Me, Et, 99-100°; Me, 4-Me, H, 140-1°; H, 4-Cl, H, 245-8°; H, 4-Cl, Et, 134-6°; Me, 4-Cl, H, 139-42°; H, 4-CF<sub>3</sub>, H, 225-6°; H, 4-CF<sub>3</sub>, Me, 147-8°; Me, 4-CF<sub>3</sub>, H, 154-6°; H, 4-OMe, H, 228-30°; H, OMe, Et, 104°; Me, 4-OMe, H, 164-6°; H, 5-Cl, Me, 157-8°; H, 5-Cl, Et, 127-8°; Me, 5-Cl, H, 160°; Me, 5-Cl, Me, 92-3°; H, 5-OMe, Me, 149°; H, 5-SMe, Et, 187-8°; Me, 5-SMe, Me, 102-3°; H, 6-Cl, Me, 119-20°; H, 5'-Cl, Et, 106-7°; H, 5'-OMe, H, 235-7°; H, 4'-Cl, H, 232-5°; H, 4'-Cl, Me, 138°; H, 4'-OMe, H, 240°; Me, 4'-OMe, H, 168-72°. To a cooled solution of 5.9 g. K in 110 ml. tert-BuOH was added under stirring 12 g. MeSH. At 20°, a solution of 40.3 g. I (R<sub>1</sub> = R<sub>3</sub> = Me, R<sub>2</sub> = 5-Cl) in 300 ml. HCONMe<sub>2</sub> was added. After 2 hrs. stirring at 80°, evaporation to dryness in vacuo, distribution between benzene and NaHCO<sub>3</sub> solution, evaporation of the benzene, and crystallization from Et<sub>2</sub>O/petr. ether gave 40 g. I (R<sub>1</sub> = R<sub>3</sub> = Me, R<sub>2</sub> = 5-SMe), m. 102-3°. To 135.6 g. I (R<sub>1</sub> = R<sub>3</sub> = H, R<sub>2</sub> = 5-Cl) 10.3, suspended in 1.8 l. 2N aqueous NH<sub>3</sub> was added within 3 hrs. 266 g. Na<sub>2</sub>S<sub>2</sub>O<sub>4</sub>. The mixture was heated to 80° till solution was complete. Charcoal treatment, acidification to pH 4.5 with AcOH, addition of NaCl, and work-up gave 121.3 g. II (R<sub>1</sub> = R<sub>3</sub> = H, R<sub>2</sub> = 5-Cl), m. 208-5° (decomposition) (MeOH-H<sub>2</sub>O). Similarly prepared were the II derivs. (R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, m.p. given): H, 4-Me, H, 213-15°; Me, 4-Me, H, 144-6°; H, 4-Cl, H, 200-5°; Me, 4-Cl, H, 155°; H, 4-CF<sub>3</sub>, H, 214-15°; Me, 4-CF<sub>3</sub>, H, 160°; H, 4-OMe, H, 200°; Me, 4-OMe, H, 132-4°; H, 5-Cl, Me, 117-18°; Me, 5-Cl, H, 155°; H, 5-OMe, H, 178-9°; H, 5-SMe, H, 170-2°; H, 6-Cl, Me, 135-9°; H, 5'-Cl, H, 175-7°; H, 5'-OMe, H, 182-4°; H, 4'-Cl, H, 197-8°. II (R<sub>1</sub> = R<sub>3</sub> = H, R<sub>2</sub> = 5-Cl) (121.3 g.) was refluxed in 3 l. xylene 40 hrs. under continuous removal of H<sub>2</sub>O. After distillation of the solvent and vapor distillation for removal of impurities, the residue was made alkaline with dilute NH<sub>3</sub>, filtered, treated with charcoal, and crystallized from Me<sub>2</sub>CO-H<sub>2</sub>O to give 71.3 g. III (R<sub>1</sub> = H, R<sub>2</sub> = 7-Cl), m. 253-4°. The same compound was also obtained by refluxing of 2.5 g. II (R<sub>1</sub> = H, R<sub>2</sub> = 5-Cl, R<sub>3</sub> = Me) with 0.39 g. NaNH<sub>2</sub> in 20 ml. dioxane, dilution with H<sub>2</sub>O, and filtration in 83% yield. Similarly prepared were the following III derivs. (R<sub>1</sub>, R<sub>2</sub>, m.p. given): H, 2-Cl, 259-60°; H, 2-OMe, 220-1°; Me, 2-OMe, 200-12°; H, 3-Cl, 271°; H, 3-OMe, 232-3°;

H, 3-Me, 267-9°; H, 6-Cl, 244-6°; Me, 7-Cl, 226-7°;  
H, 7-OMe, 239-40°; H, 7-SMe, 211-12°; Me, 7-SMe,  
225-6°; H, 8-Cl, 231-2°; Me, 8-Cl, 214-15°; H, 8-Me,  
194-5°; Me, 8-Me, 228-9°; H, 8-CF<sub>3</sub>, 176-7°; Me,  
8-CF<sub>3</sub>, 239-40°; H, 8-OMe, 174-6°; Me, 8-OMe, 221-3°.

III (R<sub>1</sub> = H, R<sub>2</sub> = 7-Cl) (52.5 g.) was refluxed 1 hr. with 9.2 g. NaNH<sub>2</sub> in 350 ml. dioxane, then 29 g. ClCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub> in 50 ml. benzene was added and the mixture refluxed 16 hrs. Concentration in vacuo, distribution between benzene/H<sub>2</sub>O, extraction of the benzene with diluted HCl, alkalization of the extract with NH<sub>3</sub>, extraction with CHCl<sub>3</sub>, evaporation of the solvent, and crystallization from

Me<sub>2</sub>CO/Et<sub>2</sub>O gave 50.8 g. IV (R<sub>1</sub> = H, R<sub>2</sub> = 7-Cl), m. 165-6°,  
ε<sub>D</sub><sup>20</sup> 32,740 (EtOH); hydrochloride m. 225-33° (EtOH-Et<sub>2</sub>O).

The same compound was obtained by refluxing 11.4 g. II (R<sub>1</sub> = H, R<sub>2</sub> = 5-Cl, R<sub>3</sub> = Me) 90 min. with 1.8 g. NaNH<sub>2</sub> in 90 ml. dioxane, then adding 6 g. ClCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub> in 20 ml. benzene, and refluxing 15 hrs. (and usual work-up) in 56% yield. Similarly prepared were the following IV derivs. (R<sub>1</sub> R<sub>2</sub>, m.p. free base, m.p. hydrochloride, L.D. 59 mg./kg. mouse per os given): H, H, 112-14°, -, 705; Me, H, 116-17°, 234-40°, 215; H, 2-Cl, 172-3°, -, 175; Me, 2-OMe, -, 205-10°, 900; H, 3-Cl, 159-60°, -, 305; H, 3-OMe, 141-3°, -, 150; H, 6-Cl, 122-3°, -, 260; H, 7-Cl, 165-6°, 225-33°, 330; Me, 7-Cl, -, 247-53°, 500; H, 7-OMe, 152-3°, -, 220; H, 7-SMe, 126-9°, -, 345; Me, 7-SMe, -, 205-7°, 520; H, 8-Cl, 140-5°, -, -; Me, 8-Cl, -, 240-5°, 500; H, 8-OMe, 126-7°, -, 220; H, 8-CF<sub>3</sub>, 115-18°, -, 150; Me, 8-CF<sub>3</sub>, -, 222-6°, 240; H, 8-Me, 137-8°, -, 127; Me, 8-Me, -, 214-17°, 100. Also prepared were the V derivs. (X, m.p., D.L. 50 mg./kg. mouse per os given): 2-pyrrolidinoethyl, 159-60°, 700; 2-piperidinoethyl, 187-9°, 700; 2-morpholinoethyl, 220-2°, >2500; CH<sub>2</sub>CHMeNMe<sub>2</sub>, 197-9°, 320; (CH<sub>2</sub>)<sub>3</sub>NMe<sub>2</sub>, 137-9°, 1000.

Reduction of the corresponding oxo derivs. with LiAlH<sub>4</sub> in tetrahydrofuran gave the VI derivs. (R<sub>1</sub>, R<sub>2</sub>, m.p., L.D. 50 mg./kg. mouse per os given): H, H, (maleate m. 100°), 600; Me, H, - (maleate m. 149-51°), 760;


H, Cl, 87-9°, 275. IV (R<sub>1</sub> = H, R<sub>2</sub> = 2-Cl) (20 g.) was refluxed 24 hrs. in 200 ml. 5N HCl. Concentration in vacuo, addition of NaOH, and

isolation of


the resulting base gave 14.8 g. VII, b.p. 130-8°. Acetylation with Ac<sub>2</sub>O in pyridine gave VIII, m. 109-11°. To prove the structure, VIII was also synthesized independently. Thus, IX was acetylated to give X, m. 89-90° (Et<sub>2</sub>O-petr. ether). X (31 g.) was alkylated with 4 g. NaNH<sub>2</sub> and 9.5 g. ClCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub> in 150 ml. dioxane to give after usual work-up 31.5 g. VIII. To test the influence of the N bridge on the pharmacol. properties, XI was prepared by refluxing 11.7 g. phenanthridone with 2.95 g. NaNH<sub>2</sub> in 120 ml. dioxane for 2 hrs. Addition of 7 g. ClCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub> in 50 ml. dioxane during 4 hrs., refluxing for 10 hrs, and normal work-up gave XI; hydrochloride m. 268-70° (MeOH-Et<sub>2</sub>O). The XII derivs. were also prepared (X, m.p., L.D. 50 mg./kg. mouse per os given): S, 268-71° (hydrochloride) 870; SO<sub>2</sub>, 113-23°, 620; O, 230-3° (hydrochloride), 500. The influence of the chemical constitution on the pharmacological activity was studied. A heterocyclic bridge in position 5 is indispensable for activity; derivs. of benzanilide and phenanthridone having basic substituents are inactive. An unsubstituted NH-group in position 5 has a more favorable effect than the Me-substituted N and is superior in activity to other hetero-bridges such as SO<sub>2</sub>, S, and O. Compds. with substituents in position 7 show greater activity than the unsubstituted compound. A carbonyl group in position 11 is essential for activity, the corresponding VI derivs., although closely related to known antihistamines of the benzyraniline group are practically inactive in vivo. In agreement with other classes of antihistamines, the (CH<sub>2</sub>)<sub>2</sub>NMe<sub>2</sub> and (CH<sub>2</sub>)<sub>3</sub>NMe<sub>2</sub> groups are the most effective basic

substituents. IV (R1 = H, R2 = 7-Cl) and the corresponding 7-SMe derivative belong to the most potent antihistaminics of today.


IT **82096-44-4**, 11H-Dibenzo[b,e][1,4]diazepin-11-one,  
2-chloro-5,10-dihydro- **90353-73-4**, 11H-Dibenzo[b,e][1,4]diazepin-  
11-one, 3-chloro-5,10-dihydro- **92148-65-7**, 11H-  
Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-methyl-  
**93533-09-6**, 11H-Dibenzo[b,e][1,4]diazepin-11-one,  
5,10-dihydro-3-methoxy- **94860-63-6**, 11H-  
Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-methoxy-5-methyl-  
**167997-02-6**, 11H-Dibenzo[b,e][1,4]diazepin-11-one,  
5,10-dihydro-2-methoxy-  
(preparation of)  
RN **82096-44-4** CAPLUS  
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro- (7CI, 9CI)  
(CA INDEX NAME)



RN **90353-73-4** CAPLUS  
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro- (7CI, 9CI)  
(CA INDEX NAME)




RN **92148-65-7** CAPLUS  
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-methyl- (7CI) (CA  
INDEX NAME)




RN **93533-09-6** CAPLUS  
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-methoxy- (7CI) (CA  
INDEX NAME)

10/785,120




RN 94860-63-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-methoxy-5-methyl-  
(7CI) (CA INDEX NAME)



RN 167997-02-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-methoxy- (9CI) (CA  
INDEX NAME)





10/785,120

=> d his

(FILE 'HOME' ENTERED AT 15:02:16 ON 01 MAR 2006)

FILE 'REGISTRY' ENTERED AT 15:02:41 ON 01 MAR 2006  
ACT A10785120/A

-----  
L1 STR  
L2 3101 SEA FILE=REGISTRY SSS FUL L1  
-----

FILE 'STNGUIDE' ENTERED AT 15:03:13 ON 01 MAR 2006

FILE 'REGISTRY' ENTERED AT 15:05:08 ON 01 MAR 2006  
L3 STRUCTURE UPLOADED  
L4 QUE L3  
L5 46 S L4 SAM SUB=L2  
L6 1087 S L4 FUL SUB=L2

FILE 'CAPLUS' ENTERED AT 15:06:47 ON 01 MAR 2006  
L7 128 S L6


FILE 'REGISTRY' ENTERED AT 15:06:58 ON 01 MAR 2006  
L8 45 S L6  
L9 1151 S L6 FUL

FILE 'CAPLUS' ENTERED AT 15:08:55 ON 01 MAR 2006  
L10 129 S L9

=> d l1; d l4; d his; log y

L1 HAS NO ANSWERS

L1 STR



G1 C,N

G2 O,N

Structure attributes must be viewed using STN Express query preparation.

L4 HAS NO ANSWERS

L3 STR